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A B S T R A C T
Background
Malignant pleural effusion (MPE) is a common problem for people with cancer as a result of malignant infiltration of the pleura.
It is usually associated with considerable breathlessness. A number of treatment options are available to manage the uncontrolled
accumulation of pleural fluid including administration of a pleurodesis agent (either via a chest tube or at thoracoscopy) or indwelling
pleural catheter insertion.
Objectives
To ascertain the optimal management strategy for adults with malignant pleural effusion in terms of pleurodesis success. Additionally,
to quantify differences in patient-reported outcomes and adverse effects between management strategies.
Search methods
We searched The Cochrane Central Register of Controlled Trials (CENTRAL), OvidMEDLINE, Ovid EMBASE; EBSCOCINAHL;
SCI-EXPANDED and SSCI (ISI Web of Science) to April 2015.
Selection criteria
We included randomised controlled trials of intrapleural interventions for adults with symptomatic MPE in the review.
Data collection and analysis
Two review authors independently extracted data on study design, study characteristics, outcome measures, potential effect modifiers
and risk of bias.
The primary outcome measure was pleurodesis failure rate. Secondary outcome measures were adverse effects and complications,
patient-reported control of breathlessness, quality of life, cost, mortality, duration of inpatient stay and patient acceptability.
We performed network meta-analysis with random effects to analyse the primary outcome data and those secondary outcomes with
enough data. We also performed pair-wise random-effects meta-analyses of direct comparison data. If interventions were not deemed
jointly randomisable, or insufficient data were available, we reported the results by narrative synthesis. We performed sensitivity analyses
to explore heterogeneity and to evaluate only those pleurodesis agents administered via a chest tube at the bedside.
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Main results
Of the 1888 records identified, 62 randomised trials, including a total of 3428 patients, were eligible for inclusion. All studies were at
high or uncertain risk of bias for at least one domain.
Network meta-analysis evaluating the rate of pleurodesis failure, suggested talc poudrage to be a highly effective method (ranked second
of 16 (95% credible interval (Cr-I) 1 to 5)) and provided evidence that it resulted in fewer pleurodesis failures than eight other methods.
The estimated ranks of other commonly used agents were: talc slurry (fourth; 95% Cr-I 2 to 8), mepacrine (fourth; 95% Cr-I 1 to 10),
iodine (fifth; 95% Cr-I 1 to 12), bleomycin (eighth; 95% Cr-I 5 to 11) and doxycyline (tenth; 95% Cr-I 4 to 15). The estimates were
imprecise as evidenced by the wide credible intervals and both high statistical and clinical heterogeneity.
Most of the secondary outcomes, including adverse events, were inconsistently reported by the included studies and the methods used
to describe them varied widely. Hence the majority of the secondary outcomes were reported descriptively in this review. We obtained
sufficient data to perform network meta-analysis for the most commonly reported adverse events: pain, fever and mortality. The fever
network was imprecise and showed substantial heterogeneity, but suggested placebo caused the least fever (ranked first of 11 (95%
Cr-I 1 to 7)) and mepacrine and Corynebacterium parvum (C. parvum) appeared to be associated with the most fever (ranked tenth
(95% Cr-I 6 to 11) and eleventh (95% Cr-I 7 to 11) respectively). No differences between interventions were revealed by the network
meta-analysis of the pain data. The only potential difference in mortality identified in the mortality network was that those receiving
tetracycline appeared to have a longer survival than those receiving mitoxantrone (OR 0.16 (95% Confidence Interval (CI) 0.03 to
0.72)). Indwelling pleural catheters were examined in two randomised studies, both of which reported improved breathlessness when
compared to talc slurry pleurodesis, despite lower pleurodesis success rates.
The risk of bias in a number of the included studies was substantial, for example the vast majority of studies were unblinded, and the
methods used for sequence generation and allocation concealment were often unclear. Overall, however, the risk of bias for all studies
was moderate. We have not reported the GRADE quality of evidence for the outcomes, as the role of GRADE is not well established
in the context of Network Meta-analysis (NMA).
Authors’ conclusions
Based on the available evidence, talc poudrage is a more effective pleurodesis method in MPE than a number of other frequently used
methods, including tetracycline and bleomycin. However further data are required to definitively confirm whether it is more effective
than certain other commonly used interventions such as talc slurry and doxycycline, particularly in view of the high statistical and
clinical heterogeneity within the network and the high risk of bias of many of the included studies. Based on the strength of the evidence
from both direct and indirect comparisons of randomised data of sclerosants administered at the bedside, there is no evidence to suggest
large differences between the other highly effective methods (talc slurry, mepacrine, iodine and C. parvum). However, local availability,
global experience of these agents and their adverse events, which may not be identified in randomised trials, must also be considered
when selecting a sclerosant. Further research is required to delineate the roles of different treatments according to patient characteristics
(e.g. according to their prognosis or presence of trapped lung) and to explore patient-centred outcomes, such as breathlessness and
quality of life, in more detail. Careful consideration to minimise the risk of bias and standardise outcome measures is essential for future
trial design.
P L A I N L A N G U A G E S U M M A R Y
Interventions for the management of fluid around the lungs (pleural fluid) caused by cancer
Review Question
We reviewed the evidence about the effectiveness of different methods to manage fluid around the lung in patients with a build up of
this fluid caused by cancer.
Background
Malignant pleural effusion (MPE) is a condition whereby cancer of the lining of the lung results in fluid building up in the space
between the lung and rib cage (pleural cavity), often resulting in breathlessness. Treatment options include removal of the fluid using
either a temporary chest drain, a camera examination of the pleural cavity (thoracoscopy) or a semi-permanent chest drain tunnelled
under the skin (an indwelling pleural catheter). Introducing a chemical into the pleural cavity can also be used to prevent the fluid
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coming back (pleurodesis). We wanted to find out which method was the most effective in terms of preventing fluid build up and
which was best in terms of side effects and patient-reported outcomes such as pain, fever, breathlessness and quality of life.
Study Characteristics
We searched databases for trials comparing different interventions in adults with symptomatic MPE to April 2015, written in any
language. Since we were only interested in rigorously conducted research, we restricted our search to randomised controlled trials (in
which participants are randomly allocated to the methods being tested). We analysed the majority of the data using a technique called
’network meta-analysis’ which allows lots of different interventions to be compared in one analysis. This analysis ranks the interventions
in order of their effectiveness.
Key Results
We found 62 studies involving 3428 patients.
In the network meta-analysis, the use of thoracoscopy to remove the fluid and blow talc into the pleural cavity (talc poudrage) appeared
to be more effective in preventing fluid build up than a number of other commonly used methods. However, we could not say definitely
that it is better than some other methods such as giving talc or doxycycline through a chest drain.
Side effects, quality of life and patient satisfaction were reported inconsistently by the included studies, but are important factors to
consider when selecting the best management strategy for a patient. There was enough data to perform network meta-analysis for
pain, fever and mortality. We found placebo caused the least fever and Corynebacterium parvum (C. parvum) and mepacrine were
likely to cause the most. We found no differences in the pain caused by the interventions evaluated. Only one comparison showed a
possible difference, revealing that those receiving tetracycline may live longer than those receiving mitoxantrone. As we only evaluated
randomised controlled trials, it is possible some harms of treatments were not identified by this review.
Quality of the Evidence
Many of the studies were of low quality and the characteristics of the individual studies were quite different to each other. This high
risk of bias makes it difficult to reach definite conclusions.
Conclusions
The available evidence shows that talc poudrage can stop fluid building up. However, we can not be sure that this is definitely the
best method, and further research is needed. It is also important to consider global experience of these agents and knowledge of their
safety and side effects when selecting the most appropriate pleurodesis method. Indwelling pleural catheters may help improve patient
breathlessness, but may be less good at stopping the fluid coming back.
Further research is also required to look at particular patient groups and explore patient-centred outcomes, such as breathlessness and
quality of life in more detail. Ideally a fuller understanding of the potential harms of the treatments from the patients’ perspective would
also be beneficial.
B A C K G R O U N D
Malignant pleural effusion (MPE) is a common clinical problem,
with an estimated annual incidence of at least 150,000 in the
USA alone (American Thoracic Society 2000). Fifteen percent of
people diagnosed with cancer will develop pleural effusion during
the course of their disease as a result of malignant infiltration of
the pleura. It often confers a poor prognosis (Rodrîguez-Panadero
1989). Breathlessness results from compression of the underlying
lung and impaired diaphragmatic and chest wall movement and
is often relieved by pleural fluid aspiration.
Description of the condition
MPE is a condition whereby excess fluid accumulates in the pleu-
ral cavity, caused by direct pleural tumour invasion, resulting in
increased permeability of the pleural microvessels and involve-
ment of local lymph nodes causing reduced fluid reabsorption
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(Rodrîguez-Panadero 2008). The most common primary sites
which metastasise to the pleura are lung cancer in men and breast
cancer in women, but other primary sites include lymphoma, gen-
itourinary and gastrointestinal malignancy (DiBonito 1992; Sears
1987). In addition, the pleura may be the primary site of the ma-
lignancy, as is the case in mesothelioma. In the majority of cases,
the diagnosis of pleural malignancy is made by cytological analysis
of the pleural fluid or pleural biopsy. Depending on the clinical
situation, confirmation of malignancy elsewhere and an otherwise
unexplained (usually exudative) effusion may also be attributed to
malignancy. Survival of these patients varies widely (Bielsa 2008;
Burrows 2000) and estimation of an individual’s prognosis may
help with the selection of the most appropriate management strat-
egy (Clive 2014).
Trapped lung can occur when full lung expansion is limited by
either a visceral pleural peel or endobronchial obstruction and in
this situation, even once the fluid is drained, visceral and parietal
pleural apposition does not occur. This results in pleurodesis at-
tempts being less effective and often limits the treatment options
to either an indwelling pleural catheter or surgery.
Description of the intervention
A number of different approaches may be used to manage MPE
and the chosen method is likely to depend on clinical factors, pa-
tient preferences and local availability of the various techniques.
Instillation of a sclerosant into the pleural cavity through an inter-
costal chest drain after complete fluid drainage has been the main-
stay of treatment for many years (known as ‘bedside’ or ‘slurry’
pleurodesis). This technique aims to fuse the pleural layers to-
gether by means of local inflammation induced by the pleurode-
sis agent, thereby preventing pleural fluid re-accumulation. The
optimal management strategy to maximise pleurodesis success in
terms of the size of chest drain, patient positioning, use of analgesia
and type of sclerosant is still the subject of debate (Roberts 2010).
The role of intrapleural fibrinolytics to break down septations and
loculations within the effusion prior to administration of the pleu-
rodesis agent is also yet to be formally established (Davies 1999;
Gilkeson 1999; Hsu 2006).
Thoracoscopy is an alternative method, which is used to drain the
effusion and deliver a sclerosant into the pleural cavity. This can
either be performed under conscious sedation (local anaesthetic
thoracoscopy), or as a surgical procedure under general anaes-
thetic (Video Assisted Thoracoscopic Surgery (VATS)). In both
techniques, the pleural fluid is drained and the pleural cavity is
visualised using a fibre-optic camera. Loculations can be broken
down and biopsies may be taken to gain a histological diagnosis.
A pleurodesis agent can then be delivered by way of insufflation
(poudrage) prior to the insertion of a chest drain (Rahman 2010).
An alternative approach in the management of MPE is the use
of indwelling pleural catheters (IPCs). These are chest tubes,
which are tunnelled under the skin and allow long-term, inter-
mittent fluid drainage to be performed in the community, thereby
minimising recurrent hospital attendances. They have an estab-
lished role in the management of pleural effusions in patients with
trapped lung, but are increasingly being used for the primary man-
agement of malignant effusions as an alternative to chemical pleu-
rodesis (Davies 2012; Demmy 2012). In a proportion of patients
with IPCs, spontaneous pleurodesis occurs, allowing the drain to
be removed without recurrence of the effusion (Tremblay 2006).
In certain clinical scenarios, none of the above options may be
suitable and simple pleural fluid aspiration or medical manage-
ment of a patient’s breathlessness (for example using opiates) may
be deemed more appropriate. This may be the case for patients in
the terminal phase of their illness where invasive techniques may
be felt to confer unnecessary discomfort.
How the intervention might work
Pleurodesis aims to fibrose the pleural layers together in order to
obliterate the pleural space and by so doing prevent fluid recur-
rence. For pleurodesis to be successful the visceral and parietal
pleural surfaces must be opposed and hence if lung expansion is
incomplete (for example if the effusion is very loculated or the
patient has trapped lung), pleurodesis is more likely to fail. The
sclerosant stimulates an inflammatory reaction within the pleural
cavity, which results in fusion of the visceral and parietal pleura.
Indwelling pleural catheters allow intermittent pleural fluid
drainage, which relieves the pressure on the diaphragm and chest
wall and promotes lung re-expansion. By so doing, breathlessness
is improved and spontaneous pleurodesis occurs in up to 50% of
patients (Putnam 2000).
Why it is important to do this review
Due to wider availability of pleural interventions, such as tho-
racoscopy and indwelling pleural catheters, the management op-
tions available to patients with MPE are expanding. This review
will help to delineate the specific roles of the different techniques
and identify factors which may improve pleurodesis rates for those
undergoing a bedside pleurodesis. This review includes an update
of a Cochrane systematic review first published in 2004, ’Pleu-
rodesis for malignant pleural effusions’ (Shaw 2004) and will sub-
sequently help to inform national guidelines in this area.
Given the availability of many pair-wise comparisons for the
method of pleurodesis administration and type of pleurodesis
agent, this is a multiple interventions review. Network meta-anal-
ysis has been performed to synthesise all the available evidence and
investigate a treatment hierarchy.
O B J E C T I V E S
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To ascertain the optimal management strategy for adults with ma-
lignant pleural effusion in terms of pleurodesis success. Addition-
ally, to quantify differences in patient-reported outcomes and ad-
verse effects between management strategies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We only included reports of randomised controlled trials (RCTs)
in this review. This would have included randomised cross-over
trials and cluster randomised trials, although no studies of these
types were identified. We included both single and multi-centre
studies. Studies, which were stated to be randomised but were
found to be at high risk of bias for adequate sequence generation
or allocation concealment, were excluded.
Types of participants
Inclusion
• Adults over the age of 16.
• Symptomatic pleural effusion resulting from an underlying
malignant process (of any type and stage).
Exclusion
• Studies recruiting both malignant and non-malignant
participants with no clear distinction between the two groups in
the results section.
• Studies evaluating the effect of a drug administered via any
method other than the intra-pleural route.
• Studies including participants with effusions within a
variety of body cavities (e.g. pleural, peritoneal, pericardial),
where the effect of the treatments in the subgroup of patients
with pleural effusions cannot be distinguished in the results
section.
Types of interventions
We identified studies comparing the following.
• Type of sclerosant.
• Mode of administration of sclerosant (thoracoscopic
pleurodesis and bedside pleurodesis).
• Bedside or thoracoscopic pleurodesis and indwelling pleural
catheter insertion.
• Techniques used to optimise pleurodesis success rate,
namely:
◦ chest drain size;
◦ type of analgesia given;
◦ duration of drainage after instillation of sclerosant;
◦ patient positioning after pleurodesis (for example,
patient rotation);
◦ use of intrapleural fibrinolytics.
We generated a network of interventions, including comparisons
between the types of sclerosant, mode of administration and IPC
use. We assumed that any participant meeting the inclusion crite-
ria could be, in principle, randomised to any of the eligible inter-
ventions. This is referred to as the interventions being ‘jointly ran-
domisable’. However, if an intervention was not felt to be jointly
randomisable, for example the treatment was specific to a certain
tumour type, we reported the results separately from the network
(Salanti 2012).
Interventions of direct interest
We included RCTs that evaluated one or more of the following
intrapleural interventions: talc poudrage, talc slurry, bleomycin,
tetracycline, doxycycline, iodine, C.parvum, IPC, mitoxantrone,
mustine, mepacrine, interferon, triethylenethiophosphoramide
and adriamycin, compared with another intervention or placebo.
If we identified other sclerosants that wewere not aware of, we con-
sidered them as eligible and we included them in the network after
assessing their comparability with the pre-specified set of compet-
ing interventions. We reported the findings for these interventions
in the results and the conclusions of the review.
Types of outcome measures
Primary outcomes
The efficacy of pleurodesis was our primary outcome measure.
Definitions of pleurodesis failure varied between studies and al-
though current practice would define this by a lack of recurrence of
symptoms or need for a repeat pleural intervention to manage the
effusion, in some older studies, less clinically relevant definitions
were used (for example, re-accumulation of effusion on imaging).
We still included these studies in the review, and documented the
method used to define pleurodesis for all studies in the assessment
of the risk of bias.
For the purposes of the primary outcome, we used the following
hierarchy of preferences to judge pleurodesis failure (if a study re-
ported more than one definition of pleurodesis failure, the highest
of these according to this hierarchy was used):
• need for a repeat pleural procedure to manage recurrence of
the effusion, or ongoing drainage of pleural fluid from an
indwelling pleural catheter (if applicable);
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• evidence of significant pleural fluid re-accumulation on
radiological imaging (for example, chest X-ray or ultrasound);
• pleurodesis failure in the opinion of the trial investigators.
Similarly, we selected the time point used to define pleurodesis
efficacy was selected using the following hierarchy of preferences:
• 2 - 4 months;
• > 4 - 7 months;
• > 7 - 11 months;
• > 11 - 12 months;
• < 2 months;
• > 12 months.
Participants who died before the time point at which pleurodesis
efficacy was assessed, were classified according to their last known
pleurodesis outcome prior to their death (i.e. their last observation
carried forward). If these data were not provided, we used the
available reported data.
Secondary outcomes
• Adverse effects and complications due to interventions,
specifically the presence or absence of pain and fever after the
intervention.
• Patient-reported control of breathlessness, as measured by a
valid and reliable scale (for example, visual analogue scale (VAS),
numeric rating scale or dyspnoea/breathlessness specific
multidimensional scale)∗
• The participants’ quality of life and symptom control
(including pain), as measured by a valid and reliable scale∗
• Relative costs of the comparative techniques as reported by
the individual trials. For ease of comparison, data reported in
other currencies were converted to USD.∗
• The overall mortality (we used the data for the reported
outcomes closest to three months).
• Median survival.
• Duration of inpatient stay in days (both total length of stay
and from time of intervention until discharge).∗
• Patient acceptability of the interventions as judged by a
valid scale (for example, visual analogue scale or numeric rating
scale).∗
* if available
Search methods for identification of studies
Trials that compared at least two of the interventions (includ-
ing placebo) were eligible. We included all possible comparisons
formed by the interventions of interest.
Electronic searches
To identify studies for inclusion in this review, we searched the
following databases:
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library) Issue 3 of 12, 2015;
• MEDLINE (Ovid) 1948 to 1/04/15;
• EMBASE (Ovid) 1974 to 1/04/15;
• CINAHL (EBSCO) 1980 to April 2015;
• Web of Science Science Citation Index Expanded (SCI-
EXPANDED) and Social Sciences Citation Index (SSCI)
searched to 2015.
The search strategies can be viewed in Appendix 1. There were no
language restrictions.We included single andmulti-centre studies.
Searching other resources
We screened the reference lists from the included studies for addi-
tional publications. We also searched the reference lists from rele-
vant chapters in key resources, such as the British Thoracic Society
Pleural Disease Guidelines (Roberts 2010).
Data collection and analysis
Selection of studies
One author screened all titles and abstracts retrieved by the search
for relevance (AOC).We identified potentially eligible studies and
obtained the full papers. Two review authors (AOC and NAM)
independently assessed each study for inclusion in the review and
any disagreement was resolved through discussion or by a third
author (NP).
Data extraction and management
Two of the review authors (AOCwith NAM,NP or RB) extracted
data from each included study.We resolved disagreements through
discussion and referral to one of the other review authors. If an
author was involved in one of the included studies, they did not
perform the data extraction for that study. Data collected included
the following.
• Publication details including:
◦ title, author(s), date, country and other citation details;
◦ study aim and design;
◦ primary and secondary outcomes;
◦ number of participants randomised.
• Details of the interventions and comparison group
including type of intervention, duration, dose, mode of
administration and number of doses.
• Primary and secondary outcome measures (as detailed
above) and data on adverse events and complications.
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• Assessment of the study’s risk of bias.
• Data on potential effect modifiers including the following
study and patient characteristics:
◦ how pleurodesis was defined (radiology only or
including clinical need as well as radiology);
◦ whether patients with trapped lung were included or
not;
◦ the size of the chest tube through which bedside
pleurodesis was administered (defined as small (< 20 French),
large (≥ 20 French) or unknown);
◦ the time point at which pleurodesis was defined;
◦ the tumour types included in the study.
We had planned to look at specific areas of study quality, which
were incorporated into the assessment of the risk of bias. We re-
quested additional data from the study authors as required. One
author (AOC) entered data suitable for pooling into the Cochrane
Collaboration’s statistical software, Review Manager (RevMan)
(RevMan 2014) .Where we performed network meta-analysis, we
transferred data to the WinBUGS software (Lunn 2000).
Assessment of risk of bias in included studies
We limited inclusion to studies that were randomised as a min-
imum. Two of the review authors (AOC with NP, RB or NM)
independently assessed risk of bias for each study, using the criteria
outlined in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011a), and adapted from those used by the
Cochrane Pregnancy and Childbirth Group, with any disagree-
ments resolved by discussion. In our original protocol, we had
planned to include sample size in our risk of bias assessment. How-
ever, in view of Cochrane guidance stating imprecision should not
be considered a risk of bias, we did not perform this assessment
(Higgins 2011a). We assessed the following for each study.
Random sequence generation (checking for possible
selection bias)
We assessed the method used to generate the allocation sequence
as: low risk of bias (any truly random process, e.g. random num-
ber table; computer random-number generator); unclear risk of
bias (method used to generate sequence not clearly stated). We ex-
cluded studies using a non-random process i.e. at high risk of bias
(e.g. odd or even date of birth; hospital or clinic record number).
Allocation concealment (checking for possible selection bias)
The method used to conceal allocation to interventions prior to
assignment determines whether intervention allocation could have
been foreseen in advance of, or during, recruitment, or changed
after assignment. We assessed the methods as: low risk of bias
(e.g. telephone or central randomisation; consecutively numbered
sealed opaque envelopes); unclear risk of bias (method not clearly
stated).We excluded studies at high risk of bias that did not conceal
allocation (e.g. open list).
Blinding of participants and personnel (checking for possible
performance bias)
We assessed the methods used to blind study participants and per-
sonnel from knowledge of which intervention a participant re-
ceived. We assessed the methods as: low risk of bias (study stated
there was blinding of participants and key study personnel and
unlikely blinding could be broken, or no blinding or incomplete
blinding but the outcome not likely to be influenced by lack of
blinding); unclear risk of bias (insufficient information to permit
judgement of low or high risk of bias); high risk of bias (no blind-
ing or incomplete blinding, which is likely to influence the trial
outcome or blinding attempted but likely it could have been bro-
ken and the outcome is likely to be influenced by lack of blinding).
Blinding of outcome assessment (checking for possible
detection bias)
We assessed the methods used to blind outcome assessors from
knowledge of which intervention a participant received. We as-
sessed the methods as: low risk of bias (study stated that it was not
blinded but the review authors judged that the outcome measure-
ment is not likely to be influenced by lack of blinding or blinding
of outcome assessment was ensured); unclear risk of bias (study
provided an inadequate description to permit judgment of ’low
risk’ or ’high risk’); high risk of bias (no blinding of outcome as-
sessment and outcome likely to be influenced by lack of blinding,
or there was blinding of the outcome assessment but likely that
the blinding could have been broken).
Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We assessed the methods used to deal with loss to follow up for
each of the given studies. Due to the challenges of inevitable miss-
ing outcome data given the predictable attrition of patients due
to death in the palliative care population, we took into account
whether missing data had been justified, whether the rate was sim-
ilar in the different treatment arms, whether the treatment being
evaluated was felt to have an impact on the degree of missing out-
come data and whether an intention to treat analysis had been
attempted. We assessed the methods used to deal with incomplete
data as: low risk (rate of missing data were balanced between the
treatment arms, seemed reasonable and had been justified; data
had been analysed according to the patients’ randomised treatment
allocation; a suitable imputation method may have been used to
account for missing data); unclear risk of bias (insufficient infor-
mation given to allocate trial to ’high’ or ’low’ risk group); high
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risk of bias (imbalanced missing outcome data between the treat-
ment arms or missing outcome data felt to be related to the true
outcome; reasons for loss to follow up poorly justified; no attempt
at ITT analysis; inappropriate imputation used).
Selective Outcome Reporting
We assessed the studies for selective outcome reporting using the
following criteria: low risk of bias (all outcomes pre-defined and
reported, for example in a published protocol, or all clinically rele-
vant and reasonably expected outcomes were reported); uncertain
risk of bias (unclear whether all pre-defined and clinically relevant
outcomes were reported); high risk of bias (one or more clinically
relevant and reasonably expected outcome was not reported and
data on these outcomes were likely to have been recorded).
Other sources of bias
This section was used to report other biases, which were detected
but did not fit into the above categories (for example, industry bias,
academic bias or other methodological flaws that may have caused
bias). We assessed the methods used to deal with other sources of
bias as: low risk (the trial appeared to be free from other potential
biases); unclear risk of bias; high risk of bias (other source of bias
was identified).
Measures of treatment effect
Relative treatment effects
For proportions (dichotomous outcomes), such as pleurodesis effi-
cacy and mortality, we calculated the Odds Ratio (OR) with 95%
confidence intervals (CIs). For continuous data (such as length
of hospital stay and cost) we planned to use the mean difference
(MD) with 95% CIs and also the number needed to treat (NNT)
to benefit for efficacy outcome, and the number needed to harm
(NNH) for adverse events.
We planned to treat ordinal outcome measures (for example,
breathlessness scales and quality of life data) as continuous so long
as the scale was long enough. If different scales were used by the
included studies, we planned to use the standardised mean differ-
ence in meta-analyses.
We presented results from both pair-wise standard meta-analysis
and network meta-analysis (NMA) as summary relative effect sizes
(OR, MD or SMD with 95% CIs) for each possible pair of treat-
ments (Deeks 2011).
Relative treatment ranking
Based on the results of the network meta-analysis, we estimated
the rank of each competing intervention’s effectiveness. We pre-
sented estimated ranks (medians) with 95% credible intervals (Cr-
Is) (representing uncertainty about the true rank) produced from
the Bayesian analyses (Higgins 2011b).
Unit of analysis issues
If repeated observations on the same participants occurred during
the trial (for example, pleurodesis success rate at different time
points), we analysed these separately. Only one measure per par-
ticipant was used for the primary endpoint (according to the hi-
erarchy of preferences detailed above Primary outcomes).
For the purpose of meta-analysis, if a study had multiple doses
for a certain substance, we combined and compared all relevant
experimental intervention groups with the combination of all rel-
evant control groups. We reported any evidence for effects of the
different doses descriptively.
For cross-over trials, we planned to analyse data using pair-wise
meta-analysis, taking into account the cross-over design. If meta-
analysis had been performed containing cluster randomised trials
and the presented results had not accounted for clustering, then
we planned to make an appropriate adjustment, as described in
the Cochrane Handbook (Higgins 2011b).
We treated multi-arm studies as multiple independent two-arm
studies in the standard pair-wise meta-analysis. In the network
meta-analysis, we accounted for the correlation between the effect
sizes from multi-arm studies.
Dealing with missing data
We attempted to contact the study authors of included studies
to clarify any missing data. We would have imputed the missing
standard deviations based on the average standard deviations from
the other included studies if standard deviations for mean scores
had not been reported and it had not been possible to obtain the
information from the study authors. We only included data for
those participants whose results were known if an intention-to-
treat analysis was not reported by the study. However, we assessed
the potential impact of these missing data in the ’Risk of bias’
table.
Assessment of heterogeneity
Assessment of clinical and methodological heterogeneity
within treatment comparisons
We extracted data from study reports regarding clinical hetero-
geneity such as details on the intervention and control treatments,
participant characteristics and the outcomes evaluated.
We assessed the presence of clinical heterogeneity within each pair-
wise comparison by comparing the study population character-
istics across all eligible trials. We only performed meta-analysis
when considered reasonable based on the degree of heterogeneity.
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Assessment of transitivity across treatment comparisons
We assessed the assumption of transitivity by comparing the dis-
tribution of the potential effect modifiers across the different pair-
wise comparisons.
Assessment of reporting biases
We performed searches in multiple databases to ensure all poten-
tially eligible studies were identified (Electronic searches). The re-
view authors were alert to duplicated publication of results when
analysing the studies to ensure each participant was only included
once in the analysis.
If unpublished studies were identified, we tried to obtain sufficient
information in order for them to be included in the analysis. The
same applied for data published in abstract format.
In studies published in a language other than English, wemade ev-
ery effort to obtain a translation of at least the abstract. If sufficient
information was available, we included the study in the analysis.
Data synthesis
Methods for direct treatment comparisons
Since we expected some clinical heterogeneity between studies (for
example due to different definitions of pleurodesis success, dif-
ferent time points and doses used), we believed that the assump-
tion of a single fixed intervention effect across included studies
was unlikely to be valid. Our primary analyses therefore employed
random-effects models. Since pooled effect estimates from ran-
dom-effects models give relatively more weight to smaller studies,
which is often considered undesirable, we performed sensitivity
analyses using fixed-effect meta-analysis models. We performed
standard pair-wise meta-analysis using a random-effects model in
Cochrane’s statistical software, RevMan 2014 for every treatment
comparison with two or more studies.
For binary outcome data, we meta-analysed odds ratios (ORs).
For continuous data we planned to use the mean difference (MD)
or standardised mean difference (SMD) and perform a check to
identify if continuous outcome data were skewed. If this was the
case, we planned to analyse the data on a log scale.
If we assessed studies as unsuitable for meta-analysis, or insuffi-
cient studies were identified for meta-analysis to be performed, we
planned to present data by means of a narrative synthesis.
If sufficient data were available, we used similar analysis methods
to analyse the adverse effects data. Alternatively we summarised
this qualitatively.
Methods for indirect and mixed comparisons
Wherever possible, we performed a multiple-intervention, net-
work meta-analysis of primary and (separately) of each secondary
outcome measure. We used a Bayesian random-effects model, fit-
ted using the WinBUGS software (Lunn 2000). We assumed a
binomial likelihood and an uninformative normal prior distribu-
tion, with mean 0 and standard deviation of 100 for all baseline
event rates and intervention effects on the logit scale. When net-
work meta-analyses were performed, we used the Stata software
to generate a network plot (using the networkplot command) and
inconsistency plot (using the ifplot command) (Chaimani 2013).
Subgroup analysis and investigation of heterogeneity
Assessment of statistical heterogeneity
In pair-wise meta-analyses we estimated the between-study stan-
dard deviation (Tau2 ) separately for each intervention comparison.
For the direct treatment comparisons, we quantified the hetero-
geneity across studies using the I2 statistic, which we interpreted
taking into account the magnitude and direction of effect as well
as the confidence interval (Higgins 2003).
The assessment of statistical heterogeneity in the network meta-
analysis was based on the magnitude of and credible intervals for
the between-studies standard deviation (Tau) estimated from the
NMA models. In network meta-analysis we assumed a common
Tau across all comparisons. We assumed a vague uniform(0,2)
prior distribution for Tau.
As described below, reasons for heterogeneity were investigated
using subgroup or sensitivity analyses.
Assessment of statistical inconsistency
Inconsistency in the network refers to differences between the
direct and indirect effect estimates for the same comparison
(Donegan 2013). We used both a loop-specific approach and a
global approach to evaluate these effects.
To evaluate the presence of inconsistency locally we used the loop-
specific approach. This assesses the consistency assumption in each
closed loop of the network separately. We identified all the tri-
angular loops (comprising three direct treatment comparisons, all
compared with each other) and all the quadratic loops (involv-
ing four comparisons) in the network. We compared the differ-
ences between the direct and indirect estimates for these loops to
generate inconsistency factors, with 95% CIs, calculated and dis-
played graphically using the ’ifplot’ command in Stata (Chaimani
2013). We assumed the estimated between-study standard devia-
tion (Tau) from the Bayesian analysis of the full network for each
loop. We used the magnitude of the inconsistency factors to infer
the presence and degree of inconsistency in each loop.
In addition to this, we used a global approach, involving formally
comparing the fit of the network meta-analysis model (which as-
sumes consistency) with that of an ‘inconsistency’ model (in which
all consistency constraints are removed). The inconsistency model
used is equivalent to fitting a random-effects meta-analysis model
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for all pair-wise comparisons, with a shared between-studies vari-
ance parameter but no assumptions about direct and indirect ev-
idence forming coherent ‘loops’. We calculated the Deviance In-
formation Criterion (DIC) for each model. If the DIC for the in-
consistency model was more than five units higher than that of the
consistency model, this was viewed as evidence of inconsistency
(Dias 2013).
Assessment of statistical imprecision
We evaluated precision of results, and subsequent rankings, based
on their 95% CIs (for pair-wise analysis) or Cr-Is (for Bayesian
network meta-analysis).
Sensitivity analysis
Sensitivity analysis and investigation of heterogeneity and
inconsistency
We conducted subgroup or sensitivity network meta-analyses by
re-running the model on restricted numbers of studies according
to the following potential effect modifiers, which we felt could be
sources of inconsistency and/or heterogeneity:
• analysis only including studies which used a clinico-
radiological definition of pleurodesis failure;
• analysis only including studies which analysed pleurodesis
efficacy at one month after the intervention;
• analysis only including studies which analysed pleurodesis
efficacy at three months after the intervention;
• analysis only including studies which analysed pleurodesis
efficacy at more than six months after the intervention;
• analysis only including studies which excluded patients
with trapped lung;
• analysis only including studies which administered bedside
pleurodesis through a large-bore chest tube (> 20 Fr)
• analysis only including studies at a lower risk of bias (two or
fewer domains at high risk of bias).
In the protocol, we had planned to investigate different tumour
types, age of participants and baseline performance status, al-
though there were insufficient data on this in the included studies
to perform these subgroup analyses.
Sensitivity analysis
We performed a post-hoc sensitivity network meta-analysis evalu-
ating only pleurodesis agents delivered via a chest tube (as opposed
to being given at thoracoscopy). We removed the trials evaluating
talc poudrage and IPC use from the main network and repeated
the analysis.
R E S U L T S
Description of studies
Results of the search
We performed the literature search in April 2015 (see Figure 1).
10Interventions for the management of malignant pleural effusions: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram
11Interventions for the management of malignant pleural effusions: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We identified 1888 records from database searches and 21
records from other sources before exclusion of duplicates. We
screened 1650 abstracts, of which 207 full text articles were
retrieved and assessed for eligibility by two independent re-
searchers (AOC, NAM). Of these, 62 met the eligibility criteria
(Characteristics of included studies) and 10 are pending classifi-
cation as they are awaiting translation (Characteristics of studies
awaiting classification). Six on-going studies were also identified
(Characteristics of ongoing studies).
Across the 62 included studies, a total of 3428 participants were
randomised between 1977 and 2015. There was one foreign lan-
guage study which was translated from the German (Schmidt
1997).
Included studies
The majority of studies (39/62) explored the efficacy of a vari-
ety of pleurodesis agents. Talc was evaluated in 23 trials, making
it the most studied agent. The other most commonly examined
agents were bleomycin and tetracycline. Two studies compared in-
dwelling pleural catheters with talc slurry (Davies 2012; Demmy
2012).
Four studies evaluated themode of administration of the pleurode-
sis agent (three studies comparing talc poudrage with talc slurry
(Dresler 2005; Terra 2009; Yim 1996) and one comparing instil-
lation of tetracycline thoracoscopically or through an intercostal
cannula (Evans 1993)). A number of studies evaluated alternative
methods to improve pleurodesis (one study examined catheter size
(Clementsen 1998); three evaluated the duration of drainage after
pleurodesis (Goodman 2006; Villanueva 1994; Yildirim 2005);
one evaluated the duration of drainage prior to instillation of the
sclerosant (Ozkul 2014); one assessed whether patient rotation
improved pleurodesis rate (Mager 2002) and one evaluated the
effect of talc particle size (Maskell 2004)). We identified one RCT
which examined the role of intrapleural fibrinolytics (Okur 2011).
One RCT evaluated administration of three different doses of sil-
ver nitrate through a chest tube (Terra 2015).
Two studies compared talc pleurodesis with surgical methods to
treat malignant effusion (one comparing either talc pleurodesis
with pleurectomy (Rintoul 2014) and one comparing talc slurry
with thoracoscopic mechanical pleurodesis (Crnjac 2004)).
Additionally, we identified seven studies of agents specifically for
the treatment of effusions due to lung cancer (Du 2013; Ishida
2006; Kasahara 2006; Luh 1992; Masuno 1991; Yoshida 2007;
Zhao 2009).
There were a number of methodological differences between the
included studies. Forty five of 62 studies included all tumour types;
two included all exceptmesothelioma, one included onlymesothe-
lioma; one included only adenocarcinoma; six only breast cancer,
and in seven studies only lung cancer patients were included.
The methods to define pleurodesis failure varied between studies.
Eighteen of 62 studies used radiological criteria only to define a
pleurodesis failure, 44 of 62 studies also incorporated symptomatic
recurrence or need for a repeat pleural intervention into their def-
inition. The time point at which pleurodesis was defined varied
widely between studies, from 1 to 12 months.
The pleurodesis techniques were not standardised. Studies used a
variety of chest drain sizes and durations of pleural fluid drainage
after the sclerosant was administered. Additionally, patients with
trapped lung were excluded from 25 of 62 studies, but not from
the others.
Excluded studies
We placed 11 studies in the excluded studies section, having ini-
tially identified them as eligible for inclusion but with reasons
for exclusion identified later (Characteristics of excluded studies).
One study had insufficient data for extraction (Tattersall 1982).
Three studies included data for patients with ascites, which could
not be separated from those with pleural effusions even after at-
tempting to contact the study authors (Kwasniewska-Rokicinska
1979; Lissoni 1995; Nio 1999). As per the published protocol,
seven studies were found to be high risk of bias for sequence
generation and therefore excluded (Caglayan 2008; Dryzer 1993;
Elayouty 2012; Engel 1981; Gust 1990; Maiche 1993; Manes
2000). Causes of the inadequate sequence generation included al-
locating patients to groups using alternation (Caglayan 2008); or
according to certain clinical criteria (Maiche 1993), patient hos-
pital number (Dryzer 1993), date of consent (Engel 1981) or date
of diagnosis (Manes 2000). We excluded one study as the data
contained both randomised and non-randomised data, which was
not distinguishable (Gust 1990) and we could not obtain con-
tact details for the study authors. Another stated patients were ‘di-
vided’ between groups, not mentioning if this process was random
(Elayouty 2012) and there was no response from the study authors
when contacted to clarify this further.
Risk of bias in included studies
A summary assessment of the risk of bias is presented in the
Characteristics of included studies, Figure 2 and Figure 3. No
studies were at low risk of bias for all domains.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Thirty three of 62 studies documented adequate sequence gen-
eration. The most commonly used methods were computer or
telephone randomisation services, block randomisation, stratifi-
cation, opaque sealed envelopes or a random number generator.
Since studies with inadequate sequence generation were excluded
as per the protocol, we assessed sequence generation as unclear in
the remaining 29 studies. In all cases, the study was stated to have
been randomised.
Regarding allocation concealment, we assessed 31 studies as low
risk of bias for this domain. Since studies with inadequate allo-
cation concealment were excluded as per the protocol, allocation
concealment was ‘unclear’ for the remaining 31 studies.
Blinding
Blinding of participants and personnel (performance bias)
Due to the nature of many of the interventions evaluated in this
review, blinding of the participants and clinicians was often not
possible and therefore we assessed 40 of 62 studies as high risk of
bias for this domain. Many of the pleurodesis agents have differ-
ing visual appearances and those studies randomising patients to
different modes of administration of a pleurodesis agent, an in-
dwelling pleural catheter or surgery, could not feasibly be blinded.
Four studies were assessed as low risk of performance bias (Bjermer
1995; Maskell 2004; Terra 2015; Zaloznik 1983).
Blinding of outcome assessment (detection bias)
The assessment of pleurodesis success could often not be blinded
as it was reliant on participants (who were not blinded) reporting
symptoms, in association with the radiological findings of effusion
recurrence. Very few studies reported whether the radiological as-
sessments were performed in a blinded fashion. Twenty nine of
62 studies were at high risk of detection bias, and a further 25 of
62 studies had an unclear risk of bias for this domain. Eight stud-
ies were low risk of detection bias (Bjermer 1995; Maskell 2004;
Masuno 1991; Ong 2000; Ozkul 2014; Terra 2015; Ukale 2004;
Zaloznik 1983).
Incomplete outcome data
Themajority of studieswere low risk of bias because although some
inevitable attrition due to death was reported, the rates were com-
parable for the treatment arms and were deemed reasonable for the
size of the population. We classified 12 studies as high risk of bias
(eight due to very high attrition rates (Kefford 1980; Kessinger
1987; Masuno 1991; Ostrowski 1989; Patz 1998; Ruckdeschel
1991; Sorensen 1984; Zaloznik 1983; Kefford 1980); one due
to very imbalanced loss to follow up (LTFU) between the treat-
ment arms (Fentiman 1986); one the number randomised was not
stated (Zimmer 1997); one the numbers provided did not add
up (Hillerdal 1986); one excluded patients from the analysis who
discontinued treatment due to an allergic reaction (Gaafar 2014)).
Three were unclear risk of bias (Kuzdzal 2003: number of ran-
domised patients not stated, only number analysed; Alavi 2011:
unable to access tables, and numbers only given as percentages,
rather than absolute values; Ozkul 2014: numbers of patients lost
to follow up not stated).
Selective reporting
The majority of studies were assessed to be at low risk of bias
for selective outcome reporting. We classified two studies as un-
clear, one as minimal raw data were presented in the text and the
tables could not be accessed (Alavi 2011) and the other because
pleurodesis success data were not collected in an RCT of talc and
tetracycline pleurodesis (although the study was not designed to
evaluate this) (Maskell 2004). Five studies were high risk (four
provided minimal or no data regarding side effects or survival, or
both (Evans 1993; Kuzdzal 2003; Ozkul 2014; Salomaa 1995)
and one did not report data on 15 of the randomised patients
(Ruckdeschel 1991).
Other potential sources of bias
We classified nine of 62 studies as high risk of bias in the ‘other’
domain and three of 62 studies as unclear. This was for a variety
of reasons (see Characteristics of included studies). The remaining
studies had a low risk of bias for this domain.
Effects of interventions
PRIMARY OUTCOME
Selection of trials for inclusion in the network
All the interventions from the included studies were evaluated
and assessed for inclusion in the network. A number of interven-
tions were not felt to be jointly randomisable and hence were not
included in the network. This was the case for specific surgical
techniques (Crnjac 2004; Rintoul 2014), different talc particle
sizes (Maskell 2004), interventions aimed to improve the efficacy
of pleurodesis (Clementsen 1998; Evans 1993; Goodman 2006;
Mager 2002; Okur 2011; Ozkul 2014; Villanueva 1994; Yildirim
2005), tumour-specific intra-pleural therapy (Du 2013; Ishida
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2006; Kasahara 2006; Luh 1992; Masuno 1991; Yoshida 2007;
Zhao 2009) and different doses of silver nitrate (Terra 2015).
Two interventions (silver nitrate and combined tetracycline and
bleomycin), which we initially felt to be eligible for inclusion in
the network had to be removed for the evaluation of pleurodesis
efficacy. These agents were only evaluated in one trial each and no
participants who received these agents had a pleurodesis failure,
which led to computational problems such that a treatment effect
could not be estimated (Emad 1996; Paschoalini 2005).One study
was not included in the analysis of pleurodesis efficacy as there
were no pleurodesis failures in either study arm (Yim 1996). Such
studies cannot statistically contribute to the estimate of relative
intervention effects (Higgins 2011b).
The majority of studies included all cell types and 36 of 62 tri-
als (58%) did not exclude patients with trapped lung. Pleurodesis
was defined using symptom recurrence and radiology in 44 of 62
studies (71%) and it was usually defined within four months of
the intervention. It was very difficult to assess whether the dis-
tribution of potential effect modifiers was comparable for all the
direct treatment comparisons because there were few studies per
direct comparison (see Appendix 2).
The final network can be seen in Figure 4. Any studies in the
systematic review which were not included in the network were
reported descriptively.
Figure 4. Network plot of the pleurodesis efficacy network. The nodes are weighted according to the
number of participants randomised to the intervention. The edges (line thicknesses) are weighted according
to the number of studies included in each comparison.
Primary outcomes for the methods included in the network
meta-analysis
Direct meta-analysis
Results of the direct, pair-wise random-effects meta-analysis of the
main pleurodesis agents are presented in Table 1. Given the small
number of studies making the same direct comparisons, meta-
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analysis was only possible for eight direct comparisons.
In the majority of cases, there was no evidence against the null
hypothesis of no true difference between interventions (Table 1).
However in 10 of the direct comparisons, the OR and 95% CI
lay away from the null value of 1, giving evidence against the
null hypothesis of no difference. A number of methods were less
effective than talc poudrage at inducing pleurodesis, including
bleomycin (OR 9.70 (95% CI 2.10 to 44.78), participants = 57;
studies = 2) (Analysis 1.1), tetracycline (OR 12.10 (95% CI 1.32
to 111.30), participants = 33; studies = 1) (Analysis 4.1), mustine
(OR 8.00 (95% CI 1.40 to 45.76), participants = 37; studies =
1) (Analysis 17.1) and doxycycline (OR 42.69 (95% CI 2.13 to
856.61), participants = 31; studies = 1) (Analysis 8.1). Interferon
was less effective than bleomycin (OR3.25 (95%CI 1.54 to 6.89),
participants = 160; studies = 1) (Analysis 13.1). Bleomycin was
less effective than mepacrine (OR 0.16 (0.03, 0.89), participants
= 36; studies = 1) (Analysis 12.3).
Those treatedwith an IPChadmore pleurodesis failures than those
receiving talc slurry (OR 3.35 (95%CI 1.64 to 6.83), participants
= 160; studies = 2) (Analysis 6.1). Triethylenephosphoramide was
less effective than mepacrine (OR 4.95 (95% CI 1.02 to 24.10),
participants = 29; studies = 1) (Analysis 14.1). There was also some
evidence that tetracycline andmitoxantronewere less effective than
bleomycin (OR 2.00 (95% CI 1.07 to 3.75); participants = 220;
studies = 5) ) (Analysis 4.1) and OR 3.18 (95% CI 1.17 to 8.65);
participants = 85; studies = 1 (Analysis 18.1) respectively). The
comparison between talc slurry and talc poudrage gave some weak
evidence that talc slurry may be less effective as the 95% CI was
close to one (OR 1.31 (95% CI 0.92 to 1.85); participants = 599;
studies = 3) (Analysis 2.1).
The heterogeneity between studies making similar comparisons
was generally low. However, the comparison between C. parvum
and bleomycin revealed a very high level of heterogeneity (Tau2 =
10.59, I2 = 94%) because the two included studies had conflict-
ing results: (OR 0.05 (95% CI 0.01 to 0.29) in Hillerdal 1986;
OR 5.69 (95% CI 1.38 to 23.48) in Ostrowski 1989) (Analysis
5.1). The number of participants in the comparison was small (98
patients randomised across the two studies; 78 of whom had suf-
ficient data to be included in the primary outcome analysis) and
Hillerdal 1986 was high risk of bias for two domains and unclear
risk of bias for a further two. Hillerdal 1986 only included pa-
tients with adenocarcinoma or bronchogenic carcinoma, whereas
Ostrowski 1989 included all cell types.
Sensitivity analysis of the direct comparisons using the fixed effect
meta-analysis model did not reveal any clinically or statistically
meaningful differences (see Appendix 3).
Network meta-analysis
The results of the relative efficacies of the pleurodesismethods gen-
erated by the network meta-analysis, which comprised 41 studies
of 16 agents, including 2345 participants are shown in Table 2.
The estimated ranks for each of the methods in terms of pleurode-
sis success are shown in Figure 5.
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Figure 5. Estimated (95% Cr-I) ranks for each of the pleurodesis methods from the main network
The network comparisons between talc poudrage and bleomycin,
tetracycline, interferon (IFN), IPC, placebo, mustine, mitox-
antrone and doxycycline, all provided evidence against the null
hypotheses of no difference in favour of talc poudrage resulting
in fewer pleurodesis failures (See Table 2). The estimated rank of
talc poudrage was second of 16 pleurodesis methods (95% Cr-I 1
to 5).
Other potentially efficacious agents were viscum, talc slurry,
mepacrine, iodine and C. parvum, with estimated ranks of second
(95% Cr-I 1 to 12), fourth (95% Cr-I 2 to 8), fourth (95% Cr-I
1 to 10), fifth (95% Cr-I 1 to 12) and sixth (95% Cr-I 2 to 11)
respectively (see Figure 5). The ORs and 95% Cr-Is comparing
talc slurry with tetracycline, placebo, mustine and mitoxantrone,
lay far away from the null value of 1, providing evidence that talc
slurry is more effective than these other agents. The comparisons
between talc slurry and bleomycin and IFN had 95% Cr-I close
to 1, providing some evidence that talc slurry may result in fewer
pleurodesis failures.
The network provides some evidence that viscum is more effective
than placebo and mitoxantrone, with ORs and 95% Cr-Is lying
far away from the null value of 1. However, the direct evidence
on this agent was from only a single small study of 17 patients
and the confidence intervals for its estimated rank are very wide,
reflecting uncertainty within the network as to its true rank.
Placebo was most probably the least successful pleurodesis agent,
with an estimated rank of fifteenth of 16 methods (95%Cr-I 11 to
16). The ORs and 95% Cr-Is comparing placebo with talc slurry,
talc poudrage, bleomycin, C. parvum, iodine and mepacrine were
all far away from1, providing evidence that placebo is less effective.
Heterogeneity
The between-study standard deviation in treatment effect esti-
mates (log odds ratios) across the whole network was estimated to
be Tau = 0.88 (95% Cr-I 0.42 to 1.48), suggesting a high degree
of heterogeneity, although the wide credible interval indicates a
substantial degree of uncertainty around this.
We performed a number of sensitivity analyses to explore the het-
erogeneity found in themain network based on pre-defined poten-
tial clinical effect modifiers (see Appendix 4). Due to the smaller
number of studies in these analyses, many of them contained fewer
pleurodesis methods than the main network.
The majority of the sensitivity analyses found less evidence of true
differences between the efficacies of individual methods. The esti-
mated ranks were generally similar to the main network, although
all ranks had very wide credible intervals and therefore were im-
precise. The sensitivity analyses showed very wide credible inter-
vals for the between-study standard deviation (representing het-
erogeneity), with the upper limits of 95% Cr-Is often being close
to 2. Since a uniform(0,2) prior distribution was assumed for Tau
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in each analysis, it is likely that the upper limits would increase
further still if a wider prior distribution was assumed.
However, the estimate of the between-studies standard deviation
was reduced when we restricted analysis to those studies with a
lower risk of bias (defined as two or fewer ‘high risk’ domains in
the risk of bias tool). The credible intervals for Tau did however
overlap, so it is unclear whether heterogeneity was truly reduced
(Tau 0.46 (95% Cr-I 0.03 to 1.09)) for the low risk of bias sub-
group vs Tau 0.88 (95% Cr-I 0.43 to 1.49) for the main network)
(Appendix 4, Appendix 5, Appendix 6). However, the overlap-
ping credible intervals reflect considerable uncertainty about this.
Results were fairly robust to exclusion of the higher risk studies,
although with doxycycline and C. parvum perhaps appearing a
little better, probably due to the removal of two particular studies
(Kuzdzal 2003; Ostrowski 1989).
Due to the diversity of doses used for many of the pleurodesis
agents evaluated, we were unable to examine the effect of dose
on the degree of heterogeneity observed. This is one potential
cause for the unexplained heterogeneity, which was not feasible to
examine in the network.
Inconsistency
Several estimated loop-specific inconsistency factors (Chaimani
2013) were very large, suggesting potential inconsistencies be-
tween the direct and indirect evidence (see Figure 6). The CIs
around the estimated inconsistency factors were also very wide,
due to the small volume of evidence per loop. Only two incon-
sistency factors had 95% CIs which did not cross the null value
of 1. The loop involving talc slurry, talc poudrage and bleomycin
did provide evidence of a difference between the direct and in-
direct evidence, with a ratio of odds ratios (ROR) of 7.0 (95%
Cr-I 1.1 to 43.8). The talc slurry, bleomycin and mepacrine loop
also showed significant inconsistency (ROR 10.2 (95% Cr-I 1.1
to 96.9). There were no obvious differences between the distribu-
tion of potential effect modifiers between the three direct compar-
isons (see Appendix 2; Appendix 4) and hence these inconsisten-
cies could not be explained.
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Figure 6. Inconsistency plot for the main network. Treatment codes: 01 = Talc slurry; 02 = Talc poudrage; 03
= Bleomycin; 04 = Tetracycline; 05 = C. parvum; 06 = Interferon; 07 = Iodine; 08 = Indwelling pleural catheter;
09 = Placebo; 10 = Mustine; 11 = Mitoxantrone; 12 = Mepacrine; 13 = Doxycyline; 14 =
Triethylenethiophosphoramide; 15 = Adriamycin. Abbreviations: ROR = Ratio of Odds Ratios; 95% CI = 95%
Confidence interval. Heterogeneity variance was set at 0.8847 (reflecting the estimation of Tau from the
network)
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Across the entire network, there was no evidence of global incon-
sistency. The Deviance Information Criterion (DIC) was 398 for
the consistency model and 404 for the inconsistency model, sug-
gesting that the consistency model fits the data marginally better.
Similarly, there was no evidence of global inconsistency for any of
the subgroup or sensitivity network meta-analyses (Appendix 4).
Additional post-hoc sensitivity analysis
The sensitivity analysis that only evaluated agents given through
an intercostal chest tube included 29 studies of 13 agents (see
Appendix 7 and Appendix 8). There was very little evidence of
substantial differences between the agents, the credible intervals
were wide and the estimated rankings for the individual agents
were also very imprecise.
The degree of heterogeneity was even higher than the main net-
work (Tau 0.98 (95% Cr-I 0.45 to 1.72). There was no evidence
of global inconsistency (DICs for the consistency and inconsis-
tency models were 271 and 276 respectively). Similar to the main
network, there was evidence of loop-specific inconsistency for the
talc slurry, bleomycin and mepacrine loop (ROR 10.2 (95% Cr-I
1.1 to 96.5)).
Primary outcomes for the methods not included in the
network meta-analysis
Pleurodesis methods
The results of the pair-wise comparisons of the pleurodesis meth-
ods not included in the network meta-analysis are shown in Table
3.
Two agents (silver nitrate and the combination of bleomycin and
tetracycline together) were excluded as there were no pleurodesis
failures for the agents, resulting in numerical difficulties when we
attempted to include them in the network meta-analysis model.
The pair-wise comparisons in these studies did not provide evi-
dence against the null hypothesis of no true difference between
interventions (see Table 3).
One study was not included in the network as it was a three-arm
trial evaluating different doses of silver nitrate administered via a
chest tube (Terra 2015). There were only two of 60 participants
who had a failed pleurodesis, both in the group receiving the high-
est dose of silver nitrate.
Seven studies could not be included in the network meta-analysis
as they evaluated tumour-specific therapies for patients with MPE
due to non-small cell lung cancer (NSCLC) (Du 2013; Ishida
2006; Kasahara 2006; Luh 1992; Masuno 1991; Yoshida 2007;
Zhao 2009). The results could not be generalised to patients with
other tumour types andhence these interventionswere not deemed
jointly randomisable. All the studies randomised only small num-
bers of participants. However in four of the direct comparisons,
the OR and 95% CI lay far away from the null value of 1, giving
evidence against the null hypothesis of no difference.
Du 2013 randomised patients with NSCLC to receive three cycles
of either cisplatin and intra-pleural bevacizumab (a humanised
monoclonal antibody to VEGF) or cisplatin alone. More patients
in the cisplatin-alone group had pleurodesis failure than in the
combination group (6/36 vs 17/34 respectively; OR 5.00 (95%
CI 1.66 to 15.09); participants = 70; studies = 1) (Analysis 23.1)
(Du 2013).
Masuno 1991 randomised NSCLC patients with MPE to receive
up to two doses of either intra-pleural LC9018 (lyophilised Lac-
tobacillus casei) and Adriamycin or Adriamycin alone. There were
more pleurodesis failures in the control group compared to those
who received LC9018 (23/38 vs 10/38 respectively; OR 4.29
(95% CI 1.62 to 11.35); participants = 76; studies = 1) (Analysis
15.1) (Masuno 1991).
Finally, Ishida 2006 conducted a three-arm trial, comparing in-
trapleural OK-432, an inactivated product of Streptococcus pyo-
genes A3 with anti-tumour immune-modulatory effects in lung
cancer, with cisplatin and combined therapy (both OK-432 and
cisplatin). Those treated with OK-432 alone had a higher pleu-
rodesis failure rate than those receiving combination treatment
(OR 12.44 (95% CI 1.32 to 117.03; participants = 32; studies
= 1) but a lower failure rate than those receiving cisplatin alone
(OR 0.48 (95% CI 0.12 to 1.92); participants = 34; studies = 1)
(Analysis 11.1).
Other methods to optimise pleurodesis
We evaluated a number of methods to optimise pleurodesis, but
these were not included in the network because they were not con-
sidered jointly randomisable (see Table 4). All the studies included
very small numbers of patients and none provided evidence of a
difference in pleurodesis failure rates between the treatments be-
ing compared (see Table 4). The results of the ongoing TIME-1
and TIME-3 studies will provide additional data regarding the
effect of drain size, analgesia use and intrapleural fibrinolytics in
the future. No randomised controlled trials examining the role of
pleuro-peritoneal shunts were identified.
SECONDARY OUTCOMES
Due to the diversity of reporting techniques and outcome mea-
sures, it was not possible to perform a formal statistical analysis of
many of the pre-defined secondary outcomes.
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Adverse effects/complications
The majority of studies reported data on adverse effects of the
interventions, however three studies did not (Evans 1993; Kuzdzal
2003; Villanueva 1994). Kefford 1980 reported side effects but
the patients with pleural effusions could not be differentiated from
those with ascites or pericardial effusions . Data on side effects
were provided inpersonal communicationswith two study authors
(Goodman 2006;Mager 2002). The methods used to describe the
side effects observed varied widely between studies.
Network meta-analysis was used to compare rates of the most
commonly reported side effects, fever and pain.
Fever
The direct evidence regarding fever is shown in Appendix 9. The
fever network consisted of 23 trials of 11 different treatments, in-
cluding 1518 participants. The odds ratios are shown in Table 5
and estimated rankings of the interventions in Figure 7. All the
estimates had very wide credible intervals, indicating a large degree
of imprecision. However, placebo appeared to be associated with
the least fever (estimated rank first of 11 interventions (95%Cr-I 1
to 7)). The methods associated with the most fever appeared to be
C. parvum and mepacrine, with estimated ranks of eleventh (95%
Cr-I 7 to 11) and tenth (95% Cr-I 6 to 11) respectively. However,
the between-studies standard deviation (Tau) for the whole net-
work was 1.35 (95% Cr-I 0.58 to 1.95), suggesting a very high
degree of heterogeneity. There was no evidence for global inconsis-
tency (DIC for consistency and inconsistency models was 230 and
231 respectively).However, the loop-specific inconsistency factors
were large, suggesting potential inconsistencies between the direct
and indirect evidence. The 95% CIs around the inconsistency fac-
tors were wide and crossed the null value of 1 in all but one loop.
There was strong evidence of inconsistency regarding fever in the
bleomycin/tetracycline/C. parvum loop (ROR 59.2 (95% CI 2.6
to 1353.7)).
Figure 7. Estimated rank (95% Cr-I) for causing fever (a low rank suggests less fever)
For those studies, which were not included in the network meta-
analysis but provided data on fever, the majority revealed no dif-
ference between the interventions (Emad 1996; Kasahara 2006;
Masuno 1991; Paschoalini 2005; Terra 2015). Two studies evalu-
ating OK-432 revealed more fever in this group compared to the
control groups (Ishida 2006; Luh 1992; Yoshida 2007) (Analysis
11.3). The mixed talc group had more fever than the graded talc
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group (OR 15.92 (95% CI 1.81 to 140.16; participants = 46;
studies = 1) (Maskell 2004) (Analysis 21.3). The group who re-
ceived cisplatin alone had less fever than those who also received
rAd-p53 (OR 0.09 (95% CI 0.02 to 0.51; participants = 35; stud-
ies = 1) (Zhao 2009) (Analysis 23.3)
Pain
Six studies were not included in the network meta-analysis as they
collected pain scores (rather than whether or not each patient had
pain post procedure) (Agarwal 2011; Alavi 2011; Bjermer 1995;
Davies 2012; Paschoalini 2005; Zimmer 1997). Bjermer 1995
reported higher levels of pain in themepacrine group compared to
themitoxantrone group asmeasured by theWHOanalgesic ladder
(no raw figures provided) (WHO 2016). The other six studies did
not provide evidence of a difference in pain between the methods
studied.
Only 17 studies and nine treatments (including 1279 participants)
could be included in the network meta-analysis regarding pain
(see Appendix 10, Appendix 11 and Appendix 12). There was no
evidence to support a difference between the methods in terms of
the proportion of participants complaining of pain after the inter-
vention. All the estimates had very wide confidence intervals, in-
dicating a large degree of imprecision. The between-studies stan-
dard deviation (Tau) for the network was 0.65 (95% Cr-I 0.05
to 1.63), indicating considerable heterogeneity. There was no evi-
dence of global inconsistency (DIC 177 for the consistency model
versus 177 for the inconsistency model). Several of the estimated
inconsistency factors were large, although all had 95% CIs which
crossed 1, indicating no clear evidence of loop-specific inconsis-
tency.
Of those studies which reported pain outcomes but were not in-
cluded in the network for pain, themajority revealed no difference
between interventions (Kasahara 2006; Luh 1992; Masuno 1991;
Okur 2011; Paschoalini 2005; Terra 2015; Yoshida 2007; Zhao
2009). Those who underwent a small-bore drain insertion had less
pain at the time of insertion than those with a large-bore drain
(OR 0.08 (95% CI 0.01 to 0.75) (Clementsen 1998) (Analysis
19.2)). One study revealed more pain in the OK-432 groups than
controls (Ishida 2006) (Analysis 11.2).
Patient reported breathlessness
Eleven studies reported information regarding control of breath-
lessness, using a variety of techniques (MRC dyspnoea scale
(Mohsen 2011); VAS score (Bjermer 1995; Davies 2012; Diacon
2000; Terra 2015); ’dyspnoea index’ (Demmy 2012); QLQ-C30/
LC13 questionnaires (Rintoul 2014), functional class (Masuno
1991; Rafiei 2014; Zimmer 1997), scale of 0 - 10 (Alavi 2011)).
The two studies comparing talc slurry with IPC reported breath-
lessness scores (Davies 2012 using a VAS score and Demmy 2012
using a ’dyspnoea index’). Davies 2012 found dyspnoea improved
in both study arms, to a similar extent at 42 days. However the
IPC group had a greater improvement at six months compared to
the talc group (mean difference of -14 mm (95% CI -25.2 to -
2.8) P = 0.01). Demmy 2012 found that the IPC group had better
dyspnoea scores at 30 days than the talc slurry group (8.5 vs 6.1;
P = 0.047).
Rafiei 2014 found more patients receiving doxycycline had severe
dyspnoea at two months compared to those receiving bleomycin
(5/20 (24%) vs 1/21 (5%) respectively; P = 0.01). Bjermer 1995
noted that those receiving mitoxantrone had a larger reduction in
breathlessness than themepacrine-treated patients (absolute values
not reported; P < 0.001). Masuno 1991 did not provide the ab-
solute figures but reported “statistically significant” improvements
in dyspnoea one week after treatment at ‘the final judgement’ in
the LC9018 group. In the remaining studies reporting dyspnoea,
no differences were identified between the study arms in terms
of the degree of improvement of dyspnoea (Alavi 2011; Diacon
2000; Mohsen 2011; Rintoul 2014; Terra 2015; Zimmer 1997).
Quality of life and symptom control
Fifteen of 62 studies reported quality of life or assessed a symp-
toms score other than dyspnoea. The methods used were Karnof-
sky performance scale (Demmy 2012; Du 2013; Groth 1991;
Masuno 1991; Zhao 2009), QLQ-C30 questionnaire (Davies
2012, Dresler 2005, Rintoul 2014), SF36 scale (Terra 2009),
WHOQoL-bref scale (Terra 2015), EQ5D (Rintoul 2014), VAS
Score (Diacon 2000), a symptom questionnaire (Bjermer 1995)
and numeric pain scale (Alavi 2011; Paschoalini 2005; Zimmer
1997). Most studies did not report any evidence of a difference
between the treatment groups (Alavi 2011; Davies 2012; Diacon
2000; Groth 1991; Paschoalini 2005; Terra 2009; Terra 2015
Zimmer 1997). Bjermer 1995 reported a bigger improvement in
tiredness in the mitoxatrone group compared to the mepacrine
group (absolute figures not provided; P < 0.001). Dresler 2005
noted less fatigue in the talc poudrage group than the talc slurry
group (absolute figures not provided; P = 0.016). Those partici-
pants who received LC9018 had better performance scores at one
week than those who did not (absolute figures not provided; P
< 0.05) (Masuno 1991). Zhao 2009 found that more patients
who received combination treatment with cisplatin and Ad-p53
had an improvement in their Performance Score at six weeks than
those receiving cisplatin alone (11/17 (65%) vs 6/18 (33%) re-
spectively, P < 0.05). The participants who underwent a VATS
partial pleurectomy had better EQ5D scores at six months than
the talc group in the MesoVATS study (MD 0.08 (0.003, 0.16);
P = 0.042) but no difference in their QLQ-C30 scores (Rintoul
2014).Demmy 2012 did not provide data by treatment group.Du
2013 reported 30 patients (83%) receiving bevacizumab and cis-
platin had an improvement in their Karnofsky performance score
as opposed to 15 (50%) in the cisplatin group.
Costs
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Only seven of 62 trials reported the relative costs of the interven-
tions. Rapid pleurodesis was found to be cheaper than standard
care in Yildirim 2005 (USD 245 (SD 71.5) vs USD 860 (SD
496) respectively). Talc slurry was cheaper than bleomycin in three
studies: Ong 2000 evaluated the cost per dose (USD 1 vs USD
309 per dose respectively); Haddad 2004 calculated the complete
cost for the entire procedure (USD 488 (SD 212.5) vs USD 796
(SD 207.3) respectively) and Zimmer 1997 calculated the cost of
each treatment (USD 12.36 vs USD 955.83 respectively). Talc
poudrage was also cheaper than bleomycin in Diacon 2000 (CHF
3893 (Swiss Francs) (USD 4206) vs CHF 4169 (USD 4504) re-
spectively). The total cost of VATS pleurectomywasmore than talc
pleurodesis (GBP 14,252 (USD 21,682) vs GBP 10,436 (USD
15,876)) (Rintoul 2014). Dresler 2005 reported no difference be-
tween the cost of talc slurry and poudrage (no figures quoted).
Mortality
Thirty-four trials provided data on patient mortality. Evaluating
the direct evidence, only two of these found evidence of a differ-
ence between the treatment arms. Evans 1993 found survival was
longer after thoracoscopic tetracycline pleurodesis than bedside
administration (total n = 34; P = 0.03 (raw data only available as a
survival curve)). In the comparison between bleomycin and IFN,
those receiving bleomycin appeared to live longer (OR 0.46 (95%
CI 0.25 to 0.87); n = 160) (Analysis 1.3).
Twenty trials of 12 treatments, including 1430 participants, were
incorporated into a network meta-analysis looking at mortality
(see Appendix 13; Appendix 14 and Appendix 15). All but one
of the OR 95% Cr-Is crossed 1, providing no evidence against
the null hypothesis of no effect. There was limited evidence that
those who received tetracycline lived longer than those receiving
mitoxantrone (OR 0.16 (95% Cr-I 0.03 to 0.72)) (see Appendix
14). Although some of the credible intervals were wide, they were
generally narrower than those seen in the pleurodesis efficacy net-
works. The rankings were very imprecise, with wide confidence
intervals: statistically there was no evidence that the rankings of
any of the pleurodesis methods differed from each other. The de-
gree of heterogeneity was low (Tau 0.40 (95% Cr-I 0.02 to 1.21)).
There was no evidence of global inconsistency (DIC 211 for the
consistency model vs 217 for the inconsistency model) or loop-
specific inconsistency.
The majority of studies, which were not included in the net-
work also showed no differences in mortality (Clementsen 1998;
Crnjac 2004; Goodman 2006; Ishida 2006; Mager 2002; Maskell
2004; Rintoul 2014; Terra 2015; Villanueva 1994; Yildirim 2005;
Yoshida 2007; Zhao 2009). Evans 1993 reported a longer sur-
vival after surgical administration of tetracycline than after medi-
cal treatment although no raw data were provided (P = 0.03).
Median survival
Twenty-five studies reported median survivals for the treatment
groups and only one of these found a survival difference between
the treatment arms (Masuno 1991: median survival of 232 days in
the LC9018 group versus 125 days in the control arm; n = 95; P =
0.008). Kasahara 2006 reported a longer median survival in those
receiving high doseOK-432 than low dose, but did not report the
spread or whether this difference was significant (33.6 days versus
22.6 days respectively; n = 38).
Length of inpatient stay
Sixteen of 62 studies reported total length of hospital stay.Many re-
ported no evidence of a statistically significant difference between
the groups (Bayly 1978; Haddad 2004; Lynch 1996; Ong 2000;
Paschoalini 2005; Schmidt 1997; Terra 2009; Yim 1996; Zimmer
1997). Yildirim 2005 andGoodman 2006 reported shorter length
of stay in the group whose drains were removed earlier follow-
ing sclerosant administration compared to standard care (Yildirim
2005 : mean 2.33 days (SD 0.62) vs 8.33 (SD 4.85) respectively
(P < 0.001) 27 participants; Goodman 2006: median 4 days (IQR
4 - 8) vs 8 (6 - 9) respectively (P < 0.01) 41 participants). Ozkul
2014, which evaluated a rapid drainage strategy prior to sclerosant
administration, also showed this group had a shorter length of
stay than the standard care group (mean 2.2 days versus 9.0 days
respectively (P < 0.001) 79 participants). The talc group had a
shorter length of stay than the VATS partial pleurectomy group
in the MesoVATS study (median 3 days (IQR 2 - 5) vs 7 days
(IQR 5 - 11) respectively (P < 0.001); 196 participants) (Rintoul
2014). Those undergoing TMP had a shorter hospital stay than
those receiving talc slurry in Crnjac 2004 (mean 5.5 days (SD 2.5)
vs 7.5 (SD 3.3) respectively (P = 0.001); 87 participants). Mohsen
2011 found patients receiving iodine had a shorter length of stay
than those undergoing talc poudrage (mean 4.5 days (SD 1.1) vs
5.7 (SD 2) respectively (P = 0.02); 42 participants). In TIME-
2, the IPC participants had a shorter inpatient stay than the talc
slurry participants (-3.5 days (95% CI -4.8 to -1.5) (P < 0.001);
106 participants) (Davies 2012).
There were insufficient data to report length of hospital stay from
date of the intervention to discharge.
Patient acceptability
Two trials reported patient acceptability of the interventions
(Demmy 2012, Dresler 2005). Demmy 2012 did not provide raw
data by treatment group. There was no difference between talc
slurry and poudrage in terms of patients’ perception of conve-
nience in Dresler 2005 (no raw data provided).
The only trial evaluating the agent viscum reported that two of 13
participants in the viscum armwithdrew their consent for ongoing
study participation after experiencing allergic reactions to the first
dose. The outcomes for these participants were not available and
hence the trial deemed them non-evaluable.
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D I S C U S S I O N
Summary of main results
The management of MPE has long been subject to debate and
research. This systematic review of the current literature attempts
to combine all the available randomised evidence regarding the
wide variety of interventions for the condition.
Our primary outcome measure was pleurodesis efficacy. Our anal-
ysis showed that talc poudrage ranked highly compared with other
agents. It has an estimated rank of second of 16 interventions
(95% Cr-I 1 to 5) and there was good evidence (robust to exclu-
sion of higher risk of bias studies) for it being better than seven
other pleurodesis methods including bleomycin and tetracycline.
There was also some evidence in the full network for it being more
efficacious than talc Slurry and doxycyline but this evidence was
considerably weakened when the analysis was restricted to only
lower risk of bias studies. Uncertainty around the relative efficacy
of talc poudrage compared to some other agents is also exacer-
bated by the relatively high degree of unexplained heterogeneity
within the networks and some loop-specific inconsistencies. The
presently recruiting TAPPS trial, comparing talc poudrage with
talc slurry will add further data to this comparison in the future
(TAPPS), which may add further clarity regarding these conclu-
sions.
The relative efficacy of the other methods examined in terms of
pleurodesis success is also inconclusive. A number of agents ap-
peared to be of comparable efficacy, both within themain network
and in the sensitivity analysis, in which we looked only at agents
used for bedside pleurodesis. This may be because the agents are
truly equivalent in their ability to induce a pleurodesis, however
these findings could equally reflect lack of evidence to date (sta-
tistical imprecision).
All the comparisons showed a substantial degree of both statisti-
cal and clinical heterogeneity. Aside from the analysis restricted to
studies at lower risk of bias, which did appear to reduce the degree
of heterogeneity somewhat, the other sensitivity analyses, selected
on the basis of factors hypothesised to be clinical effect modifiers,
did not appear to explain the high level of heterogeneity, since
estimates of the between-study standard deviation remained very
high. This signifies the complexity of this condition and the treat-
ments, which results in substantial clinical heterogeneity. Possible
explanations include different effects of varying tumour subtypes,
early lung entrapment, which is not clinically detectable, varying
drug doses and subtle procedural factors in terms of the pleurode-
sis technique such as adequacy of pleural fluid drainage prior to
instillation of the sclerosant.
The available data for the secondary outcomes evaluatedweremore
restricted. The network provided some evidence that mepacrine
and C. parvum cause more fever than several other agents, how-
ever this network had very high unexplained heterogeneity and
loop-specific inconsistency. Only two direct comparisons and one
from the network meta-analysis found evidence of a difference in
mortality between treatment groups.
The studies comparing IPC and talc slurry suggested those with
an IPC experienced less dyspnoea, although we note the ongoing
AMPLE study may add further data regarding this in the future
(AMPLE Trial). There were insufficient data to formally analyse
the other secondary outcome measures.
Although there were insufficient data to perform meta-analysis,
we also evaluated a number of techniques that could improve the
effectiveness of pleurodesis if the agent was delivered via a chest
tube. There was a lack of evidence either way regarding the effect
of the duration of drainage pre- or post-sclerosant administration,
chest tube size, use of fibrinolytics and patient rotation on pleu-
rodesis failure rate. There are a number of ongoing studies which
will add further information regarding these factors in the future
(TIME-1; TIME-3).
Overall completeness and applicability of
evidence
This is the largest systematic review of the evidence surrounding
interventions in MPE in the published literature. We used robust
search strategies to identify all the available randomised evidence
and have diligently contacted the study authors regarding missing
data where possible.
However, despite this, we had to exclude a number of studies due
to insufficient availability of study data. During the process of se-
lecting studies for inclusion in this review, we identified a number
of conference abstracts. Given the paucity of data contained in
them, we did not feel it valid to include them without obtain-
ing more detailed information. Despite attempting to contact the
study authors, in 34 cases we could not obtain additional unpub-
lished data and hence excluded the studies, suggesting the poten-
tial for publication bias, which could affect the validity of the re-
sults. The small number of studies for each pair-wise comparison
(maximum of five), meant funnel plots would not be informative
(Sterne 2011). As the interventions could not be logically ordered,
we also decided a comparison-adjusted funnel plot for the network
was not valid (Salanti 2014).
A number of the studies included in this review had very small
numbers of participants, which raises the possibility of small study
effects which may have resulted in an overestimation of treatment
efficacy. Only five of the included studies had outcome data for
more than100patients (Davies 2012;Dresler 2005;Rintoul 2014;
Sartori 2004; Yoshida 2007). However, sensitivity analysis for the
direct evidence using random- and fixed-effect models did not
show any meaningful differences.
When evaluating different pleurodesis agents, we elected to com-
bine different doses of each agent from the available studies for
the purposes of comparison. This was necessary due to variation
in the doses between studies, which would have made the net-
work extremely complex. This is a limitation of our review, since
differential treatment effects according to doses could have been
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missed. This is one possible explanation for the high levels of het-
erogeneity observed in our study, which we were unable to investi-
gate further due to the complexity of the data. One included study
was designed to compare different doses of silver nitrate and this
revealed no difference in terms of pleurodesis efficacy or adverse
events Terra 2015).
Many of the included studies failed to assess patient quality of life,
symptom control, acceptability of the intervention to the patient,
length of stay and costs. Although these were secondary objectives
of our review, they are important factors when selecting manage-
ment strategies and hence limit the applicability of the evidence
from this review to everyday clinical practice. This may be partic-
ularly important when considering the potential benefits of IPCs
which, despite having a lower pleurodesis rate, may be comparable
to talc slurry in terms of control of breathlessness (Davies 2012;
Demmy 2012) and may be more acceptable to certain patients
due to the shorter length of hospital stay.
It is also important to consider the global availability of some of
these agents, when considering the clinical applicability of our
findings. In a survey of five English speaking countries, the most
commonly used pleurodesis agents were talc poudrage, talc slurry,
tetracycline, doxycycline and bleomycin (Lee 2003). Parenteral
tetracycline derivatives and C. parvum are not widely available,
which precludes their routine use. Other agents included in this
review are unlicensed for use as a pleurodesis agent.
Our data regarding the adverse effects of these treatments are lim-
ited. As we have selected only RCTs for inclusion in this review,
there is the potential that rare but important side effects were
missed using our methodology. There are reports of adverse ef-
fects of pleurodesis agents resulting from absorption of the agent
into the systemic circulation. For example, systemic absorption of
mixed particle size talc is thought to be linked to rare but occasion-
ally life-threatening acute respiratory distress syndrome (ARDS),
a risk which is minimised by the use of graded (large particle) talc
(Maskell 2004). Mepacrine gained popularity in Scandinavia as a
pleurodesis agent, although rare psychotic episodes and seizures,
thought to be related to systemic absorption if administered at
high doses, limited its use (Bjorkman 1989).
We have only managed to synthesise the data on the main adverse
events and so we cannot reliably infer the full side effect profiles
of these treatments from this review. An appreciation of the side
effect profile of these interventions is vital when weighing up the
risks and benefits of the procedures, particularly as many of the
patients in this population have a limited life expectancy and hence
limiting discomfort during their remaining time is imperative.
Pleurodesis success is one important factor in the successful man-
agement of MPE, but may not be the ‘be all and end all’. The def-
inition of pleurodesis efficacy varied between studies, with many
studies relying on radiology alone, which is increasingly felt to
be inadequate without taking into account symptom recurrence
as well. Many patients would rather avoid a hospital admission
and be treated as an outpatient which may make use of an in-
dwelling pleural catheter more appealing than a chemical pleu-
rodesis. Moreover, those with a particularly poor prognosis may
prefer to be symptomatically treated with a simple thoracentesis
and optimal symptomcontrol and avoidmore invasive procedures.
It was not possible to incorporate these subjective factors into the
review process, but they are clearly a crucial element of clinical
decision making in this population. Therefore, the ‘best’ approach
may not be the same for all patient groups; a question we have not
been able to adequately address in this review.
Quality of the evidence
The risk of bias in a number of the included studies is substan-
tial. The vast majority of studies were unblinded, which in part
reflects the nature of the interventions being randomised but also
the symptom-based nature of the endpoints measured, precluding
blinding of the outcome reporting as well. Documentation of the
methods used for sequence generation and allocation concealment
were frequently omitted and it was often not possible to obtain
this information retrospectively. The sensitivity analysis evaluating
only the studies with a lower risk of bias, showed the heterogeneity
estimate was reduced in this subgroup, and the overall rankings of
most interventions were relatively robust.
There was also variation in the methods used by the different
studies to determine pleurodesis failure, in terms of the definition,
how patient attrition was handled and the time point at which
it was assessed. We did state how this would be handled a priori,
using hierarchies of preferences, however these factors may have
impacted on the results of the final meta-analysis.
Given the inevitable death of patients in this palliative population,
true intention-to-treat analysis was often not performed, resulting
in the potential for attrition bias. These missing data were handled
differently by the various included studies. Some studies included
patients on the basis of their ‘last observation carried forward’ (i.e.
their last outcome prior to death) and others excluded these pa-
tients from the analysis completely. No studies used other impu-
tation methods to account for these missing data.
The majority of the studies reported the main outcome measures
of pleurodesis success, side effects and mortality. However, in a
palliative population such as this, patient-focused outcomes, such
as quality of life, symptom control, length of hospital stay and
patient acceptability provide valuable, clinically relevant informa-
tion, but were inconsistently reported in the included studies, pre-
cluding robust synthesis. The newer, suitably powered RCTs will
report these important outcomes and hence future revisions of
this review will hopefully be able to incorporate them into their
findings.
We have not reported the Grading of Recommendations, Assess-
ment, Development and Evaluations (GRADE) for our findings
in this review and did not state in our protocol that we would. The
role of GRADE is not well established in the context of Network
Meta-analysis (NMA) and the approach to how it should be im-
26Interventions for the management of malignant pleural effusions: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
plemented is still a subject of debate (Puhan 2014, Salanti 2014).
We felt its inclusion would be highly complex and the results ex-
tremely subjective and hence elected not to incorporate it.
Potential biases in the review process
This review is based on the available published evidence and not
on individual patient data, which would give a more accurate esti-
mation of treatment effect and a clearer understanding of the het-
erogeneity (Deeks 2011). However, as several of the studies were
published many years ago and individual patient information was
therefore not available, patient level meta-analysis would not be
possible without excluding the majority of the available evidence.
In order to allow inclusion of as many eligible studies as possible,
we combined data obtained using different definitions of pleu-
rodesis failure and timings in the same analysis. We pre-defined
the methodology for this in the protocol using hierarchies of pref-
erences. We performed sensitivity analyses to ensure the results
were robust.
A potential source of bias in our primary outcome measure, pleu-
rodesis efficacy, is the inevitable patient attrition due to mortality
reported inmany studies. If there had been real differences in mor-
tality (and therefore drop out) across the interventions, this could
bias the estimates of relative pleurodesis failure rates. However,
analysis of the data on mortality and median survival times did
not reveal evidence of differences in the vast majority of compar-
isons. Only two of 33 studies reporting overall mortality found a
difference between treatment arms, and only one of the 24 studies
which reported median survival times found a difference between
treatment arms. The network meta-analysis of the mortality data
only found evidence of one potential survival difference in the
comparison between tetracycline and mitoxantrone.
Another very important consideration is the high degree of be-
tween-study heterogeneity across our treatment effect estimates.
We have attempted to explore heterogeneity using subgroup anal-
yses, but were unable to identify any specific reasons for it. The
heterogeneity is likely to be related to a combination of factors
related to study quality and the diversity of the methodology used
in the included trials.
It should also be noted that the initial screening of titles and ab-
stracts was performed by just one reviewer.
Agreements and disagreements with other
studies or reviews
A number of other systematic reviews have been published in this
area (Shaw 2004; Tan 2006; Xia 2014). All have presented only
direct comparisons, rather than also incorporating indirect com-
parisons of alternative agents using network meta-analysis meth-
ods. We feel that network meta-analysis is more valid in this field
as the diversity of the control groups used when comparing one
agent with ‘all others’ means that important relative treatment ef-
fects may be either over or under estimated.
We used robust inclusion and exclusion criteria to identify eligi-
ble studies, which resulted in some studies included in other sys-
tematic reviews in this field being excluded from this one. These
studies have been entered into the ‘Excluded studies’ section of
this review, with justifications given for their exclusion. The main
reasons were failure to use a truly random process to assign treat-
ment groups and the inclusion of ascites or pericardial fluid accu-
mulation, which could not be differentiated in the results section.
The previously publishedmeta-analyses have all suggested that talc
is the most effective agent and is best delivered thoracoscopically.
Our data predominantly supports the use of thoracoscopic talc
poudrage as an effective pleurodesis method, although we have
found a lack of conclusive evidence to suggest it is more effective
than some other methods. The choice of agent given via a chest
tube based on our network of evidence is inconclusive, which
differs from the conclusions drawn by other systematic reviews in
this field . Talc does appear to be effective, although other agents
such as mepacrine and C. parvum may be equally good.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This systematic review suggests that talc poudrage at thoracoscopy
ranks highly as an effective method of delivering a sclerosant into
the pleural cavity and is likely to be more effective at achieving
a pleurodesis than many other commonly used methods such as
bleomycin and tetracycline. However, there is a lack of definitive
evidence to conclude it is certainly superior to some other com-
monly used methods, such as talc slurry and doxycycline. This is
likely to be a reflection of the imprecision and unexplained hetero-
geneity within the network, as well as the high risk of bias of many
of the included studies. The currently recruiting studies may pro-
vide further clarity regarding this and thereby help guide clinical
practice more clearly in the future.
In contrast to previous systematic reviews, the main network
and sensitivity analysis looking specifically at bedside pleurodesis
agents (by excluding talc poudrage and IPCs) show less conclusive
evidence of which agent is best. Talc, C. parvum, iodine, viscum
and mepacrine all appear to be effective agents, although far more
studies have directly evaluated talc than these other agents. We did
not find evidence of a difference between these agents in terms
of the main side effects (fever and pain) or mortality. However,
graded (large particle talc) has less systemic absorption thanmixed
particle size talc and should therefore be used to reduce the rare
but potentially catastrophic risk of ARDS (Maskell 2004).
This reviewwas not designed to evaluate rarer but potentially clini-
cally important adverse events, whichmay not have been identified
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by randomised controlled trials, which are important to consider
when choosing a pleurodesis agent. Concerns regarding the dose-
dependant systemic absorption of intra-pleural mepacrine, and the
subsequent risk of transient psychotic episodes and seizures, have
not been identified in the randomised trials of these agents, but
are likely to limit its routine use (Bjorkman 1989). Viscum has
only been appraised in one small clinical trial with 17 evaluable
participants. Minimal adverse event data were reported, but two
out of 13 participants who received viscum experienced an allergic
reaction necessitating their withdrawal from ongoing trial involve-
ment (Gaafar 2014). A much fuller understanding of the toxicity
of this drug and trial data from a larger number of participants is
necessary before its routine clinical use can be recommended.
Worldwide, talc is reported to be the most commonly used pleu-
rodesis agent (Lee 2003; Roberts 2010; Zarogoulidis 2013) and
consequently it is likely to have the best appreciated side effect pro-
file. Therefore, despite the equivalent efficacy seen in the network
meta-analysis when compared to a number of other agents, if talc
is available, this would appear to be a safe and effective choice for
bedside pleurodesis supported by the largest body of evidence.
However, despite lower pleurodesis success rates, other techniques
may have advantages over a traditional pleurodesis. Indwelling
pleural catheters have been shown in two randomised studies to
improve breathlessness to a greater extent than talc slurry pleu-
rodesis (Davies 2012; Demmy 2012). They may also be associ-
ated with a shorter length of hospital stay (Davies 2012). There-
fore, IPCs confer alternative, but highly clinically relevant benefits
for patients, which make them appropriate as alternative first-line
treatment options depending on the clinical scenario and patient
preference.
Implications for research
An important limitation of this review is the heterogeneous re-
porting of outcome measures across trials and a paucity of data
on patient-centred outcomes. This has important implications
for future research. Selection of appropriate, clinically relevant,
standardised outcome measures is essential to aid robust, un-
biased analysis of trial data and facilitate future systematic re-
views (Williamson 2012). Specific to this review, an internationally
agreed definition of pleurodesis success and the timing at which
it should be assessed would be hugely beneficial when combining
data from future RCTs, along with a consensus about how to han-
dle the inevitable patient attrition due to death.
The paucity of data regarding patient-focused outcomes such as
quality of life and patient preference and also the health economic
implications of the available interventions are important factors
that warrant further research. Specifically, an improved under-
standing of the key outcomes which are important to patients with
MPE would be beneficial.
Additionally, understanding the factors contributing to the high
risk of bias in a large number of the previous studies in this field is
crucial when designing future clinical trials in MPE. Attempting
to minimise these risks by careful trial design has the potential to
improve our evidence base and ensure robust, valid conclusions
are drawn from the available evidence.
In light of the diversity of the doses used in the previously published
studies, future work evaluating whether there is a dose response in
terms of pleurodesis efficacy for the most effective agents may be
beneficial.
There is a limited evidence regarding the most effective manage-
ment of patients with trapped lung. Case series suggest trapped
lung effects 10% to 20% of patients with MPE and the rapid re-
currence of fluid after pleural interventions and the loss of elas-
ticity of the visceral pleura often results in severe symptoms of
recurrent breathlessness and pain during fluid aspirations (Brims
2012; Lan 1997; Warren 2008). Often these patients are excluded
from MPE trials given the lack of efficacy of pleurodesis in this
subgroup and hence there is a dearth of evidence on how best to
manage them. Future RCTs to delineate the optimal management
strategy in this population would be beneficial.
There is also a lack of robust randomised evidence for surgical
interventions in this population. Audit data reports that 6% of
the UK mesothelioma patients (for whom data were available)
underwent a surgical procedure rather than a chemical pleurodesis
between 2008 and 2012 (National Lung Cancer Audit Project
Team 2014). Further RCT research in this area is warranted to
better delineate the role of surgery.
As our knowledge about the pathology of MPE develops and our
understanding of the different available techniques expands, a ‘one
size fits all’ approach tomalignant effusions is likely to be outdated
and our hunt for the ‘best’ pleurodesis technique over-simplified.
Different techniques are already known to have unique advantages
and disadvantages and may therefore be suited to different cohorts
of patients. Improved understanding of prognostication will help
select the most appropriate management strategy for an individ-
ual (Clive 2014). Also, combining techniques to amalgamate the
benefits of the varying methods is an exciting potential area of
ongoing and future research (IPC-Plus; OPUS Trial).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agarwal 2011
Methods Single centre RCT comparing the efficacy of cosmetic talc with iodopovidone for pleu-
rodesis (India)
Participants Inclusion: recurrent symptomatic pleural effusion with improvement of breathlessness
with thoracentesis; or primary or secondary pneumothorax
Exclusion: allergy to iodine; thyroid disorder; trapped lung; air leak; advancedmalignancy
with expected survival < 30 days
36 participants randomised
Interventions 28 Fr intercostal drain to completely drain effusion or treat pneumothorax. Pleurodesis
agent given when < 150ml/day drainage and complete lung re-expansion on chest x-
ray. All participants received intrapleural lignocaine (2 mg/kg) and IV tramadol prior to
pleurodesis
Iodopovidone: 20 ml 10% iodopovidone in 80 ml saline
Cosmetic talc: 5 g sterilised ’baby powder’
After agent administered, chest tube clamped for four hours. Repeat administration of
agent if > 250 ml/day drainage. Drain removed when < 100 ml/day output
Followed up at 1 week, 1 month, 3 months and 6 months and then every 3 months
thereafter
Outcomes Pleurodesis success according to need for thoracentesis (complete success = relief of
symptoms related to the effusion and no re-accumulation on CXR at 30 days; partial
success = reduced dyspnoea related to the effusion with only partial re-accumulation of
fluid on chest x-ray and no requirement for therapeutic thoracentesis; failure = lack of
success as defined above)
Chest pain (measured by visual analogue scale score)
Complications
Time to pleurodesis
Notes People with trapped lung excluded.
Unpublished data obtained from authors relating to subgroup of participants in the
study with malignant pleural effusion- only this data was included for the purposes of
this review
Included in network meta-analysis for pleurodesis efficacy and fever
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Low risk Opaque sealed envelopes
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Agarwal 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Blinding of the allocation to treatments
was not possible”. Agents have different ap-
pearances
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Symptom recurrence, visucal analogue
scale scores and complications would all be
biased by lack of patient blinding. Mortal-
ity would not be effected by lack of blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow up. Intention-to-treat
analysis performed
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk Cosmetic talc used rather than medicinal
talc, but sterilised and comparable parti-
cle size by electronmicroscopy. No external
funding for the study
Alavi 2011
Methods Single centre RCT of povidone-iodine and bleomycin pleurodesis for malignant pleural
effusion (Iran)
Participants Inclusion: biopsy or cytologically proven malignant pleural effusion (all tumour types)
; recurrent and symptomatic effusion; chest radiograph confirming lung expansion of
90% after thoracentesis; Karnofsky Performance Score > 70
Exclusion: co-morbidities that preclude general anaesthesia; bleeding disorders; massive
thoracic skin infiltration; active infectious disease
39 participants randomised
Interventions All participants underwent a 28 Fr intercostal drain under local anaesthetic (+/- IV
opiates if required). Study agent administered intrapleurally the next day with 5 ml 2%
lidocaine
Bleomycin group: 1 mg/kg bleomycin in 60 ml saline. 1 dose
Povidone-iodine group: 5% (volume unclear). 1 dose
After administration of the study agent, the drain was clamped for one hour and removed
when < 200ml fluid output/day. If the fluid output remained high after 10 days, they
were discharged home with a Heimlich valve in place
Outcomes Effusion recurrence on chest x-ray at 30 days
Pain (measured by numeric scale) at discharge and day 30
Dysponea (measured by numeric scale) at discharge and day 30
Notes Minimal raw data in results section - tables quoted in text but not available on line.
Attempted to contact study authors by e mails - no response
People with trapped lung excluded from trial entry
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Alavi 2011 (Continued)
Pleurodesis success measured only using chest x-ray criteria
Included in network meta-analysis for pleurodesis efficacy.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Low risk Block randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Differing appearances of bleomycin and io-
dine make blinding not possible (although
not stated explicitly in paper)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Pain and dyspnoea may be biased by lack
of blinding. Not stated whether CXRs were
evaluated by a blinded clinician. No re-
sponse from study authors regarding this
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unable to see the tables. Response rates
only given as % (no actual numbers), so
unclear whether there was LTFU
Selective reporting (reporting bias) Unclear risk Raw data not provided formany of the out-
comes. Tables missing
Other bias Low risk No other biases identified
Bayly 1978
Methods Two-centre RCT of intrapleural quinacrine (mepacrine) vs tetracycline via tube thora-
costomy for malignant pleural effusion (USA)
Participants Inclusion: (1) documented cancer with pleural effusion (2) pleural fluid cytology or
pleural biopsy confirming malignancy or exudate effusion presumed to be malignant (3)
symptomatic from the effusion or rapidly re-accumulating effusion > 500 ml
All cell types. No exclusion criteria
20 participants randomised.
Interventions Both groups had a closed tube thoracostomy, drained overnight prior to the installation
Quinacrine group: intrapleural quinacrine (100 mg in 30 ml normal saline) once daily
for four days
Tetracycline group: one dose of intrapleural tetracycline (500 mg in 30 ml N saline)
The drains were clamped for six hours post installation with patient rotation. Drain
removed when < 60 ml/24 hour drainage
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Bayly 1978 (Continued)
Outcomes Pleurodesis success (defined on chest x-ray criteria only at 30 days as ’Complete response’
(complete lack of re-accumulation of pleural fluid); ’Partial response’ (re-accumulation of
pleural fluid < 50% of the volume present before the sclerosis); ’Failure’ (re-accumulation
of fluid to > 50% of the volume present before the attempted sclerosis))
Side effects of treatment (pain, fever)
Notes People with trapped lung not excluded.
CR and PR counted as a pleurodesis success for purposes of analysis
One participant allocated to quinacrine arm having had treatment failure with tetracy-
cline not included in the analysis
Included in network meta-analysis for pleurodesis efficacy and pain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified and unable to contact study
authors
Allocation concealment (selection bias) Unclear risk Not specified and unable to contact study
authors
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No comment on whether study was
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated whether CXR evaluation was
blinded. Pain and fever outcomes may have
been affected if patients were unblinded to
treatment allocation, however not stated in
the paper whether this was the case
Incomplete outcome data (attrition bias)
All outcomes
Low risk Two of 14 randomised to tetracycline ex-
cluded from analysis (one died and one
LTFU). No LTFU in mepacrine arm (over-
all LTFU 13%)
Selective reporting (reporting bias) Low risk All specified endpoints reported
Other bias High risk Eight of 22 participants included in the
study did not have proven pleural malig-
nancy
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Bjermer 1995
Methods RCT of mitoxantrone versus mepacrine via an intercostal drain (Sweden - number of
centres not specified)
Participants Cytologically proven, symptomatic MPE with an expected survival of greater than three
months (Karnofsky Performance Score > 60). Excluded if cytotoxic chemotherapy in the
preceding month
All cell types included
30 participants randomised
Interventions Both groups had a 12-14 Fr chest tube inserted and effusion drained. Pleurodesis agent
was given through the chest tube and patient’s position changed for two hours after
administration
Group 1: 1 dose of intrapleural mitoxantrone 30 mg in 50 ml N saline was given; the
drain was closed for 48 hours and removed after the ’pleural cavity was emptied’
Group 2: 2 doses of intrapleural mepacrine chloride 200 mg in 20 ml N saline were
given on consecutive days and the drain removed when < 150 ml fluid production/day
Outcomes Pleural fluid re-accumulation at 4 and 12 weeks (defined as ’Complete response’ (CR),
’Partial response’ (PR) (if recurrence of pleural fluid but thoracocentesis not considered
to be indicated) or ’Progressive disease’
Side effects/toxicity (visual analogue scale pain and fever scores)
Symptom questionnaires (participant grades symptom on a numeric scale for four key
symptoms- pain, shortness of breath, nausea and tiredness)
Pharmacokinetics of mitoxantrone
Notes People with trapped lung not excluded from the study
CR and PR counted as pleurodesis success for analysis
Included in network meta-analysis for pleurodesis efficacy and mortality
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified and unable to find contact
details for study authors
Allocation concealment (selection bias) Unclear risk Not specified and unable to find contact
details for study authors
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study personnel not blinded as drugs are
of different colours. However, participants
were blinded to treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants blind to treatment alloca-
tion, therefore fever, pain and symptom
scores unbiased. ”Radiological evaluation
was made by an independent radiologist’
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Bjermer 1995 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant in each study arm did
not receive treatment due to “unexpected
medical emergencies”, therefore deemed
non-evaluable. Follow-up data clearly doc-
umented for the remaining patients
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Other bias Low risk Drain suction use was imbalanced between
the treatment arms (10/14 received suc-
tion in mepacrine group vs 1/14 in mitox-
antrone group)
Clementsen 1998
Methods Single centreRCTof tetracycline pleurodesis using a small percutaneous catheter (CH10)
, compared to a large-bore chest tube (CH24) inserted after thoracoscopy (Denmark)
Participants Symptomatic, recurrent MPE, proven on pleural fluid cytology. Expected survival of >
3 months (all tumour types included)
21 participants randomised
Interventions Group 1: small percutaneous catheter (CH10 65 cm) inserted under local anaesthesia
Group 2: medical thoracoscopy, followed by insertion of a large-bore chest tube (CH24)
Both groups received pleurodesis with 500 mg tetracycline and 100 mg bupivicaine
intrapleurally. The drain was clamped for six hours after instillation after which suction
was applied. Drain removed when fluid output < 200 ml in 24 hours
Outcomes Treatment response at 3, 6 and 9weeks defined by roentgenographic response (’Complete
response’ - no recurrence of pleural fluid; ’Partial response’ - slight re-accumulation with
blunted costophrenic angle; ’No response’ - complete recurrence of pleural fluid) and
clinical response (by the need for new thoracentesis)
Questionnaire evaluating discomfort in connection with the tube and the pleurodesis
Notes Trapped lung not accounted for in inclusion/exclusion criteria, but one patient excluded
as they had hydropneumothorax at time of instillation
CR and PR included as pleurodesis successes for analysis
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Allocation by lot”
Allocation concealment (selection bias) Unclear risk Not stated
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Clementsen 1998 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind, as different drain
sizes used (although not stated explicitly in
the paper)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “All data were evaluated by the same physi-
cian, who was without knowledge of the
result of the randomisation”. However,
symptom-based adverse events and symp-
tomatic need for repeat pleural interven-
tion may be biased by lack of patient blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data reported and justified.Missing out-
come data balanced between the two treat-
ment arms (two excluded from group 1
(one died of cancer soon after drain inser-
tion and one developed hydropneumoth-
orax necessitating large-bore drain), one
excluded from group 2 (patient withdrew
consent for study participation)
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk No other biases identified
Crnjac 2004
Methods Single centre RCT comparing thoracoscopic mechanical pleurodesis (TMP) with talc
slurry (Slovenia)
Participants Inclusion: breast carcinoma and a resulting morphologically confirmed MPE
Exclusion: unfit for general anaesthetic (GA)
87 participants randomised
Interventions TMP arm: thoracoscopy (under GA) with adhesiolysis, pleural biopsy and scarification
of the visceral and parietal pleura to induce bleeding. Chest tube inserted at the end of
procedure
Talc slurry arm: chest tube inserted under local anaesthetic. 5 g talc in 100 ml saline
insufflated through chest tube
Participants in both arms had the drain removed when < 100ml/24hour drainage
Outcomes Recurrence of effusion on chest x-ray (CXR) at 1 day, 1 week, 1 month, 3 months and
6 months
Duration of chest tube drainage
Duration of hospitalisation
Complications
Mortality (30 days and 6 months)
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Crnjac 2004 (Continued)
Notes People with trapped lung not excluded.
Pleurodesis success defined using CXR criteria alone
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not feasible to blind the study as compar-
ing talc slurry with thoracoscopy
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated whether radiological assess-
ments were done in a blinded fash-
ion. Complication reporting, time of tube
drainage may be effected by lack of patient
andpersonnel blinding.Mortality outcome
not effected by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed. Minimal missing
data. 6/45 patients died within six months
in TMP group vs 8/42 in talc slurry arm
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No documentation of patient experience
(e.g. QOL or degree of discomfort), rela-
tive costs or need for repeat pleural inter-
vention
Pleurodesis success defined using radiology
only. Participants who did not have evi-
dence of recurrence at death were classified
as pleurodesis successes
Davies 2012
Methods Unblinded, multi-centre RCT comparing indwelling pleural catheter (IPC) with talc
slurry pleurodesis (UK)- TIME-2 Trial
Participants Inclusion criteria: clinically confident diagnosis of MPE requiring pleurodesis
Exclusion criteria: age < 18, expected survival of < 3 months, chylothorax, previous ipsi-
lateral lobectomy or pneumonectomy, previous attempted pleurodesis, pleural infection,
WCC < 1000/microlitre, hypercapnic ventilatory failure, pregnancy, lactating mothers,
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Davies 2012 (Continued)
irreversible bleeding diathesis, irreversible visual impairment
106 participants randomised
Interventions Group 1: IPC inserted with drainage three times a week (or as required to relieve dysp-
noea)
Group 2: 12 F Seldinger chest tube and 4 g talc slurry as an inpatient
All patients had standard oncological management for the primary tumour
Outcomes Primary outcome: mean daily dyspnoea visual analogue score (VAS) over the first 42
days
Secondary outcomes: proportion achieving clinically significant decrease in mean VAS
dyspnoea; mean VAS dyspnoea at 6 weeks, 3 months and 6 months; mean daily chest
pain VAS over the first 42 days; meanVAS chest pain at 6 weeks, 3months and 6months;
nights spent in hospital; self-reported quality of life; frequency of adverse events
Notes Participants with trapped lung in group 2 did not receive talc pleurodesis, but remained
in trial follow-up
Pleurodesis in the IPC group was defined as removal of IPC following spontaneous cessa-
tion of drainage with no significant fluid recurrence on chest x-ray (CXR) or ultrasound
scan (USS) and no further ipsilateral pleural intervention. In the talc group, pleurodesis
failure defined as the need for further ipsilateral pleural intervention
If participants died during follow up, included as a pleurodesis success if no intervention
prior to death
Included in network meta-analysis for pleurodesis efficacy and mortality
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central telephone randomisation
Allocation concealment (selection bias) Low risk Central telephone randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants or per-
sonnel due to nature of interventions (IPC
vs talc slurry)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk VAS scores, QOL and symptom recurrence
(which informs assessment of pleurodesis
efficacy) could be biased by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk LTFU clearly documented with reasons
given
Selective reporting (reporting bias) Low risk All predefined endpoints reported
Other bias Low risk No other biases identified
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Demmy 2012
Methods Multi-centre RCT comparing bedside talc pleurodesis and daily tunnelled catheter
drainage for management of malignant pleural effusion (USA)
Participants Inclusion: symptomatic patients with histo/cytologically provenmalignancy and a previ-
ously untreated, unilateral pleural effusion requiring management; ECOG performance
score 0-2
Exclusion: active pleural infection; talc allergy; contraindications to talc use; trapped
lung; survival < 60 days; severe comorbid medical conditions
68 participants randomised
Interventions Talc pleurodesis group: 4 g to 5 g sterile talc slurry in 100 ml saline infused into pleural
space via > 24 Fr chest drain. Tube clamped for two hours. Drain removed when < 150
ml drainage/24hours
Indwelling pleural catheter (IPC) group: PleurX catheter inserted and drained daily
(output volumes recorded). Removed when < 30 ml output on three consecutive days
Outcomes Primary: compare the proportion of maintained successful treatments 30 days after the
intervention (success defined as being (1) alive (2) no effusion recurrence (3) > 90% lung
re-expansion after complete drainage (4) completion of the intervention by two weeks
ie drain removed or IPC functioning normally)
Secondary: Quality of life (QOL); dyspnoea; patient satisfaction and acceptability; lung
expansion; pleurodesis success; fluid drainage volume; days device in place; removal of
device before death; survival
Notes Pleurodesis success measured at 30 days according to chest x-ray (CXR) and need for
repeat pleural intervention
People with known trapped lung excluded from trial entry
Included in network meta-analysis for pleurodesis efficacy and mortality
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Permuted block randomisation via a web-
based randomisation service
Allocation concealment (selection bias) Low risk Permuted block randomisation via a web-
based randomisation service
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Due tonature of interventions, not possible
to blind participants or personnel (IPC vs
talc slurry)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Pleurodesis successwas classified by anun-
blinded local investigator” (personal com-
munication). QOL, symptom recurrence
and patient satisfaction questionnaires may
be biased by lack of patient blinding
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Demmy 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Five excluded from analysis in each arm,
but justifications given
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk Target recruitment numbers not reached
Diacon 2000
Methods Prospective, single centre RCT of thoracoscopic talc poudrage versus bedside bleomycin
pleurodesis via a small-bore chest tube (Switzerland)
Participants Inclusion criteria: documented MPE (all cell types); complete lung expansion on post
drainage chest x-ray (CXR); improvement in symptoms after drainage; expected survival
of > 1 month; capable of undergoing medical thoracoscopy
Exclusion criteria: loculated effusion; previous drainages or previous pleurodesis; adverse
reaction to the study medication; severe coagulation disorder
36 participants randomised
Interventions Group 1: bedside pleurodesis via small-bore chest tube (OD = 2.7 mm) of 60 IU
bleomycin. Tube unclamped after two hours and left on suction until removal at least
48 hours later
Group 2: thoracoscopy with induced pneumothorax under sedation. 5 g talc sprayed into
pleural cavity under direct vision after drainage of effusion and disruption of adhesions.
Drain kept under suction for at least 48 hours
Outcomes Recurrence of effusion (defined as a newly detected effusion needing drainage or occu-
pying > 33% of the pleural space on CXR as compared with the first CXR after drain
removal, or death from any cause) at 30, 90 and 180 days
Medication use
Volume of fluid drained
Duration of hospital stay
Cost
Symptom VAS Scores (pain, shortness of breath, cough and general well-being)
Notes People with trapped lung excluded from study enrolment
Included in network meta-analysis for pleurodesis efficacy, mortality, fever and pain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Low risk Sequential sealed envelopes
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Diacon 2000 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants or per-
sonnel due to nature of interventions (talc
poudrage vs bleomycin via chest tube)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated if radiology was interpreted by a
blinded physician. However length of stay,
VAS scores and symptom recurrence may
be biased by lack of participant blinding.
Mortality would not be affected by un-
blinded nature of the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Five withdrawals in total, but a similar
number in each group
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No external funding source
Dresler 2005
Methods Multi-centre RCT comparing talc poudrage with talc slurry pleurodesis in MPE. Both
groups received 4 g - 5 g sterile talc intrapleurally (USA)
Participants Inclusion criteria: history of malignancy (all tumour types), pleural effusion requiring
sclerosis, ECOG performance status 0-2, life expectancy > 2 months, ability to undergo
general anaesthesia
Exclusion criteria: pregnancy, previous intrapleural therapy or radiation therapy encom-
passing the entire hemithorax, changes in systemic therapy within two weeks, chylous
or bilateral effusions requiring therapy
501 participants randomised
Interventions TS Group: talc administered as a slurry in 100 ml saline through a chest tube at the
bedside
TTI Group: talc insufflated during thoracoscopy in the operating room
Outcomes Primary endpoint: the percentage of patients whose lung initially re-expanded > 90%
and who had a successful pleurodesis at 30 days after treatment (defined according to
cvhest x-ray (CXR) criteria)
Secondary endpoint: time to recurrence of effusion; frequency of complications and
toxicities; ability to re-expand the lung as assessed by CXR; oain; patient satisfaction;
quality of life (QOL)
Notes People with trapped lung excluded from analysis
Included in network meta-analysis for pleurodesis efficacy, mortality, pain and fever
Risk of bias
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Dresler 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation lists
Allocation concealment (selection bias) Low risk Computer-generated randomisation lists
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind the study due to the
nature of the interventions (talc poudrage
vs talc slurry)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated if radiological assessment was
blinded. QOL and complications may be
affected by lack of patient and personnel
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data accounted for and balanced
between the treatment arms (10 in slurry
group and 9 in thoracoscopy group ex-
cluded as ineligible or participant withdrew
consent; 33/163 slurry participants and 25/
177 thoracoscopy participants died within
30 days of randomisation)
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk Trapped lung defined by differentmeans in
the two treatment arms, which may have
effected their primary endpoint. However,
this does not have an impact on the pleu-
rodesis success rates
Du 2013
Methods Single centre RCT of intrapleural cisplatin +/- bevacizumab in MPE due to non-small
cell lung cancer (NSCLC) (China)
Participants Inclusion: Advanced NSCLC; large uni- or bilateral pleural effusion; positive pleural
fluid cytology; no intrapleural therapy in previous month; Karnofsky performance score
> 60%; age > 18; predicted survival > 3months; no major organ disfunction; no previous
chemotherapy in previous six weeks
Exclusion: squamous cell carcinoma; allergy to biological agents; no detectable lesions;
uncontrolled central nervous system metastasis; pregnancy or breastfeeding; infected
wound; refractory psychiatric illness
72 participants randomised
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Du 2013 (Continued)
Interventions Participants underwent pleural fluid drainage by thoracentesis. Treatment given in-
trapleurally. Rest for two hours. Then rotate every 15 mins. Given every two weeks for
3 cycles
Cisplatin: 30 mg cisplatin intrapleurally
Cisplatin and bevacizumab: 30 mg cisplatin and 300 mg bevacizumab intrapleurally
Outcomes Treatment response (’Complete remission (CR)’ = accumulated fluid disappeared and
stable for at least four weeks; ’Partial remission (PR)’ = > 50% of the accumulated fluid
had disappeared, symptoms had improved and the remaining fluid had not increased for
at least four weeks; ’Remission not obvious (NC)’ = < 50% of the accumulated fluid had
disappeared; ’Progression (PD)’ = accumulated fluid had increased). Treatment success
defined as CR + PR
Progression-free survival
Overall survival
Adverse reactions
Quality of life (QOL)
Pleural fluid VEGF levels
Notes People with trapped lung eligible for trial involvement
Pleurodesis defined clinically and using radiology
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Methods not stated and no response from
study authors to clarify
Allocation concealment (selection bias) Unclear risk Methods not stated and no response from
study authors to clarify
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated if blinded and no response from
study authors to clarify
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated if anyone was blinded. If not
blinded, QOL, performance status, side ef-
fects and symptom recurrence could be bi-
ased by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data accounted for. ITT analysis
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk No other biases identified
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Emad 1996
Methods Three-arm, single centre RCT comparing intrapleural bleomycin, tetracycline and com-
bination treatment for pleurodesis of MPE (Iran)
Participants Inclusion: histologically or cytologically proven, symptomatic MPE (all cell types)
Exclusion: none
60 participants randomised
Interventions All participants had 28 Fr intercostal drain inserted into 6th intercostal space. Complete
drainage of the effusion was confirmed on chest x-ray (CXR). All participants given 10-
15ml 1% lignocaine intrapleurally
Tetracycline arm: 20 mg/kg tetracycline (max 2 g) in 50 ml saline given intrapleurally. 1
dose
Bleomycin arm: 1 u/kg (max 60 units) in 50 ml saline given intrapleurally. 1 dose
Combination arm: 20 mg/kg tetracycline in 40 ml saline and 1 u/kg bleomycin in 50
ml saline, given intrapleurally, one after the other (tube clamped for five mins between
instillations)
Drain clamped for two hours post instillation with patient rotation. Suction connected
after 24 hours. Drain removed when < 50 ml/8 hours drainage and complete lung
expansion on CXR
Outcomes Pleurodesis success (defined as ’complete response’ (no accumulation of effusion on
CXR), ’partial response’ (effusion recurred but did not require aspiration) or ’failure’
(participant required repeat thoracentesis for re-accumulation of the effusion) at 30 days
(also at 60 days, 90 days and 6 months)
Side effects
Notes All participants in the study were receiving chemotherapy or tamoxifen, or both
People with trapped lung not excluded from participation in the study
Participants who died prior to the analysed time point were excluded from the analysis
Combination of clinical need for repeat intervention and radiological re-accumulation
of effusion used to define pleurodesis failure
Included in network meta-analysis for pleurodesis efficacy, mortality and fever
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “’...simple randomised manner”. No fur-
ther details given
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated explicitly and unable to contact
authors. However, different volumes and
regimes were used for the two groups
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated if radiology reported blindly.
Complication-reporting may have been af-
fected by lack of participant blinding
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Emad 1996 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Minimal data on baseline patient charac-
teristics, but all outcome data reported and
withdrawals justified. Six participants died
within six months of randomisation (2 in
tetracycline arm; 1 in bleomycin arm and
3 in combination arm)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified
Evans 1993
Methods Single centre RCT of medical vs surgical pleurodesis with tetracycline (UK)
Participants Inclusion criteria: cytology-proven MPE and histological or cytological evidence of
metastatic breast cancer
Exclusion criteria: unsuitable for general anaesthetic (GA); > 75 years old; severe non-
metastatic lung disease; evidence of life-threatening metastatic disease at other sites
34 participants randomised
Interventions Medical group: intercostal cannula inserted into mid-axillary line 7th/8th intercostal
space and fluid aspirated. When drainage complete, 500 mg tetracycline in 100 ml N
saline inserted IP. Drain removed after 24 hours
Surgical group: under GA, bronchoscopy then thoracoscopy performed. 500 ml tetra-
cycline in 100 ml saline inserted after fluid removed. Drain removed at 24 hours
Outcomes Fluid re-accumulation on chest x-ray (CXR)
Need for repeat pleural aspirations
Mortality
Notes Pleurodesis failure defined as need for repeat aspiration. Trapped lung not accounted for
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given regarding randomisation
Allocation concealment (selection bias) Unclear risk No details given regarding randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind due to nature of the inter-
ventions (surgery vs chest tube)
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Evans 1993 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Need for repeat aspirations and other treat-
ments given for cancer after pleurodesis
may have been biased by lack of blinding
of personnel and participants. Not stated if
CXRs were reported by a blinded person
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons given for withdrawals (5/34 ex-
cluded (15%) - 3 never received the treat-
ment; 1 was randomised in error; 1 partic-
ipant’s records were lost)
Selective reporting (reporting bias) High risk No data on safety or side effects
Other bias Low risk No other biases identified
Fentiman 1983
Methods Single centre RCT of talc poudrage and mustine (via chest tube) in patients with breast
cancer. All patients underwent VATS procedure under general anaesthetic. (UK)
Participants Inclusion criteria: histologically confirmed breast cancer and radiologically verified pleu-
ral effusion
Exclusion criteria: no previous local treatment; non-malignant cause for the effusion
46 participants randomised
Interventions Talc group: talc poudrage performed during VATS (dose of talc not stated), two chest
drains in place for five days (with or without suction)
Mustine group: after VATS and once lung fully re-expanded on CXR, 15 mg mustine
solution instilled via intercostal drain. Clamped for two hours. Drain removed when
drainage stopped
Outcomes Success of pleurodesis (defined by lack of re-accumulation of effusion on CXR) at one
month; complications
Notes If died prior to one-month follow up, excluded from analysis of pleurodesis success
Participants with trapped lung eligible for enrolment
Included in network meta-analysis for pleurodesis efficacy and mortality
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified for metastatic disease requiring
treatment. “balanced randomisation”
Allocation concealment (selection bias) Unclear risk Not stated
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Fentiman 1983 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind patients or personnel
due to the nature of the procedures
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated whether radiographic inter-
pretation of CXRs were performed by a
blinded person. Reporting of complica-
tions could be biased by lack of participant
and personnel blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3/23 non-evaluable in talc group; 6/23
non-evaluable in mustine group. All non-
evaluable patients died prior to one-month
follow up
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias High risk Different number of intercostal drains in
the two groups. Different duration of
drainage for two groups
Fentiman 1986
Methods Single centre RCT of intrapleural talc and tetracycline inMPE secondary to breast cancer
(UK)
Participants Inclusion criteria: histologically confirmed breast cancer and a symptomatic pleural ef-
fusion on radiology
Exclusion criteria: previous treatment for effusion, other than simple needle aspiration;
non-malignant cause for effusion; unsuitable for general anaesthetic; history of sensitivity
to tetracycline
41 participants randomised
Interventions Talc group: thoracoscopy, talc insufflated (dose not stated). Intercostal drain remained
in situ for five days
Tetracycline group: thoracoscopy. Tetracycline 500 mg in 40 ml N saline inserted 16 -
24 hours later via chest tube. Intercostal drain left in place for 3 - 5 days
Outcomes Pleurodesis success (defined by lack of re-accumulation on CXR); complications; mor-
tality
Notes Pleurodesis success defined according to CXR only
Participants with trapped lung eligible for trial entry
Included in network meta-analysis of pleurodesis efficacy and mortality
Risk of bias
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Fentiman 1986 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised with stratification for
metastatic disease”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind patients or personnel
due to the nature of the procedures
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated whether radiographic inter-
pretation of CXRs were performed by a
blinded person. Reporting of complica-
tions could be biased by lack of participant
and personnel blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants were excluded from the pri-
mary analysis if they died within the first
month. Higher proportion of deaths in the
talc group (6/18 = 33%) compared to the
tetracycline group (2/23 = 9%)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified
Gaafar 2014
Methods Single centre, prospective RCT comparing intrapleural administration of mistletoe
preparation (viscum fraxini-2) with bleomycin in patients with MPE (Egypt)
Participants Inclusion: histologically confirmed, recurrent, symptomatic MPE (all cell types); > 18
years old; ECOG performance score ≤ 2; adequate bone marrow, liver and kidney
function; written consent; ability to comply with the follow up
Exclusion: chronic air leak; known hypersensitivity to mistletoe; uncorrectable bleeding
tendency; encysted pleural effusion; pregnancy/breastfeeding; currently active second
malignancy; co-enrolment in another clinical trial; previous unsuccessful pleurodesis;
pleural infection
23 participants randomised
Interventions Participants underwent effusion drainage using a chest tube or needle drainage (depend-
ing on effusion size). Agent injected through the needle or chest tube
viscum group: 5 ampoules in 10 ml 5% glucose instilled intrapleurally
Bleomycin group: 60 units delivered intrapleurally
Outcomes Pleurodesis efficacy (assessed at six weeks)
Toxicity (measured using NCI common terminology for adverse events)
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Gaafar 2014 (Continued)
Notes People with trapped lung not excluded from participation
Pleurodesis defined using radiology and symptomatic effusion recurrence
Included in network meta-analysis for pleurodesis efficacy.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomised”. No other details given and
no response from study authors
Allocation concealment (selection bias) Unclear risk “randomised”. No other details given and
no response from study authors
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated explicitly but drugs were of dif-
ferent formulations
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated if outcome assessment was
blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Two patients in viscum arm excluded from
analysis as treatment was discontinued due
to an allergic reaction
Selective reporting (reporting bias) Low risk Data available although minimal data on
side effects
Other bias Low risk No other risks of bias identified
Goodman 2006
Methods Single centreRCTevaluatingdurationof chest tube drainage after a talc slurry pleurodesis
(UK)
Participants Inclusion criteria: confirmed MPE requiring palliation of breathlessness due to the effu-
sion (all cell types)
Exclusion criteria: expected survival < 3 months; Karnofsky score < 40; previous unsuc-
cessful pleurodesis; ipsilateral endobronchial obstruction; evidence of trapped lung
41 participants randomised
Interventions All participants had 8 - 14 Fr intercostal drain inserted under ultrasound guidance. 4 g
talc slurry when effusion fully drained and trapped lung excluded on CXR
In one group, drain removed after 24 hours. In the other group, drain removed at 72
hours. Drains removed regardless of fluid drainage
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Goodman 2006 (Continued)
Outcomes Pleurodesis failure at one month (defined according to fluid recurrence requiring repeat
aspiration). Length of hospital stay. Mortality
Notes People with trapped lung excluded from the study. Study didn’t complete recruitment
numbers required by the power calculation
Participants who died in first month after randomisation excluded from the analysis
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sealed envelopes in random blocks of 10
Allocation concealment (selection bias) Low risk Sealed envelopes in random blocks of 10
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind due to nature of in-
terventions (drain removal after 24 or 48
hours)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Need for repeat pleural interventions,
length of stay may be biased by lack of
blinding. Mortality data not biased
Incomplete outcome data (attrition bias)
All outcomes
Low risk Deathswithin the firstmonthwellmatched
between the two arms (3 patients in each
arm). No other LTFU
Selective reporting (reporting bias) Low risk All predefined outcomes reported. Unpub-
lished data on complications provided by
the authors
Other bias Low risk No other biases identified
Groth 1991
Methods RCT comparing intrapleural mitoxantrone with normal saline after thoracoscopy in
patients with MPE (Germany)
Participants Inclusion: complete resolution of the effusion after thoracoscopy; malignancy on pleural
biopsy
Exclusion: No chemotherapy within four weeks of pleurodesis
103 participants randomised
Interventions All participants underwent thoracoscopy. After 24 hours participants were randomised
Mitoxantrone arm: 30 mg mitoxantrone given intrapleurally
Control arm: isotonic saline instilled intrapleurally
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Groth 1991 (Continued)
Drain clamped for 48 hours and if > 300 ml effusion after 48 hours, a second dose was
given; if not the drain was removed. If a second dose was given, the drain was removed
48 hours later
Outcomes Pleural fluid re-accumulation at two months (defined as a complete response (complete
disappearance of all pleural effusion), partial response (half of the effusion or doubling
of the time for thoracocentesis) no change (the same volume of effusion) or progressive
disease (uncontrollable effusion)
Toxicity
Remission duration
Survival
Notes Treatment response definitions somewhat unclear
People with trapped lung eligible for trial involvement
Included in network meta-analysis for pleurodesis efficacy and fever
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding or whether drugs
were of similar appearances or volumes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated whether CXR interpretation
was blinded to treatment allocation. Side
effects and performance status reporting
could be biased if participants and person-
nel were not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8/103 participants excluded from the anal-
ysis (7 died within four weeks of randomi-
sation due to tumour progression; 1 was
lost to follow up)
Selective reporting (reporting bias) Low risk All reported
Other bias High risk Ambiguous definitions of pleurodesis suc-
cess
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Haddad 2004
Methods Single centre RCT comparing talc slurry and bleomycin pleurodesis (Brazil)
Participants Inclusion: documented recurrent symptomatic MPE (with positive cytology or con-
firmed metastatic disease elsewhere with no other cause found for the effusion); symp-
tomatic relief by therapeutic aspiration; complete lung re-expansion after therapeutic
aspiration
Exclusion: previous unsuccessful pleurodesis; pleural infection; chronic air leak; karnof-
sky performance score < 30%
71 participants randomised
Interventions 28 - 36 Fr chest tube inserted under local anaesthetic. Lung re-expansion confirmed
prior to randomisation
Talc group: 4 g talc in 100 ml saline intrapleurally
Bleomycin group: 60 units of bleomycin in 100 ml saline intrapleurally
After instillation, drain clamped for four hours, then put on suction for 24 hours. Drain
removed when < 200 ml/24hours drained
Outcomes Pleurodesis success (defined as no recurrence of effusion on clinical and radiologic follow-
up or patient symptom-free with small residual effusion not requiring thoracentesis) at
1, 3 and 6 months
Length of hospital stay
Cost analysis
Complications
Notes People with trapped lung excluded from trial entry
Included in network meta-analysis for pleurodesis efficacy and mortality
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation se-
quence
Allocation concealment (selection bias) Low risk Computer randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Study not blinded” (personal communi-
cation with authors)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “study not blinded” (personal communi-
cation with authors). Not stated if radiol-
ogy reported blindly but pleurodesis effi-
cacy also based on symptom recurrence, so
could be biased by lack of participant blind-
ing
Incomplete outcome data (attrition bias)
All outcomes
Low risk All reported
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Haddad 2004 (Continued)
Selective reporting (reporting bias) Low risk All outcomes reported and further clarifica-
tion received from authors regarding com-
plications and mortality
Other bias High risk High levels of steroid use in participants,
which may have effected pleurodesis suc-
cess rates. Steroid use not well balanced
between the treatment arms (4/37 in talc
group, 8/34 in beomycin group)
Hamed 1989
Methods Prospective, single centre RCT of bleomycin and talc in MPE secondary to breast cancer
(UK)
Participants Inclusion criteria: breast carcinoma with radiographically confirmed pleural effusion
Exclusion criteria: previous local treatment (apart from simple aspiration); evidence of a
non-malignant cause for the effusion
29 participants randomised
Interventions All participants had effusion drained to dryness under general anaesthetic
Talc group: talc pleurodesis (dose and mode of administration not specified, but assumed
to be poudrage from text)
Bleomycin group: chest tube inserted. Bleomycin 1mg/kg in 50ml normal saline instilled
after a CXR confirming lung re-expansion
Outcomes Success of pleurodesis (defined as continued absence of re-accumulation of pleural fluid
on all follow-up radiographs)
Notes Different modes of administration of talc and bleomycin
Contacted study authors for more information, but no reply
People with trapped lung eligible for study entry
Included in network meta-analysis for pleurodesis efficacy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind due to the na-
ture of the interventions (talc poudrage vs
bleomycin)
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Hamed 1989 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not statedwhether radiology reportingwas
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk A number of participants not included in
the primary analysis, but balancednumbers
between the two treatment arms (4/13 in
talc group, 3/16 in bleomycin group)
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk No other biases identified
Hillerdal 1986
Methods Multi-centre RCT of pleurodesis using Corynbacterium parvum vs bleomycin (Sweden)
Participants Inclusion criteria: pleural effusion due to metastases from cytologically- or histologically-
proven bronchogenic carcinoma or adenocarcinoma; at least two previous aspirations of
effusion
40 participants randomised
Interventions Corynebacterium parvum 7 mg in 10 - 20 ml saline IP or bleomycin 60 mg in 100 ml
saline intrapleurally
A second dose of the allocated agent was given if the first was ineffective
No details given about method of drainage prior to instillation of pleurodesis agent or
how long the drain remained in place
Outcomes Pleurodesis success (“Success” = no recurrence of fluid within six weeks; “Partial success”
= 2 instillations required within six weeks, with no recurring effusion within six weeks
of the second instillation)
Notes People with trapped lung eligible for trial entry
For the purposes of this review, if participants required more than one treatment due to
effusion recurrence within six weeks, they were counted as a failure
Included in network meta-analysis for pleurodesis efficacy, fever and pain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
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Hillerdal 1986 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No specific mention of blinding but drugs
reconstituted in different volumes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Definition of pleurodesis efficacy quite
vague and not stated if blinded. Side ef-
fect reporting may be influenced by lack of
blinding of participants and personnel
Incomplete outcome data (attrition bias)
All outcomes
High risk No data on mortality. Numbers don’t add
up for side effects data
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified
Ishida 2006
Methods Single centre RCT of intrapleural cisplatin vsOK-432 vs combination (Japan)
Participants Inclusion criteria: symptomatic, histocytologically confirmed pleural malignancy sec-
ondary toNon-small cell lung cancer(NSCLC), ECOGperformance score 0-3, adequate
renal, haematological and cardiac function
Exclusion Criteria: previous intrapleural therapy, trapped lung or atelectasis after chest
tube inserted
49 participants randomised
Interventions All participants underwent pleural fluid drainage via a 20 Fr chest tube. After administra-
tion of the allocated treatment, chest drain was clamped for six hours and then connected
to 20 cm H2O suction. Drain removed when < 100 ml/day
Cisplatin group: 50 mg cisplatin via chest tube on day 1 and 4
ok-432 group: one dose of 5 KEOK-432 via chest tube
Combination group: 50 mg cisplatin on day 1 and 4, followed by 5 KEOK-432 on day
7
Outcomes Effusion recurrence (as defined by a newly detected effusion needing drainage or occu-
pying > 33% of pleural space on CXR); mortality; adverse events
Notes people with trapped lung excluded from the study
Study authors contacted for further information, but no response
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
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Ishida 2006 (Continued)
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No mention of blinding but participants
received different dosing regimes depend-
ing on study arm
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Adverse event reporting could be affected
by knowledge of treatment allocation. Not
stated whether CXR interpretation was
performed in a blinded fashion for defini-
tion of pleurodesis efficacy
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number of deaths clearly stated. If partic-
ipants died, still included in analysis for
pleurodesis success prior to death
Selective reporting (reporting bias) Low risk All pre-defined outcomes reported
Other bias High risk Drain left in for different duration in the
three groups. Steroids were given to partic-
ipants who received cisplatin
Kasahara 2006
Methods Multicentre phase 2 trial ofOK-432, evaluating two different doses of intrapleural (IP)
OK-432 (Japan)
Participants Inclusion criteria: histological or cytological proof of MPE with non-small cell lung
cancer (NSCLC); no previous therapy for MPE; age > 20; ECOG performance score
0-3; life expectancy > 12weeks; adequate organ and bone marrow function; daily chest
tube drainage < 200 ml
Exclusion criteria: previous TB pleuritis; unstable heart disease or diabetes; active double
cancer; pregnancy; lactation; allergy to OK-432 or benzylpenicillin
38 participants randomised
Interventions All participants underwent chest tube drainage. Two doses ofOK-432 given (on days 1
and 3)
Arm A: IPOK-432 at a dose of 10 KE in 100 ml saline
Arm B: IPOK-432 at a dose of 1 KE in 100 ml saline
Outcomes MPE control on day 28 (defined as a complete response (the effusion disappeared com-
pletely and no further treatment required), partial response (the effusion persisted but
local treatment was not needed) or no change (further local treatment was needed or the
residual effusion volume was > 100 ml)
MPE control rate
Duration of drainage
Fluid volume drained
Time to progression
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Kasahara 2006 (Continued)
Drug adverse events
Overall survival
Notes People with trapped lung included in the study
For purposes of this review, complete and partial responses were counted as pleurodesis
successes
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated whether blinded. Drugs diluted
in same volume in both study arms
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Need for repeat intervention and side ef-
fects could be biased if patients and person-
nel unblinded, but not stated if this was the
case
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow up
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias High risk In arm B, if low dose ineffective, patients
given a high dose of OK-432 anyway (prior
to measurement of primary outcome)
Paper does not state whether patients were
symptomatic from MPE at enrolment
Kefford 1980
Methods Single centre RCT of intrapleural Adriamycin, nitrogen mustard and rolitetracycline
(Australia)
Participants Histocytologically confirmed malignant effusions (pleural or pericardial or peritoneal);
no previous intracavitary chemotherapy; no concurrent radiotherapy or systemic treat-
ment
38 participants reported as being randomised in total (26 of whom had malignant
pleural effusion). However in the discussion it refers to 90 participants being randomised
originally
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Kefford 1980 (Continued)
Interventions All participants had a needle thoracentesis to dryness. The drug was diluted in 20 ml
saline and injected through needle as a bolus
Adriamycin group: 30 mg intrapleurally
Nitrogen mustard group: 20 mg intrapleurally
Rolitetracycline group: 500 mg intrapleurally
Outcomes Pleurodesis success at eight weeks (defined as complete response (CR) (absence of sig-
nificant effusion on CXR), partial response (reduction in frequency of aspiration with
improvement in exercise tolerance and CXR) or no response)
Complications
Notes People with trapped lung eligible for the trial
For the purposes of this review, only data on participants with pleural effusions included
in our analysis and only CR counted as a pleurodesis success
Included in network meta-analysis for pleurodesis efficacy.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of whether anyone was
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated if CXR interpretation was done
blind to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk “More than half of the original 90 patients
randomised were ineligible for assessment
because of subsequent systemic therapy...
or... early death”. Although in the results,
it states 38 participants were randomised
Selective reporting (reporting bias) Low risk Only a brief report and side effects data for
the pleural and peritoneal effusions com-
bined. However, generally all predefined
outcomes reported
Other bias Unclear risk Six participants received more than one of
the treatments, but not clear whether re-
randomised separately each time
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Kessinger 1987
Methods Single centre RCT comparing intrapleural (IP) bleomycin and tetracycline in MPE
(USA)
Participants Inclusion: histologically proven malignancy; symptomatic pleural effusion with either >
3 g/dl protein or malignant cells on cytology
Exclusion: allergy to either study drug
42 procedures randomised in 34 participants
Interventions All participants underwent chest tube drainage
Tetracycline arm: 500 mg tetracycline in 50 ml saline IP. 1 dose
Bleomycin arm: 89 units in 50 ml saline IP. 1 dose
For both arms, drain clamped for eight hours after instillation and participant moved
positions. Thereafter, tube opened and suction applied. Drain removed when < 40 ml/
24hours drained (or on day 7 if ongoing high output)
Outcomes Treatment response at one month (’Complete response’ (no re-accumulation of the
effusion); ’Partial response’ (asymptomatic re-accumulation of the effusion developed
that was < 50% of its original volume); ’no response’)
Side effects
Length of time chest tube in place following pleurodesis
Notes Bilateral disease included. Some participants randomised to the trial more than once
People with trapped lung eligible for trial entry
Included in network meta-analysis for pleurodesis efficacy, fever and pain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Toss of coin”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding. Both drugs ad-
ministered in 50 ml saline
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated. No mention of whether CXR
interpretation was performed by a blinded
individual
Incomplete outcome data (attrition bias)
All outcomes
High risk 11/34 (32%) participants non-evaluable
for pleurodesis outcome (3 in bleomycin
group and 8 in tetracycline group)
Selective reporting (reporting bias) Low risk All stated outcomes reported
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Kessinger 1987 (Continued)
Other bias High risk Unclear whether participants who were
given both agents because the first agent
failed were included in the analysis
Koldsland 1993
Methods Single centre, prospective RCT of mepacrine versus bleomycin as pleurodesis agent in
malignant pleural effusion (Norway)
Participants Inclusion: malignant pleural effusion; previous treatment with a therapeutic tap; life
expectancy of > 1 month
Exclusion: previous pleurodesis; renal failure; participantrequiring continuous oxygen
40 patients randomised.
Interventions 28 or 32 Fr chest tube inserted under local anaesthetic. Suction applied until fluid
production about 100 ml/day and no effusion on CXR. Tube clamped and sclerosing
agent injected. Patient rotation for two hours after instillation. Drain removed when <
100 ml/day output
Mepacrine group: 800 mg mepacrine in 20 ml saline
Bleomycin group: 60 mg bleomycin in 100 ml saline
Outcomes Pleurodesis success (classified as (1) no re-accumulation (2) small amounts of fluid re-
accumulation with no or mild symptoms (3) re-accumulation of fluid with severe dysp-
noea needing thoracocentesis)
Median survival
Side effects
Notes People with trapped lung not excluded from trial entry
For purposes of this review, participants with no re-accumulation or small amount of re-
accumulation with no or mild symptoms were counted as pleurodesis successes
Included in network meta-analysis for pleurodesis efficacy, fever and pain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using sealed envelopes
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated specifically but drugs reconsti-
tuted in different volumes
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Participant reporting of symptoms may be
effected by lack of blinding. Not stated
whether CXR interpretation was blind to
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Koldsland 1993 (Continued)
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Highmortality in first three months, there-
fore data only analysed at month 1
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified
Kuzdzal 2003
Methods Single centre, prospective RCT of talc vs doxycyline in the control of MPE (Poland)
Participants Inclusion criteria: pleural effusion with clinical suspicion of malignant origin
Exclusion criteria: failure to confirmmalignancy by pleural biopsy; mesothelioma; failure
to achieve full re-expansion of the lung
33 participants randomised
Interventions All participants all VATS under general anaesthetic and pleural biopsy. First dose of
sclerosant given at end of procedure. Tube removed when full re-expansion, no air leak
and < 150 ml/day drainage. Rotation after procedure
Talc: single 10 g dose intrapleurally by insufflation
Doxycycline: 500 mg in 25 ml solution given intrapleurally. Up to 3 doses (if daily
drainage > 150 ml/day)
Outcomes ’Long term’ and ’short term’ pleurodesis outcome (definedby need for repeat thoracentesis
as ’Excellent’ (no fluid re-accumulation), ’Good’ (limited residual fluid, not increasing,
no indications for thoracentesis) or ’Poor’ (fluid re-accumulation requiring thoracentesis)
Complications
Notes For purposes of this review, ’Excellent’ and ’Good’ pleurodesis outcomes included as
pleurodesis successes for analysis
Study authors emailed for further information, but no response
Included in network meta-analysis for pleurodesis efficacy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind due to the nature of the in-
terventions, although not stated explicitly
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Kuzdzal 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Pleurodesis efficacy defined by symptom
recurrence and hence could be biased by
lack of blinding. Not stated whether as-
sessment of fluid re-accumulation was per-
formed by a blinded individual
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of participants randomised not
clear from paper
Selective reporting (reporting bias) High risk Treatment complications and survival not
reported
Other bias High risk Number of doses for the two arms, there-
fore potential for confounding
Leahy 1985
Methods RCT (two recruiting centres) of intrapleural Corynebacterium parvum and tetracycline
for pleurodesis of malignant pleural effusion (UK)
Participants Inclusion: histologically or cytologically proven MPE
Exclusion: participants on chemotherapy; participants receiving treatment with steroids
36 patients randomised.
Interventions Effusion aspirated to dryness prior to administering study agent. After agent instilled, the
participants moved from side to side for six hours. If the participant had symptomatic
recurrence of the effusion within a month, the allocated treatment was repeated
Tetracycline group: 500 mg in 20 ml saline given intrapleurally. The tetracycline was
administered via an intercostal tube at one centre and with needle drainage at the other
centre
C. parvum group: 7 mg in 20 ml saline intrapleurally through a needle, after the effusion
was drained to dryness
Outcomes Symptomatic recurrence of pleural effusion one month after the last dose
Side effects (pain, fever, nausea and vomiting, rash)
Notes People with trapped lung eligible for trial entry
The side effects were reported per procedure rather than per patient
For this review, if participants had a successful pleurodesis after the second dose of study
agent, these were included in the analysis as a success. For the tetracycline group, the
results from the two administration methods were combined for the purposes of analysis
Included in network meta-analysis for pleurodesis efficacy, fever, pain and mortality
Risk of bias
Bias Authors’ judgement Support for judgement
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Leahy 1985 (Continued)
Random sequence generation (selection
bias)
Low risk Computer randomisation
Allocation concealment (selection bias) Low risk Computer randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding not mentioned in the paper. Both
drugs reconstituted in 20 ml saline
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk If study was unblinded, reporting of side
effects, symptomatic pleural fluid re-accu-
mulation could be biased
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants excluded from analysis if died
prior to one month, but the numbers were
small and fairly well balanced between the
groups (1/17 in C. parvum group; 3/19 in
tetracycline group ie 11% LTFU in total)
Selective reporting (reporting bias) Low risk Thorough reporting of toxicity
Other bias Low risk No other biases identified
Loutsidis 1994
Methods Single centre RCT of tetracycline and mechlorethamine (mustine) for pleurodesis of
malignant pleural effusions (Greece)
Participants Inclusion: documented MPE (all tumour types); respiratory distress was the main prob-
lem of the participants
Exclusion: other therapy given simultaneously (chemotherapy or radiation therapy)
40 participants randomised
Interventions All participants had a 32 Fr intercostal drain inserted with local anaesthetic and effusion
drained overnight. Complete drainage confirmed on CXR
After pleurodesis, drain flushed with 20 ml saline. Participants rotated and drain un-
clamped after two hours and put onto -20 cm H2O suction. Drain removed when < 50
ml/day drainage
Tetracycline group: 500 mg tetracycline in 20 ml 2% lignocaine intrapleurally. 1 dose
Mechlorethamine group: 0.2 mg/kg of mechlorethamine in 20 ml saline intrapleurally.
1 dose
Outcomes Response to therapy at 60 days (’complete response’ (CR) (complete lack of re-accumu-
lation of pleural fluid for at least 60 days), ’partial response’ (PR) (small pleural effusion,
asymptomatic, not requiring further treatment), ’failure’ (all other cases))
Side effects
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Loutsidis 1994 (Continued)
Notes Minimal data provided on baseline participantcharacteristics of the two groups
Pleurodesis defined according to symptomatic effusion recurrence
For the purposes of this review, CR and PR included as a successful pleurodesis
People with trapped lung included in the study
Included in network meta-analysis for pleurodesis efficacy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Nomentionof blinding in the paper.Drugs
given in the same volume but not stated
whether their appearances were similar
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated if CXR interpretation was
blinded for assessment of pleurodesis effi-
cacy
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants followed up until the pri-
mary endpoint at 60 days
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified
Luh 1992
Methods Single centre RCT of OK-432 and mitomycin C pleurodesis in lung cancer patients
with MPE (Taiwan)
Participants Inclusion criteria: histo/cyto provenMPE due to lung cancer; effusion requiring repeated
thoracentesis; ECOG performance score 0-3
Exclusion criteria: previous anticancer chemotherapy within four weeks; previous radi-
ation therapy to the ipsilateral chest within four weeks; concomitant systemic chemo or
radio-therapy; history or evidence of penicillin allergy
55 participants randomised
Interventions All participants hospitalised and a chest drain or pigtail catheter inserted into effusion.
Drainage until < 200 ml/day. Tube clamped for one hour after drug administration.
Drug administration repeated weekly for four weeks or until effusion resolved
ok-432 group: 1 KE intrapleurally
Mitomycin C: 8 mg in 30 ml water intrapleurally
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Luh 1992 (Continued)
Outcomes Pleurodesis success at four weeks (defined as ’complete response’ (CR) (no fluid accu-
mulation and participants free of symptoms), ’partial response’ (PR) (recurrence of effu-
sion < 50% of original effusion volume, not symptomatic and no need for thoracentesis
for symptom relief ) or ’failure’ (recurrence of effusion > 50% of the original volume,
symptomatic and need for thoracentesis to relieve symptoms))
Survival
Effusion-free period
Notes People with trapped lung included in the study
For this review, PR & CR counted as pleurodesis successes
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sealed envelopes
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of whether the study was
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Two participants excluded due to early
death, both in OK-432 arm
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified
Lynch 1996
Methods RCT of bleomycin, tetracycline and talc for pleurodesis of malignant pleural effusion
Participants Inclusion: MPE (either cytology positive or an exudative effusion attributed to a histo-
logically confirmed malignancy elsewhere) (all cell types); life expectancy > 2 months
Exclusion: contraindication to placement of a chest tube; allergy to bleomycin, talc or
tetracycline
50 participants randomised
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Lynch 1996 (Continued)
Interventions Chest tube placed using blunt dissection and allowed to drain for at least 24 hours until
< 150 ml/day output. Sclerosing agent instilled intrapleurally. Participants repositioned
every seven minutes after agent instilled. Then, tube unclamped and suction applied,
until < 150 ml/24hours drainage when the drain was removed. If the drainage remained
high, a second instillation was attempted
Bleomycin group: 60 units bleomycin in 50 ml 5% dextrose
Tetracycline group: 750 mg tetracycline in 100 ml saline, with 100 mg lidocaine
Talc group: 5 g talc in 250 ml saline, with 100 mg lidocaine
Outcomes Successs of sclerosis at 30 days (defined as a lack of significant re-accumulation on CXR
with control of symptoms due to the effusion)
Survival
Median length of hospitalisation from date of sclerosis to discharge
Side effects
Notes Participantswho died within 30 days of the sclerosis were included as treatment failures
in the study
Small difference in median age and cell types between the treatment arms
Trapped lung not accounted for
Included in network meta-analysis for pleurodesis efficacy, fever and pain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number generator
Allocation concealment (selection bias) Low risk Random number generator
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated explicitly if the study was
blinded, but the different drugs were given
as different volumes
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Symptom and side effect reporting would
be affected by lack of blinding. Not stated
if CXR interpretation was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4/50 (8%) loss to follow up for primary
outcome but balanced between the treat-
ment arms
Selective reporting (reporting bias) Low risk All reported
Other bias Low risk No other biases identified
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Mager 2002
Methods Single centre RCT evaluating the distribution of talc during a talc slurry pleurodesis
- comparing rotation with non-rotation of participants after instillation of talc slurry
(Netherlands)
Participants Inclusion: symptomatic MPE confirmed by cytology or histology (all cell types)
Exclusion: haemorrhagic disease; trapped lung; previous pleurodesis on ipsilateral side;
other disease which would interfere with the study; participants on systemic treatment
or expected to be within four weeks of pleurodesis; expected survival < 1month
20 participants randomised
Interventions Chest drain inserted and pleurodesis performed when drainage < 150 ml/24 hours
and lung fully re-expanded. Talc suspension was radiolabeled. Dynamic scintigraphy
performed during, immediately after and one hour after instillation
Rotation arm: sequence of four positions changing every 10 mins after instillation of talc
for one hour
Non-rotation arm: strict bed rest in supine position after instillation
Tube removed when < 100 ml/24hour fluid drained
Outcomes Distribution of talc in the thoracic cavity, measured on scintigram immediately after
instillation of talc and after one hour
Success rate of pleurodesis (defined on CXR) at four weeks
Notes People with trapped lung excluded
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sealed envelopes (10 allocating participant
to rotation and 10 to non-rotation)
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind due to the nature of the
interventions
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated if CXR reportingwas performed
by a blinded individual
Incomplete outcome data (attrition bias)
All outcomes
Low risk Small numbers but no LTFU. Minimal
data on baseline participant characteristics
Selective reporting (reporting bias) Low risk No serious side effects. Some discomfort in
rotation group (not quantified). All study
participants alive at one months’ follow up.
(Personal communication)
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Mager 2002 (Continued)
Other bias Low risk CXR only used to define pleurodesis. Small
numbers in the study
Martinez-Moragon 1997
Methods Single centre RCT of tetracycline vs bleomycin pleurodesis in MPE (Spain)
Participants Inclusion: MPE (all cell types) causing respiratory symptoms, proved by cytological
examination or pleural biopsy and an expected survival of at least one month, with a
KPS ≥ 50
Exclusion: prior intrapleural instillation therapy; chest radiotherapy during the preceding
two weeks; previously received systemic bleomycin; trapped lung; allergy to study drugs
70 participants randomised
Interventions All participants underwent tube thoracostomy with suction drainage until < 100 ml/day
output
Tetracycline group: 1.5 g in 100 ml saline intrapleurally, with 9 ml 5% lignocaine
Bleomycin group: 60 mg in 100 ml saline intrapleurally
Tube clamped for four hours after instillation, then suction drainage. Drain removed
when < 100-150 ml/day output
Outcomes Response to pleurodesis (defined as ’complete response’ (CR) (no clinical or radiological
recurrence of effusion), ’partial response’ (PR) (small amount of fluid re-accumulation
on CXR but no symptoms), ’failure’ (re-accumulation of fluid causing symptoms or
needing thoracocentesis))
Adverse effects of the procedure
Notes People with trapped lung excluded from trial entry
For this review, CRs and PRs included as pleurodesis successes
Included in network meta-analysis for pleurodesis efficacy, fever and pain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation
Allocation concealment (selection bias) Low risk Computer randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding in the paper.
Agents given in the same volume but no
comment on whether appearances were
similar
Blinding of outcome assessment (detection
bias)
Unclear risk Not stated if CXR interpretation was
blinded. Other symptom and side effect
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Martinez-Moragon 1997 (Continued)
All outcomes outcomes could be biased if participants
and personnel not blind to treatment allo-
cation, but not stated if this was the case
Incomplete outcome data (attrition bias)
All outcomes
Low risk 8/70 (11%) excluded from analysis due to
death (5) or LTFU (3)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified
Maskell 2004
Methods Single centre RCT comparing pleurodesis using mixed particle Talc (>50% of particles
are <20µm) vs graded Talc (<50% of particles are <20µm) (UK)
Participants Inclusion: Symptomatic pleural effusion, proven to be malignant by cytology or pleural
biopsy (all cell types)
Exclusion: Expected survival <6 weeks; bleeding diathesis contraindicating intercostal
drain insertion; extensive trapped lung; previous ipsilateral pleurodesis; Age <18; Inability
to give informed consent
48 patients randomised.
Interventions 12Fr intercostal drain inserted. Drainage until <150ml/day output. Agent instilled and
left in for 2 hours, before suction being applied. Drain removed after 48 hours
Mixed particle talc group: >50% of talc particles are <20µm. Single 4g intrapleural dose
Graded talc group: <50% of talc particles are <20µm. Single 4g intrapleural dose
Outcomes Change in Aa gradient 48hours post pleurodesis breathing air
Change in PaO2 at 48hours post pleurodesis
Clinical efficacy of pleurodesis at 3 months
Presence/absence of fever at 48hours
Change in CRP
Change in IL8
Notes Patients with trapped lung excluded. Pleurodesis success defined as no re-accumulation
of pleural fluid sufficient to require drainage
Paper presented 2 trials and only trial 2 was relevant to this review (trial 1 was RCT of
mixed talc vs tetracycline, but pleurodesis success data was not collected)
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk pre-sealed numbered, opaque, sealed en-
velopes with stratification
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Maskell 2004 (Continued)
Allocation concealment (selection bias) Low risk pre-sealed numbered, opaque, sealed en-
velopes with stratification
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’investigators and patients blind to treat-
ment allocation’ (personal communication
with authors)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’investigators and patients blind to treat-
ment allocation’ (personal communication
with authors)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data justified and balanced be-
tween the 2 groups (3 patients LTFU)
Selective reporting (reporting bias) Unclear risk The study comprised of two sections and
pleurodesis success only reported for the
particle size section. The RCT of talc/tetra-
cycline did not report pleurodesis success
but this was not one of the pre-defined out-
come measures
Other bias Low risk No other biases identified
Masuno 1991
Methods Multicentre RCT of LC9018 plus doxorubicin vs doxorubicin alone in MPE secondary
to lung cancer (Japan)
LC9018 is a biologic response modifier prepared from heat-killed, freeze-dried Lacto-
bacillus casei YIT 9018
Participants Inclusion: positive histology for primary lung cancer; unilateral pleural effusion; expected
survival > 8weeks; no treatmentwithin four weeks; performance score 0-3; no concurrent
cancer; no severe hepatic/renal/bone marrow failure; age ≤ 75
Exclusion: previous intrapleural (IP) treatment with a biologic response modifier; preg-
nant women and women of child-bearing potential; history of allergy
95 participants randomised
Interventions Effusion completely drained. Both treatment arms received amaximum of two intrapleu-
ral doses, 1 week apart
Control group: doxorubicin 40 mg in 20-50 ml saline
LC9018 group: as control group, then LC9018 0.2 mg in 20-50 ml saline
Outcomes Efficacy of effusion control at four weeks (defined as ’complete response’ (CR) (nega-
tive cytologic findings with no re-accumulation of fluid), ’partial response’ (PR) (neg-
ative cytologic findings with asymptomatic minimal fluid accumulation, not requiring
additional aspiration) or ’failure’ (detectable intrapleural fluid even after tube drainage
with no improvement or exacerbation on radiology compared with before treatment, or
failure to confirm conversion to negative cytology))
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Masuno 1991 (Continued)
Side effects
Change in performance status
Notes People with trapped lung excluded post randomisation
For this review, CR and PR counted as pleurodesis success
Not included in network meta-analysis
NB: doxorubicin is the generic name for Adriamycin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central telephone randomisation system
Allocation concealment (selection bias) Low risk Central telephone randomisation system
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not clear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Blinded committee assessed data regard-
ing safety and efficacy”
Incomplete outcome data (attrition bias)
All outcomes
High risk 19/95 participants excluded from final
analysis, for a variety of reasons, including
five participants with protocol violations
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Unclear risk Primary outcome measure included CXR
resolution and conversion to cytology neg-
ative effusion. Not clear from methodol-
ogy whether some participants who were
asymptomatic had effusion drained to eval-
uate cytology status and were then classi-
fied as ’failures’
Mejer 1977
Methods Single centre RCTofmepacrine hydrochloride, triethylenethiophosphoramide and pleu-
rocentesis alone in the treatment of MPE (Denmark)
Participants Inclusion: unilateral MPE (positive cytology, > 200 IU/L LDH and > 30 g/L protein)
(all cell types); one previous pleurocentesis of > 500 ml
Exclusion: participant receiving chemotherapy or radiotherapy
41 participants randomised
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Mejer 1977 (Continued)
Interventions Pleurocenteis with intrapleural instillation of the study agent, three times a week for one
week
Mepacrine group: 100 mg for first dose, 200 mg for second dose, 200 mg for third dose
(ie 500 mg in total)
Triethylenethiophosphoromide group: 20 mg at each instillation (ie 60 mg total)
Pleurocentesis group: 10 ml saline at each instillation
All participants were followed up at 3 weeks, 6 weeks, 2 months and 3 months, when a
pleurocentesis was performed
Outcomes Treatment effect (a beneficial effect was defined as < 500 ml fluid aspirated at each
pleurocentesis performed up to three months)
Side effects
Notes People with trapped lung not excluded from trial entry
Minimal data presented on whether the treatment groups were well balanced at baseline
Included in network meta-analysis for pleurodesis efficacy, pain and fever
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk No details given
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding in the paper
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding in the paper
Incomplete outcome data (attrition bias)
All outcomes
Low risk Minimal early deaths (3/25) and numbers
well matched between the groups
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias High risk Unsure if groups well balanced at baseline.
Pleurodesis success defined by aspirating
fluid on all participants and not by clinical
need for pleural intervention
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Millar 1980
Methods RCT of intrapleural Corynebacterium parvum vs mustine in recurrent MPE (UK)
Participants Recurrent effusion associated with histologically proved malignant disease (all cell types)
; at least two previous pleural aspirations; symptoms of dyspnoea, cough or local pain
21 participants randomised
Interventions Effusion completely aspirated using an Abrams pleural biopsy needle
Group A: intrapleural mustine 20 mg (max 2 doses)
Group B: intrapleural C. parvum 7 mg (max 2 doses)
Outcomes Response to pleurodesis (defined by fluid re-accumulation on CXR and need for repeat
aspiration - success/partial success/failure) at four weeks
Symptoms (nausea, vomiting, pain)
Notes Trapped lung not accounted for
Only ’success’ counted as a pleurodesis success for analysis (not partial successes as these
participants required a further aspiration of effusion)
Included in network meta-analysis for pleurodesis efficacy and mortality
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding in the paper
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Nomention of blinding in the paper. If un-
blinded, symptom and side effect reporting
could have been biased
Incomplete outcome data (attrition bias)
All outcomes
Low risk Three participants excluded from analysis
as died before primary outcome measure
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk Unclear who provided C. parvum and their
study involvement
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Mohsen 2011
Methods Single Centre RCT of thoracoscopic talc poudrage versus povidone-iodine pleurodesis
through an intercostal drain (Egypt)
Participants Inclusion: MPE as a complication of breast carcinoma
Exclusion: performance status > 3; allergy to iodine; trapped lung; no change in MRC
dyspnoea scale after thoracentesis; pleural fluid pH < 7.2; pleural fluid glucose < 60 mg/
dl; extrathoracic metastasis
42 participants randomised
Interventions All participants underwent a VATS drainage and adhesiolysis
Talc poudrage group: 4 g talc insufflation under thoracoscopic guidance at the end of
the VATS procedure
Iodine group: recovered from VATS. Then later that day, 20 ml 10% povidone-iodine
in 30 ml saline injected through the chest drain at the bedside. Drain clamped for four
hours after instillation
Outcomes Efficacy of pleurodesis at two months (response defined as ’complete response’ (CR)
(absence of fluid re-accumulation), ’partial response’ (PR) (residual pleural fluid or re-
accumulation, which did not require further thoracocentesis or remained asymptomatic)
or ’failure’ (additional pleural procedures were necessary)
Complications
Length of hospital stay (in days)
Survival
Change in MRC dyspnoea score
Notes People with trapped lung excluded from trial entry
CR + PR counted as pleurodesis success for analysis
Included in network meta-analysis for pleurodesis efficacy, mortality and fever
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation software used
Allocation concealment (selection bias) Low risk Computer randomisation software used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not able to blind given the nature of the
interventions
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Symptom and side effect reporting would
be effected by lack of blinding. Not stated
if radiology was interpreted blindly. Mor-
tality would not be biased by lack of blind-
ing
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Mohsen 2011 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Minimal missing data (primary outcome
data available for all patients at two
months)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified
Noppen 1997
Methods Single centre RCT of talc vs bleomycin in MPE (Belgium)
Participants Inclusion criteria: hist/cytologically proven, symptomatic MPE; karnofsky performance
score ≥ 50; expected survival of one year or less
Exclusion criteria: previous pleurodesis attempt
26 participants randomised
Interventions 14 Fr chest drain with suction drainage until completely drained. Intrapleural lignocaine
and subcutaneous morphine given prior to instillation of study drug. After instillation
of drug, drain clamped for 30 mins and then left on suction drainage until output < 150
ml/24hours
Bleomycin group: 1 mg/kg bleomycin in 50 ml saline intrapleurally. 1 dose
Talc group: 5 g in 50 ml saline intrapleurally. 1 dose
Outcomes Response to therapy (defined by re-accumulation onCXRand need for repeat procedure)
. Time point unclear
Side effects
Survival
Notes People with trapped lung were included in the study
Included in network meta-analysis for pleurodesis efficacy and fever
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated numerical table
Allocation concealment (selection bias) Low risk Computer-generated numerical table
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated explicitly but drugs have differ-
ent appearances
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Symptom recurrence and side effects could
be biased by lack of blinding. Not stated if
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Noppen 1997 (Continued)
CXR interpretation was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No LTFU. Outcome data provided on all
participants
Selective reporting (reporting bias) Low risk Time point used to define pleurodesis not
specified
Other bias Unclear risk No fixed endpoint for follow up
Okur 2011
Methods Single centre RCT of intrapleural streptokinase in MPE undergoing chest drainage
(Turkey)
Participants Inclusion: definitive diagnosis of MPE with dyspnoea
Exclusion: mesothelioma; endobronchial tumour causing obstruction; anticoagulant
medication
48 participants randomised between Jan 2007 and Dec 2008
Interventions All participants had 10 Fr pleural catheter inserted under local anaesthetic. Pleurodesis
(5 g talc in 50 ml saline) given only in those patients with complete lung re-expansion
and < 250 ml drain output per day. Drain removed when output < 150 ml/day or after
three days
Those randomised to streptokinase received 3 doses of 250000 IU in 100 ml N saline
at 12-hourly intervals intrapleurally prior to pleurodesis
Outcomes Primary: lung expansion on chest X-ray
Secondary: success of pleurodesis at one month; Volume of 24-hour pleural drainage
before and after fibrinolytic
Notes Pleurodesis defined as “no accumulation of moderate to massive pleural fluid or any
accumulation which causes dyspnoea”
Didn’t pleurodese those with trapped lung.
Degree of loculation or septation on imaging at baseline was not recorded
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Web-based random-number generator
Allocation concealment (selection bias) Low risk Web-based random-number generator
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Okur 2011 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Nature of interventions precluded blinding
(one group got 3 doses of drug and other
group got nothing)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No mention of blinding and side effects
and symptom reporting could be influ-
enced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk LTFU for pleurodesis success (1/17 in con-
trol group; 4/23 in streptokinase group
- 1 died; 1 in intensive care; 3 LTFU).
Only thosewith full lung re-expansionwere
given pleurodesis and this could have been
affected by giving streptokinase, which
might effect pleurodesis success rate, al-
though this was not the study’s primary
outcome measure
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified
Ong 2000
Methods Single centre RCT of talc vs bleomycin in MPE (Singapore)
Participants Inclusion: symptomatic, unilateral MPE confirmed by cytology or pleural biopsy (all cell
types)
Exclusion: trapped lung or loculated effusion; incomplete drainage (e.g. > 100 ml/day
for 10 days); previously treated effusions; life expectancy < 1month
50 participants randomised
Interventions 20 - 24 Fr tube thoracostomy until complete lung re-expansion on CXR and < 100 ml/
day for two days. Both drugs diluted in 50 ml saline and 10 ml 1% lignocaine. After
study drug inserted, drain clamped for six hours with patient rotation. Then suction
applied. Drain removed when < 200 ml/day drainage
Talc group: 1 dose. 5 g talc intrapleurally
Bleomycin group: 1 dose. 1 unit/kg bleomycin intrapleurally
Outcomes Treatment response at one month (according to recurrence of effusion on CXR. Scoring
system 0-3 used for size of effusion)
Hospital stay (days)
Side effects within 48 hours of pleurodesis
Notes People with trapped lung excluded from trial entry
Pleurodesis success based only on radiology
Included in network meta-analysis for pluerodesis efficacy, pain, fever and mortality
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Ong 2000 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated explicitly, however drugs have
differing appearances
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “A single investigator who was blinded to
treatment allocation scored all the follow
up chest x rays”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12/50 patients excluded due to death or
LTFU infirstmonth, but balanced between
treatment arms
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified
Ostrowski 1989
Methods Multi-centre RCT bleomycin vs Corynebacterium parvum in MPE (UK)
Participants Inclusion criteria: histocytologically proven malignancy with effusion (all cell types); life
expectancy of > 30 days
Exclusion criteria: previous intrapleural drug administration; change in cancer treatment
in previous 30 days
58 participants randomised
Interventions Aspiration of effusion with a cannula. Study drug instilled through the cannula. After
cannula removed, participantrepositioned every five minutes
Bleomycin group: 60 mg bleomycin in 100 ml saline. Single dose intrapleurally
C. parvum group: 7 mg in 20 ml saline. Single dose intrapleurally
Outcomes Efficacy of pleurodesis agent at 30 days (defined as ’complete response’ (CR) (no re-
accumulation of fluid confirmed by CXR), ’partial response’ (PR) (minimal fluid re-
accumulation not sufficient to produce symptoms &/or need for a further aspiration) or
’failure’)
Duration of treatment response
Toxicity
Efficacy of pleurodesis at 2, 3, 6, 9 and 12 months
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Ostrowski 1989 (Continued)
Notes People with trapped lung included in the study
For this review, CR and PR counted as pleurodesis success
Included in network meta-analysis for pleurodesis efficacy, mortality, fever and pain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequentially labelled sealed envelopes
Allocation concealment (selection bias) Low risk Sequentially labelled sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated explicitly, but agents given as
different volumes
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Symptom recurrence and side effect report-
ing would be influenced by lack of blind-
ing. Not stated if CXR assessment was
blinded. Mortality data would not be bi-
ased by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk 14/58 (24%) excluded from primary anal-
ysis due to death or not receiving drug. But,
balanced numbers between the groups
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified
Ozkul 2014
Methods Single centre, prospective RCT comparing rapid and standard drainage prior to talc
slurry pleurodesis (Turkey)
Participants Inclusion: potentially recurrent histologically &/or cytologically proven malignant pleu-
ral effusion (all cell types)
Exclusion: participants whose lung did not expand; endobronchial lesion; suitable for
curative therapy
79 participants randomised
Interventions All participants underwent insertion of a 12 Fr chest drain in the posterior axillary lune
with local anaesthetic (bupivacaine) and IM ketorolac
Rapid group: 1 litre drained every eight hours until complete drainage. Then talc slurry
administered once CXR showed complete fluid evacuation and no trapped lung
Standard group: drainage of a maximum of 1.5 litre/day. Talc slurry administered once
CXR showed complete fluid evaluation and no trapped lung and pleural fluid drainage
85Interventions for the management of malignant pleural effusions: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ozkul 2014 (Continued)
< 300 ml/day
Outcomes Primary outcome: efficacy of pleurodesis assessed at 1, 2, 3, and 6 months
Secondary outcome: hospital length of stay
Notes people with trapped lung excluded from study entry
Pleurodesis efficacy defined using a combination of radiology and symptomatic effusion
re-accumulation
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Internet-based random-number generator
Allocation concealment (selection bias) Unclear risk Not stated and no response from study au-
thors
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind given nature of
two treatment groups with such different
drainage regimes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The assessment of success was performed
by an investigator blinded to allocation”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if any LTFU- not stated in paper
and no response from study authors
Selective reporting (reporting bias) High risk Minimal data provided on side effect and
mortality data.Not all time points reported
as stated in methods
Other bias Low risk No other sources of bias identified
Paschoalini 2005
Methods Two-centre, prospective RCT of silver nitrate vs talc slurry in MPE (Brazil)
Participants Inclusion: documented MPE (positive pleural biopsy or cytology - all cell types); karnof-
sky performance score > 60; life expectancy > 1 month
Exclusion: loculated or trapped lungs after drainage
60 participants randomised
Interventions 26/28 Fr chest tube. After study drug instilled, clamped for one hour with patient
rotation. Then suction applied. Drain removed when < 100 ml drained
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Paschoalini 2005 (Continued)
Talc group: 5 g talc in 50 ml saline. 1 dose intrapleurally
Silver nitrate group: 20 ml of 0.5 ml silver nitrate. 1 dose intrapleurally
Outcomes Radiological resolution of effusion on CXR (monthly for four months)
Pain before and after treatment (measured on a 0-10 linear scale)
Notes People with trapped lung excluded from study entry
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Picking paper from a box
Allocation concealment (selection bias) Low risk Picking paper from a box
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated if blinded but agents have dif-
ferent appearances
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated if CXR interpretation was
blinded. Pain scores may be biased if par-
ticipants not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk High rate of LTFU (11/60 (18%)) but rea-
sons explored in the discussion
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified
Patz 1998
Methods Prospective RCT of bleomycin vs doxycycline in MPE (USA)
Participants Inclusion: symptomatic effusion; proven or strongly suspected that malignancy is the
cause for the effusion
Exclusion: previous pleurodesis; allergy to bleomycin or doxycycline; chemotherapy in
the previous 30 days
106 participants randomised
Interventions All participants underwent a 14 Fr chest drain insertion. When drainage < 200 ml/day
and lung fully re-expanded on CXR, participant randomised
Bleomycin group: 60 units bleomycin in 50 ml saline intrapleurally
Doxycycline group: 500 mg doxycycline in 50 ml saline + 10 ml lignocaine
After 18 - 24 hours, if drainage < 200 ml, drain removed. If > 200 ml, second dose of
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Patz 1998 (Continued)
the same agent given and drain then removed
Outcomes Radiographic response at 30 days (classified as: complete response, partial response,
progressive disease, expired with no re-accumulation, expired with re-accumulation, lost
to follow up)
Mortality
Side effects
Notes Trapped lung not accounted for
If participants died prior to day 30, included in analysis according to their outcome at
the time of their death
For this review, complete response, partial response and expired with no re-accumulation
counted as pleurodesis success
Included in network meta-analysis for pleurodesis efficacy, mortality, fever and pain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Computer-generated randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Study investigators and participants not
blinded to treatment allocation” (personal
communication with study authors)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Study investigators and participants not
blinded to treatment allocation” (personal
communication with authors)
Incomplete outcome data (attrition bias)
All outcomes
High risk Significant LTFU rate (26/106 (ie 25%))
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk Radiological outcome on CXR used to de-
fine pleurodesis success
Rafiei 2014
Methods Single centre RCT comparing the pleurodesis success of doxycycline and bleomycin in
MPE (Iran)
Participants Inclusion: symptomatic, cytologically proven MPE
Exclusion: allergy to doxycycline or bleomycin; past history of sclerotherapy; systemic
chemotherapy immediately prior to or in the next two months after sclerotherapy
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Rafiei 2014 (Continued)
42 participants randomised
Interventions All participants underwent ’fluid evacuation’. Agent then instilled through the tube,
which was clamped for one hour. Then suction applied and drain removed when < 100
ml/24 hr drainage
Bleomycin group: 45 mg bleomycin intrapleurally
Doxycyclline group: 600 mg doxycycline in 50 ml saline and 10 ml 1% lignocaine
intrapleurally
Outcomes CXR appearances of the effusion size at two months (mild, moderate or severe)
Need for repeat pleural fluid drainage
Dyspnoea (mild, moderate or severe)
Complications
Notes People with trapped lung not excluded
Pleurodesis success primarily defined radiologically, but data presented at three months
for need for repeat pleural intervention
For this review, need for repeat pleural drainage was used as measure of pleurodesis
success
Included in network meta-analysis for pleurodesis efficacy, fever and pain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated and no response from study au-
thors to clarify
Allocation concealment (selection bias) Unclear risk Not stated and no response from study au-
thors to clarify
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated if anyone was blinded. No re-
sponse from study authors
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated if anyone was blinded. No re-
sponse from study authors
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow up
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other biases identified
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Rintoul 2014
Methods Open label, multicentre parallel group RCT of VATS pleurectomy and talc pleurodesis
(either slurry or poudrage) in mesothelioma (UK)
Participants Inclusion: age > 18; confirmed or suspected MPM with pleural effusion; fit enough for
VATS pleurectomy
Exclusion: previous pleurodesis; previous primary treatment for MPM; history of previ-
ous malignancy and suspected MPM
Thosewith suspectedMPMwhowere found to have a different cause after randomisation
were excluded from analysis
196 participants randomised
Interventions VATS pleurectomy group: thoracoscopic debulking pleurectomy-decortication under
GA, according to agreed protocol
Pleurodesis group: 4 g talc pleurodesis (either slurry or poudrage)
Outcomes Primary outcome: survival at one year post randomisation
Secondary outcomes: presence or absence of effusion on CXR, QOL (EQ5D and QLQ-
LC13, QLQ-C30), lung function and exercise tolerance, complications, healthcare util-
isation costs
Notes People with trapped lung included. No data available on whether participants in the
pleurodesis arm who had poudrage may have had trapped lung released at the same time
Pleurodesis success defined according to CXR (as assessed by reporting radiologist, un-
blinded to treatment allocation)
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random-number generator
in blocks of 10. 1:1. stratified by EORTC
score (low or high)
Allocation concealment (selection bias) Low risk Telephone randomisation line operated by
staff independent to the study
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind due to nature of the
interventions
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Participants and investigators not blinded,
leading to potential bias in reporting of
quality of life, exercise tolerance and com-
plications. CXRs not interpreted blindly
(personal communication with authors)
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Rintoul 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Participants excluded after randomisation
if MPM not confirmed, but this was stated
a-priori. Missing data well balanced be-
tween the treatment arms
Selective reporting (reporting bias) Low risk Very thorough reporting of all stated out-
comes
Other bias Low risk No other biases identified
Ruckdeschel 1991
Methods Multicentre RCT of intrapleural bleomycin and tetracycline in MPE (USA)
Participants Inclusion: exudative MPE (proven on cytology or pleural biopsy); ECOG performance
score (PS) 0-2
Exclusion: previous intrapleural therapy; prior systemic therapy with bleomycin; severe
congestive heart failure; radiotherapy to the chest in the previous two weeks
115 participants randomised
Interventions All participants had a chest tube placed and had evidence of lung re-expansion on CXR.
After the study drug was inserted the tube was clamed and the participant’s position
rotated. After several hours the chest tube was removed
Group 1: tetracycline 1 g intrapleurally in 100 ml saline
Group 2: bleomycin 120 units intrapleurally in 100 ml saline (due to slow accrual, this
group was dropped after accruing 15 participants)
Group 3: bleomycin 60 units intrapleurally in 100 ml saline
Outcomes Recurrance of effusion at 30 days and 90 days (defined according to CXR)
Time to effusion recurrence within 90 days
Time to maximum change in ECOG PS
Change from initial PS to the best PS (worsened/no change/improved)
Adverse events
Notes People with trapped lung excluded
Group 2 dropped due to slow accrual and data on the 15 participants assigned to this
group not provided
Included in network meta-analysis for pleurodesis efficacy, mortality, pain and fever
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation, with
stratification
Allocation concealment (selection bias) Low risk Computer randomisation
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Ruckdeschel 1991 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated if anyone was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated if anyone was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Lots of patients excluded from analysis (41/
115 ’non-evaluable’). Reasons given
Selective reporting (reporting bias) High risk Data on 15 patients randomised to high
dose bleomycin group not reported
Other bias Low risk No other biases identified
Salomaa 1995
Methods Single centre RCT of pleurodesis with doxycycline and C. parvum in MPE (Finland)
Participants Inclusion: pleural effusion refractory to repeat aspirations; pleural malignancy - all cell
types (histocytologically proven or confirmed malignancy elsewhere)
Exclusion: none
41 participants randomised
Interventions 16 Fr Argyll drain inserted under local anaesthetic and drained with suction until output
< 100 ml/day. CXR to confirm lung re-expansion prior to pleurodesis
D100 group: doxycycline 100 mg given intrapleurally. 1 dose
D600 group: doxycycline 600 mg given intrapleurally. 1 dose
C1 group: C. parvum 1 mg intrapleurally. 1 dose
C7 group: C. parvum 7 mg intrapleurally. 1 dose
All drugs diluted in 20 ml saline and a 50 ml flush was administered after the dose. Chest
tube removed immediately after sclerosant given
Outcomes Pleurodesis success (defined using CXR and need for repeat thoracentesis at 30 days)
Mortality
Side effects
Blood/pleural fluid IL-6
Daily CRP for seven days
Notes For the purposes of our analysis, we have decided to combine the two doses of each agent
to allow comparison between the agents themselves
People with trapped lung excluded from study
Included in network meta-analysis for pleurodesis efficacy, fever and pain
Risk of bias
Bias Authors’ judgement Support for judgement
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Salomaa 1995 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated if anyone was blinded. Unable
to contact study authors
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated if anyone was blinded. Unable
to contact study authors
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6/41 (15%) patients LTFU
Selective reporting (reporting bias) High risk Minimal data provided on survival or bio-
chemical markers. Minimal data on base-
line participant characteristics and whether
the treatment groups were well matched
Other bias Low risk Underpowered
Sartori 2004
Methods Single centre RCTevaluating intrapleural bleomycin vs interferon alfa-2b in the palliative
treatment of malignant effusion (Italy)
Participants Inclusion: cytologically proven MPE requiring at least two thoracenteses in preceding
four weeks; at least 3 L drained in the preceding four weeks; adequate pulmonary re-
expansion on CXR after thoracentesis; last systemic treatment administered at least six
weeks prior to enrolment; no further chemotherapy options; Karnofsky performance
score > 40
Exclusion: none
160 participants randomised
Interventions All patients underwent a 9 Fr intercostal drain insertion under ultrasound scan (USS)
guidance. Fluid was drained via a 3-way-tap until USS revealed no residual effusion.
Study drug administered IP via the chest tube. Tube was then clamped for two hours
and participants changed position every 15 minutes. Tube removed 24 - 48 hours after
the last dose
Bleomycin group: 0.75 mg/kg bleomycin in 50 ml saline. A repeated dose was given if
> 100 ml/day output three days after the first dose
IFN alfa-2b group: 1 million units/10 kg in 200 ml saline. Six doses given every four
days
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Sartori 2004 (Continued)
Outcomes Treatment response at 30 days (complete response (no fluid re-accumulation), partial
response (asymptomatic fluid recurrence < 50% of the original effusion, not requiring
thoracentesis), no response (fluid recurrence > 50% of the original effusion, requiring
thoracentesis))
Time to progression
Number of thoracenteses until death
Notes Deaths included in the analysis as failures (as presented in the paper as ITT analysis)
People with trapped lung excluded from trial entry
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Computer-generated randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated explicitly but two drugs were
given as different volumes
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Synptom recurrence and adverse event re-
porting may be biased by lack of blind-
ing. Mortality not biased by lack of blind-
ing. Not stated if CXR interpretation was
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk No other biases identified
Schmidt 1997
Methods Multi-centre RCT comparing pleurodesis using bleomycin with mitoxantrone (Ger-
many). Paper in German
Participants Inclusion: symptomatic, cytologically proven MPE; life expectancy > 3 months; WHO
performance score 0-2
Exclusion: prior chemotherapy or pleurodesis in previous four weeks; contraindication to
bleomycin or mitoxantrone; persistent pneumothorax; leucopenia; thrombocytopaenia;
incomplete pleural fluid drainage
102 participants randomised
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Schmidt 1997 (Continued)
Interventions All participants had a 24 Fr chest drain inserted and left in situ for 48 hours
Bleomycin group: single dose of 60 mg bleomycin in 100 ml saline intrapleurally
Mitoxantrone group: single dose of 30 mg mitoxantrone in 100 ml saline intrapleurally
Drains clamped for six hours after instillation and left in place for 24 - 48 hours with or
without suction
Outcomes Pleurodesis success rate at four weeks (defined by recurrence of effusion requiring repeat
pleural procedure)
Toxicity/adverse events
Length of hospital stay
Time to repeat pleural intervention
Notes Translated from German
People with trapped lung excluded from participation
Included in network meta-analysis for pleurodesis efficacy, mortality, fever and pain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Telephone randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated if anyone was blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated if anyone was blinded. If
unblinded, symptom recurrence, adverse
event reporting and length of stay could
have been biased
Incomplete outcome data (attrition bias)
All outcomes
Low risk Six participants excluded from analysis, but
reasons given and balanced numbers in the
two treatment arms
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk No other biases identified
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Sorensen 1984
Methods Single centre RCT comparing talc instillation with pleural drainage only in the treatment
of MPE (Denmark)
Participants Inclusion: histologically proven MPE (all cell types) causing respiratory distress, which
is progressive and resistant to conventional therapy
Exclusion: failure of the underlying lung to totally re-expand within 72 hours of the
thoracoscopy
31 participants randomised
Interventions All participants underwent thoracoscopy, during whichmultiple biopsies were taken and
a drain inserted. Suction applied until complete lung re-expansion
Drainage alone group: constant suction for 72 hours after complete lung re-expansion.
Then, drain removed
Talc and drainage group: 10 g sterile talc in 250 ml saline instilled through chest tube and
clamped for two hours. Then suction applied for 72 hours and the drain was removed
Outcomes Fluid re-accumulation on CXR every month for three months
Notes People with trapped lung excluded from trial entry
No data provided on whether treatment arms well matched at baseline
Power calculation performed
Unclear if adverse events reported for all participants or only those who completed the
follow up
Pleurodesis defined using radiology only
Included in network meta-analysis for pleurodesis efficacy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk “Closed envelope system”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind due to nature of the in-
terventions (pleural drainage alone, or with
talc administration)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Adverse event reporting could be biased by
lack of blinding. Not stated if CXR inter-
pretation was blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 10/31 (32%) excluded from primary anal-
ysis (but well balanced between the two
treatment arms)
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Sorensen 1984 (Continued)
Selective reporting (reporting bias) Low risk No comment on mortality or survival, but
an old study and not stated as an outcome
measure in the paper
Other bias Low risk No other biases identified
Terra 2009
Methods Single centre RCT evaluating VATS talc poudrage and talc slurry in malignant pleural
effusion (Brazil)
Participants Inclusion: biopsy or cytology proven MPE (all cell types); recurrent and symptomatic
effusion; chest radiograph confirming lung expansion of > 90% after thoracentesis;
Karnofsky PS ≥ 70
Exclusion: comorbidities that preclude GA; bleeding disorders; massive thoracic skin
infiltration; active infection; refusal to sign informed consent
60 participants randomised
Interventions One dose of 5 g non-calibrated talc given intrapleurally to both trial groups. Post pro-
cedure care and analgesia the same for the two groups. No suction used in either group.
Drain removed when < 200 ml/24 hr drainage, or after 10 days if drain volume too high,
participants were discharged with the drain in situ and a Heimlich valve
VATS group: VATS performed under general anaesthesia, followed by talc poudrage. 28
Fr chest drain inserted at end of procedure
Talc slurry group: 28 Fr chest drain inserted under local anaesthetic. Following day, talc
suspended in 60 ml saline with 5 ml 2% lignocaine and instilled through chest drain.
Clamped for one hour post procedure
Outcomes Lung expansion on CT measured on a 3-point scale at baseline, 1, 3 and 6 months
Clinical efficacy (success defined as no need for a new pleural procedure due to symptoms
and radiological effusion recurrence)
Quality of Life
Safety
Survival
Chest drain duration
Length of hospital stay
Perioperative complications
Notes Raw data for survival, pleurodesis rates at certain time points, intervention rates at certain
time points and QOL data not presented
People with trapped lung excluded from trial entry
Pleurodesis success rate defined using symptoms and radiology
Study authors contacted for further information, but no reply
Included in network meta-analysis for pleurodesis efficacy and fever
Risk of bias
Bias Authors’ judgement Support for judgement
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Terra 2009 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind due to nature of the inter-
ventions (talc poudrage vs talc slurry)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Symptom recurrence, quality of life, inpa-
tient stay and adverse event reporting could
be biased by lack of blinding. Interpretation
of CTs was done by two blinded observers,
however pleurodesis efficacywas defined by
need for repeat intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow up
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Low risk No other biases identified
Terra 2015
Methods Single centre RCT evaluating three different doses of silver nitrate for pleurodesis in
malignant pleural effusion (Brazil)
Participants Inclusion criteria: recurrent and symptomatic MPE (with pleural histological or cyto-
logical confirmation); previous CXR showing full lung expansion (> 90%) after chest
drainage; Karnofsky performance score > 40; written consent
Exclusion criteria: trapped lung after pleural catheter insertion; haemorrhagic diathesis
(PT < 50% or platelets < 80,000); active pleural or systemic infection; neoplastic infil-
tration of the skin at the site of pleural catheter insertion; inability to understand QoL
questionnaires; contralateral pleurodesis < 30 days before study entry
60 participants randomised
Interventions All participants were admitted for five days and had baseline assessment. All had a 14
Fr chest drain inserted under USS guidance prior to randomisation. The randomised
interventions were given via the chest tube, which was then clamped for one hour. Drain
removed on day 5
The silver nitrate was dissolved in 100 ml distilled water, which was passed through a 0.
22 micrometer filter to ensure sterility within six hours of instillation
Group 1: 30 ml of 0.3% silver nitrate (90 mg) given as a single dose intrapleurally
Group 2: 30 ml of 0.5% silver nitrate (150 mg) given as a single dose intrapleurally
Group 3: 60 ml of 0.3% silver nitrate (180 mg) given as a single dose intrapleurally
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Terra 2015 (Continued)
Outcomes Primary outcome: occurrence of serious or severe adverse event during follow up
Secondary outcomes: systemic inflammation (measured using CRP); chest pain (mea-
sured using VAS score); effusion recurrence (defined as need for additional pleural proce-
dures during trial follow up); residual pleural cavity volume (calculated using difference
between day 5 and day 30 on CT)
Notes People with trapped lung excluded from study entry
Pleurodesis failure defined as need for additional pleural procedure during follow up
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Pharmacy employees and clinicianswho in-
stilled the sclerosant were aware of treat-
ment allocation, but these clinicians were
not involved in patient follow up. Partic-
ipants, investigators that followed partici-
pants up and rated their complicationswere
blinded to group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Pharmacy employees and clinicianswho in-
stilled the sclerosant were aware of treat-
ment allocation, but these clinicians were
not involved in patient follow up. Partic-
ipants, investigators that followed partici-
pants up and rated their complicationswere
blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk LTFU well balanced and justified
Selective reporting (reporting bias) Low risk Nodata provided forMRCdyspnoea score.
Otherwise all predefined outcome mea-
sures reported
Other bias Low risk No other biases identified
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Ukale 2004
Methods Single centre RCT comparing intrapleural talc and mepacrine given via a chest tube after
thoracoscopy (Sweden)
Participants Inclusion criteria: recurrant, symptomatic pleural effusions, known or suspected to be
due to malignancy; eligible for thoracoscopy and pleurodesis
Exclusion criteria: incomplete lung re-expansion after thoracoscopy
89 participants with confirmed malignant pleural effusions were randomised (110 par-
ticipants randomised in total, but some had benign causes)
Interventions All participants underwent a local anaesthetic thoracoscopy, with biopsies and a 20 Fr
drain was inserted at the end of the procedure. A chest X-ray was performed to ensure
lung re-expansion before randomisation
Mepacrine group: 500 mg mepacrine in 200 ml saline intrapleurally
Talc group: 5 g talc in 200 ml saline intrapleurally
In both groups, a second dose was given if > 50 ml/day drainage on day 3. Drains
removed when < 50 ml/24hour drainage
Outcomes Primary: pleurodesis success (using clinical and radiological definition). Reported at day
6, 2 weeks, 2 months, 4 months and 6 months
Secondary: analgesia use; side effects; mortality
Notes People with trapped lung excluded. Note that two doses may have been given
Included in network meta-analysis for pleurodesis efficacy and mortality
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Opaque sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind as drugs different appear-
ances
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Radiologists reporting CXRs were blind to
treatment allocation. Symptom recurrence
and adverse event reporting may be biased
by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for loss to follow up and exclu-
sions reported and well matched between
the groups
Selective reporting (reporting bias) Low risk Data for those with proven MPE obtained
from authors
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Ukale 2004 (Continued)
Other bias Low risk No other biases identified
Villanueva 1994
Methods Single Centre RCT of short-term vs long-term drainage before tetracycline pleurodesis
of MPE (USA)
Participants Inclusion: moderate to large MPE, proved by cytology or pleural biopsy, causing respi-
ratory symptoms; expected survival of > 1 month; KPS > 40%
Exclusion: previous chemical pleurodesis on the ipsilateral side; ipsilateral atelectasis due
to complete airway obstruction by tumour
25 participants randomised
Interventions 28 Fr chest drain inserted. Tetracycline 1.5 g in 100 - 150 ml pleurodesis
Standard Care (long-term drainage): tube suction drainage until lung re-expansion and
< 150 ml/day drainage, then tetracycline pleurodesis and drain removed the following
day
Short-term drainage: tube suction drainage until lung re-expansion, then tetracycline
pleurodesis and drain removed the following day
Outcomes Pleurodesis success at one month (defined using CXR and need for repeat procedure)
Duration of tube drainage
Patient outcome (dead/alive - ? time point)
Notes Lung re-expansion confirmed on CXR prior to instillation of tetracycline
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation
Allocation concealment (selection bias) Low risk Computer randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind as different timings of in-
terventions
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Symptom recurrence could be biased by
lack of blinding.Not stated if radiologywas
reported blindly
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1/25 patients LTFU
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Villanueva 1994 (Continued)
Selective reporting (reporting bias) Low risk All stated outcomes reported; minimal in-
formation on safety/complications
Other bias Low risk None
Yildirim 2005
Methods Single centre RCT of rapid vs standard pleurodesis with oxytetracycline (Turkey)
Participants Symptomatic MPE, confirmed on cytology or pleural biopsy
27 participants randomised
Interventions 12 Fr drain inserted. Pleurodesis agent: oxytetracycline 35 mg/kg
Standard protocol: drainage until lung re-expansion & fluid drainage < 150 ml/day.
Then pleurodesis as a single dose. Drain clamped for six hours and removed when < 150
ml/day drainage
Rapid protocol: pleurodesis given as 4 divided doses, every six hours after aspiration
through the drain
Outcomes Response to pleurodesis (CR/PR/Failure) as defined by radiological recurrence and need
for thoracentesis
Notes People with trapped lung not excluded
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Low risk Random number table
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind as different durations of
drainage and aspiration schedules
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Symptom recurrence and duration of hos-
pital stay may be biased by lack of blinding.
Mortality not biased by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data well balanced between the
groups. At one month 2/27 had died and
were therefore non-evaluable
Selective reporting (reporting bias) Low risk All stated outcomes reported
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Yildirim 2005 (Continued)
Other bias Low risk No other biases identified
Yim 1996
Methods Single centre RCT of talc insufflation versus talc slurry for symptomatic MPE (Hong
Kong)
Participants Inclusion: established, symptomatic MPE (all cell types); dyspnoea improved after tube
thoracostomy or large volume thoracentesis
Exclusion: Karnofsky score < 30%; FEV1 < 0.5 L; trapped lung; chemotherapy or ra-
diotherapy within six months
57 participants randomised
Interventions Talc insufflation group: all participants underwent a GA with one lung ventilation in
the lateral decubitus position. 10 mm port inserted. Adehsions and loculations broken
down. 5 g talc insufflated into the chest. 28 Fr tube at end of procedure, connected to
suction. Drain removed when < 50 ml/24 hours drainage
Talc slurry group: chest tube. 5 g talc in 50 ml saline and 10 ml 2% lidocaine instilled
through the drain. Drain clamped for two hours and participant turned Drain recon-
nected to suction and removed when output < 50 ml/24hours
Outcomes Radiological recurrence of effusion
Complications of the procedure
Post-procedure chest drain duration
Length of hospital stay
Parenteral meperidine use
Notes People with trapped lung excluded from trial entry
Included in network meta-analysis for pleurodesis efficacy and mortality
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unable to blind due to nature of the inter-
ventions
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Adverse event reporting and length of
stay may be biased by lack of blinding.
Not stated whether radiology was reported
blindly
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Yim 1996 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data reported. Survial data not entirely
clear
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk Unclear howmanypatients in the poudrage
arm had a drain in situ at the time of trial
entry. Pleurodesis success only defined us-
ing radiology
Yoshida 2007
Methods Multicentre RCT of bleomycin,OK-432 and cisplatin plus etoposide (PE) pleurodesis
in MPE (Japan)
Participants Inclusion: cyto or histo proven MPE associated with newly diagnosed NSCLC; age ≤
75; ECOG performance score 0 - 2; full lung re-expansion after chest drainage; adequate
bone marrow reserve, liver and renal functions
Exclusion: prior chemotherapy, thoracic RT or thoracic surgery; bilateral pleural effu-
sion or pericardial effusion; symptomatic brain metastases; active synchronous cancer;
interstitial pneumonitis; pulmonary fibrosis; uncontrolled angina/MI in preceding three
months; uncontrolled diabetes or hypertension; pregnancy or breastfeeding; penicillin
allergy
102 participants randomised
Interventions Large- or small-bore chest tube inserted. After instillation of the study agent, participant
rotated position for three hours
Bleomycin group: 1 dose, 1 mg/kg (max 60 mg) of intrapleural bleomycin in 100 ml
saline
ok-432 group: 1 dose of 0.2 KE units/kg (max 10 KE) of intrapleuralOK-432 in 100
ml saline
PE group: 1 dose cisplatin 80 mg/m2 and etoposide 80 mg/m2 intrapleurally in 100 ml
saline
Outcomes Pleural progression-free survival at 4, 8, 12 and 24 weeks (defined on CXR and need for
local treatment)
Overall survival
Toxicity
Notes People with trapped lung not eligible for inclusion
Study authors emailed for more information, but no response
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
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Yoshida 2007 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated if anyonewas blinded. Same vol-
ume of instillate in both arms
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated if anyone was blinded. If un-
blinded, reporting of symptom recurrence
and toxicity could have been biased. Not
stated if radiology was reported blindly but
the definition of pleurodesis also incorpo-
rated symptom recurrence
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow up
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk Radiology may be difficult to assess as pop-
ulation has underlying lung cancer
Zaloznik 1983
Methods RCT of tetracycline pleurodesis versus placebo of the same pH as tetracycline (USA)
Participants Inclusion: biopsy proven malignancy; recurrent pleural effusion; expected survival > 1
month; Karnofsky performance score ≥ 40%
30 participants randomised
Interventions Chest tube inserted and in place for at least 24 hours. After pleurodesis agent instilled,
tube clamped for two hours and participant’s position changed. Then left in place for
12 - 24 hours until minimal drainage
Tetracycline group: 500 mg tetracycline in 50 ml saline intrapleurally. 1 dose
Control group: 0.6 ml multivitamins, 5 ml of 0.1 NHCl and 50 ml saline intrapleurally.
1 dose
Outcomes Reaccumulation of effusion on CXR at 1 month and 3 months (CR/PR/Stabilisation/
progression)
Side effects
Notes CR, PR & stable disease counted as pleurodesis success for purposes of analysis
Some participants with bilateral effusions entered into the study, but not clear whether
both sides were randomised. Therefore for purposes of analysis, only the first side has
been included
Included in network meta-analysis for pleurodesis efficacy
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Zaloznik 1983 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-Blind” (no further details given)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double-Blind” (no further details given)
Incomplete outcome data (attrition bias)
All outcomes
High risk Time point at which primary outcome
measured not clear. Minimal data on base-
line participant characteristics. Participants
who died within one month excluded from
analysis (11/30 not evaluable)
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk No other biases identified
Zhao 2009
Methods Single centre RCT of intrapleural Ad-p53 and cisplatin, compared with cisplatin alone
in MPE due to lung cancer (China)
Participants Inclusion: MPE due to lung cancer confirmed by CT, thoracic ultrasound and cytohis-
tological examination; expected survival of > 3 months; Karnofsky PS > 60
Exclusion: abnormal ECT, liver function, kidney function and routine blood examina-
tion; previous chemotherapy, radiotherapy or biological therapy
35 participants randomised
Interventions All participants had chest drain inserted and effusion drained completely. All received
systemic vinorelbine. All received 10mg intrapleural (IP) dexamethasone after instillation
of trial drugs. Drug administration was repeated weekly for four weeks or until pleural
effusion resolved
Combination group: Ad-p53 (1 x 1012VP) in 100 ml saline IP. Then cisplatin 40 mg/
m2 in 100 ml saline IP
Single agent group: cisplatin 40 mg/m2 in 100 ml saline IP
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Zhao 2009 (Continued)
Outcomes Therapeutic efficacy (CR/PR/SD/PD) - as defined by extent of effusion and radiology
and symptoms, at four weeks
Change in Karnofsky performance status from baseline to four weeks
Adverse events
Notes People with trapped lung not excluded from the study
CR and PR counted as a successful pleurodesis for the purposes of analysis
Study authors emailed for further information, but no response
Not included in network meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not stated explicitly but combination
group received two intrapleural treatments,
while other arm only received one
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Symptoms, quality of life and adverse
events could be biased by lack of blinding.
Not stated if radiologywas reported blindly
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow up
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk No other biases identified
Zimmer 1997
Methods Prospective RCT of talc vs bleomycin pleurodesis for symptomatic MPE (USA)
Participants Inclusion: MPE (all cell types); life expectancy > 1 month
Exclusions: significant loculated effusions; trapped lung
40 procedures randomised in 35 participants
Interventions All participants underwent tube thoracostomy (either at the end of a limited thoracotomy
(two participants) or inserted at bedside (33 participants)). Tube remained on suction.
After sclerosant injected intrapleurally, tube clamped for two hours and participant
rotated
Talc group: 5 g talc in 50 ml saline, with 20 ml 1% lignocaine. 1 dose
Bleomycin group: 60 U bleomycin in 50 ml saline, with 20 ml 1% lignocaine. 1 dose
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Zimmer 1997 (Continued)
Outcomes Effusion control on CXR (at a minimum of two weeks)
Dyspnoea (according to functional class 1 - 4)
Pain (according to scale 0 - 10)
Cost
Length of hospital stay
Notes People with trapped lung excluded
Participants only included in primary analysis if out of hospital and able to attend follow
up at two weeks
Study authors emailed for more information, but no response
Included in network meta-analysis for pleurodesis efficacy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not explicitly stated but drugs haddifferent
appearances
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Symptom recurrence, pain, breathlessness,
duration of stay and adverse events could
all be biased by lack of blinding. Not stated
radiology reported blindly
Incomplete outcome data (attrition bias)
All outcomes
High risk No clear time point when follow up per-
formed. Only those available for follow
up included in the analysis. Unclear how
many randomised to each arm (only data
on numbers analysed by treatment arm)
Selective reporting (reporting bias) Low risk All outcomes reported on
Other bias Low risk No other biases identified
ECOG: electrocochleography
IV: intravenous
LTFU: loss to follow up
QOL: quality of life
RCT: randomised controlled trial
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Caglayan 2008 Study not truly randomised. Participants allocated to treatment groups using alternation
Dryzer 1993 Unable to differentiate between participants with benign andmalignant disease in the results section.
Also high risk of bias from randomisation method (allocated to treatment groups based on the last
digit of their hospital number)
Elayouty 2012 Unclear from text if truly randomised - participants given number on entering study - allocated to
bleomycin if number was odd and allocated to povidone group if number was even. Study authors
emailed for clarification but no response
Engel 1981 Study not truly randomised. Participants allocated to treatment groups based on the day of the
calendar month
Gust 1990 Pilot data (not randomised) and randomised data presented grouped together. Unable to split out
the pilot group
Kwasniewska-Rokicinska 1979 Participants with pleural effusions and ascites included, but unable to differentiate between them
in the results section
Lissoni 1995 Unable to differentiate between pleural, pericardial and peritoneal effusions in the results. No
response from study authors
Maiche 1993 Study not truly randomised. Participants allocated to bleomycin group if met a list of criteria,
otherwise given mitoxantrone
Manes 2000 Study not truly randomised. Participants allocated to treatment groups based on the month of their
diagnosis with MPE
Nio 1999 Participants with pleural and peritoneal effusions included in the study and unable to differentiate
them in the results
Tattersall 1982 Insufficient information in paper to extract required data (e.g. unclear how pleurodesis success was
defined and at what time point)
Characteristics of studies awaiting assessment [ordered by study ID]
Bo 1998
Methods Randomised study comparing highly agglutinative staphylococcin plus cisplatin with cisplatin alone
Participants 74 participants with malignant pleural effusion and ascites
Interventions Unclear from abstract how agents were delivered
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Bo 1998 (Continued)
Outcomes Reduction in effusion/ascites volume
Karnofsky score
Notes Full text only available in Chinese and unable to translate. Need to confirm if pleural and ascites data is presented
separately and how the agents were delivered
Cong 2010
Methods RCT of pleural perfusion of nedaplatin and cisplatin in MPE due to non-small cell lung cancer
Participants 68 participants with lung cancer associated with malignant pleural effusion
Interventions Participants randomised into two groups:
1. 40 mg/m2 nedaplatin and 10 mg dexamethasone given intrapleurally
2. 40 mg/m2 cisplatin and 10 mg dexamethasone in 40 ml saline given intrapleurally
Agents given weekly for 2 - 4 weeks
Outcomes Treatment response
Side effects
Karnofsky performance status
Survival
Notes Full text only available in Chinese and unable to translate
Fukuoka 1984
Methods RCT of intrapleural Adriamycin and Nocardia rubra cell wall skeleton, compared with Adriamycin alone
Participants 55 participants with MPE due to lung cancer
Interventions Agents given via tube thoracostomy. No other details available
Outcomes Treatment response
Notes In Japanese. Unable to translate
Miyanaga 2011
Methods Trial comparing bleomycin,OK-432 and cisplatin plus etoposide in MPE due to non-small cell lung cancer
Participants Malignant pleural effusion due to previously untreated non-small cell lung cancer
Interventions Intrapleural bleomycin,OK-432 and cisplatin plus etoposide
Outcomes Progression-free survival
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Miyanaga 2011 (Continued)
Notes In Japanese. Unable to translate. No details in abstract as to whether it is randomised or the number of participants
in the study
Song 2013
Methods RCT comparing intrapleural pseudomonas aeruginosa, with cisplatin and interleukin-2
Participants 90 participants with malignant pleural effusion
Interventions Agents administered through intrathoracic infusion. No other information available
Outcomes Clinical efficacy and adverse reactions
Notes Written in Chinese and unable to obtain a translation. Only abstract available in English
Sun 2002
Methods RCT of intrapleural Ya-Dan-Zhi’s grease (YDZ) and cisplatin in MPE
Participants 72 participants with MPE
Interventions Randomly divided between three groups:
• YDZ 80 ml and cisplatin 60 mg intrapleurally once per week
• YDZ 80 ml intrapleurally once per week
• cisplatin 60 mg intrapleurally once per week
Outcomes Treatment effect
Side effects
Notes In Chinese and unable to obtain a translation. Unclear from abstract if study would be eligible for inclusion in the
review
Won 1997
Methods RCT comparing intrapleural doxycycline and bleomycin
Participants 34 patients with MPE requiring repeated thoracentesis
Interventions Participants received either intrapleural doxycycline or bleomycin
Outcomes Fluid volume
Side effects
Response to treatment (on CXR and clinical examination)
Survival
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Won 1997 (Continued)
Notes In Korean. Only abstract available in English. Unable to obtain a translation
Xu 2010
Methods RCT evaluating the effect of intrapleural highly agglutinative staphylococcin (HAS) combined with nedaplatin,
compared to nedaplatin alone
Participants 58 participants with MPE
Interventions Participants randomised to two groups:
• intrapleural HAS with nedaplatin
• nedaplatin alone
Outcomes Treatment response
Adverse effects
Quality of life
Notes In Chinese. Only abstract available in English and unclear from it whether the study is eligible. Unable to obtain
translation of the full text
Yu 2003
Methods RCT comparing cisplatin and lentinan in malignant pleural effusion
Participants 64 participants with MPE
Interventions Randomised into two groups:
• intrathoracic cisplatin and lentinan
• intrathoracic cisplatin only
Outcomes Response rates
Notes In Chinese. Only abstract available in English and unclear from it whether the study is eligible. Unable to obtain
translation of the full text
Zhuang 2012
Methods RCT comparing matrine injection (yanshu) combined with intrapleural cisplatin for treatment of haematologic
malignancies complicated by pleural effusion
Participants 46 participants with haematological malignancy complicated by pleural effusion
Interventions Participants randomly divided into two groups:
• intrapleural cisplatin 20 mg/m2 and yanshu 10 ml/m2 and dexamethasone 5 mg/m2
• intrapleural cisplatin 20 mg/m2 and dexamethasone 5 mg/m2
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Zhuang 2012 (Continued)
Outcomes Efficacy
Adverse effects
Notes In Chinese. Only abstract available in English and unclear from it whether the study is eligible. Unable to obtain
translation of the full text
Characteristics of ongoing studies [ordered by study ID]
AMPLE Trial
Trial name or title Australasian Malignant Pleural Effusion (AMPLE) Trial
Methods Multicentre, international RCT comparing IPC to talc pleurodesis
Participants Aiming to recruit 146 participants to the study
Inclusion: symptomatic MPE requiring intervention and written informed consent
Exclusion: age < 18; effusion < 2 cm max depth; expected survival < 3 months; chylothorax; previous ip-
silateral lobectomy or pneumonectomy; previous pleurodesis; pleural infection; white cell count < 1 x109/
L; hypercapnic ventilatory failure; pregnancy or lactation; irreversible bleeding diathesis; irreversible visual
impairment; inability to give informed consent or comply with the protocol
Interventions Participants randomised 1:1 to IPC or talc pleurodesis
Outcomes Primary: number of days spent in hospital for any cause following intervention until death or end of study
follow-up
Secondary: admissions for pleural effusion-associated causes; survival and adverse events; breathlessness and
QOL; health cost assessment
Starting date 1 June 2012
Contact information gary.lee@uwa.ed.au
Notes
IPC-Plus
Trial name or title The efficacy of indwelling pleural catheter placement versus IPC placement plus sclerosant (talc) in patients
with malignant pleural effusions managed exclusively as outpatients
Methods Multi-centre, single-blind RCT of talc slurry or placebo administered via an indwelling pleural catheter
Participants Aiming to recruit 154 participants to the study
Inclusion criteria:
Exclusion criteria:
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IPC-Plus (Continued)
Interventions Participants in both arms undergo IPC insertion. At day 10 post insertion, participants randomised to 4 g
intrapleural talc or placebo. Followed up for 10 weeks. Participants blinded to treatment allocation
Outcomes Primary: pleurodesis success at five weeks post randomisation
Secondary: QOL; pain and breathlessness VAS Scores; volume of pleural fluid drained; mortality; hospital
inpatient bed days; degree of loculation on ultrasound; pleurodesis success at 10 weeks post randomisation;
number of pleural procedures required to relieve pleural fluid
Starting date 11 July 2012
Contact information rbhatnagar@doctors.org.uk
Notes
OPUS Trial
Trial name or title Effectiveness of doxycycline for treating pleural effusions related to cancer in an outpatient population (OPUS)
Methods RCT of doxycycline versus placebo administration via a PleurX catheter in MPE
Participants Malignant pleural effusion; fully expanded lung post drainage of the pleural effusion
Target recruitment of 50 participants
Interventions Participants have a PleurX catheter inserted and are then randomised to intrapleural doxycycline or placebo
Outcomes Primary: pleurodesis rate at 90 days
Secondary: time to pleurodesis
Starting date 2009
Contact information brepatenaude@toh.on.ca; kamjadi@toh.on.ca
Notes NCT01411202
TAPPS
Trial name or title Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry: a randomised
trial to determine the most effective method for the management of malignant pleural effusions in patients
with a good performance status (The TAPPS Study)
Methods The TAPPS trial is a multi-centre randomised controlled study which compares the efficacy of chest drain
insertion and talc slurry instillation with local anaesthetic thoracoscopy and talc poudrage, in themanagement
of malignant pleural effusions
Participants Inclusion: clinically confident diagnosis of malignant pleural effusion requiring pleurodesis; fit enough to
undergo local anaesthetic thoracoscopy; expected survival > 3 months
Exclusion: patients requiring a thoracoscopy to make a diagnosis; age < 18 years; pregnancy or lactation; evi-
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TAPPS (Continued)
dence of extensive lung entrapment; insufficient pleural fluid to safely perform local anaesthetic thoracoscopy;
adverse reaction to talc; contraindication to thoracoscopy or chest tube insertion
Aiming to recruit 330 participants.
Interventions Control arm: 12 - 14 Fr seldinger drain, then 4 g talc slurry pleurodesis
Intervention arm: medical thoracoscopy, with 4 g talc poudrage at end of the procedure
Outcomes Primary endpoint: the number of participants who experience pleurodesis failure up to three months (90
days) post randomisation
Secondary endpoints: requirement for further pleural procedures up to six months post-randomisation; per-
centage radiographic (chest X-ray) pleural opacification at 1, 3 and 6 months post randomisation; quality of
life; thoracic pain; breathlessness; pleurodesis failure at 1 and 6 months; mortality
Starting date 26 September 2012
Contact information rbhatnagar@doctors.org.uk
Notes
TIME-1
Trial name or title The first therapeutic interventions in malignant effusion trial (TIME-1)
Methods 2 x 2 randomised factorial trial to assess whether non-steroidal analgesia and the use of small-bore chest tubes
will reduce pain during pleurodesis for MPE, compared to standard care
Participants 320 target recruitment (interim analysis after 120 participants)
Inclusion: clinically confident diagnosis of MPE requiring pleurodesis; written informed consent; expected
survival > 1 month
Exclusion: age < 18; primary lymphoma or small cell lung carcinoma; pregnancy or lactation; history of gastro
intestinal (GI) bleeding or untreated peptic ulceration; known sensitivity to non-steroidal anti-inflammatory
drugs (NSAIDs) or opiates; hypercapnic ventilatory failure; intravenous drug use; severe renal or liver disease;
bleeding diathesis; warfarin therapy which must be continued; current or recent corticosteroid therapy
Interventions Participants will be randomised to one of the following arms:
• Large-bore (24 F) chest drain and NSAID-based analgesic regimen
• Small-bore (12 F)chest drain and NSAID-based analgesic regimen
• Large-bore chest drain (24 F) and opiate-based analgesic regimen
• Small-bore chest drain (12 F) and opiate-based analgesic regimen
Outcomes Primary: pain score over 72 hours post pleurodesis
Secondary: success of pleurodesis at 6 weeks and 3 months; presence of ipsilateral, chronic chest pain at 6
weeks and 3 months
Starting date 1 September 2006
Contact information emma.hedley@ouh.nhs.uk
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TIME-1 (Continued)
Notes
TIME-3
Trial name or title Adjuvant urokinase in the treatment of malignant pleural effusion: the third therapeutic intervention in
malignant effusion trial (TIME3-UK)
Methods A double blind, randomised controlled trial to evaluate whether use of intrapleural urokinase aids the drainage
of multi-septated pleural effusion compared to placebo
Participants Inclusion: clinically confident diagnosis of pleural malignancy; significant multi-loculated pleural effusion
despite the presence of a patent in-situ chest tube; MPE requiring drainage and pleurodesis for symptom
control
Exclusion: age <18; expected survival < 28 days; previous ipsilateral pneumonectomy; previous IP fibrinolytics;
ipsilateral pleural infection; sensitivity to urokinase; coincidental stroke, major haemorrhage or trauma; major
surgery in past five days; chylothorax; white cell count < 1 x 109; pregnancy or lactation; irreversible bleeding
diathesis; platelets < 100 x 109; irreversible visual impairment
Interventions Participants randomised to three doses of 100,000 IU urokinase 12 hourly intrapleurally or placebo through
an intercostal drain. All participants then undergo a talc pleurodesis. Followed up for 12 months
Outcomes Primary: mean daily breathlessness score over 28 days from randomisation; time to pleurodesis failure
Secondary: improvement of effusion on radiology; volume of pleural fluid drained; QOL; healthcare costs
Starting date 2008
Contact information emma.hedley@ouh.nhs.uk
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Bleomycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 21 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Bleomycin vs iodine 1 39 Odds Ratio (M-H, Random, 95% CI) 0.8 [0.18, 3.57]
1.2 Bleomycin vs talc slurry 5 199 Odds Ratio (M-H, Random, 95% CI) 1.22 [0.55, 2.70]
1.3 Bleomycin vs tetracycline 5 220 Odds Ratio (M-H, Random, 95% CI) 0.50 [0.27, 0.93]
1.4 Bleomycin vs talc
poudrage
2 57 Odds Ratio (M-H, Random, 95% CI) 9.70 [2.10, 44.78]
1.5 Bleomycin vs C. parvum 2 78 Odds Ratio (M-H, Random, 95% CI) 1.81 [0.02, 189.25]
1.6 Bleomycin vs doxycycline 2 122 Odds Ratio (M-H, Random, 95% CI) 1.50 [0.54, 4.20]
1.7 Bleomycin vs IFN 1 160 Odds Ratio (M-H, Random, 95% CI) 0.31 [0.15, 0.65]
1.8 Bleomycin vs
mitoxantrone
1 85 Odds Ratio (M-H, Random, 95% CI) 0.31 [0.12, 0.86]
1.9 Bleomycin vs mepacrine 1 36 Odds Ratio (M-H, Random, 95% CI) 6.40 [1.12, 36.44]
1.10 Bleomycin vs combined
tetracycline and bleomycin
1 38 Odds Ratio (M-H, Random, 95% CI) 5.57 [0.25, 124.19]
1.11 Bleomycin vs cisplatin
and etoposide
1 69 Odds Ratio (M-H, Random, 95% CI) 1.1 [0.39, 3.07]
1.12 Bleomycin vs OK-432 1 68 Odds Ratio (M-H, Random, 95% CI) 1.43 [0.49, 4.17]
1.13 Bleomycin vs viscum 1 17 Odds Ratio (M-H, Random, 95% CI) 5.33 [0.62, 45.99]
2 Pain 14 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Bleomycin vs talc slurry 2 73 Odds Ratio (M-H, Random, 95% CI) 1.66 [0.41, 6.80]
2.2 Bleomycin vs tetracycline 4 220 Odds Ratio (M-H, Random, 95% CI) 0.61 [0.29, 1.27]
2.3 Bleomycin vs talc
poudrage
1 32 Odds Ratio (M-H, Random, 95% CI) 0.28 [0.01, 7.31]
2.4 Bleomycin vs C. parvum 2 71 Odds Ratio (M-H, Random, 95% CI) 0.70 [0.27, 1.85]
2.5 Bleomycin vs IFN 1 160 Odds Ratio (M-H, Random, 95% CI) 32.34 [1.89, 552.23]
2.6 Bleomycin vs
mitoxantrone
1 96 Odds Ratio (M-H, Random, 95% CI) 0.48 [0.15, 1.56]
2.7 Bleomycin vs mepacrine 1 40 Odds Ratio (M-H, Random, 95% CI) 0.46 [0.11, 1.94]
2.8 Bleomycin vs doxycycline 2 148 Odds Ratio (M-H, Random, 95% CI) 0.84 [0.26, 2.70]
2.9 Bleomycin vs OK-432 1 67 Odds Ratio (M-H, Random, 95% CI) 0.40 [0.14, 1.12]
2.10 Bleomycin vs cisplatin
and etoposide
1 69 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.32, 2.16]
3 Mortality 11 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Bleomycin vs combined
tetracycline and bleomycin
1 40 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.06, 17.18]
3.2 Bleomycin vs talc slurry 2 116 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.29, 2.75]
3.3 Bleomycin vs tetracycline 2 125 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.27, 1.44]
3.4 Bleomycin vs talc
poudrage
1 32 Odds Ratio (M-H, Random, 95% CI) 0.82 [0.20, 3.43]
3.5 Bleomycin vs C. parvum 1 55 Odds Ratio (M-H, Random, 95% CI) 0.60 [0.19, 1.94]
3.6 Bleomycin vs IFN 1 160 Odds Ratio (M-H, Random, 95% CI) 0.46 [0.25, 0.87]
3.7 Bleomycin vs
mitoxantrone
1 96 Odds Ratio (M-H, Random, 95% CI) 2.15 [0.95, 4.86]
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3.8 Bleomycin vs OK-432 1 68 Odds Ratio (M-H, Random, 95% CI) 2.66 [0.98, 7.23]
3.9 Bleomycin vs doxycycline 2 122 Odds Ratio (M-H, Random, 95% CI) 1.44 [0.53, 3.90]
3.10 Bleomycin vs cisplatin
and etoposide
1 69 Odds Ratio (M-H, Random, 95% CI) 2.22 [0.82, 6.01]
4 Fever 16 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Bleomycin vs talc Slurry 3 99 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.31, 2.56]
4.2 Bleomycin vs talc
poudrage
1 32 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.11, 7.05]
4.3 Bleomycin vs tetracycline 5 250 Odds Ratio (M-H, Random, 95% CI) 2.05 [0.67, 6.34]
4.4 Tetracycline vs C. parvum 2 80 Odds Ratio (M-H, Random, 95% CI) 0.43 [0.17, 1.12]
4.5 Bleomycin vs IFN 1 160 Odds Ratio (M-H, Random, 95% CI) 151.35 [9.08, 2522.
62]
4.6 Bleomycin vs
mitoxantrone
1 96 Odds Ratio (M-H, Random, 95% CI) 1.11 [0.37, 3.36]
4.7 Bleomycin vs mepacrine 1 40 Odds Ratio (M-H, Random, 95% CI) 0.52 [0.14, 1.92]
4.8 Bleomycin vs doxycycline 2 148 Odds Ratio (M-H, Random, 95% CI) 2.69 [0.08, 89.51]
4.9 Bleomycin vs combined
tetracycline and bleomycin
1 40 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.04, 5.69]
4.10 Bleomycin vs OK432 1 67 Odds Ratio (M-H, Random, 95% CI) 0.7 [0.23, 2.13]
4.11 Bleomycin vs cisplatin
and etoposide
1 69 Odds Ratio (M-H, Random, 95% CI) 2.22 [0.82, 6.01]
Comparison 2. Talc slurry
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 15 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Talc slurry vs talc poudrage 3 599 Odds Ratio (M-H, Random, 95% CI) 1.31 [0.92, 1.85]
1.2 Talc slurry vs bleomycin 5 199 Odds Ratio (M-H, Random, 95% CI) 0.82 [0.37, 1.82]
1.3 Talc slurry vs IPC 2 160 Odds Ratio (M-H, Random, 95% CI) 0.30 [0.15, 0.61]
1.4 Talc slurry vs mepacrine 1 89 Odds Ratio (M-H, Random, 95% CI) 0.48 [0.14, 1.60]
1.5 Talc slurry vs placebo 1 21 Odds Ratio (M-H, Random, 95% CI) 0.07 [0.00, 1.51]
1.6 Talc slurry vs iodine 1 36 Odds Ratio (M-H, Random, 95% CI) 2.13 [0.18, 25.78]
1.7 Talc slurry vs tetracycline 1 32 Odds Ratio (M-H, Random, 95% CI) 1.29 [0.32, 5.17]
1.8 Talc slurry vs silver nitrate 1 25 Odds Ratio (M-H, Random, 95% CI) 5.82 [0.21, 158.82]
1.9 Talc slurry vs TMP 1 87 Odds Ratio (M-H, Random, 95% CI) 2.31 [0.77, 6.93]
2 Mortality 9 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Talc slurry vs talc poudrage 2 397 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.33, 2.85]
2.2 Talc slurry vs bleomycin 2 116 Odds Ratio (M-H, Random, 95% CI) 1.12 [0.36, 3.46]
2.3 Talc slurry vs iodine 1 36 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 Talc slurry vs IPC 2 163 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.45, 2.10]
2.5 Talc slurry vs mepacrine 1 89 Odds Ratio (M-H, Random, 95% CI) 1.88 [0.70, 5.02]
2.6 Talc slurry vs TMP 1 87 Odds Ratio (M-H, Random, 95% CI) 10.64 [0.55, 203.85]
3 Pain 7 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Talc slurry vs bleomycin 3 99 Odds Ratio (M-H, Random, 95% CI) 0.60 [0.15, 2.46]
3.2 Talc slurry vs talc poudrage 1 482 Odds Ratio (M-H, Random, 95% CI) 2.13 [1.04, 4.36]
3.3 Talc slurry vs tetracycline 1 34 Odds Ratio (M-H, Random, 95% CI) 0.30 [0.07, 1.36]
3.4 Talc slurry vs iodine 1 36 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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3.5 Talc slurry vs IPC 1 57 Odds Ratio (M-H, Random, 95% CI) 0.31 [0.01, 7.95]
3.6 Talc slurry vs placebo 1 31 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Fever 7 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Talc slurry vs talc poudrage 2 479 Odds Ratio (M-H, Random, 95% CI) 1.65 [0.42, 6.48]
4.2 Talc slurry vs bleomycin 3 98 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.36, 2.51]
4.3 Talc slurry vs tetracycline 1 34 Odds Ratio (M-H, Random, 95% CI) 1.09 [0.28, 4.32]
4.4 Talc slurry vs iodine 1 36 Odds Ratio (M-H, Random, 95% CI) 1.6 [0.23, 10.94]
4.5 Talc slurry vs silver nitrate 1 60 Odds Ratio (M-H, Random, 95% CI) 0.7 [0.15, 3.24]
Comparison 3. Talc poudrage
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 9 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Talc poudrage vs talc
slurry
3 599 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.54, 1.09]
1.2 Talc poudrage vs
bleomycin
2 57 Odds Ratio (M-H, Fixed, 95% CI) 0.10 [0.02, 0.48]
1.3 Talc poudrage vs
tetracycline
1 33 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 0.76]
1.4 Talc poudrage vs iodine 1 42 Odds Ratio (M-H, Fixed, 95% CI) 0.57 [0.08, 3.80]
1.5 Talc poudrage vs mustine 1 37 Odds Ratio (M-H, Fixed, 95% CI) 0.13 [0.02, 0.71]
1.6 Talc poudrage vs
doxycycline
1 31 Odds Ratio (M-H, Fixed, 95% CI) 0.02 [0.00, 0.47]
2 Mortality 6 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Talc poudrage vs talc
slurry
2 397 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.35, 3.00]
2.2 Talc poudrage vs
bleomycin
1 32 Odds Ratio (M-H, Random, 95% CI) 1.22 [0.29, 5.13]
2.3 Talc poudrage vs
tetracycline
1 41 Odds Ratio (M-H, Random, 95% CI) 5.25 [0.91, 30.22]
2.4 Talc poudrage vs iodine 1 42 Odds Ratio (M-H, Random, 95% CI) 2.64 [0.58, 12.09]
2.5 Talc poudrage vs mustine 1 46 Odds Ratio (M-H, Random, 95% CI) 0.43 [0.09, 1.96]
3 Pain 3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Talc poudrage vs talc
slurry
1 482 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.23, 0.96]
3.2 Talc poudrage vs
bleomycin
1 32 Odds Ratio (M-H, Random, 95% CI) 3.62 [0.14, 95.78]
3.3 Talc poudrage vs iodine 1 42 Odds Ratio (M-H, Random, 95% CI) 9.97 [0.50, 198.04]
4 Fever 4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Talc poudrage vs talc
slurry
2 479 Odds Ratio (M-H, Random, 95% CI) 0.60 [0.15, 2.37]
4.2 Talc poudrage vs
bleomycin
1 32 Odds Ratio (M-H, Random, 95% CI) 1.15 [0.14, 9.38]
4.3 Talc poudrage vs iodine 1 42 Odds Ratio (M-H, Random, 95% CI) 4.22 [0.43, 41.45]
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Comparison 4. Tetracycline
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 11 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Tetracycline vs C. parvum 1 32 Odds Ratio (M-H, Random, 95% CI) 3.18 [0.52, 19.64]
1.2 Tetracycline vs talc slurry 1 32 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.19, 3.13]
1.3 Tetracycline vs Adriamycin 1 21 Odds Ratio (M-H, Random, 95% CI) 0.9 [0.05, 16.59]
1.4 Tetracyclines vs placebo 1 20 Odds Ratio (M-H, Random, 95% CI) 0.30 [0.05, 1.94]
1.5 Tetracycline vs talc
poudrage
1 33 Odds Ratio (M-H, Random, 95% CI) 12.10 [1.32, 111.30]
1.6 Tetracycline vs mustine 2 59 Odds Ratio (M-H, Random, 95% CI) 0.37 [0.10, 1.35]
1.7 Tetracycline vs combined
tetracycline and bleomycin
1 38 Odds Ratio (M-H, Random, 95% CI) 8.27 [0.40, 172.05]
1.8 Tetracycline vs bleomycin 5 220 Odds Ratio (M-H, Random, 95% CI) 2.00 [1.07, 3.75]
1.9 Tetracycline vs mepacrine 1 21 Odds Ratio (M-H, Random, 95% CI) 1.6 [0.12, 20.99]
2 Pain 8 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Tetracycline vs talc slurry 1 34 Odds Ratio (M-H, Random, 95% CI) 3.28 [0.73, 14.68]
2.2 Tetracycline vs bleomycin 4 220 Odds Ratio (M-H, Random, 95% CI) 1.65 [0.79, 3.43]
2.3 Tetracycline vs C. parvum 1 41 Odds Ratio (M-H, Random, 95% CI) 0.41 [0.12, 1.45]
2.4 Tetracycline vs mustine 1 40 Odds Ratio (M-H, Random, 95% CI) 33.87 [1.80, 636.88]
2.5 Tetracycline vs mepacrine 1 22 Odds Ratio (M-H, Random, 95% CI) 0.18 [0.03, 1.23]
2.6 Tetracycline vs placebo 1 22 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Fever 9 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Tetracycline vs talc slurry 1 34 Odds Ratio (M-H, Random, 95% CI) 0.92 [0.23, 3.63]
3.2 Tetracycline vs bleomycin 5 250 Odds Ratio (M-H, Random, 95% CI) 0.49 [0.16, 1.50]
3.3 Tetracycline vs C. parvum 1 36 Odds Ratio (M-H, Random, 95% CI) 0.00 [0.00, 0.06]
3.4 Tetracycline vs mepacrine 1 22 Odds Ratio (M-H, Random, 95% CI) 0.13 [0.02, 0.89]
3.5 Tetracycline vs
combination tetracycline and
bleomycin
1 40 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.04, 5.69]
3.6 Tetracycline vs placebo 1 22 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.7 Tetracycline vs mustine 1 40 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Mortality 4 202 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.30, 3.26]
4.1 Tetracycline vs talc
poudrage
1 41 Odds Ratio (M-H, Random, 95% CI) 0.19 [0.03, 1.10]
4.2 Tetracycline vs bleomycin 2 125 Odds Ratio (M-H, Random, 95% CI) 1.60 [0.69, 3.69]
4.3 Tetracycline vs C. parvum 1 36 Odds Ratio (M-H, Random, 95% CI) 3.0 [0.28, 31.99]
Comparison 5. C. parvum
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 5 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 C. parvum vs bleomycin 2 78 Odds Ratio (M-H, Random, 95% CI) 0.55 [0.01, 57.48]
1.2 C. parvum vs tetracycline 1 32 Odds Ratio (M-H, Random, 95% CI) 0.31 [0.05, 1.94]
1.3 C. parvum vs doxycycline 1 35 Odds Ratio (M-H, Random, 95% CI) 0.52 [0.12, 2.33]
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1.4 C. parvum vs mustine 1 18 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.04, 2.52]
2 Pain 4 153 Odds Ratio (M-H, Random, 95% CI) 2.51 [1.10, 5.75]
2.1 C. parvum vs bleomycin 2 71 Odds Ratio (M-H, Random, 95% CI) 1.42 [0.54, 3.75]
2.2 C . parvum vs tetracycline 1 41 Odds Ratio (M-H, Random, 95% CI) 2.44 [0.69, 8.66]
2.3 C. parvum vs doxycycline 1 41 Odds Ratio (M-H, Random, 95% CI) 7.37 [1.84, 29.55]
3 Fever 5 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 C. parvum vs bleomycin 2 80 Odds Ratio (M-H, Random, 95% CI) 2.30 [0.90, 5.92]
3.2 C. parvum vs tetracycline 1 36 Odds Ratio (M-H, Random, 95% CI) 288.00 [16.62,
4991.05]
3.3 C. parvum vs mustine 1 21 Odds Ratio (M-H, Random, 95% CI) 4.41 [0.16, 121.68]
3.4 C. parvum vs doxycycline 1 41 Odds Ratio (M-H, Random, 95% CI) 7.37 [1.84, 29.55]
4 Mortality 3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 C. parvum vs bleomycin 1 55 Odds Ratio (M-H, Random, 95% CI) 1.66 [0.51, 5.38]
4.2 C. parvum vs tetracycline 1 36 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.03, 3.55]
4.3 C. parvum vs mustine 1 21 Odds Ratio (M-H, Random, 95% CI) 0.42 [0.07, 2.66]
Comparison 6. Indwelling pleural catheter (IPC)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 IPC vs talc slurry 2 160 Odds Ratio (M-H, Random, 95% CI) 3.35 [1.64, 6.83]
2 Mortality 2 163 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.48, 2.23]
3 Pain 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 7. Iodine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Iodine vs talc poudrage 1 42 Odds Ratio (M-H, Random, 95% CI) 1.76 [0.26, 11.83]
1.2 Iodine vs talc slurry 1 36 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.04, 5.71]
1.3 Iodine vs bleomycin 1 39 Odds Ratio (M-H, Random, 95% CI) 1.25 [0.28, 5.59]
2 Fever 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Iodine vs talc slurry 1 36 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.09, 4.28]
2.2 Iodine vs talc poudrage 1 42 Odds Ratio (M-H, Random, 95% CI) 0.24 [0.02, 2.33]
3 Mortality 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Iodine vs talc poudrage 1 42 Odds Ratio (M-H, Random, 95% CI) 0.38 [0.08, 1.73]
4 Pain 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Iodine vs talc slurry 1 36 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Iodine vs talc poudrage 1 42 Odds Ratio (M-H, Random, 95% CI) 0.10 [0.01, 1.99]
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Comparison 8. Doxycycline
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Doxycycline vs talc
poudrage
1 31 Odds Ratio (M-H, Fixed, 95% CI) 42.69 [2.13, 856.61]
1.2 Doxycycline vs bleomycin 2 122 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.24, 1.83]
1.3 Doxycycline vs C. parvum 1 35 Odds Ratio (M-H, Fixed, 95% CI) 1.91 [0.43, 8.48]
2 Pain 3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Doxycycline vs bleomycin 2 148 Odds Ratio (M-H, Random, 95% CI) 1.19 [0.37, 3.80]
2.2 Doxycycline vs C. parvum 1 41 Odds Ratio (M-H, Random, 95% CI) 0.10 [0.01, 0.96]
3 Fever 3 189 Odds Ratio (M-H, Random, 95% CI) 0.28 [0.04, 2.16]
3.1 Doxycycline vs bleomycin 2 148 Odds Ratio (M-H, Random, 95% CI) 0.37 [0.01, 12.35]
3.2 Doxycycline vs C. parvum 1 41 Odds Ratio (M-H, Random, 95% CI) 0.14 [0.03, 0.54]
4 Mortality 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Doxycycline vs bleomycin 1 80 Odds Ratio (M-H, Random, 95% CI) 0.69 [0.26, 1.87]
Comparison 9. Mode of administration
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 4 628 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.52, 1.04]
1.1 Talc 3 599 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.54, 1.09]
1.2 Tetracycline 1 29 Odds Ratio (M-H, Random, 95% CI) 0.28 [0.04, 1.76]
Comparison 10. Duration of drainage after pleurodesis administration
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Mortality 3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
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Comparison 11. OK-432
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 OK-432 and mitomycin
C
1 53 Odds Ratio (M-H, Random, 95% CI) 0.26 [0.06, 1.11]
1.2 OK-432 vs cisplatin and
etoposide
1 67 Odds Ratio (M-H, Random, 95% CI) 0.77 [0.26, 2.27]
1.3 OK-432 and cisplatin 1 34 Odds Ratio (M-H, Random, 95% CI) 0.48 [0.12, 1.92]
1.4 High dose vs low dose 1 38 Odds Ratio (M-H, Random, 95% CI) 1.90 [0.38, 9.44]
1.5 OK-432 vs bleomycin 1 68 Odds Ratio (M-H, Random, 95% CI) 0.70 [0.24, 2.03]
1.6 OK-432 vs OK-432 and
cisplatin
1 32 Odds Ratio (M-H, Random, 95% CI) 12.44 [1.32, 117.03]
2 Pain 3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 OK-432 vs cisplatin 1 34 Odds Ratio (M-H, Random, 95% CI) 6.67 [1.15, 38.60]
2.2 OK-432 vs OK-432 and
cisplatin
1 32 Odds Ratio (M-H, Random, 95% CI) 1.33 [0.33, 5.43]
2.3 OK-432 vs mitomycin C 1 53 Odds Ratio (M-H, Random, 95% CI) 1.04 [0.14, 8.00]
2.4 OK-432 vs bleomycin 1 67 Odds Ratio (M-H, Random, 95% CI) 2.53 [0.89, 7.15]
2.5 OK-432 vs cisplatin and
etoposide
1 66 Odds Ratio (M-H, Random, 95% CI) 2.1 [0.73, 6.01]
3 Fever 3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 OK-432 vs cisplatin 1 34 Odds Ratio (M-H, Random, 95% CI) 256.00 [14.70,
4457.27]
3.2 OK-432 vs OK-432 and
cisplatin
1 32 Odds Ratio (M-H, Random, 95% CI) 14.00 [1.46, 134.25]
3.3 OK-432 vs mitomycin C 1 53 Odds Ratio (M-H, Random, 95% CI) 26.67 [5.91, 120.42]
3.4 OK-432 vs bleomycin 1 67 Odds Ratio (M-H, Random, 95% CI) 1.43 [0.47, 4.35]
3.5 OK-432 vs cisplatin and
etoposide
1 66 Odds Ratio (M-H, Random, 95% CI) 3.17 [1.08, 9.30]
4 Mortality 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 OK-432 vs cisplatin 1 34 Odds Ratio (M-H, Random, 95% CI) 1.31 [0.31, 5.53]
4.2 OK-432 vs combined
OK-432 and cisplatin
1 32 Odds Ratio (M-H, Random, 95% CI) 2.18 [0.44, 10.91]
4.3 OK-432 vs bleomycin 1 68 Odds Ratio (M-H, Random, 95% CI) 0.38 [0.14, 1.03]
4.4 OK-432 vs cisplatin and
etoposide
1 67 Odds Ratio (M-H, Random, 95% CI) 0.84 [0.32, 2.18]
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Comparison 12. Mepacrine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 3 114 Odds Ratio (M-H, Random, 95% CI) 4.56 [1.66, 12.52]
1.1 Mepacrine vs bleomycin 1 40 Odds Ratio (M-H, Random, 95% CI) 2.15 [0.52, 9.00]
1.2 Mepacrine vs tetracycline 1 22 Odds Ratio (M-H, Random, 95% CI) 5.6 [0.81, 38.51]
1.3 Mepacrine vs placebo 1 23 Odds Ratio (M-H, Random, 95% CI) 14.53 [0.71, 298.21]
1.4 Mepacrine vs
triethylenethiophosphoramide
1 29 Odds Ratio (M-H, Random, 95% CI) 23.71 [1.19, 474.06]
2 Fever 3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Mepacrine vs bleomycin 1 40 Odds Ratio (M-H, Random, 95% CI) 1.91 [0.52, 7.01]
2.2 Mepacrine vs tetracycline 1 22 Odds Ratio (M-H, Random, 95% CI) 8.00 [1.13, 56.79]
2.3 Mepacrine vs placebo 1 23 Odds Ratio (M-H, Random, 95% CI) 62.43 [2.85, 1365.
52]
2.4 Mepacrine vs triethylene... 1 29 Odds Ratio (M-H, Random, 95% CI) 23.83 [3.35, 169.39]
3 Pleurodesis failure 5 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Mepacrine vs talc slurry 1 89 Odds Ratio (M-H, Random, 95% CI) 2.08 [0.62, 6.96]
3.2 Mepacrine vs bleomycin 1 36 Odds Ratio (M-H, Random, 95% CI) 0.16 [0.03, 0.89]
3.3 Mepacrine vs tetracycline 1 21 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.05, 8.20]
3.4 Mepacrine vs placebo 1 23 Odds Ratio (M-H, Random, 95% CI) 0.07 [0.01, 0.73]
3.5 Mepacrine vs
mitoxantrone
1 26 Odds Ratio (M-H, Random, 95% CI) 7.61 [0.35, 163.82]
3.6 Mepacrine vs triethylene... 1 29 Odds Ratio (M-H, Random, 95% CI) 0.20 [0.04, 0.98]
4 Mortality 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Mepacrine vs talc slurry 1 89 Odds Ratio (M-H, Random, 95% CI) 0.53 [0.20, 1.43]
4.2 Mepacrine vs
mitoxantrone
1 28 Odds Ratio (M-H, Random, 95% CI) 1.64 [0.23, 11.70]
Comparison 13. Interferon (IFN)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 IFN vs bleomycin 1 160 Odds Ratio (M-H, Random, 95% CI) 3.25 [1.54, 6.89]
2 Pain 1 160 Odds Ratio (M-H, Random, 95% CI) 0.03 [0.00, 0.53]
3 Fever 1 160 Odds Ratio (M-H, Random, 95% CI) 0.01 [0.00, 0.11]
4 Mortality 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
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Comparison 14. Triethylenethiophophoramide
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Triethylene... vs placebo 1 24 Odds Ratio (M-H, Random, 95% CI) 0.34 [0.03, 3.69]
1.2 Triethylene... vs mepacrine 1 29 Odds Ratio (M-H, Random, 95% CI) 4.95 [1.02, 24.10]
2 Pain 1 53 Odds Ratio (M-H, Random, 95% CI) 1.39 [0.10, 20.15]
2.1 Triethylene... vs mepacrine 1 29 Odds Ratio (M-H, Random, 95% CI) 0.48 [0.10, 2.30]
2.2 Triethylene... vs placebo 1 24 Odds Ratio (M-H, Random, 95% CI) 7.43 [0.35, 156.28]
3 Fever 1 53 Odds Ratio (M-H, Random, 95% CI) 0.32 [0.00, 26.74]
3.1 Triethylene... vs placebo 1 24 Odds Ratio (M-H, Random, 95% CI) 3.52 [0.15, 81.92]
3.2 Triethylene... vs mepacrine 1 29 Odds Ratio (M-H, Random, 95% CI) 0.04 [0.01, 0.30]
Comparison 15. Adriamycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Adriamycin vs mustine 1 20 Odds Ratio (M-H, Random, 95% CI) 0.37 [0.01, 10.18]
1.2 Adriamycin vs tetracycline 1 21 Odds Ratio (M-H, Random, 95% CI) 1.11 [0.06, 20.49]
1.3 Adriamycin vs LC9018
and Adriamycin
1 76 Odds Ratio (M-H, Random, 95% CI) 4.29 [1.62, 11.35]
2 Fever 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3 Pain 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 16. Placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Placebo vs mepacrine 1 23 Odds Ratio (M-H, Random, 95% CI) 14.40 [1.37, 150.81]
1.2 Placebo vs mitoxantrone 1 95 Odds Ratio (M-H, Random, 95% CI) 1.33 [0.56, 3.17]
1.3 Placebo vs triethylene... 1 24 Odds Ratio (M-H, Random, 95% CI) 2.91 [0.27, 31.21]
1.4 Placebo vs talc slurry 1 21 Odds Ratio (M-H, Random, 95% CI) 13.93 [0.66, 293.99]
1.5 Placebo vs tetracycline 1 20 Odds Ratio (M-H, Random, 95% CI) 3.33 [0.51, 21.58]
2 Pain 3 100 Odds Ratio (M-H, Random, 95% CI) 0.10 [0.01, 0.82]
2.1 Placebo vs talc slurry 1 31 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Placebo vs tetracycline 1 22 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Placebo vs mepacrine 1 23 Odds Ratio (M-H, Random, 95% CI) 0.07 [0.00, 1.41]
2.4 Placebo vs triethylene... 1 24 Odds Ratio (M-H, Random, 95% CI) 0.13 [0.01, 2.83]
3 Fever 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Placebo vs mepacrine 1 95 Odds Ratio (M-H, Random, 95% CI) 0.31 [0.12, 0.79]
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3.2 Placebo vs mitoxantone 1 23 Odds Ratio (M-H, Random, 95% CI) 0.02 [0.00, 0.35]
3.3 Placebo vs triethylene... 1 24 Odds Ratio (M-H, Random, 95% CI) 0.28 [0.01, 6.62]
Comparison 17. Mustine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Mustine vs tetracycline 2 59 Odds Ratio (M-H, Random, 95% CI) 2.72 [0.74, 9.98]
1.2 Mustine vs talc poudrage 1 37 Odds Ratio (M-H, Random, 95% CI) 8.00 [1.40, 45.76]
1.3 Mustine vs C. parvum 1 31 Odds Ratio (M-H, Random, 95% CI) 10.8 [1.64, 70.93]
1.4 Mustine vs Adriamycin 1 20 Odds Ratio (M-H, Random, 95% CI) 2.71 [0.10, 74.98]
2 Fever 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Mustine vs tetracycline 1 40 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Mustine vs C. parvum 1 21 Odds Ratio (M-H, Random, 95% CI) 0.23 [0.01, 6.25]
3 Mortality 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Mustine vs talc poudrage 1 46 Odds Ratio (M-H, Random, 95% CI) 2.35 [0.51, 10.86]
3.2 Mustine vs C. parvum 1 21 Odds Ratio (M-H, Random, 95% CI) 2.4 [0.38, 15.32]
4 Pain 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 18. Mitoxantrone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Mitoxantrone vs placebo 1 95 Odds Ratio (M-H, Random, 95% CI) 0.75 [0.32, 1.79]
1.2 Mitoxantrone vs
mepacrine
1 26 Odds Ratio (M-H, Random, 95% CI) 7.61 [0.35, 163.82]
1.3 Mitoxantrone vs
bleomycin
1 85 Odds Ratio (M-H, Random, 95% CI) 3.18 [1.17, 8.65]
2 Pain 1 96 Odds Ratio (M-H, Random, 95% CI) 2.08 [0.64, 6.76]
3 Fever 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Mitoxantrone vs
bleomycin
1 96 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.30, 2.71]
3.2 Mitoxantrone vs placebo 1 95 Odds Ratio (M-H, Random, 95% CI) 3.28 [1.26, 8.49]
4 Mortality 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Mitoxantrone vs
bleomycin
1 96 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.21, 1.05]
4.2 Mitoxantrone vs
mepacrine
1 28 Odds Ratio (M-H, Random, 95% CI) 0.61 [0.09, 4.37]
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Comparison 19. Drain size
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 1 18 Odds Ratio (M-H, Random, 95% CI) 0.57 [0.07, 4.64]
2 Pain 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3 Mortality 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 20. Thoracoscopic mechanical pleurodesis (TMP)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 1 87 Odds Ratio (M-H, Random, 95% CI) 0.43 [0.14, 1.30]
2 Mortality 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 21. Other
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 4 205 Odds Ratio (M-H, Random, 95% CI) 1.26 [0.70, 2.30]
1.1 Rotation vs no rotation 1 20 Odds Ratio (M-H, Random, 95% CI) 2.25 [0.17, 29.77]
1.2 Streptokinase vs no
streptokinase
1 35 Odds Ratio (M-H, Random, 95% CI) 2.18 [0.53, 9.02]
1.3 Mixed particle talc vs
graded talc
1 28 Odds Ratio (M-H, Random, 95% CI) 1.64 [0.23, 11.70]
1.4 Talc pleurodesis vs VATS
parietal pleurectomy
1 122 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.49, 2.09]
2 Pain 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Streptokinase vs control 1 47 Odds Ratio (M-H, Random, 95% CI) 3.0 [0.12, 77.47]
3 Fever 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Mixed particle talc vs
graded talc
1 46 Odds Ratio (M-H, Random, 95% CI) 15.92 [1.81, 140.16]
4 Mortality 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Mixed particle talc vs
graded talc
1 43 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.25, 3.07]
4.2 Talc pleurodesis vs VATS
partial pleurectomy
1 175 Odds Ratio (M-H, Random, 95% CI) 0.92 [0.45, 1.90]
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Comparison 22. Silver nitrate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2 Fever 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 23. Cisplatin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Cisplatin vs cisplatin and
bevacizumab
1 70 Odds Ratio (M-H, Random, 95% CI) 5.0 [1.66, 15.09]
1.2 Cisplatin vs OK-432 1 34 Odds Ratio (M-H, Random, 95% CI) 2.06 [0.52, 8.17]
1.3 Cisplatin vs OK-432 and
cisplatin
1 32 Odds Ratio (M-H, Random, 95% CI) 25.67 [2.68, 245.84]
1.4 Cisplatin vs rAd-p53 and
cisplatin
1 35 Odds Ratio (M-H, Random, 95% CI) 4.67 [0.99, 22.03]
2 Pain 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Cisplatin vs OK-432 1 34 Odds Ratio (M-H, Random, 95% CI) 0.15 [0.03, 0.87]
2.2 Cisplatin vs OK-432 and
cisplatin
1 32 Odds Ratio (M-H, Random, 95% CI) 0.2 [0.03, 1.21]
3 Fever 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Cisplatin vs OK-432 1 34 Odds Ratio (M-H, Random, 95% CI) 0.00 [0.00, 0.07]
3.2 Cisplatin vs OK-432 and
cisplatin
1 32 Odds Ratio (M-H, Random, 95% CI) 0.05 [0.01, 0.52]
3.3 Cisplatin vs rAd-p53 and
cisplatin
1 35 Odds Ratio (M-H, Random, 95% CI) 0.09 [0.02, 0.51]
4 Mortality 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Cisplatin vs OK-432 1 34 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.18, 3.23]
4.2 Cisplatin vs combination
OK-432 and cisplatin
1 32 Odds Ratio (M-H, Random, 95% CI) 1.67 [0.32, 8.59]
4.3 Cisplatin vs combination
rAd-p53 and cisplatin
1 35 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 24. Duration of drainage prior to administration of sclerosant
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 1 79 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.22, 2.82]
Comparison 25. Dose of silver nitrate
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pleurodesis failure 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Silver nitrate 90 mg vs
150 mg
1 40 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Silver nitrate 90 mg vs
180 mg
1 40 Odds Ratio (M-H, Random, 95% CI) 0.18 [0.01, 4.01]
1.3 Silver nitrate 150 mg vs
180 mg
1 40 Odds Ratio (M-H, Random, 95% CI) 0.18 [0.01, 4.01]
2 Mortality 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Silver nitrate 90 mg vs
150 mg
1 39 Odds Ratio (M-H, Random, 95% CI) 3.18 [0.30, 33.58]
2.2 Silver nitrate 90 mg vs
180 mg
1 39 Odds Ratio (M-H, Random, 95% CI) 7.80 [0.38, 161.87]
2.3 Silver nitrate 150 mg vs
180 mg
1 38 Odds Ratio (M-H, Random, 95% CI) 3.16 [0.12, 82.64]
3 Pain 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Silver nitrate 90 mg vs
150 mg
1 40 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.13, 7.89]
3.2 Silver nitrate 90 mg vs
180 mg
1 40 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.13, 7.89]
3.3 Silver nitrate 150 mg vs
180 mg
1 40 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.13, 7.89]
4 Fever 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Silver nitrate 90 mg vs
150 mg
1 40 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.09, 4.24]
4.2 Silver nitrate 90 mg vs
180 mg
1 40 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.13, 7.89]
4.3 Silver nitrate 150 mg vs
180 mg
1 40 Odds Ratio (M-H, Random, 95% CI) 1.59 [0.24, 10.70]
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Analysis 1.1. Comparison 1 Bleomycin, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 1 Bleomycin
Outcome: 1 Pleurodesis failure
Study or subgroup Bleomycin Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Bleomycin vs iodine
Alavi 2011 4/19 5/20 100.0 % 0.80 [ 0.18, 3.57 ]
Subtotal (95% CI) 19 20 100.0 % 0.80 [ 0.18, 3.57 ]
Total events: 4 (Bleomycin), 5 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
2 Bleomycin vs talc slurry
Haddad 2004 7/34 6/37 34.6 % 1.34 [ 0.40, 4.48 ]
Lynch 1996 4/14 9/17 24.2 % 0.36 [ 0.08, 1.59 ]
Noppen 1997 3/12 3/14 17.1 % 1.22 [ 0.20, 7.59 ]
Ong 2000 6/20 2/18 18.4 % 3.43 [ 0.59, 19.80 ]
Zimmer 1997 1/14 0/19 5.7 % 4.33 [ 0.16, 114.58 ]
Subtotal (95% CI) 94 105 100.0 % 1.22 [ 0.55, 2.70 ]
Total events: 21 (Bleomycin), 20 (Others)
Heterogeneity: Tau2 = 0.10; Chi2 = 4.53, df = 4 (P = 0.34); I2 =12%
Test for overall effect: Z = 0.48 (P = 0.63)
3 Bleomycin vs tetracycline
Emad 1996 2/19 3/19 10.7 % 0.63 [ 0.09, 4.26 ]
Kessinger 1987 5/13 7/18 18.3 % 0.98 [ 0.23, 4.25 ]
Lynch 1996 4/14 7/15 16.5 % 0.46 [ 0.10, 2.13 ]
Martinez-Moragon 1997 2/25 4/24 12.1 % 0.43 [ 0.07, 2.63 ]
Ruckdeschel 1991 11/37 19/36 42.4 % 0.38 [ 0.14, 0.99 ]
Subtotal (95% CI) 108 112 100.0 % 0.50 [ 0.27, 0.93 ]
Total events: 24 (Bleomycin), 40 (Others)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 4 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.030)
4 Bleomycin vs talc poudrage
Diacon 2000 10/17 2/15 74.3 % 9.29 [ 1.57, 54.77 ]
Hamed 1989 5/15 0/10 25.7 % 11.00 [ 0.54, 225.13 ]
Subtotal (95% CI) 32 25 100.0 % 9.70 [ 2.10, 44.78 ]
0.01 0.1 1 10 100
Favours bleomycin Favours others
(Continued . . . )
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(. . . Continued)
Study or subgroup Bleomycin Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 15 (Bleomycin), 2 (Others)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0036)
5 Bleomycin vs C. parvum
Hillerdal 1986 17/19 6/20 49.4 % 19.83 [ 3.45, 114.09 ]
Ostrowski 1989 8/22 13/17 50.6 % 0.18 [ 0.04, 0.73 ]
Subtotal (95% CI) 41 37 100.0 % 1.81 [ 0.02, 189.25 ]
Total events: 25 (Bleomycin), 19 (Others)
Heterogeneity: Tau2 = 10.59; Chi2 = 17.04, df = 1 (P = 0.00004); I2 =94%
Test for overall effect: Z = 0.25 (P = 0.80)
6 Bleomycin vs doxycycline
Patz 1998 10/42 7/38 90.0 % 1.38 [ 0.47, 4.10 ]
Rafiei 2014 1/21 0/21 10.0 % 3.15 [ 0.12, 81.74 ]
Subtotal (95% CI) 63 59 100.0 % 1.50 [ 0.54, 4.20 ]
Total events: 11 (Bleomycin), 7 (Others)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
7 Bleomycin vs IFN
Sartori 2004 13/83 29/77 100.0 % 0.31 [ 0.15, 0.65 ]
Subtotal (95% CI) 83 77 100.0 % 0.31 [ 0.15, 0.65 ]
Total events: 13 (Bleomycin), 29 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 3.08 (P = 0.0021)
8 Bleomycin vs mitoxantrone
Schmidt 1997 8/47 15/38 100.0 % 0.31 [ 0.12, 0.86 ]
Subtotal (95% CI) 47 38 100.0 % 0.31 [ 0.12, 0.86 ]
Total events: 8 (Bleomycin), 15 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.024)
9 Bleomycin vs mepacrine
Koldsland 1993 8/18 2/18 100.0 % 6.40 [ 1.12, 36.44 ]
Subtotal (95% CI) 18 18 100.0 % 6.40 [ 1.12, 36.44 ]
Total events: 8 (Bleomycin), 2 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.036)
10 Bleomycin vs combined tetracycline and bleomycin
Emad 1996 2/19 0/19 100.0 % 5.57 [ 0.25, 124.19 ]
Subtotal (95% CI) 19 19 100.0 % 5.57 [ 0.25, 124.19 ]
Total events: 2 (Bleomycin), 0 (Others)
Heterogeneity: not applicable
0.01 0.1 1 10 100
Favours bleomycin Favours others
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(. . . Continued)
Study or subgroup Bleomycin Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.08 (P = 0.28)
11 Bleomycin vs cisplatin and etoposide
Yoshida 2007 11/35 10/34 100.0 % 1.10 [ 0.39, 3.07 ]
Subtotal (95% CI) 35 34 100.0 % 1.10 [ 0.39, 3.07 ]
Total events: 11 (Bleomycin), 10 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
12 Bleomycin vs OK-432
Yoshida 2007 11/35 8/33 100.0 % 1.43 [ 0.49, 4.17 ]
Subtotal (95% CI) 35 33 100.0 % 1.43 [ 0.49, 4.17 ]
Total events: 11 (Bleomycin), 8 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
13 Bleomycin vs viscum
Gaafar 2014 4/7 2/10 100.0 % 5.33 [ 0.62, 45.99 ]
Subtotal (95% CI) 7 10 100.0 % 5.33 [ 0.62, 45.99 ]
Total events: 4 (Bleomycin), 2 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Chi2 = 35.95, df = 12 (P = 0.00), I2 =67%
0.01 0.1 1 10 100
Favours bleomycin Favours others
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Analysis 1.2. Comparison 1 Bleomycin, Outcome 2 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 1 Bleomycin
Outcome: 2 Pain
Study or subgroup Bleomycin Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Bleomycin vs talc slurry
Lynch 1996 4/16 4/19 79.4 % 1.25 [ 0.26, 6.07 ]
Ong 2000 2/20 0/18 20.6 % 5.00 [ 0.22, 111.43 ]
Subtotal (95% CI) 36 37 100.0 % 1.66 [ 0.41, 6.80 ]
Total events: 6 (Bleomycin), 4 (Others)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Bleomycin vs tetracycline
Kessinger 1987 6/16 16/26 22.8 % 0.38 [ 0.10, 1.35 ]
Lynch 1996 4/16 7/15 17.8 % 0.38 [ 0.08, 1.74 ]
Martinez-Moragon 1997 10/31 16/31 30.2 % 0.45 [ 0.16, 1.25 ]
Ruckdeschel 1991 11/44 7/41 29.2 % 1.62 [ 0.56, 4.68 ]
Subtotal (95% CI) 107 113 100.0 % 0.61 [ 0.29, 1.27 ]
Total events: 31 (Bleomycin), 46 (Others)
Heterogeneity: Tau2 = 0.19; Chi2 = 4.51, df = 3 (P = 0.21); I2 =34%
Test for overall effect: Z = 1.33 (P = 0.18)
3 Bleomycin vs talc poudrage
Diacon 2000 0/17 1/15 100.0 % 0.28 [ 0.01, 7.31 ]
Subtotal (95% CI) 17 15 100.0 % 0.28 [ 0.01, 7.31 ]
Total events: 0 (Bleomycin), 1 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
4 Bleomycin vs C. parvum
Hillerdal 1986 3/11 8/16 34.4 % 0.38 [ 0.07, 1.95 ]
Ostrowski 1989 13/25 10/19 65.6 % 0.98 [ 0.30, 3.22 ]
Subtotal (95% CI) 36 35 100.0 % 0.70 [ 0.27, 1.85 ]
Total events: 16 (Bleomycin), 18 (Others)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
5 Bleomycin vs IFN
Sartori 2004 14/83 0/77 100.0 % 32.34 [ 1.89, 552.23 ]
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(. . . Continued)
Study or subgroup Bleomycin Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 83 77 100.0 % 32.34 [ 1.89, 552.23 ]
Total events: 14 (Bleomycin), 0 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.016)
6 Bleomycin vs mitoxantrone
Schmidt 1997 5/49 9/47 100.0 % 0.48 [ 0.15, 1.56 ]
Subtotal (95% CI) 49 47 100.0 % 0.48 [ 0.15, 1.56 ]
Total events: 5 (Bleomycin), 9 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
7 Bleomycin vs mepacrine
Koldsland 1993 13/20 16/20 100.0 % 0.46 [ 0.11, 1.94 ]
Subtotal (95% CI) 20 20 100.0 % 0.46 [ 0.11, 1.94 ]
Total events: 13 (Bleomycin), 16 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
8 Bleomycin vs doxycycline
Patz 1998 6/52 11/54 58.3 % 0.51 [ 0.17, 1.50 ]
Rafiei 2014 17/21 15/21 41.7 % 1.70 [ 0.40, 7.20 ]
Subtotal (95% CI) 73 75 100.0 % 0.84 [ 0.26, 2.70 ]
Total events: 23 (Bleomycin), 26 (Others)
Heterogeneity: Tau2 = 0.30; Chi2 = 1.72, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 0.29 (P = 0.77)
9 Bleomycin vs OK-432
Yoshida 2007 19/35 24/32 100.0 % 0.40 [ 0.14, 1.12 ]
Subtotal (95% CI) 35 32 100.0 % 0.40 [ 0.14, 1.12 ]
Total events: 19 (Bleomycin), 24 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.081)
10 Bleomycin vs cisplatin and etoposide
Yoshida 2007 19/35 20/34 100.0 % 0.83 [ 0.32, 2.16 ]
Subtotal (95% CI) 35 34 100.0 % 0.83 [ 0.32, 2.16 ]
Total events: 19 (Bleomycin), 20 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Chi2 = 10.99, df = 9 (P = 0.28), I2 =18%
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Analysis 1.3. Comparison 1 Bleomycin, Outcome 3 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 1 Bleomycin
Outcome: 3 Mortality
Study or subgroup Bleomycin Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Bleomycin vs combined tetracycline and bleomycin
Emad 1996 1/20 1/20 100.0 % 1.00 [ 0.06, 17.18 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.06, 17.18 ]
Total events: 1 (Bleomycin), 1 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Bleomycin vs talc slurry
Haddad 2004 30/33 34/37 45.4 % 0.88 [ 0.17, 4.71 ]
Ong 2000 4/24 4/22 54.6 % 0.90 [ 0.20, 4.14 ]
Subtotal (95% CI) 57 59 100.0 % 0.89 [ 0.29, 2.75 ]
Total events: 34 (Bleomycin), 38 (Others)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
3 Bleomycin vs tetracycline
Emad 1996 1/20 1/20 8.6 % 1.00 [ 0.06, 17.18 ]
Ruckdeschel 1991 15/44 19/41 91.4 % 0.60 [ 0.25, 1.44 ]
Subtotal (95% CI) 64 61 100.0 % 0.63 [ 0.27, 1.44 ]
Total events: 16 (Bleomycin), 20 (Others)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
4 Bleomycin vs talc poudrage
Diacon 2000 6/17 6/15 100.0 % 0.82 [ 0.20, 3.43 ]
Subtotal (95% CI) 17 15 100.0 % 0.82 [ 0.20, 3.43 ]
Total events: 6 (Bleomycin), 6 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
5 Bleomycin vs C. parvum
Ostrowski 1989 7/29 9/26 100.0 % 0.60 [ 0.19, 1.94 ]
Subtotal (95% CI) 29 26 100.0 % 0.60 [ 0.19, 1.94 ]
Total events: 7 (Bleomycin), 9 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
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(. . . Continued)
Study or subgroup Bleomycin Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
6 Bleomycin vs IFN
Sartori 2004 36/83 48/77 100.0 % 0.46 [ 0.25, 0.87 ]
Subtotal (95% CI) 83 77 100.0 % 0.46 [ 0.25, 0.87 ]
Total events: 36 (Bleomycin), 48 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
7 Bleomycin vs mitoxantrone
Schmidt 1997 28/49 18/47 100.0 % 2.15 [ 0.95, 4.86 ]
Subtotal (95% CI) 49 47 100.0 % 2.15 [ 0.95, 4.86 ]
Total events: 28 (Bleomycin), 18 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
8 Bleomycin vs OK-432
Yoshida 2007 25/35 16/33 100.0 % 2.66 [ 0.98, 7.23 ]
Subtotal (95% CI) 35 33 100.0 % 2.66 [ 0.98, 7.23 ]
Total events: 25 (Bleomycin), 16 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
9 Bleomycin vs doxycycline
Patz 1998 13/42 9/38 100.0 % 1.44 [ 0.53, 3.90 ]
Rafiei 2014 0/21 0/21 Not estimable
Subtotal (95% CI) 63 59 100.0 % 1.44 [ 0.53, 3.90 ]
Total events: 13 (Bleomycin), 9 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
10 Bleomycin vs cisplatin and etoposide
Yoshida 2007 25/35 18/34 100.0 % 2.22 [ 0.82, 6.01 ]
Subtotal (95% CI) 35 34 100.0 % 2.22 [ 0.82, 6.01 ]
Total events: 25 (Bleomycin), 18 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi2 = 17.74, df = 9 (P = 0.04), I2 =49%
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Analysis 1.4. Comparison 1 Bleomycin, Outcome 4 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 1 Bleomycin
Outcome: 4 Fever
Study or subgroup Bleomycin Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Bleomycin vs talc Slurry
Lynch 1996 5/16 8/19 47.1 % 0.63 [ 0.15, 2.52 ]
Noppen 1997 3/12 5/14 33.4 % 0.60 [ 0.11, 3.30 ]
Ong 2000 4/20 1/18 19.5 % 4.25 [ 0.43, 42.19 ]
Subtotal (95% CI) 48 51 100.0 % 0.90 [ 0.31, 2.56 ]
Total events: 12 (Bleomycin), 14 (Others)
Heterogeneity: Tau2 = 0.10; Chi2 = 2.26, df = 2 (P = 0.32); I2 =11%
Test for overall effect: Z = 0.21 (P = 0.84)
2 Bleomycin vs talc poudrage
Diacon 2000 2/17 2/15 100.0 % 0.87 [ 0.11, 7.05 ]
Subtotal (95% CI) 17 15 100.0 % 0.87 [ 0.11, 7.05 ]
Total events: 2 (Bleomycin), 2 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.89)
3 Bleomycin vs tetracycline
Emad 1996 1/20 1/20 12.1 % 1.00 [ 0.06, 17.18 ]
Kessinger 1987 8/16 2/16 22.7 % 7.00 [ 1.18, 41.36 ]
Lynch 1996 5/16 6/15 27.5 % 0.68 [ 0.16, 2.99 ]
Martinez-Moragon 1997 6/31 0/31 11.6 % 16.06 [ 0.86, 298.78 ]
Ruckdeschel 1991 4/44 3/41 26.1 % 1.27 [ 0.27, 6.04 ]
Subtotal (95% CI) 127 123 100.0 % 2.05 [ 0.67, 6.34 ]
Total events: 24 (Bleomycin), 12 (Others)
Heterogeneity: Tau2 = 0.63; Chi2 = 6.60, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 1.25 (P = 0.21)
4 Tetracycline vs C. parvum
Hillerdal 1986 10/16 14/20 46.0 % 0.71 [ 0.18, 2.87 ]
Ostrowski 1989 6/25 10/19 54.0 % 0.28 [ 0.08, 1.03 ]
Subtotal (95% CI) 41 39 100.0 % 0.43 [ 0.17, 1.12 ]
Total events: 16 (Bleomycin), 24 (Others)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.084)
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(. . . Continued)
Study or subgroup Bleomycin Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
5 Bleomycin vs IFN
Sartori 2004 41/83 0/77 100.0 % 151.35 [ 9.08, 2522.62 ]
Subtotal (95% CI) 83 77 100.0 % 151.35 [ 9.08, 2522.62 ]
Total events: 41 (Bleomycin), 0 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 3.50 (P = 0.00047)
6 Bleomycin vs mitoxantrone
Schmidt 1997 8/49 7/47 100.0 % 1.11 [ 0.37, 3.36 ]
Subtotal (95% CI) 49 47 100.0 % 1.11 [ 0.37, 3.36 ]
Total events: 8 (Bleomycin), 7 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
7 Bleomycin vs mepacrine
Koldsland 1993 11/20 14/20 100.0 % 0.52 [ 0.14, 1.92 ]
Subtotal (95% CI) 20 20 100.0 % 0.52 [ 0.14, 1.92 ]
Total events: 11 (Bleomycin), 14 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
8 Bleomycin vs doxycycline
Patz 1998 7/52 0/54 43.5 % 17.97 [ 1.00, 323.17 ]
Rafiei 2014 5/21 7/21 56.5 % 0.63 [ 0.16, 2.42 ]
Subtotal (95% CI) 73 75 100.0 % 2.69 [ 0.08, 89.51 ]
Total events: 12 (Bleomycin), 7 (Others)
Heterogeneity: Tau2 = 5.18; Chi2 = 4.91, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 0.55 (P = 0.58)
9 Bleomycin vs combined tetracycline and bleomycin
Emad 1996 1/20 2/20 100.0 % 0.47 [ 0.04, 5.69 ]
Subtotal (95% CI) 20 20 100.0 % 0.47 [ 0.04, 5.69 ]
Total events: 1 (Bleomycin), 2 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
10 Bleomycin vs OK432
Yoshida 2007 25/35 25/32 100.0 % 0.70 [ 0.23, 2.13 ]
Subtotal (95% CI) 35 32 100.0 % 0.70 [ 0.23, 2.13 ]
Total events: 25 (Bleomycin), 25 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
11 Bleomycin vs cisplatin and etoposide
Yoshida 2007 25/35 18/34 100.0 % 2.22 [ 0.82, 6.01 ]
Subtotal (95% CI) 35 34 100.0 % 2.22 [ 0.82, 6.01 ]
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(. . . Continued)
Study or subgroup Bleomycin Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 25 (Bleomycin), 18 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi2 = 21.30, df = 10 (P = 0.02), I2 =53%
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Analysis 2.1. Comparison 2 Talc slurry, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 2 Talc slurry
Outcome: 1 Pleurodesis failure
Study or subgroup Talc Slurry Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Talc slurry vs talc poudrage
Dresler 2005 114/240 97/242 94.0 % 1.35 [ 0.94, 1.94 ]
Terra 2009 4/30 5/30 6.0 % 0.77 [ 0.19, 3.20 ]
Yim 1996 0/29 0/28 Not estimable
Subtotal (95% CI) 299 300 100.0 % 1.31 [ 0.92, 1.85 ]
Total events: 118 (Talc Slurry), 102 (Other)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
2 Talc slurry vs bleomycin
Haddad 2004 6/37 7/34 34.6 % 0.75 [ 0.22, 2.49 ]
Lynch 1996 9/17 4/14 24.2 % 2.81 [ 0.63, 12.61 ]
Noppen 1997 3/14 3/12 17.1 % 0.82 [ 0.13, 5.08 ]
Ong 2000 2/18 6/20 18.4 % 0.29 [ 0.05, 1.68 ]
Zimmer 1997 0/19 1/14 5.7 % 0.23 [ 0.01, 6.10 ]
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(. . . Continued)
Study or subgroup Talc Slurry Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 105 94 100.0 % 0.82 [ 0.37, 1.82 ]
Total events: 20 (Talc Slurry), 21 (Other)
Heterogeneity: Tau2 = 0.10; Chi2 = 4.53, df = 4 (P = 0.34); I2 =12%
Test for overall effect: Z = 0.48 (P = 0.63)
3 Talc slurry vs IPC
Davies 2012 12/54 25/51 71.2 % 0.30 [ 0.13, 0.69 ]
Demmy 2012 4/29 9/26 28.8 % 0.30 [ 0.08, 1.14 ]
Subtotal (95% CI) 83 77 100.0 % 0.30 [ 0.15, 0.61 ]
Total events: 16 (Talc Slurry), 34 (Other)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.32 (P = 0.00089)
4 Talc slurry vs mepacrine
Ukale 2004 5/48 8/41 100.0 % 0.48 [ 0.14, 1.60 ]
Subtotal (95% CI) 48 41 100.0 % 0.48 [ 0.14, 1.60 ]
Total events: 5 (Talc Slurry), 8 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
5 Talc slurry vs placebo
Sorensen 1984 0/9 5/12 100.0 % 0.07 [ 0.00, 1.51 ]
Subtotal (95% CI) 9 12 100.0 % 0.07 [ 0.00, 1.51 ]
Total events: 0 (Talc Slurry), 5 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.090)
6 Talc slurry vs iodine
Agarwal 2011 2/18 1/18 100.0 % 2.13 [ 0.18, 25.78 ]
Subtotal (95% CI) 18 18 100.0 % 2.13 [ 0.18, 25.78 ]
Total events: 2 (Talc Slurry), 1 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
7 Talc slurry vs tetracycline
Lynch 1996 9/17 7/15 100.0 % 1.29 [ 0.32, 5.17 ]
Subtotal (95% CI) 17 15 100.0 % 1.29 [ 0.32, 5.17 ]
Total events: 9 (Talc Slurry), 7 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
8 Talc slurry vs silver nitrate
Paschoalini 2005 1/9 0/16 100.0 % 5.82 [ 0.21, 158.82 ]
Subtotal (95% CI) 9 16 100.0 % 5.82 [ 0.21, 158.82 ]
Total events: 1 (Talc Slurry), 0 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
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Study or subgroup Talc Slurry Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
9 Talc slurry vs TMP
Crnjac 2004 11/42 6/45 100.0 % 2.31 [ 0.77, 6.93 ]
Subtotal (95% CI) 42 45 100.0 % 2.31 [ 0.77, 6.93 ]
Total events: 11 (Talc Slurry), 6 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Chi2 = 21.60, df = 8 (P = 0.01), I2 =63%
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Analysis 2.2. Comparison 2 Talc slurry, Outcome 2 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 2 Talc slurry
Outcome: 2 Mortality
Study or subgroup Talc slurry Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Talc slurry vs talc poudrage
Dresler 2005 33/163 25/177 58.8 % 1.54 [ 0.87, 2.73 ]
Yim 1996 15/29 19/28 41.2 % 0.51 [ 0.17, 1.49 ]
Subtotal (95% CI) 192 205 100.0 % 0.98 [ 0.33, 2.85 ]
Total events: 48 (Talc slurry), 44 (Others)
Heterogeneity: Tau2 = 0.43; Chi2 = 3.20, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 0.04 (P = 0.96)
2 Talc slurry vs bleomycin
Haddad 2004 34/37 30/33 45.4 % 1.13 [ 0.21, 6.04 ]
Ong 2000 4/22 4/24 54.6 % 1.11 [ 0.24, 5.11 ]
Subtotal (95% CI) 59 57 100.0 % 1.12 [ 0.36, 3.46 ]
Total events: 38 (Talc slurry), 34 (Others)
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Study or subgroup Talc slurry Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
3 Talc slurry vs iodine
Agarwal 2011 0/18 0/18 Not estimable
Subtotal (95% CI) 18 18 Not estimable
Total events: 0 (Talc slurry), 0 (Others)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Talc slurry vs IPC
Davies 2012 20/54 16/52 61.6 % 1.32 [ 0.59, 2.97 ]
Demmy 2012 8/29 11/28 38.4 % 0.59 [ 0.19, 1.79 ]
Subtotal (95% CI) 83 80 100.0 % 0.97 [ 0.45, 2.10 ]
Total events: 28 (Talc slurry), 27 (Others)
Heterogeneity: Tau2 = 0.08; Chi2 = 1.33, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 0.08 (P = 0.94)
5 Talc slurry vs mepacrine
Ukale 2004 15/48 8/41 100.0 % 1.88 [ 0.70, 5.02 ]
Subtotal (95% CI) 48 41 100.0 % 1.88 [ 0.70, 5.02 ]
Total events: 15 (Talc slurry), 8 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
6 Talc slurry vs TMP
Crnjac 2004 4/42 0/45 100.0 % 10.64 [ 0.55, 203.85 ]
Subtotal (95% CI) 42 45 100.0 % 10.64 [ 0.55, 203.85 ]
Total events: 4 (Talc slurry), 0 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi2 = 3.32, df = 4 (P = 0.51), I2 =0.0%
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Analysis 2.3. Comparison 2 Talc slurry, Outcome 3 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 2 Talc slurry
Outcome: 3 Pain
Study or subgroup Talc Slurry Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Talc slurry vs bleomycin
Lynch 1996 4/19 4/16 79.4 % 0.80 [ 0.16, 3.88 ]
Noppen 1997 0/14 0/12 Not estimable
Ong 2000 0/18 2/20 20.6 % 0.20 [ 0.01, 4.46 ]
Subtotal (95% CI) 51 48 100.0 % 0.60 [ 0.15, 2.46 ]
Total events: 4 (Talc Slurry), 6 (Other)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Talc slurry vs talc poudrage
Dresler 2005 24/240 12/242 100.0 % 2.13 [ 1.04, 4.36 ]
Subtotal (95% CI) 240 242 100.0 % 2.13 [ 1.04, 4.36 ]
Total events: 24 (Talc Slurry), 12 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.039)
3 Talc slurry vs tetracycline
Lynch 1996 4/19 7/15 100.0 % 0.30 [ 0.07, 1.36 ]
Subtotal (95% CI) 19 15 100.0 % 0.30 [ 0.07, 1.36 ]
Total events: 4 (Talc Slurry), 7 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
4 Talc slurry vs iodine
Agarwal 2011 18/18 18/18 Not estimable
Subtotal (95% CI) 18 18 Not estimable
Total events: 18 (Talc Slurry), 18 (Other)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Talc slurry vs IPC
Demmy 2012 0/29 1/28 100.0 % 0.31 [ 0.01, 7.95 ]
Subtotal (95% CI) 29 28 100.0 % 0.31 [ 0.01, 7.95 ]
Total events: 0 (Talc Slurry), 1 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
0.01 0.1 1 10 100
Favours Talc Slurry Favours Other
(Continued . . . )
143Interventions for the management of malignant pleural effusions: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Talc Slurry Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
6 Talc slurry vs placebo
Sorensen 1984 14/14 17/17 Not estimable
Subtotal (95% CI) 14 17 Not estimable
Total events: 14 (Talc Slurry), 17 (Other)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 7.26, df = 3 (P = 0.06), I2 =59%
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Analysis 2.4. Comparison 2 Talc slurry, Outcome 4 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 2 Talc slurry
Outcome: 4 Fever
Study or subgroup Talc Slurry Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Talc slurry vs talc poudrage
Dresler 2005 68/196 68/223 83.2 % 1.21 [ 0.80, 1.82 ]
Terra 2009 3/30 0/30 16.8 % 7.76 [ 0.38, 157.14 ]
Subtotal (95% CI) 226 253 100.0 % 1.65 [ 0.42, 6.48 ]
Total events: 71 (Talc Slurry), 68 (Other)
Heterogeneity: Tau2 = 0.54; Chi2 = 1.45, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.72 (P = 0.47)
2 Talc slurry vs bleomycin
Lynch 1996 8/19 6/15 49.7 % 1.09 [ 0.28, 4.32 ]
Noppen 1997 5/14 3/12 32.5 % 1.67 [ 0.30, 9.16 ]
Ong 2000 1/18 4/20 17.9 % 0.24 [ 0.02, 2.34 ]
Subtotal (95% CI) 51 47 100.0 % 0.95 [ 0.36, 2.51 ]
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Study or subgroup Talc Slurry Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 14 (Talc Slurry), 13 (Other)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.89, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
3 Talc slurry vs tetracycline
Lynch 1996 8/19 6/15 100.0 % 1.09 [ 0.28, 4.32 ]
Subtotal (95% CI) 19 15 100.0 % 1.09 [ 0.28, 4.32 ]
Total events: 8 (Talc Slurry), 6 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
4 Talc slurry vs iodine
Agarwal 2011 3/18 2/18 100.0 % 1.60 [ 0.23, 10.94 ]
Subtotal (95% CI) 18 18 100.0 % 1.60 [ 0.23, 10.94 ]
Total events: 3 (Talc Slurry), 2 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
5 Talc slurry vs silver nitrate
Paschoalini 2005 3/27 5/33 100.0 % 0.70 [ 0.15, 3.24 ]
Subtotal (95% CI) 27 33 100.0 % 0.70 [ 0.15, 3.24 ]
Total events: 3 (Talc Slurry), 5 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Chi2 = 0.91, df = 4 (P = 0.92), I2 =0.0%
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Analysis 3.1. Comparison 3 Talc poudrage, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 3 Talc poudrage
Outcome: 1 Pleurodesis failure
Study or subgroup Talc poudrage Other Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Talc poudrage vs talc slurry
Dresler 2005 97/242 114/240 95.4 % 0.74 [ 0.52, 1.06 ]
Terra 2009 5/30 4/30 4.6 % 1.30 [ 0.31, 5.40 ]
Yim 1996 0/28 0/29 Not estimable
Subtotal (95% CI) 300 299 100.0 % 0.77 [ 0.54, 1.09 ]
Total events: 102 (Talc poudrage), 118 (Other)
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
2 Talc poudrage vs bleomycin
Diacon 2000 2/15 10/17 65.5 % 0.11 [ 0.02, 0.64 ]
Hamed 1989 0/10 5/15 34.5 % 0.09 [ 0.00, 1.86 ]
Subtotal (95% CI) 25 32 100.0 % 0.10 [ 0.02, 0.48 ]
Total events: 2 (Talc poudrage), 15 (Other)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.90 (P = 0.0037)
3 Talc poudrage vs tetracycline
Fentiman 1986 1/12 11/21 100.0 % 0.08 [ 0.01, 0.76 ]
Subtotal (95% CI) 12 21 100.0 % 0.08 [ 0.01, 0.76 ]
Total events: 1 (Talc poudrage), 11 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
4 Talc poudrage vs iodine
Mohsen 2011 2/22 3/20 100.0 % 0.57 [ 0.08, 3.80 ]
Subtotal (95% CI) 22 20 100.0 % 0.57 [ 0.08, 3.80 ]
Total events: 2 (Talc poudrage), 3 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
5 Talc poudrage vs mustine
Fentiman 1983 2/20 8/17 100.0 % 0.13 [ 0.02, 0.71 ]
Subtotal (95% CI) 20 17 100.0 % 0.13 [ 0.02, 0.71 ]
Total events: 2 (Talc poudrage), 8 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
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(. . . Continued)
Study or subgroup Talc poudrage Other Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
6 Talc poudrage vs doxycycline
Kuzdzal 2003 0/18 7/13 100.0 % 0.02 [ 0.00, 0.47 ]
Subtotal (95% CI) 18 13 100.0 % 0.02 [ 0.00, 0.47 ]
Total events: 0 (Talc poudrage), 7 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 17.61, df = 5 (P = 0.00), I2 =72%
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Analysis 3.2. Comparison 3 Talc poudrage, Outcome 2 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 3 Talc poudrage
Outcome: 2 Mortality
Study or subgroup Talc poudrage Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Talc poudrage vs talc slurry
Dresler 2005 25/177 33/163 58.8 % 0.65 [ 0.37, 1.15 ]
Yim 1996 19/28 15/29 41.2 % 1.97 [ 0.67, 5.78 ]
Subtotal (95% CI) 205 192 100.0 % 1.02 [ 0.35, 3.00 ]
Total events: 44 (Talc poudrage), 48 (Others)
Heterogeneity: Tau2 = 0.43; Chi2 = 3.20, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 0.04 (P = 0.96)
2 Talc poudrage vs bleomycin
Diacon 2000 6/15 6/17 100.0 % 1.22 [ 0.29, 5.13 ]
Subtotal (95% CI) 15 17 100.0 % 1.22 [ 0.29, 5.13 ]
Total events: 6 (Talc poudrage), 6 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
0.01 0.1 1 10 100
Favours talc poudrage Favours others
(Continued . . . )
147Interventions for the management of malignant pleural effusions: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Talc poudrage Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Talc poudrage vs tetracycline
Fentiman 1986 6/18 2/23 100.0 % 5.25 [ 0.91, 30.22 ]
Subtotal (95% CI) 18 23 100.0 % 5.25 [ 0.91, 30.22 ]
Total events: 6 (Talc poudrage), 2 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
4 Talc poudrage vs iodine
Mohsen 2011 7/22 3/20 100.0 % 2.64 [ 0.58, 12.09 ]
Subtotal (95% CI) 22 20 100.0 % 2.64 [ 0.58, 12.09 ]
Total events: 7 (Talc poudrage), 3 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
5 Talc poudrage vs mustine
Fentiman 1983 3/23 6/23 100.0 % 0.43 [ 0.09, 1.96 ]
Subtotal (95% CI) 23 23 100.0 % 0.43 [ 0.09, 1.96 ]
Total events: 3 (Talc poudrage), 6 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Chi2 = 5.53, df = 4 (P = 0.24), I2 =28%
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Analysis 3.3. Comparison 3 Talc poudrage, Outcome 3 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 3 Talc poudrage
Outcome: 3 Pain
Study or subgroup Talc poudrage Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Talc poudrage vs talc slurry
Dresler 2005 12/242 24/240 100.0 % 0.47 [ 0.23, 0.96 ]
Subtotal (95% CI) 242 240 100.0 % 0.47 [ 0.23, 0.96 ]
Total events: 12 (Talc poudrage), 24 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.039)
2 Talc poudrage vs bleomycin
Diacon 2000 1/15 0/17 100.0 % 3.62 [ 0.14, 95.78 ]
Subtotal (95% CI) 15 17 100.0 % 3.62 [ 0.14, 95.78 ]
Total events: 1 (Talc poudrage), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
3 Talc poudrage vs iodine
Mohsen 2011 4/22 0/20 100.0 % 9.97 [ 0.50, 198.04 ]
Subtotal (95% CI) 22 20 100.0 % 9.97 [ 0.50, 198.04 ]
Total events: 4 (Talc poudrage), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 5.00, df = 2 (P = 0.08), I2 =60%
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Analysis 3.4. Comparison 3 Talc poudrage, Outcome 4 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 3 Talc poudrage
Outcome: 4 Fever
Study or subgroup Talc poudrage Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Talc poudrage vs talc slurry
Dresler 2005 68/223 68/196 83.2 % 0.83 [ 0.55, 1.24 ]
Terra 2009 0/30 3/30 16.8 % 0.13 [ 0.01, 2.61 ]
Subtotal (95% CI) 253 226 100.0 % 0.60 [ 0.15, 2.37 ]
Total events: 68 (Talc poudrage), 71 (Other)
Heterogeneity: Tau2 = 0.54; Chi2 = 1.45, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.72 (P = 0.47)
2 Talc poudrage vs bleomycin
Diacon 2000 2/15 2/17 100.0 % 1.15 [ 0.14, 9.38 ]
Subtotal (95% CI) 15 17 100.0 % 1.15 [ 0.14, 9.38 ]
Total events: 2 (Talc poudrage), 2 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.89)
3 Talc poudrage vs iodine
Mohsen 2011 4/22 1/20 100.0 % 4.22 [ 0.43, 41.45 ]
Subtotal (95% CI) 22 20 100.0 % 4.22 [ 0.43, 41.45 ]
Total events: 4 (Talc poudrage), 1 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Chi2 = 2.06, df = 2 (P = 0.36), I2 =3%
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Analysis 4.1. Comparison 4 Tetracycline, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 4 Tetracycline
Outcome: 1 Pleurodesis failure
Study or subgroup Tetracyclines Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tetracycline vs C. parvum
Leahy 1985 5/16 2/16 100.0 % 3.18 [ 0.52, 19.64 ]
Subtotal (95% CI) 16 16 100.0 % 3.18 [ 0.52, 19.64 ]
Total events: 5 (Tetracyclines), 2 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
2 Tetracycline vs talc slurry
Lynch 1996 7/15 9/17 100.0 % 0.78 [ 0.19, 3.13 ]
Subtotal (95% CI) 15 17 100.0 % 0.78 [ 0.19, 3.13 ]
Total events: 7 (Tetracyclines), 9 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
3 Tetracycline vs Adriamycin
Kefford 1980 9/10 10/11 100.0 % 0.90 [ 0.05, 16.59 ]
Subtotal (95% CI) 10 11 100.0 % 0.90 [ 0.05, 16.59 ]
Total events: 9 (Tetracyclines), 10 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
4 Tetracyclines vs placebo
Zaloznik 1983 4/12 5/8 100.0 % 0.30 [ 0.05, 1.94 ]
Subtotal (95% CI) 12 8 100.0 % 0.30 [ 0.05, 1.94 ]
Total events: 4 (Tetracyclines), 5 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
5 Tetracycline vs talc poudrage
Fentiman 1986 11/21 1/12 100.0 % 12.10 [ 1.32, 111.30 ]
Subtotal (95% CI) 21 12 100.0 % 12.10 [ 1.32, 111.30 ]
Total events: 11 (Tetracyclines), 1 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
6 Tetracycline vs mustine
Kefford 1980 9/10 9/9 15.3 % 0.33 [ 0.01, 9.26 ]
Loutsidis 1994 4/20 8/20 84.7 % 0.38 [ 0.09, 1.54 ]
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(. . . Continued)
Study or subgroup Tetracyclines Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 30 29 100.0 % 0.37 [ 0.10, 1.35 ]
Total events: 13 (Tetracyclines), 17 (Other)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
7 Tetracycline vs combined tetracycline and bleomycin
Emad 1996 3/19 0/19 100.0 % 8.27 [ 0.40, 172.05 ]
Subtotal (95% CI) 19 19 100.0 % 8.27 [ 0.40, 172.05 ]
Total events: 3 (Tetracyclines), 0 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
8 Tetracycline vs bleomycin
Emad 1996 3/19 2/19 10.7 % 1.59 [ 0.23, 10.82 ]
Kessinger 1987 7/18 5/13 18.3 % 1.02 [ 0.24, 4.41 ]
Lynch 1996 7/15 4/14 16.5 % 2.19 [ 0.47, 10.21 ]
Martinez-Moragon 1997 4/24 2/25 12.1 % 2.30 [ 0.38, 13.91 ]
Ruckdeschel 1991 19/36 11/37 42.4 % 2.64 [ 1.01, 6.91 ]
Subtotal (95% CI) 112 108 100.0 % 2.00 [ 1.07, 3.75 ]
Total events: 40 (Tetracyclines), 24 (Other)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 4 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.030)
9 Tetracycline vs mepacrine
Bayly 1978 2/12 1/9 100.0 % 1.60 [ 0.12, 20.99 ]
Subtotal (95% CI) 12 9 100.0 % 1.60 [ 0.12, 20.99 ]
Total events: 2 (Tetracyclines), 1 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 14.39, df = 8 (P = 0.07), I2 =44%
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Analysis 4.2. Comparison 4 Tetracycline, Outcome 2 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 4 Tetracycline
Outcome: 2 Pain
Study or subgroup Tetracyclines Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tetracycline vs talc slurry
Lynch 1996 7/15 4/19 100.0 % 3.28 [ 0.73, 14.68 ]
Subtotal (95% CI) 15 19 100.0 % 3.28 [ 0.73, 14.68 ]
Total events: 7 (Tetracyclines), 4 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
2 Tetracycline vs bleomycin
Kessinger 1987 16/26 6/16 22.8 % 2.67 [ 0.74, 9.63 ]
Lynch 1996 7/15 4/16 17.8 % 2.63 [ 0.57, 12.00 ]
Martinez-Moragon 1997 16/31 10/31 30.2 % 2.24 [ 0.80, 6.28 ]
Ruckdeschel 1991 7/41 11/44 29.2 % 0.62 [ 0.21, 1.79 ]
Subtotal (95% CI) 113 107 100.0 % 1.65 [ 0.79, 3.43 ]
Total events: 46 (Tetracyclines), 31 (Other)
Heterogeneity: Tau2 = 0.19; Chi2 = 4.51, df = 3 (P = 0.21); I2 =34%
Test for overall effect: Z = 1.33 (P = 0.18)
3 Tetracycline vs C. parvum
Leahy 1985 9/20 14/21 100.0 % 0.41 [ 0.12, 1.45 ]
Subtotal (95% CI) 20 21 100.0 % 0.41 [ 0.12, 1.45 ]
Total events: 9 (Tetracyclines), 14 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
4 Tetracycline vs mustine
Loutsidis 1994 9/20 0/20 100.0 % 33.87 [ 1.80, 636.88 ]
Subtotal (95% CI) 20 20 100.0 % 33.87 [ 1.80, 636.88 ]
Total events: 9 (Tetracyclines), 0 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
5 Tetracycline vs mepacrine
Bayly 1978 5/12 8/10 100.0 % 0.18 [ 0.03, 1.23 ]
Subtotal (95% CI) 12 10 100.0 % 0.18 [ 0.03, 1.23 ]
Total events: 5 (Tetracyclines), 8 (Other)
Heterogeneity: not applicable
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Study or subgroup Tetracyclines Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.75 (P = 0.080)
6 Tetracycline vs placebo
Zaloznik 1983 0/13 0/9 Not estimable
Subtotal (95% CI) 13 9 Not estimable
Total events: 0 (Tetracyclines), 0 (Other)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 13.89, df = 4 (P = 0.01), I2 =71%
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Analysis 4.3. Comparison 4 Tetracycline, Outcome 3 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 4 Tetracycline
Outcome: 3 Fever
Study or subgroup Tetracyclines Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tetracycline vs talc slurry
Lynch 1996 6/15 8/19 100.0 % 0.92 [ 0.23, 3.63 ]
Subtotal (95% CI) 15 19 100.0 % 0.92 [ 0.23, 3.63 ]
Total events: 6 (Tetracyclines), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
2 Tetracycline vs bleomycin
Emad 1996 1/20 1/20 12.1 % 1.00 [ 0.06, 17.18 ]
Kessinger 1987 2/16 8/16 22.7 % 0.14 [ 0.02, 0.84 ]
Lynch 1996 6/15 5/16 27.5 % 1.47 [ 0.33, 6.43 ]
Martinez-Moragon 1997 0/31 6/31 11.6 % 0.06 [ 0.00, 1.16 ]
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Study or subgroup Tetracyclines Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ruckdeschel 1991 3/41 4/44 26.1 % 0.79 [ 0.17, 3.76 ]
Subtotal (95% CI) 123 127 100.0 % 0.49 [ 0.16, 1.50 ]
Total events: 12 (Tetracyclines), 24 (Control)
Heterogeneity: Tau2 = 0.63; Chi2 = 6.60, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 1.25 (P = 0.21)
3 Tetracycline vs C. parvum
Leahy 1985 1/19 16/17 100.0 % 0.00 [ 0.00, 0.06 ]
Subtotal (95% CI) 19 17 100.0 % 0.00 [ 0.00, 0.06 ]
Total events: 1 (Tetracyclines), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.89 (P = 0.00010)
4 Tetracycline vs mepacrine
Bayly 1978 4/12 8/10 100.0 % 0.13 [ 0.02, 0.89 ]
Subtotal (95% CI) 12 10 100.0 % 0.13 [ 0.02, 0.89 ]
Total events: 4 (Tetracyclines), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.038)
5 Tetracycline vs combination tetracycline and bleomycin
Emad 1996 1/20 2/20 100.0 % 0.47 [ 0.04, 5.69 ]
Subtotal (95% CI) 20 20 100.0 % 0.47 [ 0.04, 5.69 ]
Total events: 1 (Tetracyclines), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
6 Tetracycline vs placebo
Zaloznik 1983 0/13 0/9 Not estimable
Subtotal (95% CI) 13 9 Not estimable
Total events: 0 (Tetracyclines), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Tetracycline vs mustine
Loutsidis 1994 0/20 0/20 Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (Tetracyclines), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 13.37, df = 4 (P = 0.01), I2 =70%
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Analysis 4.4. Comparison 4 Tetracycline, Outcome 4 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 4 Tetracycline
Outcome: 4 Mortality
Study or subgroup Tetracyclines Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tetracycline vs talc poudrage
Fentiman 1986 2/23 6/18 25.5 % 0.19 [ 0.03, 1.10 ]
Subtotal (95% CI) 23 18 25.5 % 0.19 [ 0.03, 1.10 ]
Total events: 2 (Tetracyclines), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
2 Tetracycline vs bleomycin
Emad 1996 1/20 1/20 13.4 % 1.00 [ 0.06, 17.18 ]
Ruckdeschel 1991 19/41 15/44 43.6 % 1.67 [ 0.70, 4.00 ]
Subtotal (95% CI) 61 64 57.0 % 1.60 [ 0.69, 3.69 ]
Total events: 20 (Tetracyclines), 16 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
3 Tetracycline vs C. parvum
Leahy 1985 3/19 1/17 17.5 % 3.00 [ 0.28, 31.99 ]
Subtotal (95% CI) 19 17 17.5 % 3.00 [ 0.28, 31.99 ]
Total events: 3 (Tetracyclines), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Total (95% CI) 103 99 100.0 % 0.99 [ 0.30, 3.26 ]
Total events: 25 (Tetracyclines), 23 (Control)
Heterogeneity: Tau2 = 0.64; Chi2 = 5.40, df = 3 (P = 0.14); I2 =44%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 5.27, df = 2 (P = 0.07), I2 =62%
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Analysis 5.1. Comparison 5 C. parvum, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 5 C. parvum
Outcome: 1 Pleurodesis failure
Study or subgroup C.parvum Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 C. parvum vs bleomycin
Hillerdal 1986 6/20 17/19 49.4 % 0.05 [ 0.01, 0.29 ]
Ostrowski 1989 13/17 8/22 50.6 % 5.69 [ 1.38, 23.48 ]
Subtotal (95% CI) 37 41 100.0 % 0.55 [ 0.01, 57.48 ]
Total events: 19 (C.parvum), 25 (Others)
Heterogeneity: Tau2 = 10.59; Chi2 = 17.04, df = 1 (P = 0.00004); I2 =94%
Test for overall effect: Z = 0.25 (P = 0.80)
2 C. parvum vs tetracycline
Leahy 1985 2/16 5/16 100.0 % 0.31 [ 0.05, 1.94 ]
Subtotal (95% CI) 16 16 100.0 % 0.31 [ 0.05, 1.94 ]
Total events: 2 (C.parvum), 5 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
3 C. parvum vs doxycycline
Salomaa 1995 4/18 6/17 100.0 % 0.52 [ 0.12, 2.33 ]
Subtotal (95% CI) 18 17 100.0 % 0.52 [ 0.12, 2.33 ]
Total events: 4 (C.parvum), 6 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
4 C. parvum vs mustine
Millar 1980 2/7 6/11 100.0 % 0.33 [ 0.04, 2.52 ]
Subtotal (95% CI) 7 11 100.0 % 0.33 [ 0.04, 2.52 ]
Total events: 2 (C.parvum), 6 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Chi2 = 0.24, df = 3 (P = 0.97), I2 =0.0%
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Analysis 5.2. Comparison 5 C. parvum, Outcome 2 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 5 C. parvum
Outcome: 2 Pain
Study or subgroup C.parvum Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 C. parvum vs bleomycin
Hillerdal 1986 8/16 3/11 18.9 % 2.67 [ 0.51, 13.88 ]
Ostrowski 1989 10/19 13/25 29.5 % 1.03 [ 0.31, 3.39 ]
Subtotal (95% CI) 35 36 48.4 % 1.42 [ 0.54, 3.75 ]
Total events: 18 (C.parvum), 16 (Others)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
2 C . parvum vs tetracycline
Leahy 1985 14/21 9/20 27.4 % 2.44 [ 0.69, 8.66 ]
Subtotal (95% CI) 21 20 27.4 % 2.44 [ 0.69, 8.66 ]
Total events: 14 (C.parvum), 9 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
3 C. parvum vs doxycycline
Salomaa 1995 13/19 5/22 24.2 % 7.37 [ 1.84, 29.55 ]
Subtotal (95% CI) 19 22 24.2 % 7.37 [ 1.84, 29.55 ]
Total events: 13 (C.parvum), 5 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
Total (95% CI) 75 78 100.0 % 2.51 [ 1.10, 5.75 ]
Total events: 45 (C.parvum), 30 (Others)
Heterogeneity: Tau2 = 0.23; Chi2 = 4.46, df = 3 (P = 0.22); I2 =33%
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Chi2 = 3.62, df = 2 (P = 0.16), I2 =45%
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Analysis 5.3. Comparison 5 C. parvum, Outcome 3 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 5 C. parvum
Outcome: 3 Fever
Study or subgroup C.parvum Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 C. parvum vs bleomycin
Hillerdal 1986 14/20 10/16 46.0 % 1.40 [ 0.35, 5.63 ]
Ostrowski 1989 10/19 6/25 54.0 % 3.52 [ 0.97, 12.73 ]
Subtotal (95% CI) 39 41 100.0 % 2.30 [ 0.90, 5.92 ]
Total events: 24 (C.parvum), 16 (Others)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.084)
2 C. parvum vs tetracycline
Leahy 1985 16/17 1/19 100.0 % 288.00 [ 16.62, 4991.05 ]
Subtotal (95% CI) 17 19 100.0 % 288.00 [ 16.62, 4991.05 ]
Total events: 16 (C.parvum), 1 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 3.89 (P = 0.00010)
3 C. parvum vs mustine
Millar 1980 1/9 0/12 100.0 % 4.41 [ 0.16, 121.68 ]
Subtotal (95% CI) 9 12 100.0 % 4.41 [ 0.16, 121.68 ]
Total events: 1 (C.parvum), 0 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
4 C. parvum vs doxycycline
Salomaa 1995 13/19 5/22 100.0 % 7.37 [ 1.84, 29.55 ]
Subtotal (95% CI) 19 22 100.0 % 7.37 [ 1.84, 29.55 ]
Total events: 13 (C.parvum), 5 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
Test for subgroup differences: Chi2 = 10.58, df = 3 (P = 0.01), I2 =72%
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Analysis 5.4. Comparison 5 C. parvum, Outcome 4 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 5 C. parvum
Outcome: 4 Mortality
Study or subgroup C.parvum Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 C. parvum vs bleomycin
Ostrowski 1989 9/26 7/29 100.0 % 1.66 [ 0.51, 5.38 ]
Subtotal (95% CI) 26 29 100.0 % 1.66 [ 0.51, 5.38 ]
Total events: 9 (C.parvum), 7 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
2 C. parvum vs tetracycline
Leahy 1985 1/17 3/19 100.0 % 0.33 [ 0.03, 3.55 ]
Subtotal (95% CI) 17 19 100.0 % 0.33 [ 0.03, 3.55 ]
Total events: 1 (C.parvum), 3 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
3 C. parvum vs mustine
Millar 1980 5/9 9/12 100.0 % 0.42 [ 0.07, 2.66 ]
Subtotal (95% CI) 9 12 100.0 % 0.42 [ 0.07, 2.66 ]
Total events: 5 (C.parvum), 9 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Chi2 = 2.39, df = 2 (P = 0.30), I2 =16%
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Analysis 6.1. Comparison 6 Indwelling pleural catheter (IPC), Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 6 Indwelling pleural catheter (IPC)
Outcome: 1 Pleurodesis failure
Study or subgroup IPC Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 IPC vs talc slurry
Davies 2012 25/51 12/54 71.2 % 3.37 [ 1.45, 7.83 ]
Demmy 2012 9/26 4/29 28.8 % 3.31 [ 0.88, 12.50 ]
Subtotal (95% CI) 77 83 100.0 % 3.35 [ 1.64, 6.83 ]
Total events: 34 (IPC), 16 (Others)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.32 (P = 0.00089)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Indwelling pleural catheter (IPC), Outcome 2 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 6 Indwelling pleural catheter (IPC)
Outcome: 2 Mortality
Study or subgroup IPC Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Davies 2012 16/52 20/54 61.6 % 0.76 [ 0.34, 1.69 ]
Demmy 2012 11/28 8/29 38.4 % 1.70 [ 0.56, 5.17 ]
Total (95% CI) 80 83 100.0 % 1.03 [ 0.48, 2.23 ]
Total events: 27 (IPC), 28 (Others)
Heterogeneity: Tau2 = 0.08; Chi2 = 1.33, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Indwelling pleural catheter (IPC), Outcome 3 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 6 Indwelling pleural catheter (IPC)
Outcome: 3 Pain
Study or subgroup IPC Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Demmy 2012 1/28 0/29 3.22 [ 0.13, 82.38 ]
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Iodine, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 7 Iodine
Outcome: 1 Pleurodesis failure
Study or subgroup Iodine Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Iodine vs talc poudrage
Mohsen 2011 3/20 2/22 100.0 % 1.76 [ 0.26, 11.83 ]
Subtotal (95% CI) 20 22 100.0 % 1.76 [ 0.26, 11.83 ]
Total events: 3 (Iodine), 2 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
2 Iodine vs talc slurry
Agarwal 2011 1/18 2/18 100.0 % 0.47 [ 0.04, 5.71 ]
Subtotal (95% CI) 18 18 100.0 % 0.47 [ 0.04, 5.71 ]
Total events: 1 (Iodine), 2 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
3 Iodine vs bleomycin
Alavi 2011 5/20 4/19 100.0 % 1.25 [ 0.28, 5.59 ]
Subtotal (95% CI) 20 19 100.0 % 1.25 [ 0.28, 5.59 ]
Total events: 5 (Iodine), 4 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 0.70, df = 2 (P = 0.71), I2 =0.0%
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Analysis 7.2. Comparison 7 Iodine, Outcome 2 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 7 Iodine
Outcome: 2 Fever
Study or subgroup Iodine Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Iodine vs talc slurry
Agarwal 2011 2/18 3/18 100.0 % 0.63 [ 0.09, 4.28 ]
Subtotal (95% CI) 18 18 100.0 % 0.63 [ 0.09, 4.28 ]
Total events: 2 (Iodine), 3 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
2 Iodine vs talc poudrage
Mohsen 2011 1/20 4/22 100.0 % 0.24 [ 0.02, 2.33 ]
Subtotal (95% CI) 20 22 100.0 % 0.24 [ 0.02, 2.33 ]
Total events: 1 (Iodine), 4 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Chi2 = 0.41, df = 1 (P = 0.52), I2 =0.0%
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Analysis 7.3. Comparison 7 Iodine, Outcome 3 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 7 Iodine
Outcome: 3 Mortality
Study or subgroup Iodine Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Iodine vs talc poudrage
Mohsen 2011 3/20 7/22 100.0 % 0.38 [ 0.08, 1.73 ]
Subtotal (95% CI) 20 22 100.0 % 0.38 [ 0.08, 1.73 ]
Total events: 3 (Iodine), 7 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 Iodine, Outcome 4 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 7 Iodine
Outcome: 4 Pain
Study or subgroup Iodine Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Iodine vs talc slurry
Agarwal 2011 18/18 18/18 Not estimable
Subtotal (95% CI) 18 18 Not estimable
Total events: 18 (Iodine), 18 (Others)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Iodine vs talc poudrage
Mohsen 2011 0/20 4/22 100.0 % 0.10 [ 0.01, 1.99 ]
Subtotal (95% CI) 20 22 100.0 % 0.10 [ 0.01, 1.99 ]
Total events: 0 (Iodine), 4 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Doxycycline, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 8 Doxycycline
Outcome: 1 Pleurodesis failure
Study or subgroup Doxycyline Others Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Doxycycline vs talc poudrage
Kuzdzal 2003 7/13 0/18 100.0 % 42.69 [ 2.13, 856.61 ]
Subtotal (95% CI) 13 18 100.0 % 42.69 [ 2.13, 856.61 ]
Total events: 7 (Doxycyline), 0 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
2 Doxycycline vs bleomycin
Patz 1998 7/38 10/42 84.1 % 0.72 [ 0.24, 2.14 ]
Rafiei 2014 0/21 1/21 15.9 % 0.32 [ 0.01, 8.26 ]
Subtotal (95% CI) 59 63 100.0 % 0.66 [ 0.24, 1.83 ]
Total events: 7 (Doxycyline), 11 (Others)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
3 Doxycycline vs C. parvum
Salomaa 1995 6/17 4/18 100.0 % 1.91 [ 0.43, 8.48 ]
Subtotal (95% CI) 17 18 100.0 % 1.91 [ 0.43, 8.48 ]
Total events: 6 (Doxycyline), 4 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Chi2 = 7.15, df = 2 (P = 0.03), I2 =72%
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Analysis 8.2. Comparison 8 Doxycycline, Outcome 2 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 8 Doxycycline
Outcome: 2 Pain
Study or subgroup Doxycyline Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Doxycycline vs bleomycin
Patz 1998 11/54 6/52 58.3 % 1.96 [ 0.67, 5.76 ]
Rafiei 2014 15/21 17/21 41.7 % 0.59 [ 0.14, 2.49 ]
Subtotal (95% CI) 75 73 100.0 % 1.19 [ 0.37, 3.80 ]
Total events: 26 (Doxycyline), 23 (Others)
Heterogeneity: Tau2 = 0.30; Chi2 = 1.72, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Doxycycline vs C. parvum
Salomaa 1995 1/22 6/19 100.0 % 0.10 [ 0.01, 0.96 ]
Subtotal (95% CI) 22 19 100.0 % 0.10 [ 0.01, 0.96 ]
Total events: 1 (Doxycyline), 6 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Chi2 = 3.63, df = 1 (P = 0.06), I2 =72%
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Analysis 8.3. Comparison 8 Doxycycline, Outcome 3 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 8 Doxycycline
Outcome: 3 Fever
Study or subgroup Doxycyline Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Doxycycline vs bleomycin
Patz 1998 0/54 7/52 23.9 % 0.06 [ 0.00, 1.00 ]
Rafiei 2014 7/21 5/21 38.2 % 1.60 [ 0.41, 6.19 ]
Subtotal (95% CI) 75 73 62.1 % 0.37 [ 0.01, 12.35 ]
Total events: 7 (Doxycyline), 12 (Others)
Heterogeneity: Tau2 = 5.18; Chi2 = 4.91, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 0.55 (P = 0.58)
2 Doxycycline vs C. parvum
Salomaa 1995 5/22 13/19 37.9 % 0.14 [ 0.03, 0.54 ]
Subtotal (95% CI) 22 19 37.9 % 0.14 [ 0.03, 0.54 ]
Total events: 5 (Doxycyline), 13 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
Total (95% CI) 97 92 100.0 % 0.28 [ 0.04, 2.16 ]
Total events: 12 (Doxycyline), 25 (Others)
Heterogeneity: Tau2 = 2.34; Chi2 = 8.24, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
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Analysis 8.4. Comparison 8 Doxycycline, Outcome 4 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 8 Doxycycline
Outcome: 4 Mortality
Study or subgroup Doxycyline Others Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Doxycycline vs bleomycin
Patz 1998 9/38 13/42 100.0 % 0.69 [ 0.26, 1.87 ]
Subtotal (95% CI) 38 42 100.0 % 0.69 [ 0.26, 1.87 ]
Total events: 9 (Doxycyline), 13 (Others)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Mode of administration, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 9 Mode of administration
Outcome: 1 Pleurodesis failure
Study or subgroup Thoracoscopy Slurry Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Talc
Dresler 2005 97/242 114/240 90.7 % 0.74 [ 0.52, 1.06 ]
Terra 2009 5/30 4/30 5.8 % 1.30 [ 0.31, 5.40 ]
Yim 1996 0/28 0/29 Not estimable
Subtotal (95% CI) 300 299 96.5 % 0.76 [ 0.54, 1.09 ]
Total events: 102 (Thoracoscopy), 118 (Slurry)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
2 Tetracycline
Evans 1993 2/15 5/14 3.5 % 0.28 [ 0.04, 1.76 ]
Subtotal (95% CI) 15 14 3.5 % 0.28 [ 0.04, 1.76 ]
Total events: 2 (Thoracoscopy), 5 (Slurry)
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
Total (95% CI) 315 313 100.0 % 0.74 [ 0.52, 1.04 ]
Total events: 104 (Thoracoscopy), 123 (Slurry)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.69, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.084)
Test for subgroup differences: Chi2 = 1.12, df = 1 (P = 0.29), I2 =11%
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Analysis 10.1. Comparison 10 Duration of drainage after pleurodesis administration, Outcome 1
Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 10 Duration of drainage after pleurodesis administration
Outcome: 1 Pleurodesis failure
Study or subgroup Rapid Standard Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Goodman 2006 2/16 4/19 0.54 [ 0.08, 3.40 ]
Villanueva 1994 2/9 3/15 1.14 [ 0.15, 8.59 ]
Yildirim 2005 0/12 2/8 0.10 [ 0.00, 2.50 ]
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 Duration of drainage after pleurodesis administration, Outcome 2 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 10 Duration of drainage after pleurodesis administration
Outcome: 2 Mortality
Study or subgroup Rapid Standard Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Goodman 2006 3/19 3/22 1.19 [ 0.21, 6.72 ]
Villanueva 1994 9/9 13/15 3.52 [ 0.15, 81.92 ]
Yildirim 2005 3/15 4/12 0.50 [ 0.09, 2.86 ]
Test for subgroup differences: Not applicable
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Analysis 11.1. Comparison 11 OK-432, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 11 OK-432
Outcome: 1 Pleurodesis failure
Study or subgroup OK432 Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 OK-432 and mitomycin C
Luh 1992 3/26 9/27 100.0 % 0.26 [ 0.06, 1.11 ]
Subtotal (95% CI) 26 27 100.0 % 0.26 [ 0.06, 1.11 ]
Total events: 3 (OK432), 9 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.068)
2 OK-432 vs cisplatin and etoposide
Yoshida 2007 8/33 10/34 100.0 % 0.77 [ 0.26, 2.27 ]
Subtotal (95% CI) 33 34 100.0 % 0.77 [ 0.26, 2.27 ]
Total events: 8 (OK432), 10 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
3 OK-432 and cisplatin
Ishida 2006 8/17 11/17 100.0 % 0.48 [ 0.12, 1.92 ]
Subtotal (95% CI) 17 17 100.0 % 0.48 [ 0.12, 1.92 ]
Total events: 8 (OK432), 11 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
4 High dose vs low dose
Kasahara 2006 5/19 3/19 100.0 % 1.90 [ 0.38, 9.44 ]
Subtotal (95% CI) 19 19 100.0 % 1.90 [ 0.38, 9.44 ]
Total events: 5 (OK432), 3 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
5 OK-432 vs bleomycin
Yoshida 2007 8/33 11/35 100.0 % 0.70 [ 0.24, 2.03 ]
Subtotal (95% CI) 33 35 100.0 % 0.70 [ 0.24, 2.03 ]
Total events: 8 (OK432), 11 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
6 OK-432 vs OK-432 and cisplatin
Ishida 2006 8/17 1/15 100.0 % 12.44 [ 1.32, 117.03 ]
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(. . . Continued)
Study or subgroup OK432 Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 17 15 100.0 % 12.44 [ 1.32, 117.03 ]
Total events: 8 (OK432), 1 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.027)
Test for subgroup differences: Chi2 = 9.77, df = 5 (P = 0.08), I2 =49%
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Analysis 11.2. Comparison 11 OK-432, Outcome 2 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 11 OK-432
Outcome: 2 Pain
Study or subgroup OK432 Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 OK-432 vs cisplatin
Ishida 2006 8/17 2/17 100.0 % 6.67 [ 1.15, 38.60 ]
Subtotal (95% CI) 17 17 100.0 % 6.67 [ 1.15, 38.60 ]
Total events: 8 (OK432), 2 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
2 OK-432 vs OK-432 and cisplatin
Ishida 2006 8/17 6/15 100.0 % 1.33 [ 0.33, 5.43 ]
Subtotal (95% CI) 17 15 100.0 % 1.33 [ 0.33, 5.43 ]
Total events: 8 (OK432), 6 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
3 OK-432 vs mitomycin C
Luh 1992 2/26 2/27 100.0 % 1.04 [ 0.14, 8.00 ]
Subtotal (95% CI) 26 27 100.0 % 1.04 [ 0.14, 8.00 ]
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(. . . Continued)
Study or subgroup OK432 Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 2 (OK432), 2 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
4 OK-432 vs bleomycin
Yoshida 2007 24/32 19/35 100.0 % 2.53 [ 0.89, 7.15 ]
Subtotal (95% CI) 32 35 100.0 % 2.53 [ 0.89, 7.15 ]
Total events: 24 (OK432), 19 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.081)
5 OK-432 vs cisplatin and etoposide
Yoshida 2007 24/32 20/34 100.0 % 2.10 [ 0.73, 6.01 ]
Subtotal (95% CI) 32 34 100.0 % 2.10 [ 0.73, 6.01 ]
Total events: 24 (OK432), 20 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Chi2 = 2.61, df = 4 (P = 0.62), I2 =0.0%
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Analysis 11.3. Comparison 11 OK-432, Outcome 3 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 11 OK-432
Outcome: 3 Fever
Study or subgroup OK432 Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 OK-432 vs cisplatin
Ishida 2006 16/17 1/17 100.0 % 256.00 [ 14.70, 4457.27 ]
Subtotal (95% CI) 17 17 100.0 % 256.00 [ 14.70, 4457.27 ]
Total events: 16 (OK432), 1 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 3.80 (P = 0.00014)
2 OK-432 vs OK-432 and cisplatin
Ishida 2006 16/17 8/15 100.0 % 14.00 [ 1.46, 134.25 ]
Subtotal (95% CI) 17 15 100.0 % 14.00 [ 1.46, 134.25 ]
Total events: 16 (OK432), 8 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
3 OK-432 vs mitomycin C
Luh 1992 20/26 3/27 100.0 % 26.67 [ 5.91, 120.42 ]
Subtotal (95% CI) 26 27 100.0 % 26.67 [ 5.91, 120.42 ]
Total events: 20 (OK432), 3 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 4.27 (P = 0.000020)
4 OK-432 vs bleomycin
Yoshida 2007 25/32 25/35 100.0 % 1.43 [ 0.47, 4.35 ]
Subtotal (95% CI) 32 35 100.0 % 1.43 [ 0.47, 4.35 ]
Total events: 25 (OK432), 25 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
5 OK-432 vs cisplatin and etoposide
Yoshida 2007 25/32 18/34 100.0 % 3.17 [ 1.08, 9.30 ]
Subtotal (95% CI) 32 34 100.0 % 3.17 [ 1.08, 9.30 ]
Total events: 25 (OK432), 18 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Chi2 = 18.37, df = 4 (P = 0.00), I2 =78%
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Analysis 11.4. Comparison 11 OK-432, Outcome 4 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 11 OK-432
Outcome: 4 Mortality
Study or subgroup OK432 Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 OK-432 vs cisplatin
Ishida 2006 6/17 5/17 100.0 % 1.31 [ 0.31, 5.53 ]
Subtotal (95% CI) 17 17 100.0 % 1.31 [ 0.31, 5.53 ]
Total events: 6 (OK432), 5 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
2 OK-432 vs combined OK-432 and cisplatin
Ishida 2006 6/17 3/15 100.0 % 2.18 [ 0.44, 10.91 ]
Subtotal (95% CI) 17 15 100.0 % 2.18 [ 0.44, 10.91 ]
Total events: 6 (OK432), 3 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
3 OK-432 vs bleomycin
Yoshida 2007 16/33 25/35 100.0 % 0.38 [ 0.14, 1.03 ]
Subtotal (95% CI) 33 35 100.0 % 0.38 [ 0.14, 1.03 ]
Total events: 16 (OK432), 25 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
4 OK-432 vs cisplatin and etoposide
Yoshida 2007 16/33 18/34 100.0 % 0.84 [ 0.32, 2.18 ]
Subtotal (95% CI) 33 34 100.0 % 0.84 [ 0.32, 2.18 ]
Total events: 16 (OK432), 18 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 4.12, df = 3 (P = 0.25), I2 =27%
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Analysis 12.1. Comparison 12 Mepacrine, Outcome 1 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 12 Mepacrine
Outcome: 1 Pain
Study or subgroup Mepacine Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mepacrine vs bleomycin
Koldsland 1993 16/20 13/20 50.0 % 2.15 [ 0.52, 9.00 ]
Subtotal (95% CI) 20 20 50.0 % 2.15 [ 0.52, 9.00 ]
Total events: 16 (Mepacine), 13 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 Mepacrine vs tetracycline
Bayly 1978 8/10 5/12 27.5 % 5.60 [ 0.81, 38.51 ]
Subtotal (95% CI) 10 12 27.5 % 5.60 [ 0.81, 38.51 ]
Total events: 8 (Mepacine), 5 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
3 Mepacrine vs placebo
Mejer 1977 6/14 0/9 11.2 % 14.53 [ 0.71, 298.21 ]
Subtotal (95% CI) 14 9 11.2 % 14.53 [ 0.71, 298.21 ]
Total events: 6 (Mepacine), 0 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.083)
4 Mepacrine vs triethylenethiophosphoramide
Mejer 1977 6/14 0/15 11.4 % 23.71 [ 1.19, 474.06 ]
Subtotal (95% CI) 14 15 11.4 % 23.71 [ 1.19, 474.06 ]
Total events: 6 (Mepacine), 0 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.038)
Total (95% CI) 58 56 100.0 % 4.56 [ 1.66, 12.52 ]
Total events: 36 (Mepacine), 18 (Other)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.93, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.94 (P = 0.0033)
Test for subgroup differences: Chi2 = 2.83, df = 3 (P = 0.42), I2 =0.0%
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Analysis 12.2. Comparison 12 Mepacrine, Outcome 2 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 12 Mepacrine
Outcome: 2 Fever
Study or subgroup Mepacine Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mepacrine vs bleomycin
Koldsland 1993 14/20 11/20 100.0 % 1.91 [ 0.52, 7.01 ]
Subtotal (95% CI) 20 20 100.0 % 1.91 [ 0.52, 7.01 ]
Total events: 14 (Mepacine), 11 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
2 Mepacrine vs tetracycline
Bayly 1978 8/10 4/12 100.0 % 8.00 [ 1.13, 56.79 ]
Subtotal (95% CI) 10 12 100.0 % 8.00 [ 1.13, 56.79 ]
Total events: 8 (Mepacine), 4 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.038)
3 Mepacrine vs placebo
Mejer 1977 11/14 0/9 100.0 % 62.43 [ 2.85, 1365.52 ]
Subtotal (95% CI) 14 9 100.0 % 62.43 [ 2.85, 1365.52 ]
Total events: 11 (Mepacine), 0 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0086)
4 Mepacrine vs triethylene...
Mejer 1977 11/14 2/15 100.0 % 23.83 [ 3.35, 169.39 ]
Subtotal (95% CI) 14 15 100.0 % 23.83 [ 3.35, 169.39 ]
Total events: 11 (Mepacine), 2 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Chi2 = 7.18, df = 3 (P = 0.07), I2 =58%
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Analysis 12.3. Comparison 12 Mepacrine, Outcome 3 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 12 Mepacrine
Outcome: 3 Pleurodesis failure
Study or subgroup Mepacine Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mepacrine vs talc slurry
Ukale 2004 8/41 5/48 100.0 % 2.08 [ 0.62, 6.96 ]
Subtotal (95% CI) 41 48 100.0 % 2.08 [ 0.62, 6.96 ]
Total events: 8 (Mepacine), 5 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
2 Mepacrine vs bleomycin
Koldsland 1993 2/18 8/18 100.0 % 0.16 [ 0.03, 0.89 ]
Subtotal (95% CI) 18 18 100.0 % 0.16 [ 0.03, 0.89 ]
Total events: 2 (Mepacine), 8 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.036)
3 Mepacrine vs tetracycline
Bayly 1978 1/9 2/12 100.0 % 0.63 [ 0.05, 8.20 ]
Subtotal (95% CI) 9 12 100.0 % 0.63 [ 0.05, 8.20 ]
Total events: 1 (Mepacine), 2 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
4 Mepacrine vs placebo
Mejer 1977 5/14 8/9 100.0 % 0.07 [ 0.01, 0.73 ]
Subtotal (95% CI) 14 9 100.0 % 0.07 [ 0.01, 0.73 ]
Total events: 5 (Mepacine), 8 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.026)
5 Mepacrine vs mitoxantrone
Bjermer 1995 3/14 0/12 100.0 % 7.61 [ 0.35, 163.82 ]
Subtotal (95% CI) 14 12 100.0 % 7.61 [ 0.35, 163.82 ]
Total events: 3 (Mepacine), 0 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.20)
6 Mepacrine vs triethylene...
Mejer 1977 5/14 11/15 100.0 % 0.20 [ 0.04, 0.98 ]
Subtotal (95% CI) 14 15 100.0 % 0.20 [ 0.04, 0.98 ]
0.01 0.1 1 10 100
Favours mepacrine Favours other
(Continued . . . )
180Interventions for the management of malignant pleural effusions: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Mepacine Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 5 (Mepacine), 11 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Chi2 = 14.04, df = 5 (P = 0.02), I2 =64%
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Analysis 12.4. Comparison 12 Mepacrine, Outcome 4 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 12 Mepacrine
Outcome: 4 Mortality
Study or subgroup Mepacine Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mepacrine vs talc slurry
Ukale 2004 8/41 15/48 100.0 % 0.53 [ 0.20, 1.43 ]
Subtotal (95% CI) 41 48 100.0 % 0.53 [ 0.20, 1.43 ]
Total events: 8 (Mepacine), 15 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
2 Mepacrine vs mitoxantrone
Bjermer 1995 12/14 11/14 100.0 % 1.64 [ 0.23, 11.70 ]
Subtotal (95% CI) 14 14 100.0 % 1.64 [ 0.23, 11.70 ]
Total events: 12 (Mepacine), 11 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi2 = 1.00, df = 1 (P = 0.32), I2 =0.0%
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Analysis 13.1. Comparison 13 Interferon (IFN), Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 13 Interferon (IFN)
Outcome: 1 Pleurodesis failure
Study or subgroup IFN other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 IFN vs bleomycin
Sartori 2004 29/77 13/83 100.0 % 3.25 [ 1.54, 6.89 ]
Subtotal (95% CI) 77 83 100.0 % 3.25 [ 1.54, 6.89 ]
Total events: 29 (IFN), 13 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 3.08 (P = 0.0021)
Test for subgroup differences: Not applicable
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Analysis 13.2. Comparison 13 Interferon (IFN), Outcome 2 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 13 Interferon (IFN)
Outcome: 2 Pain
Study or subgroup IFN other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sartori 2004 0/77 14/83 100.0 % 0.03 [ 0.00, 0.53 ]
Total (95% CI) 77 83 100.0 % 0.03 [ 0.00, 0.53 ]
Total events: 0 (IFN), 14 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 13.3. Comparison 13 Interferon (IFN), Outcome 3 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 13 Interferon (IFN)
Outcome: 3 Fever
Study or subgroup IFN other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sartori 2004 0/77 41/83 100.0 % 0.01 [ 0.00, 0.11 ]
Total (95% CI) 77 83 100.0 % 0.01 [ 0.00, 0.11 ]
Total events: 0 (IFN), 41 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 3.50 (P = 0.00047)
Test for subgroup differences: Not applicable
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Analysis 13.4. Comparison 13 Interferon (IFN), Outcome 4 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 13 Interferon (IFN)
Outcome: 4 Mortality
Study or subgroup IFN other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sartori 2004 48/77 36/83 2.16 [ 1.15, 4.07 ]
Test for subgroup differences: Not applicable
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Analysis 14.1. Comparison 14 Triethylenethiophophoramide, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 14 Triethylenethiophophoramide
Outcome: 1 Pleurodesis failure
Study or subgroup triethylene.... other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Triethylene... vs placebo
Mejer 1977 11/15 8/9 100.0 % 0.34 [ 0.03, 3.69 ]
Subtotal (95% CI) 15 9 100.0 % 0.34 [ 0.03, 3.69 ]
Total events: 11 (triethylene....), 8 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
2 Triethylene... vs mepacrine
Mejer 1977 11/15 5/14 100.0 % 4.95 [ 1.02, 24.10 ]
Subtotal (95% CI) 15 14 100.0 % 4.95 [ 1.02, 24.10 ]
Total events: 11 (triethylene....), 5 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Chi2 = 3.36, df = 1 (P = 0.07), I2 =70%
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Analysis 14.2. Comparison 14 Triethylenethiophophoramide, Outcome 2 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 14 Triethylenethiophophoramide
Outcome: 2 Pain
Study or subgroup triethylene.... other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Triethylene... vs mepacrine
Mejer 1977 4/15 6/14 61.4 % 0.48 [ 0.10, 2.30 ]
Subtotal (95% CI) 15 14 61.4 % 0.48 [ 0.10, 2.30 ]
Total events: 4 (triethylene....), 6 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
2 Triethylene... vs placebo
Mejer 1977 4/15 0/9 38.6 % 7.43 [ 0.35, 156.28 ]
Subtotal (95% CI) 15 9 38.6 % 7.43 [ 0.35, 156.28 ]
Total events: 4 (triethylene....), 0 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Total (95% CI) 30 23 100.0 % 1.39 [ 0.10, 20.15 ]
Total events: 8 (triethylene....), 6 (other)
Heterogeneity: Tau2 = 2.40; Chi2 = 2.57, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 2.45, df = 1 (P = 0.12), I2 =59%
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Analysis 14.3. Comparison 14 Triethylenethiophophoramide, Outcome 3 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 14 Triethylenethiophophoramide
Outcome: 3 Fever
Study or subgroup triethylene.... other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Triethylene... vs placebo
Mejer 1977 2/15 0/9 46.1 % 3.52 [ 0.15, 81.92 ]
Subtotal (95% CI) 15 9 46.1 % 3.52 [ 0.15, 81.92 ]
Total events: 2 (triethylene....), 0 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
2 Triethylene... vs mepacrine
Mejer 1977 2/15 11/14 53.9 % 0.04 [ 0.01, 0.30 ]
Subtotal (95% CI) 15 14 53.9 % 0.04 [ 0.01, 0.30 ]
Total events: 2 (triethylene....), 11 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 3.17 (P = 0.0015)
Total (95% CI) 30 23 100.0 % 0.32 [ 0.00, 26.74 ]
Total events: 4 (triethylene....), 11 (other)
Heterogeneity: Tau2 = 8.41; Chi2 = 5.70, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Chi2 = 5.48, df = 1 (P = 0.02), I2 =82%
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Analysis 15.1. Comparison 15 Adriamycin, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 15 Adriamycin
Outcome: 1 Pleurodesis failure
Study or subgroup Adriamycin Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Adriamycin vs mustine
Kefford 1980 10/11 9/9 100.0 % 0.37 [ 0.01, 10.18 ]
Subtotal (95% CI) 11 9 100.0 % 0.37 [ 0.01, 10.18 ]
Total events: 10 (Adriamycin), 9 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
2 Adriamycin vs tetracycline
Kefford 1980 10/11 9/10 100.0 % 1.11 [ 0.06, 20.49 ]
Subtotal (95% CI) 11 10 100.0 % 1.11 [ 0.06, 20.49 ]
Total events: 10 (Adriamycin), 9 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
3 Adriamycin vs LC9018 and Adriamycin
Masuno 1991 23/38 10/38 100.0 % 4.29 [ 1.62, 11.35 ]
Subtotal (95% CI) 38 38 100.0 % 4.29 [ 1.62, 11.35 ]
Total events: 23 (Adriamycin), 10 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.94 (P = 0.0033)
Test for subgroup differences: Chi2 = 2.49, df = 2 (P = 0.29), I2 =20%
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Analysis 15.2. Comparison 15 Adriamycin, Outcome 2 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 15 Adriamycin
Outcome: 2 Fever
Study or subgroup Adriamycin Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Masuno 1991 13/45 11/41 1.11 [ 0.43, 2.85 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Adriamycin Favours Other
Analysis 15.3. Comparison 15 Adriamycin, Outcome 3 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 15 Adriamycin
Outcome: 3 Pain
Study or subgroup Adriamycin Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Masuno 1991 13/45 6/41 2.37 [ 0.81, 6.98 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Adriamycin Favours other[control]
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Analysis 16.1. Comparison 16 Placebo, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 16 Placebo
Outcome: 1 Pleurodesis failure
Study or subgroup placebo other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Placebo vs mepacrine
Mejer 1977 8/9 5/14 100.0 % 14.40 [ 1.37, 150.81 ]
Subtotal (95% CI) 9 14 100.0 % 14.40 [ 1.37, 150.81 ]
Total events: 8 (placebo), 5 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.026)
2 Placebo vs mitoxantrone
Groth 1991 16/46 14/49 100.0 % 1.33 [ 0.56, 3.17 ]
Subtotal (95% CI) 46 49 100.0 % 1.33 [ 0.56, 3.17 ]
Total events: 16 (placebo), 14 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
3 Placebo vs triethylene...
Mejer 1977 8/9 11/15 100.0 % 2.91 [ 0.27, 31.21 ]
Subtotal (95% CI) 9 15 100.0 % 2.91 [ 0.27, 31.21 ]
Total events: 8 (placebo), 11 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
4 Placebo vs talc slurry
Sorensen 1984 5/12 0/9 100.0 % 13.93 [ 0.66, 293.99 ]
Subtotal (95% CI) 12 9 100.0 % 13.93 [ 0.66, 293.99 ]
Total events: 5 (placebo), 0 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.090)
5 Placebo vs tetracycline
Zaloznik 1983 5/8 4/12 100.0 % 3.33 [ 0.51, 21.58 ]
Subtotal (95% CI) 8 12 100.0 % 3.33 [ 0.51, 21.58 ]
Total events: 5 (placebo), 4 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 5.39, df = 4 (P = 0.25), I2 =26%
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Analysis 16.2. Comparison 16 Placebo, Outcome 2 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 16 Placebo
Outcome: 2 Pain
Study or subgroup placebo other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Placebo vs talc slurry
Sorensen 1984 17/17 14/14 Not estimable
Subtotal (95% CI) 17 14 Not estimable
Total events: 17 (placebo), 14 (other)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Placebo vs tetracycline
Zaloznik 1983 0/9 0/13 Not estimable
Subtotal (95% CI) 9 13 Not estimable
Total events: 0 (placebo), 0 (other)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Placebo vs mepacrine
Mejer 1977 0/9 6/14 50.4 % 0.07 [ 0.00, 1.41 ]
Subtotal (95% CI) 9 14 50.4 % 0.07 [ 0.00, 1.41 ]
Total events: 0 (placebo), 6 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.083)
4 Placebo vs triethylene...
Mejer 1977 0/9 4/15 49.6 % 0.13 [ 0.01, 2.83 ]
Subtotal (95% CI) 9 15 49.6 % 0.13 [ 0.01, 2.83 ]
Total events: 0 (placebo), 4 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Total (95% CI) 44 56 100.0 % 0.10 [ 0.01, 0.82 ]
Total events: 17 (placebo), 24 (other)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.14 (P = 0.032)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
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Analysis 16.3. Comparison 16 Placebo, Outcome 3 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 16 Placebo
Outcome: 3 Fever
Study or subgroup placebo other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Placebo vs mepacrine
Groth 1991 8/46 20/49 100.0 % 0.31 [ 0.12, 0.79 ]
Subtotal (95% CI) 46 49 100.0 % 0.31 [ 0.12, 0.79 ]
Total events: 8 (placebo), 20 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
2 Placebo vs mitoxantone
Mejer 1977 0/9 11/14 100.0 % 0.02 [ 0.00, 0.35 ]
Subtotal (95% CI) 9 14 100.0 % 0.02 [ 0.00, 0.35 ]
Total events: 0 (placebo), 11 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0086)
3 Placebo vs triethylene...
Mejer 1977 0/9 2/15 100.0 % 0.28 [ 0.01, 6.62 ]
Subtotal (95% CI) 9 15 100.0 % 0.28 [ 0.01, 6.62 ]
Total events: 0 (placebo), 2 (other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
Test for subgroup differences: Chi2 = 3.21, df = 2 (P = 0.20), I2 =38%
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Analysis 17.1. Comparison 17 Mustine, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 17 Mustine
Outcome: 1 Pleurodesis failure
Study or subgroup Mustine Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mustine vs tetracycline
Kefford 1980 9/9 9/10 15.3 % 3.00 [ 0.11, 83.36 ]
Loutsidis 1994 8/20 4/20 84.7 % 2.67 [ 0.65, 10.97 ]
Subtotal (95% CI) 29 30 100.0 % 2.72 [ 0.74, 9.98 ]
Total events: 17 (Mustine), 13 (Other)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
2 Mustine vs talc poudrage
Fentiman 1983 8/17 2/20 100.0 % 8.00 [ 1.40, 45.76 ]
Subtotal (95% CI) 17 20 100.0 % 8.00 [ 1.40, 45.76 ]
Total events: 8 (Mustine), 2 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
3 Mustine vs C. parvum
Millar 1980 6/11 2/20 100.0 % 10.80 [ 1.64, 70.93 ]
Subtotal (95% CI) 11 20 100.0 % 10.80 [ 1.64, 70.93 ]
Total events: 6 (Mustine), 2 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
4 Mustine vs Adriamycin
Kefford 1980 9/9 10/11 100.0 % 2.71 [ 0.10, 74.98 ]
Subtotal (95% CI) 9 11 100.0 % 2.71 [ 0.10, 74.98 ]
Total events: 9 (Mustine), 10 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Chi2 = 1.89, df = 3 (P = 0.60), I2 =0.0%
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Analysis 17.2. Comparison 17 Mustine, Outcome 2 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 17 Mustine
Outcome: 2 Fever
Study or subgroup Mustine Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mustine vs tetracycline
Loutsidis 1994 0/20 0/20 Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (Mustine), 0 (Other)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Mustine vs C. parvum
Millar 1980 0/12 1/9 100.0 % 0.23 [ 0.01, 6.25 ]
Subtotal (95% CI) 12 9 100.0 % 0.23 [ 0.01, 6.25 ]
Total events: 0 (Mustine), 1 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 17.3. Comparison 17 Mustine, Outcome 3 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 17 Mustine
Outcome: 3 Mortality
Study or subgroup Mustine Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mustine vs talc poudrage
Fentiman 1983 6/23 3/23 100.0 % 2.35 [ 0.51, 10.86 ]
Subtotal (95% CI) 23 23 100.0 % 2.35 [ 0.51, 10.86 ]
Total events: 6 (Mustine), 3 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 Mustine vs C. parvum
Millar 1980 9/12 5/9 100.0 % 2.40 [ 0.38, 15.32 ]
Subtotal (95% CI) 12 9 100.0 % 2.40 [ 0.38, 15.32 ]
Total events: 9 (Mustine), 5 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 17.4. Comparison 17 Mustine, Outcome 4 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 17 Mustine
Outcome: 4 Pain
Study or subgroup Mustine Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Loutsidis 1994 0/20 9/20 0.03 [ 0.00, 0.56 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Mustine Favours Other
Analysis 18.1. Comparison 18 Mitoxantrone, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 18 Mitoxantrone
Outcome: 1 Pleurodesis failure
Study or subgroup Mitoxantrone Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mitoxantrone vs placebo
Groth 1991 14/49 16/46 100.0 % 0.75 [ 0.32, 1.79 ]
Subtotal (95% CI) 49 46 100.0 % 0.75 [ 0.32, 1.79 ]
Total events: 14 (Mitoxantrone), 16 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
2 Mitoxantrone vs mepacrine
Bjermer 1995 3/14 0/12 100.0 % 7.61 [ 0.35, 163.82 ]
Subtotal (95% CI) 14 12 100.0 % 7.61 [ 0.35, 163.82 ]
Total events: 3 (Mitoxantrone), 0 (Other)
Heterogeneity: not applicable
0.01 0.1 1 10 100
Favours Mitoxantrone Favours other
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(. . . Continued)
Study or subgroup Mitoxantrone Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.30 (P = 0.20)
3 Mitoxantrone vs bleomycin
Schmidt 1997 15/38 8/47 100.0 % 3.18 [ 1.17, 8.65 ]
Subtotal (95% CI) 38 47 100.0 % 3.18 [ 1.17, 8.65 ]
Total events: 15 (Mitoxantrone), 8 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.024)
Test for subgroup differences: Chi2 = 5.69, df = 2 (P = 0.06), I2 =65%
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Favours Mitoxantrone Favours other
Analysis 18.2. Comparison 18 Mitoxantrone, Outcome 2 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 18 Mitoxantrone
Outcome: 2 Pain
Study or subgroup Mitoxantrone Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Schmidt 1997 9/47 5/49 100.0 % 2.08 [ 0.64, 6.76 ]
Total (95% CI) 47 49 100.0 % 2.08 [ 0.64, 6.76 ]
Total events: 9 (Mitoxantrone), 5 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 18.3. Comparison 18 Mitoxantrone, Outcome 3 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 18 Mitoxantrone
Outcome: 3 Fever
Study or subgroup Mitoxantrone Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mitoxantrone vs bleomycin
Schmidt 1997 7/47 8/49 100.0 % 0.90 [ 0.30, 2.71 ]
Subtotal (95% CI) 47 49 100.0 % 0.90 [ 0.30, 2.71 ]
Total events: 7 (Mitoxantrone), 8 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
2 Mitoxantrone vs placebo
Groth 1991 20/49 8/46 100.0 % 3.28 [ 1.26, 8.49 ]
Subtotal (95% CI) 49 46 100.0 % 3.28 [ 1.26, 8.49 ]
Total events: 20 (Mitoxantrone), 8 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 3.03, df = 1 (P = 0.08), I2 =67%
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Analysis 18.4. Comparison 18 Mitoxantrone, Outcome 4 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 18 Mitoxantrone
Outcome: 4 Mortality
Study or subgroup Mitoxantrone Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mitoxantrone vs bleomycin
Schmidt 1997 18/47 28/49 100.0 % 0.47 [ 0.21, 1.05 ]
Subtotal (95% CI) 47 49 100.0 % 0.47 [ 0.21, 1.05 ]
Total events: 18 (Mitoxantrone), 28 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
2 Mitoxantrone vs mepacrine
Bjermer 1995 11/14 12/14 100.0 % 0.61 [ 0.09, 4.37 ]
Subtotal (95% CI) 14 14 100.0 % 0.61 [ 0.09, 4.37 ]
Total events: 11 (Mitoxantrone), 12 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
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Analysis 19.1. Comparison 19 Drain size, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 19 Drain size
Outcome: 1 Pleurodesis failure
Study or subgroup small drain large drain Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Clementsen 1998 2/9 3/9 100.0 % 0.57 [ 0.07, 4.64 ]
Total (95% CI) 9 9 100.0 % 0.57 [ 0.07, 4.64 ]
Total events: 2 (small drain), 3 (large drain)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Not applicable
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Favours small drain Favours large drain
Analysis 19.2. Comparison 19 Drain size, Outcome 2 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 19 Drain size
Outcome: 2 Pain
Study or subgroup small drain large drain Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Clementsen 1998 2/9 7/9 0.08 [ 0.01, 0.75 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours small drain Favours large drain
199Interventions for the management of malignant pleural effusions: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 19.3. Comparison 19 Drain size, Outcome 3 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 19 Drain size
Outcome: 3 Mortality
Study or subgroup small drain large drain Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Clementsen 1998 3/9 1/9 4.00 [ 0.33, 48.66 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours small drain Favours large drain
Analysis 20.1. Comparison 20 Thoracoscopic mechanical pleurodesis (TMP), Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 20 Thoracoscopic mechanical pleurodesis (TMP)
Outcome: 1 Pleurodesis failure
Study or subgroup TMP talc slurry Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Crnjac 2004 6/45 11/42 100.0 % 0.43 [ 0.14, 1.30 ]
Total (95% CI) 45 42 100.0 % 0.43 [ 0.14, 1.30 ]
Total events: 6 (TMP), 11 (talc slurry)
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours TMP Favours talc slurry
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Analysis 20.2. Comparison 20 Thoracoscopic mechanical pleurodesis (TMP), Outcome 2 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 20 Thoracoscopic mechanical pleurodesis (TMP)
Outcome: 2 Mortality
Study or subgroup TMP talc slurry Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Crnjac 2004 0/45 4/42 0.09 [ 0.00, 1.80 ]
Test for subgroup differences: Not applicable
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Favours TMP Favours Talc slurry
Analysis 21.1. Comparison 21 Other, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 21 Other
Outcome: 1 Pleurodesis failure
Study or subgroup Treatment 1 Treatment 2 Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Rotation vs no rotation
Mager 2002 2/10 1/10 5.3 % 2.25 [ 0.17, 29.77 ]
Subtotal (95% CI) 10 10 5.3 % 2.25 [ 0.17, 29.77 ]
Total events: 2 (Treatment 1), 1 (Treatment 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
2 Streptokinase vs no streptokinase
Okur 2011 14/19 9/16 17.6 % 2.18 [ 0.53, 9.02 ]
Subtotal (95% CI) 19 16 17.6 % 2.18 [ 0.53, 9.02 ]
Total events: 14 (Treatment 1), 9 (Treatment 2)
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup Treatment 1 Treatment 2 Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.07 (P = 0.28)
3 Mixed particle talc vs graded talc
Maskell 2004 3/14 2/14 9.2 % 1.64 [ 0.23, 11.70 ]
Subtotal (95% CI) 14 14 9.2 % 1.64 [ 0.23, 11.70 ]
Total events: 3 (Treatment 1), 2 (Treatment 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
4 Talc pleurodesis vs VATS parietal pleurectomy
Rintoul 2014 25/62 24/60 67.9 % 1.01 [ 0.49, 2.09 ]
Subtotal (95% CI) 62 60 67.9 % 1.01 [ 0.49, 2.09 ]
Total events: 25 (Treatment 1), 24 (Treatment 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 105 100 100.0 % 1.26 [ 0.70, 2.30 ]
Total events: 44 (Treatment 1), 36 (Treatment 2)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.18, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Chi2 = 1.18, df = 3 (P = 0.76), I2 =0.0%
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Analysis 21.2. Comparison 21 Other, Outcome 2 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 21 Other
Outcome: 2 Pain
Study or subgroup Treatment 1 Treatment 2 Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Streptokinase vs control
Okur 2011 1/24 0/23 100.0 % 3.00 [ 0.12, 77.47 ]
Subtotal (95% CI) 24 23 100.0 % 3.00 [ 0.12, 77.47 ]
Total events: 1 (Treatment 1), 0 (Treatment 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Favours treatment 1 Favours treatment 2
Analysis 21.3. Comparison 21 Other, Outcome 3 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 21 Other
Outcome: 3 Fever
Study or subgroup Treatment 1 Treatment 2 Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mixed particle talc vs graded talc
Maskell 2004 9/22 1/24 100.0 % 15.92 [ 1.81, 140.16 ]
Subtotal (95% CI) 22 24 100.0 % 15.92 [ 1.81, 140.16 ]
Total events: 9 (Treatment 1), 1 (Treatment 2)
Heterogeneity: not applicable
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 21.4. Comparison 21 Other, Outcome 4 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 21 Other
Outcome: 4 Mortality
Study or subgroup Treatment 1 Treatment 2 Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mixed particle talc vs graded talc
Maskell 2004 7/21 8/22 100.0 % 0.88 [ 0.25, 3.07 ]
Subtotal (95% CI) 21 22 100.0 % 0.88 [ 0.25, 3.07 ]
Total events: 7 (Treatment 1), 8 (Treatment 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
2 Talc pleurodesis vs VATS partial pleurectomy
Rintoul 2014 18/88 19/87 100.0 % 0.92 [ 0.45, 1.90 ]
Subtotal (95% CI) 88 87 100.0 % 0.92 [ 0.45, 1.90 ]
Total events: 18 (Treatment 1), 19 (Treatment 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 22.1. Comparison 22 Silver nitrate, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 22 Silver nitrate
Outcome: 1 Pleurodesis failure
Study or subgroup Silver Nitrate Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Paschoalini 2005 0/16 1/9 0.17 [ 0.01, 4.68 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Silver Nitrate Favours Control
Analysis 22.2. Comparison 22 Silver nitrate, Outcome 2 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 22 Silver nitrate
Outcome: 2 Fever
Study or subgroup Silver Nitrate Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Paschoalini 2005 5/33 3/27 1.43 [ 0.31, 6.61 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Silver nitrate Favours other
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Analysis 23.1. Comparison 23 Cisplatin, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 23 Cisplatin
Outcome: 1 Pleurodesis failure
Study or subgroup Cisplatin Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cisplatin vs cisplatin and bevacizumab
Du 2013 17/34 6/36 100.0 % 5.00 [ 1.66, 15.09 ]
Subtotal (95% CI) 34 36 100.0 % 5.00 [ 1.66, 15.09 ]
Total events: 17 (Cisplatin), 6 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0043)
2 Cisplatin vs OK-432
Ishida 2006 11/17 8/17 100.0 % 2.06 [ 0.52, 8.17 ]
Subtotal (95% CI) 17 17 100.0 % 2.06 [ 0.52, 8.17 ]
Total events: 11 (Cisplatin), 8 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
3 Cisplatin vs OK-432 and cisplatin
Ishida 2006 11/17 1/15 100.0 % 25.67 [ 2.68, 245.84 ]
Subtotal (95% CI) 17 15 100.0 % 25.67 [ 2.68, 245.84 ]
Total events: 11 (Cisplatin), 1 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0049)
4 Cisplatin vs rAd-p53 and cisplatin
Zhao 2009 9/18 3/17 100.0 % 4.67 [ 0.99, 22.03 ]
Subtotal (95% CI) 18 17 100.0 % 4.67 [ 0.99, 22.03 ]
Total events: 9 (Cisplatin), 3 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.052)
Test for subgroup differences: Chi2 = 3.55, df = 3 (P = 0.31), I2 =15%
0.01 0.1 1 10 100
Favours Cisplatin Favours Other
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Analysis 23.2. Comparison 23 Cisplatin, Outcome 2 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 23 Cisplatin
Outcome: 2 Pain
Study or subgroup Cisplatin Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cisplatin vs OK-432
Ishida 2006 2/17 8/17 100.0 % 0.15 [ 0.03, 0.87 ]
Subtotal (95% CI) 17 17 100.0 % 0.15 [ 0.03, 0.87 ]
Total events: 2 (Cisplatin), 8 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
2 Cisplatin vs OK-432 and cisplatin
Ishida 2006 2/17 6/15 100.0 % 0.20 [ 0.03, 1.21 ]
Subtotal (95% CI) 17 15 100.0 % 0.20 [ 0.03, 1.21 ]
Total events: 2 (Cisplatin), 6 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
0.01 0.1 1 10 100
Favours Cisplatin Favours Other
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Analysis 23.3. Comparison 23 Cisplatin, Outcome 3 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 23 Cisplatin
Outcome: 3 Fever
Study or subgroup Cisplatin Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cisplatin vs OK-432
Ishida 2006 1/17 16/17 100.0 % 0.00 [ 0.00, 0.07 ]
Subtotal (95% CI) 17 17 100.0 % 0.00 [ 0.00, 0.07 ]
Total events: 1 (Cisplatin), 16 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 3.80 (P = 0.00014)
2 Cisplatin vs OK-432 and cisplatin
Ishida 2006 1/17 8/15 100.0 % 0.05 [ 0.01, 0.52 ]
Subtotal (95% CI) 17 15 100.0 % 0.05 [ 0.01, 0.52 ]
Total events: 1 (Cisplatin), 8 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
3 Cisplatin vs rAd-p53 and cisplatin
Zhao 2009 2/18 10/17 100.0 % 0.09 [ 0.02, 0.51 ]
Subtotal (95% CI) 18 17 100.0 % 0.09 [ 0.02, 0.51 ]
Total events: 2 (Cisplatin), 10 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 2.71 (P = 0.0066)
Test for subgroup differences: Chi2 = 3.38, df = 2 (P = 0.18), I2 =41%
0.01 0.1 1 10 100
Favours Silver Nitrate Favours other
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Analysis 23.4. Comparison 23 Cisplatin, Outcome 4 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 23 Cisplatin
Outcome: 4 Mortality
Study or subgroup Cisplatin Other Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cisplatin vs OK-432
Ishida 2006 5/17 6/17 100.0 % 0.76 [ 0.18, 3.23 ]
Subtotal (95% CI) 17 17 100.0 % 0.76 [ 0.18, 3.23 ]
Total events: 5 (Cisplatin), 6 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
2 Cisplatin vs combination OK-432 and cisplatin
Ishida 2006 5/17 3/15 100.0 % 1.67 [ 0.32, 8.59 ]
Subtotal (95% CI) 17 15 100.0 % 1.67 [ 0.32, 8.59 ]
Total events: 5 (Cisplatin), 3 (Other)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 Cisplatin vs combination rAd-p53 and cisplatin
Zhao 2009 0/18 0/17 Not estimable
Subtotal (95% CI) 18 17 Not estimable
Total events: 0 (Cisplatin), 0 (Other)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
0.01 0.1 1 10 100
Favours Cisplatin Favours Other
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Analysis 24.1. Comparison 24 Duration of drainage prior to administration of sclerosant, Outcome 1
Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 24 Duration of drainage prior to administration of sclerosant
Outcome: 1 Pleurodesis failure
Study or subgroup Rapid drainage Standard drainage Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ozkul 2014 5/40 6/39 100.0 % 0.79 [ 0.22, 2.82 ]
Total (95% CI) 40 39 100.0 % 0.79 [ 0.22, 2.82 ]
Total events: 5 (Rapid drainage), 6 (Standard drainage)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours rapid drainage Favours standard drainage
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Analysis 25.1. Comparison 25 Dose of silver nitrate, Outcome 1 Pleurodesis failure.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 25 Dose of silver nitrate
Outcome: 1 Pleurodesis failure
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Silver nitrate 90 mg vs 150 mg
Terra 2015 0/20 0/20 Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Silver nitrate 90 mg vs 180 mg
Terra 2015 0/20 2/20 100.0 % 0.18 [ 0.01, 4.01 ]
Subtotal (95% CI) 20 20 100.0 % 0.18 [ 0.01, 4.01 ]
Total events: 0 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
3 Silver nitrate 150 mg vs 180 mg
Terra 2015 0/20 2/20 100.0 % 0.18 [ 0.01, 4.01 ]
Subtotal (95% CI) 20 20 100.0 % 0.18 [ 0.01, 4.01 ]
Total events: 0 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
0.01 0.1 1 10 100
Favours lower dose Favours higher dose
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Analysis 25.2. Comparison 25 Dose of silver nitrate, Outcome 2 Mortality.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 25 Dose of silver nitrate
Outcome: 2 Mortality
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Silver nitrate 90 mg vs 150 mg
Terra 2015 3/20 1/19 100.0 % 3.18 [ 0.30, 33.58 ]
Subtotal (95% CI) 20 19 100.0 % 3.18 [ 0.30, 33.58 ]
Total events: 3 (Experimental), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
2 Silver nitrate 90 mg vs 180 mg
Terra 2015 3/20 0/19 100.0 % 7.80 [ 0.38, 161.87 ]
Subtotal (95% CI) 20 19 100.0 % 7.80 [ 0.38, 161.87 ]
Total events: 3 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
3 Silver nitrate 150 mg vs 180 mg
Terra 2015 1/19 0/19 100.0 % 3.16 [ 0.12, 82.64 ]
Subtotal (95% CI) 19 19 100.0 % 3.16 [ 0.12, 82.64 ]
Total events: 1 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 0.24, df = 2 (P = 0.89), I2 =0.0%
0.01 0.1 1 10 100
Favours lower dose Favours higher dose
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Analysis 25.3. Comparison 25 Dose of silver nitrate, Outcome 3 Pain.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 25 Dose of silver nitrate
Outcome: 3 Pain
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Silver nitrate 90 mg vs 150 mg
Terra 2015 2/20 2/20 100.0 % 1.00 [ 0.13, 7.89 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.13, 7.89 ]
Total events: 2 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Silver nitrate 90 mg vs 180 mg
Terra 2015 2/20 2/20 100.0 % 1.00 [ 0.13, 7.89 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.13, 7.89 ]
Total events: 2 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Silver nitrate 150 mg vs 180 mg
Terra 2015 2/20 2/20 100.0 % 1.00 [ 0.13, 7.89 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.13, 7.89 ]
Total events: 2 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 1.00), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 25.4. Comparison 25 Dose of silver nitrate, Outcome 4 Fever.
Review: Interventions for the management of malignant pleural effusions: a network meta-analysis
Comparison: 25 Dose of silver nitrate
Outcome: 4 Fever
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Silver nitrate 90 mg vs 150 mg
Terra 2015 2/20 3/20 100.0 % 0.63 [ 0.09, 4.24 ]
Subtotal (95% CI) 20 20 100.0 % 0.63 [ 0.09, 4.24 ]
Total events: 2 (Experimental), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
2 Silver nitrate 90 mg vs 180 mg
Terra 2015 2/20 2/20 100.0 % 1.00 [ 0.13, 7.89 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.13, 7.89 ]
Total events: 2 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Silver nitrate 150 mg vs 180 mg
Terra 2015 3/20 2/20 100.0 % 1.59 [ 0.24, 10.70 ]
Subtotal (95% CI) 20 20 100.0 % 1.59 [ 0.24, 10.70 ]
Total events: 3 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Chi2 = 0.45, df = 2 (P = 0.80), I2 =0.0%
0.01 0.1 1 10 100
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A D D I T I O N A L T A B L E S
Table 1. Direct meta-analysis of pleurodesis efficacy using the random-effects model showing the odds ratios (95% CI) of the
rows compared to the columns
Treatment Talc slurry Talc
poudrage
Bleomycin Tetracy-
cline
C. parvum Placebo Mustine Mitox-
antrone
Mepacrine
Talc
poudrage
0.76 (0.54,
1.09);
n = 3; Tau
2 = 0; I2 =
NA - - - - - - -
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Table 1. Direct meta-analysis of pleurodesis efficacy using the random-effects model showing the odds ratios (95% CI) of the
rows compared to the columns (Continued)
0%
Bleomycin 1.22 (0.55,
2.70);
n = 5*;
Tau2 = 0.1;
I2 = 12%
9.70 (2.
10, 44.78)
;
n = 2; Tau
2 = 0; I2=
0%
NA - - - - - -
Tetracy-
cline
0.78 (0.19,
3.13);
n = 1*
12.10 (1.
32, 111.
30);
n = 1
2.00 (1.
07, 3.75);
n = 5*; Tau
2 = 0; I2 =
0%
NA - - - - -
C. parvum NA NA 0.55 (0.01,
57.48);
n = 2; Tau
2 = 11; I2 =
94%
0.31 (0.05,
1.94);
n = 1
NA - - - -
Interferon NA NA 3.25 (1.
54, 6.89);
n = 1
NA NA - - - -
Iodine 0.47 (0.04,
5.71); n =1
1.76 (0.26,
11.83); n =
1
1.25 (0.28,
5.59);
n = 1
NA NA - - - -
Indwelling
pleural
catheter
3.35 (1.
64, 6.83);
n = 2 Tau
2 = 0; I2 =
0%
NA NA NA NA - - - -
Placebo 13.93
(0.66, 293.
99);
n = 1
NA NA 3.33 (0.51,
21.58);
n = 1
NA NA - - -
Mustine NA 8.00 (1.
40, 45.76)
;
n = 1
NA 2.72 (0.74,
9.98)
n = 2*; Tau
2= 0;
I2= 0%
3.00 (0.40,
22.71);
n = 1
NA NA - -
Mitox-
antrone
NA NA 3.18 (1.
17, 8.65);
n = 1
NA NA 0.75 (0.32,
1.79); n =1
NA NA -
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Table 1. Direct meta-analysis of pleurodesis efficacy using the random-effects model showing the odds ratios (95% CI) of the
rows compared to the columns (Continued)
Mepacrine 2.08 (0.62,
6.96); n =1
NA 0.16 (0.
03, 0.89);
n = 1
0.63 (0.05,
8.20);
n = 1
NA 0.15 (0.03,
0.64); n =
1*
NA 7.61 (0.35,
163.82); n
= 1
NA
Doxycy-
cline
NA 42.69 (2.
13, 856.
61);
n = 1
0.67 (0.24,
1.86);
n = 2;
Tau2= 0;
I2= 0%
NA 1.91 (0.43,
8.48);
n = 1
NA NA NA NA
Tri-
ethylenethio-
phospho-
ramide
NA NA NA NA NA 2.06 (0.43,
9.80); n =
1*
NA NA 4.95 (1.
02, 24.10)
;
n = 1*
Adri-
amycin
NA NA NA 1.11 (0.06,
20.49);
n = 1*
NA NA 0.37 (0.01,
10.18); n =
1*
NA NA
n = the number of studies included in the pair-wise comparison. * Indicates that the comparison included a three-arm study. NA =
no direct pair-wise comparison available. Results that are statistically significant at the conventional level of P < 0.05 are shaded in
grey. - indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around
Table 2. Results of network meta-analysis for pleurodesis efficacy showing the odds ratios (95% Cr-I) of the agents in the rows
compared to the agents in the columns
Talc
slurry
Talc
poudrageBleomycin
Tetra-
cy-
cline
C.
parvum
Inter-
feron
Io-
dine
In-
dwelling
pleu-
ral
catheter
Placebo
Mus-
tine
Mi-
tox-
antrone
MepacrineDoxy-
cyline
Tri-
ethylenethio-
phos-
pho-
ramide
vis-
cum
Talc
poudrage
0.
42 (0.
13, 1.
19)
NA - - - - - - - - - - - - -
Bleomycin
2.
56 (1.
05, 6.
67)
6.
03 (2.
19,
20.
46)
NA - - - - - - - - - - - -
Tetra-
cy-
cline
3.
71 (1.
22,
11.
67)
8.
77 (2.
74,
33.
01)
1.
45 (0.
59, 3.
46)
NA - - - - - - - - - - -
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Table 2. Results of network meta-analysis for pleurodesis efficacy showing the odds ratios (95% Cr-I) of the agents in the rows
compared to the agents in the columns (Continued)
C.
parvum
1.
48 (0.
34, 6.
57)
3.49
(0.79,
17.
64)
0.
58 (0.
16, 1.
95)
0.
40 (0.
10, 1.
52)
NA - - - - - - - - - -
Inter-
feron
8.49
(0.94,
82.
98)
19.
96 (2.
22,
229.
60)
3.33
(0.43,
25.
66)
2.29
(0.26,
21.
65)
5.75
(0.55,
64.
16)
NA - - - - - - - - -
Io-
dine
1.
25 (0.
22, 6.
77)
2.97
(0.55,
17.
21)
0.
49 (0.
09, 2.
49)
0.
34 (0.
05, 2.
04)
0.
85 (0.
11, 6.
35)
0.
15 (0.
01, 1.
90)
NA - - - - - - - -
In-
dwelling
pleu-
ral
catheter
3.47
(0.75,
16.
46)
8.
19 (1.
32,
59.
02)
1.
36 (0.
22, 8.
01)
0.
94 (0.
14, 6.
27)
2.36
(0.28,
19.
88)
0.
41 (0.
03, 5.
96)
2.76
(0.29,
28.
48)
NA - - - - - - -
Placebo
19.
50 (3.
73,
128.
50)
46.
51 (7.
86,
375.
90)
7.
64 (1.
55,
44.
22)
5.
29 (1.
04,
31.
95)
13.
28 (1.
91,
110.
80)
2.29
(0.18,
34.
14)
15.
63 (1.
72,
179.
10)
5.61
(0.59,
65.
18)
NA - - - - - -
Mus-
tine
7.
50 (1.
35,
43.
86)
17.
75 (3.
59,
105.
70)
2.94
(0.58,
14.
84)
2.
02 (0.
43, 9.
79)
5.07
(0.91,
29.
81)
0.88
(0.06,
11.
71)
5.98
(0.68,
58.
17)
2.16
(0.22,
22.
76)
0.
38 (0.
04, 3.
32)
NA - - - - -
Mi-
tox-
antrone
12.
87 (2.
36,
89.
02)
30.
53 (5.
11,
259.
50)
5.
04 (1.
04,
28.
67)
3.48
(0.64,
22.
72)
8.
76 (1.
24,
73.
66)
1.51
(0.12,
22.
89)
10.
28 (1.
12,
119.
70)
3.71
(0.38,
44.
85)
0.
66 (0.
13, 3.
52)
1.73
(0.19,
17.80
NA - - - -
Mepacrine
0.
98 (0.
22, 4.
15)
2.32
(0.45,
12.
99)
0.
38 (0.
09, 1.
52)
0.
27 (0.
05, 1.
17)
0.
67 (0.
10, 4.
06)
0.
12 (0.
01, 1.
31)
0.
78 (0.
09, 6.
55)
0.
28 (0.
03, 2.
32)
0.
05 (0.
01, 0.
28)
0.
13 (0.
02, 0.
99)
0.
08 (0.
01, 0.
47)
NA - - -
Doxy-
cy-
cline
3.49
(0.68,
19.
8.
23 (1.
70,
1.
37 (0.
31, 6.
0.
94 (0.
18, 5.
2.36
(0.46,
13.
0.
41 (0.
03, 5.
2.78
(0.33,
26.
1.00
(0.11,
10.
0.
18 (0.
02, 1.
0.
47 (0.
06, 3.
0.
27 (0.
03, 2.
3.56
(0.50,
NA - -
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Table 2. Results of network meta-analysis for pleurodesis efficacy showing the odds ratios (95% Cr-I) of the agents in the rows
compared to the agents in the columns (Continued)
56) 50.
18)
09) 09) 09) 14) 50) 23) 53) 77) 31) 28.
59)
Tri-
ethylenethio-
phos-
pho-
ramide
5.53
(0.40,
80.
97)
13.07
(0.89,
227.
30)
2.16
(0.16,
29.
77)
1.50
(0.10,
21.
61)
3.74
(0.21,
66.
99)
0.65
(0.02,
17.
63)
4.40
(0.22,
98.
58)
1.59
(0.08,
35.
28)
0.
28 (0.
02, 3.
62)
0.74
(0.04,
15.
00)
0.
43 (0.
02, 6.
80)
5.60
(0.55,
63.
81)
1.59
(0.08,
31.
05)
NA -
Adri-
amycin
2.31
(0.03,
165.
40)
5.53
(0.08,
403.
50)
0.90
(0.01,
59.
43)
0.62
(0.01,
38.
58)
1.57
(0.02,
114.
20)
0.27
(0.00,
27.
43)
1.85
(0.02,
162.
70)
0.67
(0.01,
62.
01)
0.
12 (0.
00, 9.
46)
0.31
(0.00,
20.
50)
0.18
(0.00,
14.
59)
2.36
(0.03,
191.
30)
0.66
(0.01,
52.
71)
0.42
(0.00,
54.
35)
NA
Vis-
cum
0.
39 (0.
01, 8.
23)
0.92
(0.03,
21.
77)
0.
15 (0.
01, 2.
73)
0.
10 (0.
00, 2.
17)
0.
26 (0.
01, 6.
21)
0.
04 (0.
00, 1.
55)
0.
31 (0.
01, 9.
07)
0.
11 (0.
00, 3.
44)
0.
02 (0.
00, 0.
53)
0.
05 (0.
00, 1.
41)
0.
03 (0.
00, 0.
79)
0.39
(0.01,
10.
28)
0.
11 (0.
00, 2.
83)
0.
07 (0.
00, 3.
48)
0.16
(0.00,
26.
60)
Results that are statistically significant at the conventional level of P < 0.05 are shaded in grey. - indicates the odds ratio is
already expressed elsewhere in the table comparing the interventions the other way around. NA= not applicable
Table 3. Results for pleurodesis efficacy of the studies evaluating pleurodesis methods, which were not included in the network
meta-analysis
Study Reason study ex-
cluded from net-
work
Intrapleu-
ral agent or inter-
vention 1
Pleurodesis fail-
ure rate for agent
1
Intrapleu-
ral agent or inter-
vention 2
Pleurodesis fail-
ure rate for agent
2
OR (95% CI)
of agent 1 com-
pared with agent
2***
Du 2013 Lung cancer spe-
cific therapy
Cisplatin andbe-
vacizumab
6/36 Cisplatin 17/34 0.20 (0.07, 0.
60)
Emad 1996* No
pleurodesis fail-
ures in the Com-
bined group
Tetracycline** 3/19 Combined tetra-
cycline and
bleomycin
0/19 8.27 (0.40, 172.
05)
Bleomycin** 2/19 Combined tetra-
cycline and
bleomycin
0/19 5.57 (0.25, 124.
19)
Ishida 2006* Lung cancer spe-
cific therapy
OK-432 8/17 Cisplatin 11/17 0.48 (0.12, 1.92)
OK-432 8/17 OK-432 and cis-
platin
1/15 12.44 (1.32,
117.03)
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Table 3. Results for pleurodesis efficacy of the studies evaluating pleurodesis methods, which were not included in the network
meta-analysis (Continued)
Cisplatin 11/17 OK-432 and cis-
platin
1/15 25.67 (2.68,
245.84)
Kasahara 2006 Lung cancer spe-
cific therapy
High dose OK-
432
5/19 Low dose OK-
432
3/19 1.90 (0.38, 9.44)
Luh 1992 Lung cancer spe-
cific therapy
OK-432 3/26 Mitomycin C 9/27 0.26 (0.06, 1.11)
Maskell 2004 Two Talc slurry
preparations
Mixed particle
talc
3/14 Graded talc (par-
ticles >20µm)
2/14 1.64 (0.23, 11.
70))
Masuno 1991 Lung cancer spe-
cific therapy
LC9018 and
Adriamycin
10/38 Adriamycin 23/38 0.23 (0.09, 0.
62)
Paschoalini 2005 No pleurodesis
failures in Silver
Nitrate group
Talc slurry 1/9 Silver nitrate 0/16 5.85 (0.21, 158.
82)
Rintoul 2014 MPM
specific surgical
technique
Talc pleu-
rodesis (slurry or
poudrage)
25/62 VATS
pleurectomy
24/60 0.88 (0.43, 1.82)
Terra 2015* Comparison of
different doses of
Silver Nitrate
90 mg silver ni-
trate
0/20 150 mg silver ni-
trate
0/20 not estimable
90 mg silver ni-
trate
0/20 180 mg silver ni-
trate
2/20 0.18 (0.01, 4.01)
150 mg silver ni-
trate
0/20 180 mg silver ni-
trate
2/20 0.19 (0.01, 4.01)
Yoshida 2007* Lung cancer spe-
cific therapy
OK-432 8/33 Bleomycin 11/35 0.70 (0.24, 2.03)
OK-432 8/33 Cisplatin and
etoposide
10/34 0.77 (0.26, 2.27)
Bleomycin 11/35 Cisplatin and
etoposide
10/34 1.10 (0.39, 3.07)
Zhao 2009 Lung cancer spe-
cific therapy
rAd-p53 and cis-
platin
3/17 Cisplatin 9/18 0.21 (0.05, 1.01)
*Three-arm study. **The results for the pair-wise comparison between tetracycline and bleomycin are included in the network meta-
analysis
***Results that are statistically significant at the conventional level of P < 0.05 are shaded in grey
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Table 4. Results for pleurodesis efficacy of the studies evaluating interventions to optimise pleurodesis, which were not included
in the network meta-analysis
Type of method
to optimise pleu-
rodesis
Study Intervention 1 Pleurodesis fail-
ure rate for inter-
vention 1
Intervention 2 Pleurodesis fail-
ure rate for inter-
vention 2
OR (95% CI)
of intervention 1
compared with
intervention 2*
Mode of admin-
istration
Evans 1993 Tetracy-
cline pleurodesis
at the end of tho-
racoscopy
2/15 Tetracy-
cline pleurodesis
through an inter-
costal cannula
5/14 0.28 (0.04, 1.76)
Chest tube size Clementsen
1998
Small-bore chest
drain
2/9 Large-bore chest
drain
3/9 0.57 (0.07, 4.64)
Patient rotation Mager 2002 Rotation af-
ter instillation of
talc
2/10 No rotation af-
ter instillation of
talc
1/10 2.25 (0.17, 29.
77)
Dura-
tion of drainage
after administra-
tion of the scle-
rosant
Goodman 2006 Drain removed
24 hours after
pleurodesis
2/16 Drain removed
72 hours after
pleurodesis
4/19 0.54 (0.08, 3.40)
Villanueva 1994 Drain re-
moval the day af-
ter pleurodesis
2/9 Drain removal
when < 150 ml/
day output
3/15 1.14 (0.15, 8.59)
Yildirim 2005 Fraction-
ated dose oxyte-
tracycline (4 di-
vided doses at 6-
hourly intervals)
0/12 Single
bedside instilla-
tion of oxytetra-
cycline
2/8 0.10 (0.00, 2.50)
Dura-
tion of drainage
prior to admin-
istration of the
sclerosant
Ozkul 2014 Early instillation
of talc slurry af-
ter drain inser-
tion
5/40 Instillation of
talc slurry when
daily drainage
fromchest tube <
300 ml/day
6/39 0.79 (0.22, 2.82)
Intrapleural fib-
rinolytics
Okur 2011 Intrapleural
streptokinase
14/19 No intrapleural
streptokinase
9/16 2.18 (0.53, 9.02)
Pleural abrasion
at thoracoscopy
Crnjac 2004 Talc slurry 11/42 Thoracoscopic
mechanical pleu-
rodesis
6/45 2.31 (0.77, 6.93)
* Results that are statistically significant at the conventional level of P < 0.05 are shaded in grey
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Table 5. Results of network meta-analysis for causing fever showing the odds ratios (95% CI) of the agents in the rows
compared to the agents in the columns
Talc
slurry
Talc
poudrage Bleomycin
Tetracy-
cline
C.
parvum
Iodine
Mepacrine
Placebo Mitox-
antrone
Doxycy-
cline
Talc
poudrage
0.66 (0.
09, 3.98)
NA - - - - - - - -
Bleomycin
1.26 (0.
24, 6.82)
1.93
(0.22, 19.
42)
NA - - - - - - -
Tetracy-
cline
0.29 (0.
04, 2.09)
0.45 (0.
04, 5.74)
0.23 (0.
06, 0.88)
NA - - - - - -
C.
parvum
6.31
(0.61, 70.
69)
9.
71 (0.65,
176.70)
5.01
(0.92, 29.
12)
21.46 (3.
10, 175.
70)
NA - - - - -
Iodine 0.27 (0.
02, 3.69)
0.42 (0.
03, 6.09)
0.21 (0.
01, 4.25)
0.93
(0.03, 23.
41)
0.04 (0.
00, 1.29)
NA - - - -
Mepacrine
4.52
(0.30, 76.
00)
6.
95 (0.34,
182.20)
3.58
(0.40, 36.
59)
15.41 (1.
62, 178.
80)
0.71
(0.05, 11.
99)
16.72 (0.
43, 831.
10)
NA - - -
Placebo 0.06 (0.
00, 2.00)
0.10 (0.
00, 4.27)
0.05 (0.
00, 1.08)
0.22 (0.
00, 5.71)
0.01 (0.
00, 0.32)
0.23
(0.00, 17.
55)
0.01 (0.
00, 0.30)
NA - -
Mitox-
antrone
0.48
(0.02, 10.
24)
0.73
(0.02, 22.
95)
0.38 (0.
02, 5.02)
1.64
(0.07, 29.
71)
0.08 (0.
00, 1.60)
1.75
(0.03, 99.
74)
0.11 (0.
00, 2.16)
7.
57 (0.59,
138.80)
NA -
Doxycy-
cline
0.49 (0.
03, 6.13)
0.75
(0.04, 14.
68)
0.39 (0.
05, 2.66)
1.67
(0.14, 17.
22)
0.08 (0.
01, 0.63)
1.81
(0.05, 69.
03)
0.11 (0.
00, 1.93)
7.
69 (0.19,
539.10)
1.02
(0.04, 33.
23)
NA
Tri-
ethylenephos-
pho-
ramide
0.24
(0.00, 17.
04)
0.37
(0.00, 35.
93)
0.19 (0.
00, 9.80)
0.81
(0.02, 47.
08)
0.04 (0.
00, 2.63)
0.
88 (0.01,
139.50)
0.05 (0.
00, 1.49)
3.
62 (0.07,
529.40)
0.49 (0.
01, 49.44
0.49
(0.01, 45.
90)
Results that are statistically significant at the conventional level of P < 0.05 are shaded in grey. - indicates the odds ratio is already
expressed elsewhere in the table comparing the interventions the other way around. NA= not applicable
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A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL ( THE COCHRANE LIBRARY)
#1 MeSH descriptor: [Pleural Effusion] explode all trees
#2 (pleura* near/5 (effusion* or fluid*)):ti,ab,kw (Word variations have been searched)
#3 #1 or #2
#4 MeSH descriptor: [Neoplasms] explode all trees
#5 (cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*):ti,ab,kw (Word variations have been searched)
#6 #4 or #5
#7 #3 and #6
MEDLINE (OVID)
1 exp Pleural Effusion/
2 (pleura* adj5 (effusion* or fluid*)).mp.
3 1 or 2
4 exp Neoplasms/
5 (cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*).mp.
6 4 or 5
7 randomized controlled trial.pt.
8 controlled clinical trial.pt.
9 randomized.ab.
10 placebo.ab.
11 clinical trials as topic.sh.
12 randomly.ab.
13 trial.ti.
14 7 or 8 or 9 or 10 or 11 or 12 or 13
15 3 and 6 and 14
key:
mp = protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject
heading word, unique identifier
pt = publication type
sh = subject heading
ab = abstract
ti = title
EMBASE (OVID)
1 exp Pleural Effusion/
2 (pleura* adj5 (effusion* or fluid*)).mp.
3 or/1-2
4 exp neoplasm/
5 (cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*).mp.
6 or/4-5
7 random$.tw.
8 factorial$.tw.
9 crossover$.tw.
10 cross over$.tw.
11 cross-over$.tw.
12 placebo$.tw.
13 (doubl$ adj blind$).tw.
14 (singl$ adj blind$).tw.
15 assign$.tw.
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16 allocat$.tw.
17 volunteer$.tw.
18 Crossover Procedure/
19 double-blind procedure.tw.
20 Randomized Controlled Trial/
21 Single Blind Procedure/
22 or/7-21
23 (animal/ or nonhuman/) not human/
24 22 not 23
25 3 and 6 and 24
CINAHL (EBSCO)
S25 S18 AND S21 AND S24
S24 S22 OR S23
S23 (cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*) Search modes -
S22 (MH “Neoplasms+”)
S21 S19 OR S20
S20 (pleura* N5 (effusion* or fluid*))
S19 (MH “Pleural Effusion+”)
S18 S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17
S17 (allocat* random*)
S16 (MH “Quantitative Studies”)
S15 (MH “Placebos”)
S14 placebo*
S13 (random* allocat*)
S12 (MH “Random Assignment”)
S11 (Randomi?ed control* trial*)
S10 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or
(singl* mask* )
S9 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8
S8 (allocat* random*)
S7 (MH “Quantitative Studies”)
S6 (MH “Placebos”)
S5 placebo*
S4 (random* allocat*)
S3 (MH “Random Assignment”)
S2 (Randomi?ed control* trial*)
S1 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or
(singl* mask* )
Web of Science (ISI) SSCI & SCI
#11 #10 AND #2
#10 #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3
#9 Topic=((((“random* allocat*”) or (“random* assign*”))))
#8 Topic=(((crossover)))
#7 Topic=((((“tripl* blind*”) or (“tripl* mask*”))))
#6 Topic=((((“trebl* blind*”) or (“trebl* mask*”))))
#5 Topic=((((“doubl* blind*”) or (“doubl* mask*”))))
#4 Topic=((((“singl* blind*”) or (“singl* mask*”))))
#3 Topic=((((“clin* trial*”))))
#2 Topic=((pleura* near/5 (effusion* or fluid*))) ANDTopic=((cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*))
#1 Topic=((pleura* near/5 (effusion* or fluid*)))
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Appendix 2. Distribution of study population characteristics across all the included studies and
within each pair-wise comparison
Potential effect modi-
fiers
Total
n (%)
Talc
poudrage
vs talc
slurry. n
(%)
Bleomycin
vs talc
slurry. n
(%)
Bleomycin
vs talc
poudrage.
n (%)
Tetracy-
cline vs
bleomycin.
n (%)
C.
parvum
vs
bleomycin.
n (%)
IPC vs
talc
slurry. n
(%)
Mustine
vs tetra-
cycline. n
(%)
Doxycy-
cline vs
bleomycin.
n (%)
Number of studies 59 3 5 2 5 2 2 2 2
Cell types
included
All 42 (71) 3 (100) 5 (100) 1 (50) 5 (100) 1 (50) 2 (100) 2 (100) 2 (100)
Only
breast
6 (10) 0 0 1 (50) 0 0 0 0 0
Only
Lung
7 (12) 0 0 0 0 0 0 0 0
Other 4 (7) 0 0 0 0 1 (50) 0 0 0
Trapped
lung
Excluded 24 (41) 2 (67) 3 (60) 1 (50) 1 (20) 0 1 (50) 0 0
Included 35 (59) 1 (33) 2 (40) 1 (50) 4 (80) 2 (100) 1 (50) 2 (100) 2 (100)
Drain size Un-
known
26 (44) 1 (33) 1 (20) 1 (50) 4 (80) 1 (50) 0 0 1 (50)
Small <
20 Fr
13 (22) 0 1 (20) 1 (50) 0 1 (50) 1 (50 1 (50) 1 (50)
Large ≥
20 Fr
17 (29) 2 (67) 3 (60) 0 1 (20) 0 1(50) 1 (50) 0
Study
compar-
ing
large with
small
drains
3 (5) 0 0 0 0 0 0 0 0
How
pleurode-
siswas de-
fined
Recur-
rence of
effusion
and need
for repeat
interven-
tion
41 (69) 1 (33) 4 (80) 1 (50) 4 (80) 2 (100) 2 (100) 2 (100) 1 (50)
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(Continued)
Radio-
logical re-
currence
only
18 (31) 2 (66) 1 (20) 1 (50) 1 (20) 0 0 0 1 (50)
Time
point
pleurode-
sis
defined*
2 - 4
months
23 (39) 1 (33) 1 (20) 1 (50) 2 (40) 1 (50) 0 2 (100) 1 (5)
> 4 - 7
months
1 (2) 1 (33) 0 0 0 0 0 0 0
> 11 - 12
months
1 (2) 0 0 0 0 0 1 (50) 0 0
< 2
months
29 (49) 1 (33) 2 (40) 0 3 (60) 1 (50) 1 (50) 0 1 (50)
Not
stated
5 (8) 0 2 (40) 1 (50) 0 0 0 0 0
* If the study reported multiple time points, the one referred to here was that used in our primary analysis (according to our hierarchy
of preferences (see Primary outcomes)). IPC = Indwelling pleural catheter.
Appendix 3. Sensitivity analysis of the direct meta-analysis results for pleurodesis efficacy using the
fixed-effect model showing odds ratios (95% CI) of the rows compared to the columns
Talc slurry Talc poudrage Bleomycin Tetracycline
Talc poudrage 0.77 (0.54, 1.09);
n = 3; Chi2 = 0.57; I2=
0%
NA - NA
Bleomycin 1.22 (0.61, 2.45); n = 5*
Chi2 = 4.53; I2 = 12%
9.81 (2.10, 45.89);
n = 2; Chi2 = 0.01; I2 =
0%
NA -
Tetracycline NA NA 2.00 (1.07, 3.73);
n = 5(*); Chi2= 1.23; I
2= 0%
NA
C. parvum NA NA 0.72 (0.32, 1.61); n = 2;
Chi2 = 17.04; I2 = 94%
NA
Indwelling pleural
catheter
3.35 (1.64, 6.83); n = 2;
Chi2 = 0.00. I2 = 0%
NA NA NA
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(Continued)
Mustine NA NA NA 2.72 (0.74, 9.99);
n = 2*;
Chi2 = 0.00; I2 = 0%
Doxycycline NA NA 0.66 (0.24, 1.83); n = 2;
Chi2 = 0.22; I2 = 0%
NA
n = the number of studies included in the pair-wise comparison. * iIndicates that the comparison included a three- arm study. NA =
no direct pair-wise comparison available. Results that are statistically significant at the conventional level of pP < 0.05 are shaded in
grey
Appendix 4. Overview of the network meta-analysis results for pleurodesis efficacy in the sensitivity
analyses
Number
of pleurodesismeth-
ods evaluated
Number of trials in-
cluded in network
Tau2 (95% CI) Global inconsis-
tency identified?
Loop-specific incon-
sistency identified?
If so, loop showing
inconsistency with
ROR (95% CI)
Whole network 16 41 0.88 (0.42, 1.482) No Yes
TS-TP-BL 7.0 (1.1,
43.8)
TS-BL-ME 10.2 (1.
1, 96.9)
Only data collected
at 1 month
13 24 0.80 (0.14, 1.66) No Yes
BL-MX-ME 54.2
(2.0, 1469.5)
Only data collected
at 3 months
9 10 0.55 (0.02, 1.84) No No
Only data collected
at 6 months
7 10 1.09 (0.09, 1.95) No Yes
TS-TP-BL 11.7 (1.
1, 123.3)
Trials excluding pa-
tients with trapped
lung
9 13 0.71 (0.04, 1.85) No No
Trials using a clin-
ico-radiological def-
inition of pleurode-
sis
16 29 1.16 (0.59, 1.87) No Yes
TS-BL-ME 12.9 (1.
3, 126.3)
TS-TP-BL 11.6 (1.
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(Continued)
02, 132.5)
Trials using large-
bore chest tubes
9 16 1.32 (0.51, 1.95) No Yes
TS-BL-TC 15.2 (1.
5, 151.4)
TS-BL-ME (12.2 (1.
2, 121.2)
Trials with a lower
risk of bias (high risk
of bias for < 2 do-
mains)
16 36 0.46 (0.03, 1.09) No Yes
TS-BL-ME 12.2 (1.
2, 125.3)
TS-TP-BL 8.5 (1.2,
60.3)
BL = Bleomycin; CP = C. parvum; DX = Doxycycline; IO = Iodine; ME = Mepacrine; MU = Mustine; MX = Mitoxantrone; PL =
Placebo; TC = Tetracycline; TP = Talc poudrage; TS = Talc slurry
Appendix 5. Results of the sensitivity analysis only evaluating those studies with a lower risk of bias.
Table of odds ratios (95% Cr-I) from network meta-analysis (agents in the rows compared to those
in the columns)
Talc
slurry
Talc
poudrageBleomycinTetra-
cy-
cline
C.
parvum
In-
ter-
feron
Io-
dine
In-
dwelling
pleu-
ral
catheter
Placebo
Mus-
tine
Mi-
tox-
antrone
MepacrineDoxy-
cy-
cline
Triehylenethio-
phos-
pho-
ramide
Adri-
amycin
Talc
poudrage
0.
60 (0.
23, 1.
18)
NA - - - - - - - - - - - - -
Bleomycin
2.
48 (1.
11, 5.
62)
4.
20 (1.
86,
11.
54)
NA - - - - - - - - - - - -
Tetra-
cy-
cline
3.
31 (1.
30, 8.
09)
5.
61 (2.
26,
15.
98)
1.
33 (0.
65, 2.
62)
NA - - - - - - - - - - -
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(Continued)
C.
parvum
0.
38 (0.
08, 1.
63)
0.
64 (0.
14, 3.
10)
0.
15 (0.
04, 0.
55)
0.
11 (0.
03, 0.
43)
NA - - - - - - - - - -
Inter-
feron
8.
29 (1.
71,
41.
07)
13.
94 (3.
07,
81.
87)
3.34
(0.85,
13.
22)
2.51
(0.56,
12.
10)
22.
05 (3.
30,
153.
40)
NA - - - - - - - - -
Io-
dine
1.
48 (0.
35, 5.
83)
2.52
(0.65,
10.
61)
0.
60 (0.
15, 2.
26)
0.
45 (0.
10, 1.
93)
3.95
(0.59,
25.
86)
0.
18 (0.
02, 1.
16)
NA - - - - - - - -
In-
dwelling
pleu-
ral
catheter
3.
47 (1.
17,
10.
63)
5.
81 (1.
70,
26.
41)
1.
39 (0.
36, 5.
52)
1.
05 (0.
26, 4.
57)
9.
32 (1.
49,
60.
52)
0.
42 (0.
06, 2.
92)
2.33
(0.41,
14.
76)
NA - - - - - - -
Placebo
16.
07 (4.
32,
70.
28)
27.
28 (7.
17,
146.
30)
6.
51 (1.
91,
25.
79)
4.
89 (1.
40,
20.
52)
43.
17 (7.
58,
289.
30)
1.94
(0.32,
13.
75)
10.
87 (1.
86,
75.
98)
4.63
(0.85,
29.
52)
NA - - - - - -
Mus-
tine
5.
82 (1.
35,
23.
26)
9.
84 (2.
59,
41.
00)
2.
32 (0.
59, 8.
80)
1.
74 (0.
50, 6.
25)
15.
22 (3.
09,
79.
85)
0.
70 (0.
10, 4.
48)
3.91
(0.64,
24.
53)
1.
68 (0.
27, 9.
52)
0.
36 (0.
06, 1.
95)
NA - - - - -
Mi-
tox-
antrone
10.
77 (2.
88,
46.
75)
18.
28 (4.
88,
96.
33)
4.
34 (1.
36,
16.
02)
3.28
(0.93,
13.
77)
28.
81 (5.
23,
188.
00)
1.
30 (0.
22, 8.
91)
7.
21 (1.
31,
50.
05)
3.12
(0.56,
19.
44)
0.
67 (0.
20, 2.
21)
1.88
(0.35,
12.
09)
NA - - - -
Mepacrine
1.
02 (0.
31, 3.
08)
1.
74 (0.
50, 6.
54)
0.
41 (0.
12, 1.
23)
0.
31 (0.
09, 1.
01)
2.72
(0.49,
14.
88)
0.
12 (0.
02, 0.
69)
0.
69 (0.
13, 3.
72)
0.
29 (0.
06, 1.
37)
0.
06 (0.
01, 0.
25)
0.
18 (0.
03, 0.
90)
0.
10 (0.
02, 0.
38)
NA - - -
Doxy-
cy-
cline
0.
75 (0.
06, 8.
34)
1.30
(0.11,
14.
97)
0.
30 (0.
03, 3.
13)
0.
23 (0.
02, 2.
49)
1.98
(0.24,
16.
02)
0.
09 (0.
01, 1.
36)
0.
51 (0.
03, 7.
34)
0.
22 (0.
01, 2.
90)
0.
05 (0.
00, 0.
61)
0.
13 (0.
01, 1.
70)
0.
07 (0.
00, 0.
96)
0.
73 (0.
05, 9.
59)
NA - -
228Interventions for the management of malignant pleural effusions: a network meta-analysis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Tri-
ethylenethio-
phos-
pho-
ramide
5.34
(0.65,
47.
58)
9.
11 (1.
09,
92.
17)
2.14
(0.27,
18.
82)
1.62
(0.20,
14.
58)
14.
32 (1.
27,
182.
00)
0.
64 (0.
05, 8.
18)
3.60
(0.33,
44.
88)
1.53
(0.15,
17.
84)
0.
33 (0.
04, 2.
79)
0.92
(0.08,
11.
35)
0.
49 (0.
05, 4.
67)
5.21
(0.83,
38.
34)
7.11
(0.33,
182.
30)
NA -
Adri-
amycin
2.07
(0.04,
104.
50)
3.56
(0.06,
181.
20)
0.84
(0.01,
40.
14)
0.63
(0.01,
30.
57)
5.54
(0.09,
290.
10)
0.25
(0.00,
14.
49)
1.40
(0.02,
78.
69)
0.60
(0.01,
33.
16)
0.
13 (0.
00, 6.
70)
0.36
(0.01,
17.
48)
0.19
(0.00,
10.
55)
2.06
(0.03,
109.
70)
2.85
(0.03,
224.
70)
0.39
(0.00,
28.
73)
NA
Vis-
cum
0.
36 (0.
02, 4.
78)
0.
62 (0.
03, 9.
01)
0.
15 (0.
01, 1.
70)
0.
11 (0.
01, 1.
43)
0.96
(0.05,
16.
17)
0.
04 (0.
00, 0.
74)
0.
24 (0.
01, 4.
26)
0.
10 (0.
00, 1.
72)
0.
02 (0.
00, 0.
34)
0.
06 (0.
00, 1.
06)
0.
03 (0.
00, 0.
49)
0.
35 (0.
02, 5.
51)
0.48
(0.01,
15.
59)
0.
07 (0.
00, 1.
81)
0.17
(0.00,
18.
96)
Results that are statistically significant at the conventional level of P < 0.05 are shaded in grey. - indicates the odds ratio is already
expressed elsewhere in the table comparing the interventions the other way around. NA= not applicable
Appendix 6. Estimated rank (95% Cr-I) for pleurodesis efficacy in the sensitivity analysis only
evaluating those trials with a lower risk of bias
Pleurodesis method Estimated rank (95% Cr-I)
C. parvum 2 (1, 6)
Viscum 2 (1, 11)
Talc poudrage 3 (1, 6)
Doxycycline 4 (1, 13)
Talc slurry 5 (3, 8)
Mepacrine 5 (2, 9)
Iodine 7 (2, 12)
Adriamycin 8 (1, 16)
Bleomycin 9 (6, 12)
Tetracycline 10 (7, 13)
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Indwelling pleural catheter 10 (6, 15)
Mustine 12 (7, 16)
Triethylenethoiphosphoramide 12 (5, 16)
Interferon 13 (8, 16)
Mitoxantrone 14 (11, 16)
Placebo 15 (12, 16)
Appendix 7. Results of the sensitivity analysis only evaluating agents given by bedside pleurodesis.
Table of odds ratios (95% Cr-I) from network meta-analysis (the agents in the rows compared to the
agents in the columns) for pleurodesis success
Talc
slurry
Doxy-
cycline Bleomycin
Tetra-
cycline
C.
parvum
Inter-
feron
Iodine Adri-
amycin
Placebo Mus-
tine
Mitox-
antrone Mepacrine
Doxy-
cycline
1.10 (0.
13, 8.
65)
NA - - - - - - - - - -
Bleomycin
1.56 (0.
53, 4.
88)
1.41 (0.
25, 9.
11)
NA - - - - - - - - -
Tetra-
cycline
2.28 (0.
58, 9.
13)
2.06 (0.
30, 15.
92)
1.46 (0.
53, 3.
90)
NA - - - - - - - -
C.
parvum
0.82 (0.
15, 4.
60)
0.75 (0.
11, 5.
33)
0.53 (0.
13, 2.
00)
0.36 (0.
08, 1.
57)
NA - - - - - - -
Inter-
feron
5.18 (0.
43, 68.
49)
4.72 (0.
28, 92.
65)
3.33 (0.
34, 32.
42)
2.28 (0.
19, 28.
27)
6.31 (0.
47, 93.
70)
NA - - - - - -
Iodine 1.13 (0.
12, 9.
77)
1.02 (0.
06, 16.
19)
0.72 (0.
08, 5.
65)
0.50 (0.
05, 4.
77)
1.37 (0.
11, 16.
45)
0.22 (0.
01, 4.
46)
NA - - - - -
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(Continued)
Adri-
amycin
1.48 (0.
02,
114.80)
1.36 (0.
01,
130.60)
0.95 (0.
01, 65.
87)
0.65 (0.
01, 41.
36)
1.80 (0.
02,
139.40)
0.28 (0.
00, 33.
67)
1.33 (0.
01,
143.20)
NA - - - -
Placebo 9.24 (0.
91,
109.90)
8.42 (0.
56,
156.30)
5.96 (0.
69, 55.
43)
4.06 (0.
50, 37.
88)
11.26
(0.99,
149.50)
1.77 (0.
08, 44.
50)
8.24 (0.
44,
188.50)
6.31 (0.
06,
765.80)
NA - - -
Mus-
tine
5.89 (0.
63, 62.
33)
5.36 (0.
43, 81.
82)
3.78 (0.
50, 31.
32)
2.59 (0.
39, 19.
27)
7.17 (0.
95, 62.
55)
1.14 (0.
05, 25.
58)
5.26 (0.
30,
109.10)
3.99 (0.
06,
354.40)
0.64 (0.
04, 11.
13)
NA - -
Mitox-
antrone
7.23 (0.
97, 69.
79)
6.57 (0.
57,
104.40)
4.63 (0.
79, 33.
87)
3.18 (0.
49, 26.
67)
8.
81 (1.
01, 98.
38)
1.39 (0.
08, 29.
47)
6.46 (0.
44,
125.50)
4.99 (0.
05,
570.00)
0.79 (0.
12, 5.
83)
1.23 (0.
09, 19.
34)
NA -
Mepacrine
0.71 (0.
12, 3.
65)
0.64 (0.
06, 7.
05)
0.46 (0.
08, 2.
15)
0.31 (0.
05, 1.
69)
0.86 (0.
10, 6.
55)
0.14 (0.
01, 2.
06)
0.63 (0.
05, 8.
48)
0.48 (0.
01, 45.
93)
0.08
(0.00,
0.91)
0.12 (0.
01, 1.
40)
0.10
(0.01,
0.82)
NA
Viscum 0.23 (0.
01, 6.
09)
0.21 (0.
01, 7.
69)
0.15 (0.
01, 3.
19)
0.10 (0.
00, 2.
60)
0.28 (0.
01, 8.
17)
0.04 (0.
00, 1.
99)
0.20 (0.
00, 8.
98)
0.15 (0.
00, 32.
36)
0.02 (0.
00, 1.
05)
0.04 (0.
00, 1.
54)
0.03 (0.
00, 1.
09)
0.33 (0.
01, 11.
30)
Results that are statistically significant at the conventional level of P < 0.05 are shaded in grey. - indicates the odds ratio is already
expressed elsewhere in the table comparing the interventions the other way around. NA= not applicable
Appendix 8. Estimated rank (95% Cr-I) for the subgroup analysis evaluating the network of agents
given via a chest tube (IPC and talc poudrage studies excluded)
Pleurodesis agent Estimated rank (95% Cr-I)
Viscum 1 (1, 10)
Mepacrine 3 (1, 9)
C. parvum 4 (1, 9)
Talc slurry 5 (2, 9)
Doxycycline 5 (1, 10)
Iodine 5 (1, 12)
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(Continued)
Bleomycin 6 (1, 13)
Adriamycin 7 (4, 10)
Tetracycline 8 (4, 11)
Mitoxantrone 11 (5, 13)
Mustine 11 (6, 13)
Interferon 11 (3, 13)
Placebo 12 (6, 13)
Appendix 9. Direct pair-wise evidence for fever, expressed as odds ratios (95% CI) for the rows
compared to the columns, using random-effects meta-analysis
Treatment Talc slurry Talc poudrage Bleomycin Tetracycline C.parvum Placebo Mepacrine
Talc poudrage 0.60 (0.15, 2.
37);
Tau2 = 0.54;
I 2= 31%; n =
2
NA - - - - -
Bleomycin 0.90 (0.31, 2.
56);
Tau2 = 0.10; I
2 = 11%;
n = 3*
0.87 (0.11, 7.
05); n = 1
NA - - - -
Tetracycline 0.92 (0.23, 3.
63);
n = 1*
- 0.49 (0.16, 1.
50);
Tau2 = 0.63;
I2 = 39%;
n = 5
NA - - -
C.
parvum
NA NA 2.30 (0.90, 5.
92);
Tau2 = 0; n =
2; I2 = 0%
288.00 (16.
62, 4991);
n = 1
NA - -
Interferon NA NA 0.01, (0.00,
0.11);
n = 1
NA NA NA NA
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Iodine 0.63 (0.09, 4.
28);
n = 1
0.24 (0.02, 2.
33);
n = 1
NA NA NA NA NA
Placebo NA NA NA NA NA NA -
Mustine NA NA NA NA 0.23 (0.01, 6.
25)
n = 1
NA NA
Mitoxantrone NA NA 0.90 (0.30, 2.
71);
n = 1
NA NA 3.28 (1.26, 8.
49);
n = 1
NA
Mepacrine NA NA 1.91 (0.52, 7.
01); n = 1
8.00 (1.13,
56.79);
n = 1
NA 62.43 (2.
85, 1365.5); n
= 1*
NA
Doxycycline NA NA 0.37 (0.01,
12.35);
Tau2 = 5.18; I
2 = 80%;
n = 2
NA 0.14 (0.03, 0.
54);
n = 1
NA NA
Tri-
ethylenethio-
phospho-
ramide
NA NA NA NA NA 3.52 (0.15,
81.92); n = 1*
0.04 (0.01, 0.
30); n =1*
n = the number of studies included in the pair-wise comparison. * indicates that the comparison included a three-arm study. NA =
no direct pair-wise comparison available. Results that are statistically significant at the conventional level of P < 0.05 are shaded in
grey- indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around
Appendix 10. Table of the relative chance of pain from direct pair-wise evidence using random-
effects model (odds ratios (95% Cr-I) (rows compared to columns)
Treatment Talc slurry Talc poudrage Bleomycin Tetracycline C. parvum Placebo Mepacrine
Talc poudrage 0.47 (0.23, 0.
96); n = 1
NA - - - - -
Bleomycin 1.66 (0.41, 6.
80)
Tau2 = 0; I2 =
0%;
n = 2*
0.28 (0.01, 7.
31); n = 1
NA - - - -
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Tetracycline 3.28 (0.73,
14.68); n = 1
NA 1.65 (0.79, 3.
43); Tau2 = 0.
19; I2 = 34%;
n = 4*
NA - - -
C.
parvum
NA NA 1.42 (0.54, 3.
75); Tau2 = 0;
I2 = 0%; n = 2
2.44 (0.69, 8.
66); n = 1
NA - -
Interferon NA NA 0.03 (0.00, 0.
53); n = 1
NA NA NA NA
Iodine NA 0.10 (0.01, 1.
99); n = 1
NA NA NA NA NA
In-
dwelling pleu-
ral catheter
3.22 (0.13,
82.38); n = 1
NA NA NA NA NA NA
Placebo NA NA NA NA NA NA -
Mustine NA NA NA 0.03 (0.00, 0.
56); n = 1
NA NA NA
Mitoxantrone NA NA 2.08 (0.64, 6.
76); n = 1
NA NA NA NA
Mepacrine NA NA 2.15 (0.52, 9.
00);
n = 1
5.60 (0.81,
38.51); n = 1
NA 14.53 (0.
71, 298.21); n
= 1*
NA
Doxycycline NA NA 1.19 (0.37, 3.
80); Tau2 = 0.
30; I2 = 42%;
n = 2
NA 0.10 (0.01, 0.
96); n = 1
NA NA
Tri-
ethylenethio-
phospho-
ramide
NA NA NA NA NA 7.43 (0.
35, 156.28); n
= 1*
0.48 (0.10, 2.
30); n = 1*
n = the number of studies included in the pair-wise comparison. * indicates that the comparison included a three-arm study. NA =
no direct pair-wise comparison available. Results that are statistically significant at the conventional level of P < 0.05 are shaded in
grey. - indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around
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Appendix 11. Table of the relative chances of pain from network meta-analysis (expressed as odds
ratios (95%Cr-I) (columns compared to the rows)
Talc slurry Talc
poudrage
Bleomycin Tetracycline C. parvum Doxycycline Tri-
ethylenethio-
phospho-
ramide
Mitox-
antrone
Talc
poudrage
0.64 (0.15,
5.32)
NA - - - - - -
Bleomycin 1.77 (0.35,
10.10)
2.67 (0.22,
21.47)
NA - - - - -
Tetracycline 2.51 (0.46,
15.34)
3.79 (0.30,
32.27)
1.42 (0.58,
3.51)
NA - - - -
C. parvum 4.81 (0.70,
39.01)
7.22 (0.49,
76.22)
2.70 (0.88,
9.22)
1.91 (0.54,
7.35)
NA - - -
Doxycycline 1.51 (0.17,
12.20)
2.29 (0.12,
24.27)
0.86 (0.21,
2.88)
0.60 (0.12,
2.57)
0.32 (0.06,
1.31)
NA - -
Tri-
ethylenethio-
phospho-
ramide
3.29 (0.13,
94.02)
4.91 (0.11,
154.80)
1.84 (0.11,
33.50)
1.30 (0.07,
24.02)
0.68 (0.03,
14.60)
2.14 (0.11,
56.85)
NA -
Mitox-
antrone
3.86 (0.29,
56.88)
5.85 (0.22,
100.00)
2.17 (0.29,
17.29)
1.54 (0.17,
14.63)
0.80 (0.07,
8.28)
2.54 (0.25,
32.33)
1.18 (0.03,
39.70)
NA
Mepacrine 7.19 (0.74,
81.81)
10.80 (0.56,
149.60)
4.01 (0.77,
23.89)
2.84 (0.53,
17.30)
1.49 (0.20,
11.48)
4.70 (0.64,
46.59)
2.18 (0.23,
22.63)
1.85 (0.13,
27.50)
Results that are statistically significant at the conventional level of P < 0.05 are shaded in grey. - indicates the odds ratio is already
expressed elsewhere in the table comparing the interventions the other way around. NA= not applicable
Appendix 12. Estimated rank (95% Cr-I) for causing pain (a low rank suggesting less pain)
Pleurodesis agent Estimated rank (95% Cr-I)
Talc poudrage 1 (1, 8)
Talc slurry 2 (1, 7)
Doxycycline 3 (1, 8)
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Bleomycin 4 (2, 6)
Tetracycline 5 (2, 8)
Triethylenethiophosphoramide 6 (1, 9)
C. parvum 7 (4, 9)
Mitoxantrone 7 (1, 9)
Mepacrine 8 (4, 9)
Appendix 13. Table of the relative chance of mortality from direct evidence using random-effects
model (odds ratios (95% Cr-I) (rows compared to columns)
Treatment Talc slurry Talc poudrage Bleomycin Tetracycline C. parvum Mitoxantrone
Talc poudrage 1.02 (0.35, 3.00)
;
Tau2 = 0.43; I2 =
69%; n = 2
NA - - - -
Bleomycin 0.89 (0.29, 2.75)
;
Tau2 = 0; I2 =
0%;
n = 2
0.82 (0.20, 3.43)
; n = 1
NA - - -
Tetracycline NA 0.19 (0.03, 0.10)
; n = 1
1.60 (0.69, 3.69)
; Tau2 = 0.0; I2 =
0%;
n = 2
NA - -
C.
parvum
NA NA 1.66 (0.51, 5.38)
; n = 1
0.33 (0.03, 3.55)
; n=1
NA -
Interferon NA NA 2.16 (1.15, 4.
07); n = 1
NA NA NA
Iodine NA 0.38 (0.08, 1.73)
; n = 1
NA NA NA NA
Indwelling pleu-
ral catheter
1.30 (0.48, 2.23)
Tau2 = 0.08; I2 =
25%; n = 2
NA NA NA NA NA
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Mustine NA 2.35 (0.51, 10.
86); n = 1
NA NA 2.40 (0.38, 15.
32); n = 1
NA
Mitoxantrone NA NA 0.47 (0.21, 1.05)
; n = 1
NA NA NA
Mepacrine 0.53 (0.28, 1.61)
; n = 1
NA NA NA NA 1.64 (0.23, 11.
70); n = 1
Doxycycline NA NA 0.69 (0.26, 1.87)
; n = 1
NA NA NA
n = the number of studies included in the pair-wise comparison. * indicates that the comparison included a three-arm study. NA =
no direct pair-wise comparison available. Results that are statistically significant at the conventional level of P < 0.05 are shaded in
grey. - indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around
Appendix 14. Table of the relative chances of mortality from network meta-analysis (expressed as
odds ratios (95% Cr-I) (rows compared to columns)
Talc
slurry
Talc
poudrage Bleomycin
Tetracy-
cline
C.
parvum
Inter-
feron
Iodine In-
dwelling
pleural
catheter
Mustine Mitox-
antrone Mepacrine
Talc
poudrage
0.85
(0.38, 2.
07)
NA - - - - - - - - -
Bleomycin
1.03
(0.38, 2.
83)
1.19
(0.43, 3.
33)
NA - - - - - - - -
Tetracy-
cline
2.70 (0.
78, 11.
57)
3.15 (0.
96, 12.
32)
2.62
(0.97, 8.
41)
NA - - - - - - -
C.
parvum
1.33
(0.28, 6.
08)
1.56
(0.34, 6.
66)
1.29
(0.35, 4.
60)
0.49
(0.10, 2.
00)
NA - - - - - -
Inter-
feron
2.23 (0.
44, 11.
82)
2.61 (0.
50, 13.
64)
2.18
(0.59, 8.
03)
0.83
(0.14, 4.
03)
1.68 (0.
28, 10.
74)
NA - - - - -
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Iodine 0.30
(0.03, 2.
39)
0.35
(0.04, 2.
27)
0.29
(0.03, 2.
53)
0.11
(0.01, 1.
01)
0.23
(0.02, 2.
49)
0.13
(0.01, 1.
62)
NA - - - -
In-
dwelling
pleural
catheter
1.04
(0.38, 3.
02)
1.22
(0.32, 4.
69)
1.02
(0.24, 4.
27)
0.39
(0.07, 1.
94)
0.78
(0.13, 5.
13)
0.47
(0.07, 3.
29)
3.47 (0.
35, 42.
07)
NA - - -
Mustine 2.60 (0.
48, 15.
49)
3.04 (0.
63, 15.
55)
2.53 (0.
47, 14.
49)
0.97
(0.14, 6.
01)
1.97 (0.
38, 11.
03)
1.17 (0.
14, 10.
17)
8.68 (0.
76, 118.
1)
2.50 (0.
34, 19.
18)
NA - -
Mitox-
antrone
0.44
(0.10, 1.
85)
0.51
(0.11, 2.
25)
0.43
(0.12, 1.
43)
0.16
(0.03, 0.
72)
0.33
(0.06, 1.
94)
0.20
(0.03, 1.
13)
1.47 (0.
12, 18.
53)
0.42
(0.07, 2.
42)
0.17
(0.02, 1.
27)
NA -
Mepacrine
0.58
(0.15, 2.
16)
0.68
(0.14, 3.
02)
0.56
(0.12, 2.
56)
0.21
(0.03, 1.
17)
0.43
(0.06, 3.
07)
0.26
(0.03, 1.
87)
1.92 (0.
17, 25.
19)
0.55
(0.10, 2.
90)
0.22
(0.03, 1.
82)
1.32
(0.27, 6.
75)
NA
Doxycy-
cline
0.69
(0.12, 4.
34)
0.81
(0.13, 4.
99)
0.68
(0.15, 3.
01)
0.26
(0.04, 1.
49)
0.52
(0.07, 3.
81)
0.31
(0.04, 2.
26)
2.32 (0.
17, 35.
56)
0.66
(0.08, 5.
37)
0.27
(0.03, 2.
52)
1.59 (0.
24, 11.
70)
1.21 (0.
15, 10.
30)
Results that are statistically significant at the conventional level of p<0.05 are shaded in grey. - indicates the odds ratio is already
expressed elsewhere in the table comparing the interventions the other way around. NA= not applicable
Appendix 15. Estimated rank (95% Cr-I) for mortality (a low rank suggesting lower mortality)
Pleurodesis agent Estimated rank (95% Cr-I)
Iodine 1 (1, 10)
Mitoxantrone 2 (1, 8)
Mepacrine 3 (1, 10)
Doxycycline 4 (1, 11)
Talc poudrage 5 (2, 10)
Bleomycin 7 (3, 10)
Talc slurry 7 (3, 10)
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Indwelling pleural catheter 7 (2, 12)
C. parvum 8 (2, 12)
Interferon 10 (3, 12)
Tetracycline 11 (7, 12)
Mustine 11 (3, 12)
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AOC, NP, RB and NAM performed the data extractions.
AOC entered the data into RevMan and undertook the direct pair-wise comparisons in RevMan.
HJ performed the network meta-analysis and provided statistical support.
AOC drafted the final report, which was reviewed and amended by all the authors.
AOC and NAM are responsible for the update.
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D E C L A R A T I O N S O F I N T E R E S T
AOC is involved in co-ordinating and recruiting to the TIME-3 trial (TIME-3).
HJ: none known.
RB has been the trial co-ordinator for the TAPPS and IPC-Plus studies since 2012 (IPC-Plus; TAPPS) but did not perform the data
extractions for these studies for the purposes of this review.
NJP: none known.
NM is a member of the trial steering committee for TIME-1 and TIME-3 trials (TIME-1; TIME-3). NM is a co-author for one of
the included studies (Maskell 2004). However, he did not perform the data extractions for this study for the purposes of this review.
North Bristol NHS Trust received unrestricted research funding from CareFusion, to run the IPC-Plus trial (IPC-Plus) (2013-2016)
for which NM was the chief investigator. NM also received honoraria from CareFusion for medical advisory board meetings (2013-
2015). This has no direct link with the Cochrane Review.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The wording of the background and methods sections have been improved to make them more concise, minimise repetition and to
reflect the recently published literature.
In the original protocol, we stated we would use relative risk for dichotomous outcomes, however, we elected to use odds ratios instead,
since network meta-analysis models are more readily available for these.
Although the use of network meta-analysis was mentioned in the published protocol, further details have been included to clarify the
methodology, including details on evaluating heterogeneity, inconsistency and imprecision. These changes are based on the protocol
template from the Comparing Multiple Interventions Methods Group, which was not available when we wrote our original protocol.
The protocol stated that the size of the study would be assessed to look for bias associated with small study effects. This was not
performed, as size in itself should not affect the study results and inclusion of sample size in risk of bias tables would be against the
advice in the Cochrane Handbook (Higgins 2011a) and training provided by the Cochrane Bias Methods Group.
The protocol combined blinding of participants and personnel and outcome assessment into a single domain. However, in light of new
guidance from Cochrane, this was separated into ’blinding of participants and personnel’ and ’blinding of outcome assessment’, as per
the Cochrane Handbook (Higgins 2011a).
The protocol stated we would evaluate mortality in the short, medium and long term. However, due to a paucity of evidence at all
these different time points, an overall assessment was done using the available study data closest to three months after the intervention.
The wording of the planned sensitivity analyses have been amended for clarity.
Post-hoc, we chose to perform a sensitivity analysis of the main network excluding talc poudrage and IPCs in order to remove the effect
of mode of administration to identify which agent may be best delivered via a standard chest tube.
For clarity, we added ’a network meta-analysis’ to the title.
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